{"results": [[0, "Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings.", [" {\"Patient\": 1, \"Progressive mobilization\": 1, \"normalization\": 1, \"laboratory findings\": 1}\n{\"Pharmacology\": 0}\n{\"Disease\": 0}\n{\"Treatment\": 1}\n{\"Laboratory findings\": 1}\n{\"Complete normalization\": 1}\n{\"Mobilization\": 1}\n{\"Normalization of laboratory findings\": 1}\n{\"Complete normalization of laboratory findings\": 1}\n{\"Patient's condition\": 1}\n{\"Laboratory findings\": 1}\n{\"Normalization\": 1}\n{\"Mobilization of patient\": 1}\n{\"Normalization of laboratory findings\": 1}\n{\"Patient's laboratory findings\": 1}\n{\"Patient's condition\": 1}\n{\"Patient's laboratory findings\": 1}\n{\"Patient's normalization\": 1}\n{\"Patient's progressive mobilization\": 1}\n{\"Patient's complete normalization\": 1}\n{\"Patient's complete normalization of laboratory findings\": 1}\n{\"Patient's progressive mobilization and normalization\": 1}\n{\"Patient's complete normalization of laboratory findings\": 1}\n{\"Patient's progressive mobilization and normalization of laboratory findings\": 1}\n{\"Patient's complete normalization and laboratory findings\": 1}\n{\"Patient's progressive mobilization, normalization, and laboratory findings\": 1}\n{\"Patient's complete normalization, mobilization, and laboratory findings\": 1}\n{\"Patient's progressive mobilization, normalization, and complete normalization of laboratory findings\": 1}\n{\"Patient's complete normalization, progressive mobilization, and laboratory findings\": 1}\n{\"Patient's progressive mobilization, normalization, and complete normalization of laboratory findings\": 1}\n{\"Patient's complete normalization, progressive mobilization, and laboratory findings\": 1}\n{\"Patient's progressive mobilization, normalization, and complete normalization of laboratory find", {}]], [1, "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event.", [" {\"trabectedin\": 1, \"heavy toxicity\": 1, \"rhabdomyolysis\": 1, \"retroperitoneal liposarcoma\": 1, \"herbal medicine\": 1}\n\n{\"frequencies\": {\"trabectedin\": 1, \"heavy toxicity\": 1, \"rhabdomyolysis\": 1, \"retroperitoneal liposarcoma\": 1, \"herbal medicine\": 1}}\n\n(Note: The frequency count is based on the number of times each entity is mentioned in the provided text. Since the text is short, the frequency count for each entity is 1.)", {"Pathology": ["rhabdomyolysis", "retroperitoneal liposarcoma", "adverse event"], "Drug": ["trabectedin"]}]], [2, "In May 2009 he underwent surgical removal of the abdominal mass achieving a complete margin negative (R0) resection.", [" {\"Surgical removal\": 1, \"abdominal mass\": 1, \"complete margin negative (R0) resection\": 1}\n{\"May 2009\": 1}\n{\"he\": 2}\n{\"underwent\": 1}\n{\"complete margin negative (R0) resection\": 1}\n{\"R0\": 1}\n{\"abdominal mass\": 1}\n{\"surgical removal\": 1}\n{\"complete margin negative\": 1}\n{\"R0 resection\": 1}\n{\"complete margin\": 1}\n{\"negative\": 1}\n{\"R0\": 1}\n{\"margin\": 1}\n{\"R0 resection\": 1}\n{\"complete\": 1}\n{\"margin negative\": 1}\n{\"R0\": 1}\n{\"complete margin negative\": 1}\n{\"R0 resection\": 1}\n{\"complete margin negative\": 1}\n{\"R0\": 1}\n{\"complete margin negative\": 1}\n{\"R0 resection\": 1}\n{\"complete margin negative\": 1}\n{\"R0\": 1}\n{\"complete margin negative\": 1}\n{\"R0 resection\": 1}\n{\"complete margin negative\": 1}\n{\"R0\": 1}\n{\"complete margin negative\": 1}\n{\"R0 resection\": 1}\n{\"complete margin negative\": 1}\n{\"R0\": 1}\n{\"complete margin negative\": 1}\n{\"R0 resection\": 1}\n{\"complete margin negative\": 1}\n{\"R0\": 1}\n{\"complete margin negative\": 1}\n{\"R0 resection\": 1}\n{\"complete margin negative\": 1}\n{\"R0\": 1}\n{\"complete margin negative\": 1}\n{\"R0 resection\": 1}\n{\"complete margin negative\": 1}\n{\"R0\": 1}\n{\"complete margin negative\": 1}\n{\"R0 resection\": 1}\n{\"complete margin negative\": 1}\n{\"R0\": 1}\n{\"complete margin negative\": 1}\n{\"R0 resection\": 1}\n{\"complete margin negative\": 1}\n{\"R0\": 1}\n{\"complete", {}]], [3, "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space.", [" {\"Chemotherapy\": 1, \"lesion\": 1, \"retro-peritoneum space\": 1}\n\nNote: The entities \"lesion\" and \"retro-peritoneum space\" are not directly cited entities but are mentioned as part of the context. However, they are relevant to the pharmacological context of the article as they relate to the progression of a condition potentially treated by chemotherapy. If the task strictly requires only direct cited entities, then these would not be included. For the purpose of this task, I've included them as they are part of the narrative.", {}]], [4, "Due to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin.", [" {\"Trabectedin\": 1, \"drugs\": 1, \"patient\": 1, \"co-morbidity\": 1}\n{\"FREQUENCY\": {\"treatment with trabectedin\": 1}}\n{\"FREQUENCY\": {\"other drugs\": 1}}\n{\"FREQUENCY\": {\"absence\": 1}}\n{\"FREQUENCY\": {\"patient\": 1}}\n{\"FREQUENCY\": {\"treatment\": 1}}\n{\"FREQUENCY\": {\"co-morbidity\": 1}}\n{\"FREQUENCY\": {\"during\": 1}}\n{\"FREQUENCY\": {\"other\": 1}}\n{\"FREQUENCY\": {\"not received\": 1}}\n{\"FREQUENCY\": {\"with\": 1}}", {"Drug": ["trabectedin"]}]], [5, "As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8].", [" {\"chemotherapeutic drugs\": 1, \"oncology practice\": 1, \"narrow therapeutic index\": 1, \"ancillary medications\": 1, \"cancer-related syndromes\": 1, \"treatment-induced toxicity\": 1}", {"Pathology": ["cancer", "cancer-related syndromes", "treatment-induced toxicity"]}]], [6, "Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms.", [" {\"Chooseberry juice\": 1, \"commercial preparation\": 1, \"compounds\": 1, \"interactions\": 1, \"death receptor\": 1}\n\n{\"Chokeberry juice\": {\"FREQUENCY\": 1}, \"commercial preparation\": {\"FREQUENCY\": 1}, \"compounds\": {\"FREQUENCY\": 1}, \"interactions\": {\"FREQUENCY\": 1}, \"death receptor\": {\"FREQUENCY\": 1}}", {"Extraction process": ["chokeberry juice"]}]], [7, "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use.", [" {\"Medicinal cannabis\": 1, \"health risks\": 1, \"case report\": 1}", {"Herb name": ["cannabis"]}]], [8, "It was discovered that the patient took cannabis for chronic back pain, and a pharmacogenomics (PGx) test indicated the presence of variants for the COMT and HTR2A genes.", [" {\"Cannabis\": 1, \"chronic back pain\": 1, \"pharmacogenomics (PGx)\": 1, \"COMT\": 1, \"HTR2A genes\": 1}\n\nNote: The frequency count is based on the number of times each entity is mentioned in the text. In this case, each entity is mentioned once. If the text had multiple mentions of any of these entities, the frequency count would reflect that. For example, if \"COMT\" was mentioned twice, the frequency count for COMT would be 2. However, based on the provided text, all entities are mentioned only once.", {"Herb name": ["cannabis"], "Pathology": ["chronic back pain"]}]], [9, "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8].", [" {\"carbidopa-levodopa\": 1, \"ropinirole\": 1, \"entacapone\": 1, \"dopamine\": 2, \"Parkinson's disease (PD)\": 1}\n\n{\"medications\": 1}\n\n{\"dopamine concentrations\": 1}\n\n{\"movement control\": 1}\n\n{\"Neuronal death\": 1}\n\n{\"Parkinson's disease (PD)\": 1}", {"Pathology": ["PD"], "Drug": ["carbidopa-levodopa", "ropinirole", "entacapone"]}]], [10, "The case described herein demonstrates the importance of considering the pharmacokinetic and pharmacodynamic effects of cannabis and an individual\u2019s pharmacogenomic (PGx) data when evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events.", [" {\"Cannabis\": 1, \"pharmacokinetic\": 1, \"pharmacodynamic\": 1, \"pharmacogenomic (PGx)\": 1, \"medication regimen\": 1, \"therapeutic response\": 1, \"adverse drug events\": 1}", {"Herb name": ["cannabis"], "Pathology": ["adverse drug events"]}]], [11, "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain.", [" {\"PD\": 1, \"spinal stenosis\": 1, \"vitamin D deficiency\": 1, \"frequent falls\": 1, \"nicotine dependence\": 1, \"alcohol dependence\": 1, \"mild kidney disease\": 1, \"chronic neck pain\": 1, \"chronic back pain\": 1, \"chronic shoulder pain\": 1}\n\n{\"PD\": 1, \"spinal stenosis\": 1, \"vitamin D deficiency\": 1, \"frequent falls\": 1, \"nicotine dependence\": 1, \"alcohol dependence\": 1, \"mild kidney disease\": 1, \"chronic neck pain\": 1, \"chronic back pain\": 1, \"chronic shoulder pain\": 1}", {"Pathology": ["PD", "spinal stenosis", "vitamin D deficiency", "frequent falls", "mild kidney disease", "chronic neck, back, and shoulder pain"]}]], [12, "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1).", [" {\"Carbidopa-Levodopa\": 1, \"Clinical Pharmacist\": 1, \"Dose Increases\": 1, \"Tremors\": 1, \"Early Morning\": 1}\n{\"FREQUENCY\": {\"Clinical Pharmacist\": 1, \"Dose Increases\": 1, \"Tremors\": 1}}\n\nNote: \"Figure 1\" is not an entity but a reference to a figure in the article, so it's not included in the entity list.", {"Drug": ["carbidopa-levodopa"], "Pathology": ["tremors"]}]], [13, "However, his PCP determined that additional medication for pain control was warranted.", [" {\"PCP\": 1, \"additional medication\": 1, \"pain control\": 1}", {}]], [14, "Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21].", [" {\"Study Results\": 1, \"Pain Models\": 1, \"Healthy Subjects\": 1, \"Patients\": 1, \"Routes of Administration\": 1, \"Inhalation\": 1, \"Oral\": 1, \"Sources of Product\": 1}", {"Pathology": ["pain", "healthy"]}]], [15, "When CB1Rs on presynaptic neurons are activated, inhibitory neurotransmitter levels are reduced and dopamine levels increase [5,24,25].", [" {\"CB1Rs\": 1, \"presynaptic neurons\": 1, \"inhibitory neurotransmitter levels\": 1, \"dopamine levels\": 1}\n{\"FREQUENCY\": {\"CB1Rs\": 1, \"presynaptic neurons\": 1, \"inhibitory neurotransmitter levels\": 1, \"dopamine levels\": 1}}\n\nNote: The frequency count is based on the number of times each entity is mentioned in the provided text. In this case, each entity is mentioned once. However, if the text were longer or contained multiple mentions of the same entities, the frequency count would reflect that.", {"Target": ["CB1Rs"], "Parameter": ["dopamine levels"]}]], [16, "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected.", [" {\"COMT Met/Met\": 1}", {}]], [17, "Additionally, a previous study evaluated patients with PD and their subsequent reactions to cannabis use, reporting that one out of five patients experienced hallucinations [12].", [" {\"Parkinson's disease (PD)\": 1, \"patients\": 1, \"reactions\": 1, \"cannabis\": 1, \"hallucinations\": 1}\n{\"FREQUENCY\": {\"patients\": 1, \"hallucinations\": 1}}", {"Pathology": ["PD", "hallucinations"], "Herb name": ["cannabis"]}]], [18, "Given this patient\u2019s genetic results, guidelines, and current pain status, the clinical pharmacist suggested morphine as an alternative, as it does not utilize CYP2D6 for metabolism [34].", [" {\"Morphine\": 1, \"CYP2D6\": 1, \"clinical pharmacist\": 1, \"genetic results\": 1, \"guidelines\": 1, \"pain status\": 1}\n{\"FREQUENCY\": {\"Morphine\": 1, \"CYP2D6\": 1, \"clinical pharmacist\": 1, \"genetic results\": 1, \"guidelines\": 1, \"pain status\": 1}}\n\nNote: The numbers in the \"FREQUENCY\" dictionary represent the number of times each entity is mentioned in the text. Since the instruction asks for a count of occurrences, the values are set to 1 for each entity mentioned. If there were multiple mentions of an entity, the count would be higher accordingly. However, based on the provided text, each entity is mentioned once.", {"Pathology": ["pain"], "Drug": ["morphine"]}]], [19, "The authors want to thank Katie Meyer for her assistance.", [" {\"PERSON\": [\"Katie Meyer\"], \"ORGANIZATION\": [], \"PRODUCT\": [], \"EVENT\": [], \"DATE\": [], \"TIME\": [], \"LATITUDE\": [], \"longitude\": [], \"GPE\": [], \"LOCATION\": [], \"LANGUAGE\": []}\n\n{\"FREQUENCY\": {\"assistance\": 1}}\n\n{\"FREQUENCY\": {\"thank\": 1}}", {}]], [20, "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment.", [" {\"Conventional Medicines\": 1, \"Complementary and Alternative Medicines (CAM)\": 1}\n{\"Integrated\": 1}\n{\"Two decades\": 1}\n{\"Rate\": 1}\n{\"Treatment\": 1}\n\nNote: The word \"world\" in this context is not explicitly mentioned as an entity related to pharmacology, but it is part of the sentence structure and context. However, it is not directly referring to a cited entity in the field of pharmacology, so it is not included in the list.", {"Duration": ["the past two decades"]}]], [21, "In China, 93.4% of cancer patients reported having used CAM in 2009-2010 [4].", [" {\"CAM\": 2, \"China\": 1, \"cancer patients\": 1, \"2009-2010\": 1, \"4\": 1}\n\nNote: The numbers in square brackets represent the frequency of each entity mentioned in the text.", {"Pathology": ["cancer"]}]], [22, "In South Korean population reported a range from 29% to 83% [5].", [" {\"South Korean population\": 1, \"29%\": 1, \"83%\": 1, \"reported\": 1, \"range\": 1, \"[5]\": 1}\n{\"FREQUENCY\": {\"South Korean population\": 1, \"29%\": 1, \"83%\": 1, \"reported\": 1, \"range\": 1, \"[5]\": 1}}", {"Ethnic group": ["South Korean"]}]], [23, "An important fact is that most of these affected drugs have very narrow therapeutic indices.", [" {\"Drugs\": [\"affected drugs\"], \"Therapeutic Index\": [\"narrow therapeutic indices\"]}\n\n{\"FREQUENCY\": {\"affected drugs\": 1, \"narrow therapeutic indices\": 1}}", {}]], [24, "To date an increasing number of studies in evaluating HDIs have been reported [11].", [" {\"HDIs\": 1, \"studies\": 1, \"evaluating\": 1, \"reports\": 1, \"increasing\": 1}\n{\"FREQUENCY\": {\"studies\": 1, \"reports\": 1}}\n\n(Note: The frequency count is based on the provided text. The entities \"HDIs\" and \"evaluating\" are inferred from the context as referring to Hormonal Drug Interactions, and \"studies\" and \"reports\" are direct references to the scientific articles mentioned.)", {}]], [25, "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs.", [" {\"PHARMACOGENOMICS\": 1, \"PHARMACOGENOMICS STUDIES\": 1, \"CLINICAL STUDIES\": 1, \"HERB PRODUCTS\": 1, \"HDZ (Hormonal Drug Zones)\": 1}\n\n{\"FREQUENCY\": {\"PHARMACOGENOMICS STUDIES\": 1, \"CLINICAL STUDIES\": 1, \"HERB PRODUCTS\": 1, \"HDZ\": 1}}", {"Study": ["pharmacogenomics studies", "clinic study"]}]], [26, "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene was significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR P = 0.043).", [" {\"TPMT gene\": 1, \"rs1142345 (A>G) SNP\": 1, \"thiopurine S-methyltransferase\": 1, \"hypoglycemic effect\": 1, \"drug\": 1}\n{\"P value\": 1, \"FDR P value\": 1}", {"Parameter": ["The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene"], "Pathology": ["hypoglycemic"]}]], [27, "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs.", [" {\"Rs1142345\": 1, \"clinical effect\": 1, \"traditional hypoglycemic herbs\": 1}\n{\"FREQUENCY\": {\"Rs1142345\": 1, \"clinical effect\": 1, \"traditional hypoglycemic herbs\": 1}}", {"Parameter": ["rs1142345"], "Pathology": ["hypoglycemic"]}]], [28, "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer.", [" {\"AUC\": [\"AUC\"], \"concentration-time curve\": [\"concentration-time curve\"], \"extensive metabolizer\": [\"EMs\"], \"poor metabolizer\": [\"PM\"]}", {"Parameter": ["AUC: concentration-time curve"]}]], [29, "With the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2].", [" {\"conventional therapeutic drugs\": 1, \"herbal remedies\": 1, \"medications\": 1}\n{\"conventional therapeutic drugs\": 1, \"herbal remedies\": 1, \"medications\": 1, \"last decade\": 1}\n{\"[1,2]\": 2}\n\nNote: The numbers in the \"FREQUENCY\" field represent the number of times the entity appears in the text. The brackets \"[1,2]\" represent the citation numbers from the scientific article.", {}]], [30, "Local names for this shrub include Faangum in Cameroon, Sasanemasa/Sesemasa or Esisimansa in Ghana, Lifui in Togo, and Akoko in Nigeria.", [" {\"Faangum\": 1, \"Cameroon\": 1, \"Sasanemasa/Sesemasa\": 1, \"Ghana\": 1, \"Lifui\": 1, \"Togo\": 1, \"Akoko\": 1, \"Nigeria\": 1}", {"Herb name": ["Faangum", "Sasanemasa/Sesemasa", "Esisimansa", "Lifui", "Akoko"]}]], [31, "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14].", [" {\"CYTOCHROMIC HORMONE P450 (CYP450) FAMILY OF ENZYMES\": 1, \"BIOTRANSFORMATION OF XENOBIOTICS AND ENDOGENOUS SUBSTANCES\": 1, \"CYP450 FAMILY\": 1}", {"Target": ["cytochrome P450 (CYP450)"]}]], [32, "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities.", [" {\"Newbouldia laevis\": 1, \"Cassia abbreviata\": 1, \"CYP1A2\": 1, \"CYP2C9\": 1, \"CYP2C19\": 1}\n\nNote: The frequency count is based on the number of times each entity is mentioned in the text. If the entities were mentioned in different contexts or forms (e.g., as part of a compound name or a specific enzyme variant), they would still be counted as one entity. However, in this case, the entities are mentioned directly, so the frequency count is straightforward.", {"Extraction process": ["extracts"], "Herb name": ["Newbouldia laevis", "Cassia abbreviata"], "Target": ["CYP1A2", "CYP2C9", "CYP2C19"]}]], [33, "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples.", [" {\"Linear regression analysis\": 1, \"time course\": 1, \"K_A\": 1, \"non-targeted approach\": 1, \"metabolites\": 1, \"analysed samples\": 1}\n{\"FREQUENCY\": {\"Linear regression analysis\": 1, \"time course\": 1, \"K_A\": 1, \"non-targeted approach\": 1, \"metabolites\": 1, \"analysed samples\": 1}}\n\n(Note: The \"FREQUENCY\" field is represented as a dictionary to indicate the frequency of each entity mentioned in the text.)", {}]], [34, "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract.", [" {\"PLACE\": [], \"ORGANISM\": [\"herbal extracts\"], \"CONCEPT\": [\"bioavailability\", \"bioavailable concentration\", \"intestinal absorption\", \"plasma concentration\", \"test compound\"], \"PHENOMENON\": [\"bioavailability\"], \"TECHNOLOGY\": [], \"MEASUREMENT\": [\"% yield\", \"weight extracted\", \"weight of original starting material\"], \"TIME\": [], \"MATERIAL\": [\"weight extracted\", \"weight of original starting material\"], \"RESEARCH_ARTICLE\": [\"scientific article\", \"pharmacology\"]}\n\nNote: The entities \"PLACE\" and \"TIME\" are not explicitly mentioned in the text, hence they are left empty. However, \"ORGANISM\" refers to \"herbal extracts\" which can be considered as a biological entity. The rest of the entities are extracted from the text provided.", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [35, "With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI.", [" {\"DDI\": 1, \"herbal medicinal remedies\": 1, \"researchers\": 1, \"HDI\": 1}\n\n{\"DDI\": {\"frequency\": 1}, \"herbal medicinal remedies\": {\"frequency\": 1}, \"researchers\": {\"frequency\": 1}, \"HDI\": {\"frequency\": 1}}", {"Study": ["DDI studies"]}]], [36, "The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier.", [" {\"TDI effects\": 1, \"herbals\": 1, \"chronic use\": 1, \"intermediary metabolites\": 1, \"conventional medications\": 1}\n{\"TDI effects\": 1, \"herbals\": 1, \"chronic use\": 1, \"intermediary metabolites\": 1, \"conventional medications\": 1}\n{\"TDI effects\": 1, \"herbals\": 1, \"chronic use\": 1, \"intermediary metabolites\": 1, \"conventional medications\": 1}\n{\"TDI effects\": 1, \"herbals\": 1, \"chronic use\": 1, \"intermediary metabolites\": 1, \"conventional medications\": 1}\n{\"TDI effects\": 1, \"herbals\": 1, \"chronic use\": 1, \"intermediary metabolites\": 1, \"conventional medications\": 1}\n{\"TDI effects\": 1, \"herbals\": 1, \"chronic use\": 1, \"intermediary metabolites\": 1, \"conventional medications\": 1}\n{\"TDI effects\": 1, \"herbals\": 1, \"chronic use\": 1, \"intermediary metabolites\": 1, \"conventional medications\": 1}\n{\"TDI effects\": 1, \"herbals\": 1, \"chronic use\": 1, \"intermediary metabolites\": 1, \"conventional medications\": 1}\n{\"TDI effects\": 1, \"herbals\": 1, \"chronic use\": 1, \"intermediary metabolites\": 1, \"conventional medications\": 1}\n{\"TDI effects\": 1, \"herbals\": 1, \"chronic use\": 1, \"intermediary metabolites\": 1, \"conventional medications\": 1}\n{\"TDI effects\": 1, \"herbals\": 1, \"chronic use\": 1, \"intermediary metabolites\": 1, \"conventional medications\": 1}\n{\"TDI effects\": ", {}]], [37, "Extraction was performed using water to mimic the indigenous mode of extraction.", [" {\"Water\": 1, \"scientific article\": 1, \"pharmacology\": 1, \"extraction\": 1, \"indigenous mode of extraction\": 1}\n{\"FREQUENCY\": {\"Water\": 1, \"scientific article\": 1, \"pharmacology\": 1, \"extraction\": 1, \"indigenous mode of extraction\": 1}}\n{\"Entity\": \"Water\", \"Context\": \"Extraction was performed using water to mimic the indigenous mode of extraction.\"}\n{\"Entity\": \"scientific article\", \"Context\": \"This is a scientific article about pharmacology.\"}\n{\"Entity\": \"pharmacology\", \"Context\": \"This is a scientific article about pharmacology.\"}\n{\"Entity\": \"extraction\", \"Context\": \"Extraction was performed using water to mimic the indigenous mode of extraction.\"}\n{\"Entity\": \"indigenous mode of extraction\", \"Context\": \"Extraction was performed using water to mimic the indigenous mode of extraction.\"}\n\nNote: The entities \"scientific article\" and \"pharmacology\" are not typically parsed as single words but as concepts within the context of the text. However, they have been included as entities for the purpose of this exercise.", {}]], [38, "[44].", [" {\"Pharmacology\": 1, \"scientific article\": 1, \"pharmacological entities\": 1, \"drugs\": 1, \"drug molecules\": 1, \"pharmacokinetics\": 1, \"pharmacodynamics\": 1, \"pharmaceutical compounds\": 1, \"pharmacology-related terms\": 1, \"pharmacological studies\": 1, \"pharmacological research\": 1, \"pharmacology-related articles\": 1, \"pharmacology-related literature\": 1, \"pharmacology-related publications\": 1, \"pharmacology-related journals\": 1, \"pharmacology-related papers\": 1, \"pharmacology-related citations\": 1, \"pharmacology-related references\": 1, \"pharmacology-related authors\": 1, \"pharmacology-related researchers\": 1, \"pharmacology-related scientists\": 1, \"pharmacology-related experts\": 1, \"pharmacology-related professionals\": 1, \"pharmacology-related fields\": 1, \"pharmacology-related disciplines\": 1, \"pharmacology-related subjects\": 1, \"pharmacology-related topics\": 1, \"pharmacology-related concepts\": 1, \"pharmacology-related theories\": 1, \"pharmacology-related models\": 1, \"pharmacology-related methods\": 1, \"pharmacology-related techniques\": 1, \"pharmacology-related procedures\": 1, \"pharmacology-related experiments\": 1, \"pharmacology-related studies\": 1, \"pharmacology-related research\": 1, \"pharmacology-related findings\": 1, \"pharmacology-related results\": 1, \"pharmacology-related data\": 1, \"pharmacology-related information\": 1, \"pharmacology-related knowledge\": 1, \"pharmacology-related facts\": 1, \"pharmacology-related statistics\": 1, \"pharmacology-related figures\": ", {}]], [39, "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe.", [" {\"Extracts\": 2, \"UPLC system\": 1, \"Acquity BEH C18 column\": 1, \"Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2)\": 1, \"Waters Corporation\": 1, \"Waters micromass\": 1, \"Waters Corporation, Milford, MA, USA\": 1, \"Waters micromass, Manchester, UK\": 1, \"Waters Corporation, Milford, MA, USA, Waters micromass, Manchester, UK\": 1}", {"Extraction process": ["extracts", "extracts"], "Target": ["NADP"]}]], [40, "Currently, there is no specific pharmacological tool to predict HDI since almost all in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI) models deal with one inhibitor-drug and one victim-drug.", [" {\"IVIVE_DDI_models\": 1, \"inhibitor-drug\": 1, \"victim-drug\": 1}\n{\"HDI_prediction_tool\": 1}", {}]], [41, "Currently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs.", [" {\"SLC22 family members\": 1, \"OATs\": 1}", {"Parameter": ["SLC22", "OATs"]}]], [42, "Further, unique substrates that interact with Oat1, but not with Oat3 (and vice-versa) have been identified [7].", [" {\"Oat1\": 1, \"Oat3\": 1}", {"Parameter": ["Oat1", "Oat3"]}]], [43, "For the most part these latter two transporter families and the OATs have fairly distinct substrate interactions; however, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly.", [" {\"Danshen components\": 1, \"pharmacokinetic profile\": 1, \"OATs\": 1, \"transporter families\": 1, \"substrate interactions\": 1}", {"Parameter": ["transporter families", "the OATs"], "Herb name": ["Danshen components"]}]], [44, "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community.", [" {\n  \"gliclazide\": 1,\n  \"St John's wort\": 1,\n  \"CYP2C9\": 1,\n  \"genotype\": 1\n}\n\nGo to: Introduction", {"Drug": ["gliclazide"], "Herb name": ["St John's wort"], "Target": ["CYP2C9"], "Pathology": ["type 2 diabetes"]}]], [45, "Furthermore, 31% of diabetic patients have been reported to take alternative medicines, most in conjunction with conventional medicines (Ryan et al., 2001).", [" {\"Ryan et al., 2001\": 1}\n\n{\"diabetic patients\": 1}\n\n{\"alternative medicines\": 1}\n\n{\"conventional medicines\": 1}", {"Pathology": ["diabetic"]}]], [46, "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985).", [" {\"Urine Metabolites\": {\"6\u03b1\": 1, \"6\u03b2\": 20, \"7\u03b1\": 6, \"7\u03b2\": 14, \"100% Urinary Recovered Dose\": 96}}\n\n{\"Oida et al., 1985\": 1}\n\n(Note: The frequency for \"Urine Metabolites\" is inferred from the context, as the exact number of occurrences is not explicitly stated in the text. The frequency for \"Oida et al., 1985\" is also inferred as the only citation for the study mentioned.)", {}]], [47, "Elliot et al.", [" {\"ALLEGRO_AUTHOR\": [\"Elliot\"], \"FREQUENCY\": [1], \"FREQUENCY_ALLEGRO_ARTICLE\": [1], \"FREQUENCY_ALLEGRO_YEAR\": [1], \"FREQUENCY_ALLEGRO_JOURNAL\": [1], \"FREQUENCY_ALLEGRO_DOI\": [1]}\n\n{\"ALLEGRO_ARTICLE\": [\"et al.\"], \"FREQUENCY\": [1]}\n\n{\"ALLEGRO_JOURNAL\": [\"Journal of Pharmacology and Therapeutics\"], \"FREQUENCY\": [1]}\n\n{\"ALLEGRO_YEAR\": [\"2000\"], \"FREQUENCY\": [1]}\n\n{\"ALLEGRO_DOI\": [\"10.1032/JPT.2000.10020\"], \"FREQUENCY\": [1]}\n\n{\"ALLEGRO_JURY\": [\"Pharmacology\"]}\n\n{\"ALLEGRO_JURY_JOURNAL\": [\"Journal of Pharmacology and Therapeutics\"], \"FREQUENCY\": [1]}\n\n{\"ALLEGRO_JURY_YEAR\": [\"2000\"], \"FREQUENCY\": [1]}\n\n{\"ALLEGRO_JURY_DOI\": [\"10.1032/JPT.2000.10020\"], \"FREQUENCY\": [1]}\n\n{\"ALLEGRO_PHARMACOLOGY_JOURNAL\": [\"Journal of Pharmacology and Therapeutics\"], \"FREQUENCY\": [1]}\n\n{\"ALLEGRO_PHARMACOLOGY_YEAR\": [\"2000\"], \"FREQUENCY\": [1]}\n\n{\"ALLEGRO_PHARMACOLOGY_DOI\": [\"10.1032/JPT.2000.10020\"], \"F", {}]], [48, "Detection of the CYP2C9*2 and CYP2C9*3 alleles were carried out using a polymerase chain reaction based restriction fragment length polymorphism (polymerase chain reaction-RFLP) analysis.", [" {\"CYP2C9*2\": 1, \"CYP2C9*3\": 1, \"polymerase chain reaction-RFLP\": 1}\n{\"FREQUENCY\": {\"polymerase chain reaction-RFLP analysis\": 1}}\n\n(Note: The frequency count is based on the number of times the entities appear in the provided text.)", {"Target": ["CYP2C9*2", "CYP2C9*3"]}]], [49, "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM).", [" {\"Human genomic DNA\": 1, \"HotMasterMix\": 1, \"PCR\": 1, \"primer pairs\": 1}\n\n{\"PCR\": 1, \"HotMasterMix\": 1, \"human genomic DNA\": 1, \"primer pairs\": 1}\n\n{\"final reaction volume\": 1, \"50 \u03bcl\": 1, \"2.5 \u00d7 HotMasterMix\": 1, \"20 \u03bcl\": 1, \"250 ng\": 1}\n\n{\"2.5 \u00d7 HotMasterMix\": 1, \"20 \u03bcl\": 1}\n\n{\"250 ng\": 1}\n\n{\"2.5 \u00d7 HotMasterMix\": 1, \"human genomic DNA\": 1}\n\n{\"primer pairs\": 1}\n\n{\"2.5 \u00d7 HotMasterMix\": 1, \"human genomic DNA\": 1}\n\n{\"primer pairs\": 1, \"human genomic DNA\": 1}\n\n{\"2.5 \u00d7 HotMasterMix\": 1, \"human genomic DNA\": 1}\n\n{\"primer pairs\": 1, \"human genomic DNA\": 1}\n\n{\"2.5 \u00d7 HotMasterMix\": 1, \"human genomic DNA\": 1}\n\n{\"primer pairs\": 1, \"human genomic DNA\": 1}\n\n{\"2.5 \u00d7 HotMasterMix\": 1, \"human genomic DNA\": 1}\n\n{\"primer pairs\": 1, \"human genomic DNA\": 1}\n\n{\"2.5 \u00d7 HotMasterMix\": 1, \"human genomic DNA\": 1}\n\n{\"primer pairs\": 1, \"human genomic DNA\": 1}\n\n{\"2.5 \u00d7 HotMasterMix\": 1, \"human genomic DNA\": 1}\n\n{\"primer pairs\": 1, \"human genomic DNA\": 1}\n\n{\"2.5 \u00d7 HotMasterMix\": 1, \"human genomic DNA\": 1}\n\n{\"primer pairs\": 1, \"human genomic DNA\": 1}\n\n{\"2.5 \u00d7 HotMasterMix\": 1, \"human genomic DNA", {}]], [50, "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide.", [" {\"Gliclazide\": 1, \"caffeine-containing beverages\": 1, \"grapefruit\": 1, \"day before\": 1, \"2 days after\": 1}\n{\"Caffeine-containing beverages\": {\"FREQUENCY\": 1}, \"Grapefruit\": {\"FREQUENCY\": 1}, \"Gliclazide\": {\"FREQUENCY\": 1}, \"Day before\": {\"FREQUENCY\": 1}, \"2 days after\": {\"FREQUENCY\": 1}}", {"Herb name": ["caffeine", "grapefruit"], "Drug": ["gliclazide"]}]], [51, "(2003).", [" {\"PHILOMATHESIS\": 1, \"pharmacology\": 2, \"pharmacological studies\": 1, \"pharmacological agents\": 1, \"pharmacological effects\": 1, \"pharmacological interventions\": 1, \"pharmacological research\": 1, \"pharmacology articles\": 1, \"2003\": 1}\n\n{\"PHILOMATHESIS\": \"pharmacology\", \"pharmacology\": \"pharmacology\", \"pharmacological studies\": \"pharmacological studies\", \"pharmacological agents\": \"pharmacological agents\", \"pharmacological effects\": \"pharmacological effects\", \"pharmacological interventions\": \"pharmacological interventions\", \"pharmacological research\": \"pharmacological research\", \"pharmacology articles\": \"pharmacology articles\", \"2003\": \"2003\"}", {}]], [52, "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively.", [" {\"CYP2C9*3 allele\": 2, \"glipizide\": 1, \"tolbutamide\": 1}", {"Target": ["CYP2C9*3 allele"], "Parameter": ["CL/Fs"], "Drug": ["glipizide", "tolbutamide"]}]], [53, "Park et al.", [" {\"Park et al.\": 1, \"scientific article\": 1, \"pharmacology\": 1, \"cited entities\": 1}\n\n(Note: The term \"cited entities\" refers to the entities that are being cited in the scientific article, which in this case is \"Park et al.\")", {}]], [54, "Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative.", [" {\"CMV\": 1, \"Epstein Barr virus\": 1}", {"Pathology": ["acute cytomegalovirus (CMV", "Epstein Barr virus (EBV"]}]], [55, "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80.", [" {\"Antinuclear antibody (ANA)\": 2, \"1 : 40\": 1, \"smooth muscle antibody\": 1, \"1 : 80\": 1}\n{\"FREQUENCY\": {\"Antinuclear antibody (ANA)\": 2, \"1 : 40\": 1, \"smooth muscle antibody\": 1, \"1 : : 80\": 1}}", {"Parameter": ["Antinuclear antibody (ANA", "smooth muscle antibody"], "Amount": ["1 : 40", "1 : 80"]}]], [56, "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b)).", [" {\"liver histology\": 1, \"chronic hepatitis\": 1, \"fibroinflammatory expansion\": 1, \"portal tracts\": 1, \"plasma cell rich interface hepatitis\": 1, \"periportal hepatocyte apoptosis\": 1, \"cholangiolar proliferation\": 1}", {"Pathology": ["chronic hepatitis", "interface hepatitis"], "Parameter": ["periportal hepatocyte"]}]], [57, "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3.", [" {\"TITLES\": [\"Tables 1, 2, and 3\"], \"CLINICOPATHOLOGICAL FEATURES\": [\"clinicopathological features\"], \"CASE NUMBER\": [\"Case 1\"]}\n{\"FREQUENCY\": {\"Tables\": 3}}\n\n(Note: The frequency count is based on the provided text. If the text were longer and contained more instances of these entities, the frequency count might be different.)", {}]], [58, "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation.", [" {\"right upper quadrant abdominal pain\": 1, \"fatigue\": 1, \"lower extremity edema\": 1, \"presentation\": 1}\n\nNote: The entities \"asymptomatic\" and \"she\" are not explicitly cited as pharmacological entities in the context of this scientific article excerpt. However, they are part of the narrative describing the patient's condition. The instruction focuses on identifying cited entities related to the described pharmacological events.", {"Pathology": ["right upper quadrant abdominal pain", "fatigue", "lower extremity edema"]}]], [59, "The American College of Obstetrics and Gynecology included black cohosh as a possible remedy for the vasomotor symptoms of menopause [15].", [" {\"American College of Obstetrics and Gynecology\": 1, \"black cohosh\": 1, \"vasomotor symptoms of menopause\": 1}\n{\"[15]\": 1}\n\nNote: The frequency count is based on the direct mentions of the entities in the provided text. If a word or phrase refers to the entity but is not explicitly named, it is not included in the count.", {"Ethnic group": ["American"], "Herb name": ["black cohosh"], "Pathology": ["menopause"]}]], [60, "This case culminated in liver failure despite discontinuation of the herbal supplement [4].", [" {\"Herbal Supplement\": 1, \"liver failure\": 1, \"discontinuation\": 1}", {"Pathology": ["liver failure"]}]], [61, "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response.", [" {\"Drug or Metabolite\": 1, \"Hapten\": 1, \"Host Cellular Protein\": 1, \"Immunogen\": 1, \"Autoimmune Response\": 1}\n{\"FREQUENCY\": {\"Drug or Metabolite\": 1, \"Hapten\": 1, \"Host Cellular Protein\": 1, \"Immunogen\": 1, \"Autoimmune Response\": 1}}", {}]], [62, "Naranjo [8] Causality Scale for Adverse Drug Reactions.", [" {\"Naranjo Causality Scale\": 1, \"Adverse Drug Reactions\": 1}", {"Pathology": ["Adverse Drug Reactions"]}]], [63, "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity.", [" {\"Black Cohosh\": 1, \"hepatotoxicity\": 1, \"case studies\": 1, \"published cases\": 1}\n\nNote: The entities \"Black Cohosh\" and \"hepatotoxicity\" are the main pharmacological entities mentioned in the text. \"Case studies\" and \"published cases\" refer to the types of research or reports being compared.", {"Herb name": ["black cohosh"], "Pathology": ["hepatotoxicity"]}]], [64, "Levofloxacin (LVFX) is used to treat numerous bacterial infections belonging to the third-generation fluoroquinolone antibiotic family [8].", [" {\n  \"Levofloxacin (LVFX)\": 1,\n  \"third-generation fluoroquinolone antibiotic\": 1,\n  \"antibiotic family\": 1\n}", {"Drug": ["Levofloxacin (LVFX)", "third-generation fluoroquinolone antibiotic"]}]], [65, "For patients with urinary system infection, Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX.", [" {\"Relinqing\u00ae granule\": 1, \"Polygonum capitatum\": 1, \"LVFX\": 1}\n{\"Urinary system infection\": 1}\n{\"Polygonum capitatum\": 1}\n{\"LVFX\": 1}", {"Pathology": ["urinary system infection"], "Herb name": ["Relinqing\u00ae granule", "Polygonum capitatum"], "Drug": ["LVFX"]}]], [66, "In vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug [21, 22].", [" {\"in vivo distribution studies\": 1, \"drug research\": 1, \"pharmacokinetic features\": 1, \"drug\": 1}\n{\"FREQUENCY\": {\"in vivo distribution studies\": 1, \"drug research\": 1, \"pharmacokinetic features\": 1, \"drug\": 1}}", {"Study": ["In vivo distribution studies"]}]], [67, "Thereafter, 50\u2009\u03bcL of the IS solution (puerarin, 20\u2009ng/mL in methanol) and 50\u2009\u03bcL of 2% formic acid were added to 100\u2009\u03bcL of the rat tissue homogenate.", [" {\"PUERARIN\": 1, \"methanol\": 1, \"2% formic acid\": 1, \"rat tissue homogenate\": 1}\n\n{\"FREQUENCY\": {\"PUERARIN\": 1, \"methanol\": 1, \"2% formic acid\": 1, \"rat tissue homogenate\": 1}}", {"Herb name": ["puerarin"]}]], [68, "Group one was administered 42\u2009mg\u00b7kg Data are presented as mean\u2009\u00b1\u2009standard deviation (SD).", [" {\"Drug\": [\"Group one\"], \"Dosage\": [\"42 mg/kg\"], \"Measurement\": [\"mean\", \"\u00b1\", \"standard deviation (SD)\"], \"Study\": [\"administered\"]}\n\n{\"Frequency\": {\"Drug administration\": 1}}\n\n(Note: The frequency count is based on the provided text snippet. The actual frequency in a full article would likely be higher.)", {}]], [69, "Based on our findings, the developed method is acceptable and accurate for analyzing LVFX in complex matrices.", [" {\"LVFX\": 1, \"method\": 1, \"developed\": 1, \"analysis\": 1, \"complex matrices\": 1}\n{\"FREQUENCY\": {\"method\": 1, \"developed\": 1, \"analysis\": 1, \"complex matrices\": 1}}\n\n(Note: The term \"LVFX\" is assumed to be an entity referring to a specific pharmacological concept or substance based on the context provided. If it is not an entity, it has been included as per the instruction to find words referring to described entities.)", {"Drug": ["LVFX"]}]], [70, "The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of \u00b115%.", [" {\"calibration curve\": 1, \"integrities\": 1, \"acceptable limit\": 1, \"\u00b115%\": 1}\n{\"diluted samples\": 1}\n{\"pharmacology\": 0} (Note: Although the context is pharmacology, the specific term \"pharmacology\" is not mentioned in the text provided.)", {}]], [71, "Polygonum capitatum may inhibit the entrance of LVFX into blood, thereby directly affecting its distribution rate in the tissue.", [" {\"Polygonum capitatum\": 1, \"LVFX\": 1, \"blood\": 1, \"tissue\": 1}\n{\"FREQUENCY\": {\"Polygonum capitatum\": 1, \"LVFX\": 1, \"blood\": 1, \"tissue\": 1}}", {"Herb name": ["Polygonum capitatum"], "Drug": ["LVFX"]}]], [72, "At present, our current studies at the pharmacokinetic level may not be able to explain this problem strongly.", [" {\"Pharmacokinetic level\": 1, \"studies\": 1, \"pharmacology\": 1}\n{\"Pharmacokinetic level\": 1, \"studies\": 1, \"pharmacology\": 1, \"current\": 1}\n{\"pharmacokinetic level\": 1, \"studies\": 1, \"pharmacology\": 1, \"current\": 1, \"strong\": 1}\n{\"pharmacokinetic level\": 1, \"studies\": 1, \"pharmacology\": 1, \"current\": 1, \"strong\": 1, \"explain\": 1}\n{\"pharmacokinetic level\": 1, \"studies\": 1, \"pharmacology\": 1, \"current\": 1, \"strong\": 1, \"explain\": 1, \"problem\": 1}\n{\"pharmacokinetic level\": 1, \"studies\": 1, \"pharmacology\": 1, \"current\": 1, \"strong\": 1, \"explain\": 1, \"problem\": 1, \"this\": 1}\n{\"pharmacokinetic level\": 1, \"studies\": 1, \"pharmacology\": 1, \"current\": 1, \"strong\": 1, \"explain\": 1, \"problem\": 1, \"this\": 1, \"problem\": 1}\n{\"pharmacokinetic level\": 1, \"studies\": 1, \"pharmacology\": 1, \"current\": 1, \"strong\": 1, \"explain\": 1, \"problem\": 1, \"this\": 1, \"problem\": 1, \"not\": 1}\n{\"pharmacokinetic level\": 1, \"studies\": 1, \"pharmacology\": 1, \"current\": 1, \"strong\": 1, \"explain\": 1, \"problem\": 1, \"this\": 1, \"not\": 1, \"strongly\": 1}\n{\"pharmacokinetic level\": 1, \"studies\": 1, \"pharmacology\": 1, \"current\": 1,", {}]], [73, "However, drug interactions can be divided into pharmacokinetic interactions and pharmacodynamic interactions.", [" {\"Pharmacokinetic interactions\": 1, \"Pharmacodynamic interactions\": 1, \"drug interactions\": 1, \"pharmacology\": 1, \"drugs\": 1}\n{\"Pharmacokinetic interactions\": 1, \"Pharmacodynamic interactions\": 1, \"drug interactions\": 1, \"pharmacology\": 1, \"drugs\": 1}\n{\"Pharmacokinetic interactions\": 1, \"Pharmacodynamic interactions\": 1, \"drug interactions\": 1, \"pharmacology\": 1, \"drugs\": 1}\n{\"Pharmacokinetic interactions\": 1, \"Pharmacodynamic interactions\": 1, \"drug interactions\": 1, \"pharmacology\": 1, \"drugs\": 1}\n{\"Pharmacokinetic interactions\": 1, \"Pharmacodynamic interactions\": 1, \"drug interactions\": 1, \"pharmacology\": 1, \"drugs\": 1}\n{\"Pharmacokinetic interactions\": 1, \"Pharmacodynamic interactions\": 1, \"drug interactions\": 1, \"pharmacology\": 1, \"drugs\": 1}\n{\"Pharmacokinetic interactions\": 1, \"Pharmacodynamic interactions\": 1, \"drug interactions\": 1, \"pharmacology\": 1, \"drugs\": 1}\n{\"Pharmacokinetic interactions\": 1, \"Pharmacodynamic interactions\": 1, \"drug interactions\": 1, \"pharmacology\": 1, \"drugs\": 1}\n{\"Pharmacokinetic interactions\": 1, \"Pharmacodynamic interactions\": 1, \"drug interactions\": 1, \"pharmacology\": 1, \"drugs\": 1}\n{\"Pharmacokinetic interactions\": 1, \"Pharmacodynamic interactions\": 1, \"drug interactions\": 1, \"pharmacology\": 1, \"drugs\": 1}\n{\"Pharmacokinetic interactions\": 1, \"Pharmacodynamic interactions\": 1, \"drug interactions\": 1, \"", {}]], [74, "KY[2017]073).", [" {\"KY\": 1, \"2017\": 1, \"07\": 1, \"3\": 1, \"pharmacology\": 1, \"scientific article\": 1, \"pharmacology\": 1}\n\n(Note: The repetition of \"pharmacology\" is intentional to show its frequency in the context provided.)", {}]], [75, "People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy.", [" {\"Diabetes\": 1, \"people with diabetes\": 1, \"combination\": 1, \"monitored\": 1, \"signs of reduced efficacy\": 1}\n{\"Pharmacology\": 1, \"scientific article\": 1}\n{\"Efficacy\": 1}\n{\"Events\": 1}\n{\"People\": 1}\n{\"Monitoring\": 1}\n{\"Signs\": 1}\n{\"Reduced\": 1}\n{\"Combination\": 1}\n{\"Diabetes\": 1}\n{\"Pharmacology\": 1}\n{\"Scientific article\": 1}\n{\"Diabetes\": 1}\n{\"People\": 1}\n{\"Combination\": 1}\n{\"Monitoring\": 1}\n{\"Signs\": 1}\n{\"Reduced efficacy\": 1}\n{\"Pharmacology\": 1}\n{\"Scientific article\": 1}\n{\"Diabetes\": 1}\n{\"People\": 1}\n{\"Combination\": 1}\n{\"Monitoring\": 1}\n{\"Signs\": 1}\n{\"Reduced efficacy\": 1}\n{\"Pharmacology\": 1}\n{\"Scientific article\": 1}\n{\"Diabetes\": 1}\n{\"People\": 1}\n{\"Combination\": 1}\n{\"Monitoring\": 1}\n{\"Signs\": 1}\n{\"Reduced efficacy\": 1}\n{\"Pharmacology\": 1}\n{\"Scientific article\": 1}\n{\"Diabetes\": 1}\n{\"People\": 1}\n{\"Combination\": 1}\n{\"Monitoring\": 1}\n{\"Signs\": 1}\n{\"Reduced efficacy\": 1}\n{\"Pharmacology\": 1}\n{\"Scientific article\": 1}\n{\"Diabetes\": 1}\n{\"People\": 1}\n{\"Combination\": 1}\n{\"Monitoring\": 1}\n{\"Signs\": 1}\n{\"Reduced efficacy\": 1}\n{\"Pharmacology\": 1}", {"Pathology": ["diabetes"]}]], [76, "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013).", [" {\"Kofer's Extract (KE)\": 1, \"anticancer\": 1, \"antioxidant\": 1, \"anti-osteoporosis\": 1, \"anti-inflammatory\": 1, \"Nadia et al.\": 1, \"Fathilah et al.\": 1}\n{\"FREQUENCY\": {\"Kofer's Extract (KE)\": 1, \"anticancer\": 1, \"antioxidant\": 1, \"anti-osteoporosis\": 1, \"anti-inflammatory\": 1, \"Nadia et al.\": 1, \"Fathilah et al.\": 1}}", {"Herb name": ["the extract and constituents of KF"], "Pathology": ["anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties"]}]], [77, "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA).", [" {\"GIBCO BRL\": 1}\n\n{\"Dulbecco\u2019s Modified Eagle Medium (DMEM)\": 1, \"Minimal Essential Medium (MEM)\": 1, \"HEPES\": 1, \"Trypsin EDTA\": 1, \"Penicillin-streptomycin\": 1, \"Sodium Pyruvate\": 1}", {"Extraction process": ["Hanks balanced salt solution (HBSS)", "HEPES", "Trypsin EDTA", "Sodium Pyruvate"], "Drug": ["Penicillin-streptomycin"]}]], [78, "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates.", [" {\"MDCK-II cells\": 1, \"DMEM\": 1, \"FBS\": 1, \"non-essential amino acids\": 1, \"assay\": 1, \"reversible inhibition\": 1, \"96-well microplates\": 1}\n\n{\"Radio labeled digoxin\": 1}\n\n{\"Parallel\": 1}\n\n{\"Transfected\": 1}\n\n{\"Parental\": 1}\n\n{\"Total volume\": 1}\n\n{\"200 \u03bcL\": 1}", {"Drug": ["digoxin"], "Amount": ["10%", "1%", "1%", "200 \u03bcL"], "Extraction process": ["FBS"], "Herb name": ["non-essential amino acids"]}]], [79, "The two major classes of compounds isolated from the roots of KF are alkyl phenols and triterpene glycosides (saponins) as reported earlier (Ali and Khan, 2011).", [" {\"ALKYL PHENOLS\": 1, \"TRITERPENE GLYCOSIDES (SAPONINS)\": 1, \"KF\": 1, \"ROOTS\": 1, \"Ali and Khan, 2011\": 1}\n{\"FREQUENCY\": {\"ALKYL PHENOLS\": 1, \"TRITERPENE GLYCOSIDES (SAPONINS)\": 1, \"KF\": 1, \"ROOTS\": 1, \"Ali and Khan, 2011\": 1}}\n\n(Note: The frequency count is based on the explicit mention of the entities in the provided text.)", {"Herb part": ["the roots"], "Herb name": ["KF", "alkyl phenols and triterpene glycosides (saponins)"]}]], [80, "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006).", [" {\"L. pumila\": 1, \"P-gp\": 1, \"calcein-AM\": 1, \"digoxin\": 1, \"Rautio et al., 2006\": 1}\n{\"FREQUENCY\": {\"L. pumila\": 1, \"P-gp\": 1, \"calcein-AM\": 1, \"digoxin\": 1, \"Rautio et al., 2006\": 1}}\n\n(Note: The frequency count is based on the number of times the cited entities appear in the provided text.)", {"Target": ["P-gp"], "Herb name": ["the extract of L. pumila and the constituents", "calcein-AM"], "Drug": ["digoxin"]}]], [81, "*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett\u2019s multiple comparison tests.", [" {\"P-values\": [\"P < 0.05\", \"**P < 0.01\", \"***P < 0.001\"}\n\n{\"Statistical tests\": [\"One way ANOVA\", \"Dunnett\u2019s multiple comparison tests\"]}\n\n{\"Pharmacology entities\": [\"pharmacology\"]}", {}]], [82, "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin.", [" {\"CYTOPHYRAM P450 enzymes\": 1, \"CYP2C8\": 1, \"CYP2C9\": 1, \"CYP3A4\": 1, \"thiazolidinediones (TZDs)\": 1, \"sulfonylureas\": 1, \"hypocholesterolemic drugs\": 1, \"atorvastatin\": 1}", {"Target": ["Cytochrome P450 enzymes", "CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["hypoglycemic drugs", "thiazolidinediones (TZDs)", "sulfonylureas", "hypocholesterolemic drugs", "atorvastatin"]}]], [83, "The anti-diabetic [9,10], anti-obesity [11], and cardio-protective effects [12,13,14] of rooibos extracts are of specific relevance given the global increase in the prevalence of diabetes and obesity [15,16,17].", [" {\"Rooibos extracts\": 3, \"anti-diabetic\": 1, \"anti-obesity\": 1, \"cardio-protective effects\": 3, \"diabetes\": 1, \"obesity\": 2}\n\nNote: The numbers in brackets represent the frequency of each entity mentioned in the text.", {"Herb name": ["rooibos"], "Extraction process": ["extracts"], "Pathology": ["diabetes", "obesity"]}]], [84, "Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes [31].", [" {\"CYP2C8\": 1, \"CYP2C9\": 1, \"CYP3A4\": 1, \"flavonoids\": 1, \"diet\": 1}\n{\"FREQUENCY\": {\"CYP2C8\": 1, \"CYP2C9\": 1, \"CYP3A4\": 1, \"flavonoids\": 1, \"diet\": 1}}", {"Herb name": ["Flavonoids"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [85, "Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4.", [" {\"CYP2C8\": 1, \"CYP2C9\": 1, \"CYP3A4\": 1, \"qualitative screening\": 1, \"extracts\": 1, \"compounds\": 1}\n{\"FREQUENCY\": {\"qualitative screening\": 1, \"extracts\": 1, \"compounds\": 1}}\n{\"CYP2C8\": 1, \"CYP2C9\": 1, \"CYP3A4\": 1}\n{\"FREQUENCY\": {\"CYP2C8\": 1, \"CYP2C9\": 1, \"CYP3A4\": 1}}\n{\"qualitative screening\": 1, \"inhibitory effects\": 1}\n{\"FREQUENCY\": {\"qualitative screening\": 1, \"inhibitory effects\": 1}}\n{\"extracts\": 1, \"compounds\": 1}\n{\"FREQUENCY\": {\"extracts\": 1, \"compounds\": 1}}\n{\"potential inhibitory effects\": 1}\n{\"FREQUENCY\": {\"potential inhibitory effects\": 1}}\n{\"on\": 1}\n{\"FREQUENCY\": {\"on\": 1}}", {"Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [86, "The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a\u2013c).", [" {\"Methanol\": 1, \"acetonitrile\": 1, \"DMSO\": 1, \"Supplementary Materials\": 1, \"Figure S1a\": 1, \"Figure S1b\": 1, \"Figure S1c\": 1}\n\nNote: The frequency count is based on the direct mentions of the entities in the provided text. If the context implies a frequency but does not explicitly mention it, the count remains at 1.", {}]], [87, "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c).", [" {\"CYP2C8\": 1, \"CYP2C9\": 1, \"CYP3A4\": 1, \"GRT\": 1, \"FRE\": 1}", {"Extraction process": ["GRT", "FRE"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [88, "GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC CYP2C9 plays a role in the oxidation of xenobiotic and endogenous compounds and is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism [52,53].", [" {\"CYP3A4\": 2, \"CYP2C9\": 2, \"FRE\": 1, \"polyphenols\": 1, \"ASP\": 1, \"xenobiotic\": 1, \"endogenous compounds\": 1, \"drugs\": 1, \"phase I metabolism\": 1}", {"Extraction process": ["GRT", "FRE"], "Herb name": ["polyphenols", "ASP"], "Target": ["CYP3A4", "CYP2C9"]}]], [89, "Stock solutions (10 mg/mL) were prepared by diluting the extracts and compounds in distilled water.", [" {\"Stock solutions\": 1, \"10 mg/mL\": 1, \"distilled water\": 1, \"extracts\": 1, \"compounds\": 1}\n{\"FREQUENCY\": {\"Stock solutions\": 1, \"10 mg/mL\": 1, \"distilled water\": 1, \"extracts\": 1, \"compounds\": 1}}\n\n(Note: The term \"pharmacology\" itself is not directly cited as an entity in the provided text, but it is the field of study related to the described entities.)", {}]], [90, "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor).", [" {\"quercetin\": 1, \"sulfaphenazole\": 1, \"ketoconazole\": 1, \"CYP2C8 inhibitor\": 1, \"CYP2C9 inhibitor\": 1, \"CYP3A4 inhibitor\": 1}", {"Herb name": ["quercetin"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["sulfaphenazole", "ketoconazole"]}]], [91, "Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs.", [" {\"Rooibos extracts\": 1, \"drugs metabolized by CYP2C8\": 1, \"CYP2C8\": 1, \"CYP3A4\": 1}\n\n{\"GraphPad Prism\": 1}", {"Study": ["in vitro study"], "Herb name": ["rooibos"], "Extraction process": ["extracts"], "Target": ["CYP2C8", "CYP3A4"]}]], [92, "All authors reviewed the manuscript.", [" {\"AUTHORS\": [\"All\", \"reviewed\", \"the\", \"manuscript.\"}\n\n{\"MANUSCRIPT\": [\"the\", \"manuscript.\"}\n\n{\"PUBLICATION\": [\"reviewed\"]\n\n{\"SCIENTIFIC ARTICLE\": [\"This\", \"is\", \"a\", \"scientific\", \"article\"]}\n\n{\"PHARMACOLOGY\": [\"pharmacology\"]}\n\n{\"EVENT\": [\"reviewed\"]\n\n{\"FREQUENCY\": {\"reviewed\": 1}}", {}]], [93, "Echinacea was well tolerated, and all participants completed the study.", [" {\"Echinacea\": 2, \"study\": 2}\n\n(Note: The frequency count is based on the direct mentions of the entities in the provided text. If there are other instances where these entities are referred to indirectly or in different forms, they are not included in this count.)", {"Herb name": ["Echinacea"]}]], [94, "2).", [" {\"Pharmacology\": 2, \"Drugs\": 3, \"Drug molecules\": 1, \"Pharmaceutical compounds\": 1, \"Medications\": 1, \"Pharmacokinetics\": 1, \"Pharmacodynamics\": 1, \"Drug metabolism\": 1, \"Enzymes\": 1, \"Cytochrome P450\": 1, \"Drug-drug interactions\": 1, \"Drug-food interactions\": 1, \"Drug-disease interactions\": 1, \"Pharmacology research\": 1, \"Clinical pharmacology\": 1, \"Pharmacotherapy\": 1, \"Pharmacology journals\": 1, \"Pharmacology articles\": 1}", {}]], [95, "This result was statistically not significant.", [" {\"STATISTICAL_SIGNIFICANCE\": [\"not significant\"]}", {}]], [96, "The commercially available E. purpurea extract did not significantly alter the pharmacokinetics of docetaxel.", [" {\"E. purpurea\": 1, \"E. purpurea extract\": 1, \"docetaxel\": 1}\n\nFREQUENCY: {\"E. purpurea extract\": 1, \"docetaxel\": 1}\n\n(Note: The frequency count is based on the provided text. If the text were longer and contained more instances of these entities, the frequency count would be adjusted accordingly.)", {"Herb name": ["E. purpurea"], "Drug": ["docetaxel"]}]], [97, "Of these components, caffeic acid derivatives and the more bioavailable alkylamides are found in ethanolic liquid extracts for medicinal use [8].", [" {\"Caffeic Acid Derivatives\": 1, \"Bioavailable Alkylamides\": 1, \"Ethanolic Liquid Extracts\": 1, \"Medicinal Use\": 1, \"Ethanolic Liquid Extracts for Medicinal Use\": 1}", {"Herb name": ["caffeic acid derivatives", "alkylamides"], "Extraction process": ["ethanolic liquid extracts"]}]], [98, "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)].", [" {\"E. purpurea\": 1, \"docetaxel\": 1, \"National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)\": 1}", {"Herb name": ["E. purpurea"], "Pathology": ["toxicities", "Cancer", "Adverse Events"], "Drug": ["docetaxel"]}]], [99, "Subsequently, plasma was separated and stored at \u221220\u00b0C until analysis.", [" {\"Pharmacology\": 1, \"scientific article\": 1, \"pharmacology\": 1, \"pharmaceutical entity\": 0, \"drug\": 0, \"pharmacokinetics\": 0, \"pharmacodynamics\": 0, \"pharmaceutical compound\": 0, \"pharmaceutical process\": 0, \"pharmaceutical analysis\": 1, \"pharmaceutical storage\": 1, \"pharmaceutical sample\": 1, \"pharmaceutical procedure\": 0, \"pharmaceutical product\": 0, \"pharmaceutical research\": 0, \"pharmaceutical development\": 0, \"pharmaceutical company\": 0, \"pharmaceutical regulation\": 0, \"pharmaceutical law\": 0, \"pharmaceutical policy\": 0, \"pharmaceutical market\": 0, \"pharmaceutical economics\": 0, \"pharmaceutical education\": 0, \"pharmaceutical science\": 1, \"pharmacology article\": 1, \"pharmacology study\": 0, \"pharmacology research\": 1, \"pharmacology journal\": 0, \"pharmacology publication\": 0, \"pharmacology paper\": 1, \"pharmacology report\": 0, \"pharmacology review\": 0, \"pharmacology book\": 0, \"pharmacology chapter\": 0, \"pharmacology section\": 0, \"pharmacology unit\": 0, \"pharmacology course\": 0, \"pharmacology lecture\": 0, \"pharmacology seminar\": 0, \"pharmacology conference\": 0, \"pharmacology symposium\": 0, \"pharmacology workshop\": 0, \"pharmacology lab\": 0, \"pharmacology department\": 0, \"pharmacology institute\": 0, \"pharmacology center\": 0, \"pharmacology program\": 0, \"pharmacology curriculum\": 0, \"pharmacology degree\": ", {}]], [100, "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax).", [" {\"AUC0\u2013\u221e\": [frequency: 1], \"elimination half-life (t1/2)\": [frequency: 1], \"maximum plasma concentration (Cmax)\": [frequency: 1]}\n\n- \"docetaxel\" [frequency: 1]\n- \"pharmacokinetic parameters\" [frequency: 1]\n- \"plasma concentration\u2013time curve\" [frequency: 1]\n- \"time zero\" [frequency: 1]\n- \"infinity\" [frequency: 1]\n- \"elimination half-life\" [frequency: 1]\n- \"maximum plasma concentration\" [frequency: 1]", {"Drug": ["docetaxel"], "Parameter": ["area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)", "elimination half-life (t1/2)", "maximum plasma concentration (Cmax)"]}]], [101, "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea).", [" {\"DOCETAXEL\": [frequences of occurrences], \"AUC0-INF\": [frequences of occurrences], \"t1/2\": [frequences of occurrences], \"Cmax\": [frequences of occurrences], \"cycle 1\": [frequences of occurrences], \"cycle 2\": [frequences of occurrences], \"E. purpurea\": [frequences of occurrences]}", {"Parameter": ["AUC0\u2013\u221e", "t1/2", "Cmax"], "Drug": ["docetaxel"], "Herb name": ["E. purpurea", "E. purpurea"]}]], [102, "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3.", [" {\"DOCETAXEL\": 1, \"AUC0-\u221e\": 1}\n\n(Note: The entities \"DOCETAXEL\" and \"AUC0-\u221e\" refer to the drug and the pharmacokinetic parameter, respectively, which are the described entities in the context of the scientific article about pharmacology.)", {"Drug": ["docetaxel"], "Parameter": ["AUC0\u2013\u221e"]}]], [103, "Compared with the clinical studies in which significant induction of CYP3A4 by E. purpurea was found using midazolam as a CYP3A4 probe [11, 12], our study differed in formulation, dose and dosing regimen, which may explain the divergent outcome.", [" {\"E. purpurea\": 1, \"midazolam\": 1, \"CYP3A4\": 2, \"clinical studies\": 1, \"formulation\": 1, \"dose\": 1, \"dosing regimen\": 1}\n\nNote: The frequency count is based on the direct mentions of the entities in the provided text. If there are synonyms or related terms used in the text that refer to the same entities, they would also be counted, but based on the given instruction, only direct mentions are counted.", {"Study": ["clinical studies"], "Target": ["CYP3A4", "CYP3A4"], "Herb name": ["E. purpurea"], "Drug": ["midazolam"]}]], [104, "Our commercial product was only labelled to contain 95% aerial parts and 5% roots of E. purpurea, and no information was provided about the total amount of extract used.", [" {\"E. purpurea\": 1}\n\n{\"aerial parts\": 1}\n\n{\"roots\": 1}\n\n{\"total amount of extract\": 1}\n\n{\"commercial product\": 1}\n\n{\"labelled content\": 1}\n\n{\"95%\": 1}\n\n{\"5%\": 1}", {"Herb part": ["aerial parts", "roots"], "Herb name": ["E. purpurea"]}]], [105, "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified.", [" {\"DTAI\": 1, \"alkylamides\": 1, \"midazolam studies\": 1}", {"Herb name": ["DTAI", "alkylamides"], "Drug": ["midazolam"]}]], [106, "For example, alkylamide content is known to vary considerably across different parts of E. purpurea plants [20], and DTAI are more abundant in roots than in leaves.", [" {\"E. purpurea\": 2, \"DTAI\": 1}\n{\"roots\": 1, \"leaves\": 1}\n{\"alkylamide content\": 1}\n{\"DTAI\": 1}\n{\"E. purpurea plants\": 1}\n{\"parts of E. purpurea plants\": 1}\n{\"variability\": 1}\n{\"different parts\": 1}\n{\"frequencies\": 1}\n{\"occurrences\": 1}\n{\"cited entities\": 1}\n{\"scientific article\": 1}\n{\"pharmacology\": 1}\n{\"cited entities\": 1}\n{\"events\": 1}\n{\"described in text\": 1}\n{\"scientific article\": 1}\n{\"parsed entities\": 1}\n{\"pharmacology\": 1}\n{\"cited entities\": 1}\n{\"scientific article\": 1}\n{\"parsing\": 1}\n{\"cited entities\": 1}\n{\"scientific article\": 1}\n{\"pharmacology\": 1}\n{\"cited entities\": 1}\n{\"scientific article\": 1}\n{\"parsing\": 1}\n{\"cited entities\": 1}\n{\"scientific article\": 1}\n{\"pharmacology\": 1}\n{\"cited entities\": 1}\n{\"scientific article\": 1}\n{\"parsing\": 1}\n{\"cited entities\": 1}\n{\"scientific article\": 1}\n{\"pharmacology\": 1}\n{\"cited entities\": 1}\n{\"scientific article\": 1}\n{\"parsing\": 1}\n{\"cited entities\": 1}\n{\"scientific article\": 1}\n{\"pharmacology\": 1}\n{\"cited entities\": 1}\n{\"scientific article\": 1}\n{\"parsing\": 1}\n{\"cited entities\": 1}\n{\"scientific article\": 1}\n{\"pharmacology\": 1}\n{\"cited entities\": 1}\n{\"scientific article\": 1}\n{\"parsing\": 1}\n{\"cited", {"Herb name": ["alkylamide", "E. purpurea", "DTAI"], "Herb part": ["roots", "leaves"]}]], [107, "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23].", [" {\"CYP3A4\": 2, \"alkylamides\": 1, \"E. purpurea\": 1, \"gene reporter assay\": 1, \"compounds\": 1}\n{\"FREQUENCY\": {\"CYP3A4 induction\": 1, \"alkylamides induction\": 1, \"E. purpurea induction\": 1, \"gene reporter assay use\": 1, \"compounds induction potential\": 1}}\n\n(Note: The frequencies are based on the direct mentions of the entities in the text. The context suggests that the induction potential and use are related to the entities, hence the inclusion in the frequency count.)", {"Target": ["CYP3A4", "CYP3A4"], "Herb name": ["alkylamides", "E. purpurea"]}]], [108, "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel.", [" {\"E. purpurea\": 1, \"docetaxel\": 2, \"dexamethasone\": 1}\n\n{\"dosing regimen\": 1, \"pharmacokinetics\": 2}", {"Herb name": ["E. purpurea", "E. purpurea"], "Drug": ["docetaxel", "dexamethasone", "docetaxel"]}]], [109, "For example, the potent P-gp inhibitors R101933 [27, 28] and zosuquidar [29] did not significantly alter plasma levels of docetaxel in cancer patients.", [" {\"P-gp inhibitors\": 2, \"R101933\": 1, \"zosuquidar\": 1, \"docetaxel\": 1, \"cancer patients\": 1}\n{\"frequencies\": {\"P-gp inhibitors\": 2, \"R101933\": 1, \"zosuquidar\": 1, \"docetaxel\": 1, \"cancer patients\": 1}}\n{\"R101933\": {\"citation_count\": 1, \"first_mention\": \"27\", \"last_mention\": \"28\"}, \"zosuquidar\": {\"citation_count\": 1, \"first_mention\": \"29\"}, \"docetaxel\": {\"citation_count\": 1, \"first_mention\": \"not specified\", \"last_mention\": \"not specified\"}}\n{\"cancer patients\": {\"citation_count\": 1, \"first_mention\": \"not specified\", \"last_mention\": \"not specified\"}}", {"Target": ["P-gp"], "Drug": ["zosuquidar", "docetaxel"], "Pathology": ["cancer"]}]], [110, "Considering the risk of tumour progression, randomization was not in the interest of patients with advanced cancer.", [" {\"RANDOMIZATION\": 1, \"ADVANCED CANCER\": 1, \"TUMOUR PROGRESSION\": 1}\n{\"FREQUENCY\": {\"RANDOMIZATION\": 1, \"ADVANCED CANCER\": 1, \"TUMOUR PROGRESSION\": 1}}", {"Pathology": ["tumour", "advanced cancer"]}]], [111, "Thus, the risk of CYP3A4-mediated interactions may be product dependent.", [" {\"CYP3A4\": 1, \"interactions\": 1, \"product-dependent\": 1}", {"Target": ["CYP3A4"]}]], [112, "Previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1.", [" {\"ABCB1\": 1, \"p-glycoprotein\": 1}", {"Herb name": ["green tea"], "Target": ["p-glycoprotein (p-gp) encoded by ABCB1"]}]], [113, "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes.", [" {\"ethyl acetate\": 1, \"ethyl gallate\": 1, \"ascorbic acid-EDTA solution\": 1, \"internal standard\": 1, \"plasma\": 1, \"1 mL\": 1, \"100 \u00b5L\": 1, \"10:1 (v/v)\": 1, \"vortexed\": 1, \"centrifuged\": 1, \"4,500 rpm\": 1, \"20 minutes\": 1}\n{\"ethyl acetate_frequency\": 1, \"ethyl gallate_frequency\": 1, \"ascorbic acid-EDTA solution_frequency\": 1, \"internal standard_frequency\": 1, \"plasma_frequency\": 1, \"1 mL_frequency\": 1, \"100 \u00b5L_frequency\": 1, \"10:1 (v/v) mixture_frequency\": 1, \"vortexed_frequency\": 1, \"centrifuged_frequency\": 1, \"4,500 rpm_frequency\": 1, \"20 minutes_frequency\": 1}\n{\"ethyl acetate\": \"\", \"ethyl gallate\": \"\", \"ascorbic acid-EDTA solution\": \"\", \"internal standard\": \"\", \"plasma\": \"\", \"1 mL\": \"\", \"100 \u00b5L\": \"\", \"10:1 (v/v)\": \"\", \"vortexed\": \"\", \"centrifuged\": \"\", \"4,500 rpm\": \"\", \"20 minutes\": \"\"}\n{\"ethyl acetate\": 1, \"ethyl gallate\": 1, \"ascorbic acid-EDTA solution\": 1, \"internal standard\": 1, \"plasma\": 1, \"1 mL\": 1, \"100 \u00b5L\": 1, \"10:1 (v/v)\": 1, \"vortexed\": 1, \"centrifuged\": 1, \"4,500 rpm\": 1, \"20 minutes\": 1}\n{\"ethyl acetate\": 1, \"ethyl gallate\": 1, \"ascorbic acid-", {}]], [114, "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively.", [" {\"M/Z values\": [\"443.10\", \"123.00\", \"307.20\", \"151.00\", \"291.20\", \"139.00\", \"199.00\", \"127.03\"]}", {"Herb name": ["ECG", "EGC", "EC"]}]], [115, "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC.", [" {\"LC-MS/MS\": 1, \"calibration curve\": 1, \"EC\": 1, \"EGCG\": 1, \"ECG\": 1, \"EGC\": 1}\n{\"0.1\u201350 ng/mL\": 1, \"50 ng/mL\": 1, \"1\u2013500 ng/mL\": 1}\n\n(Note: The frequency count is based on the number of times each entity appears in the text.)", {"Herb name": ["EC", "EGCG", "ECG", "EGC"]}]], [116, "DNA was isolated from the 200 \u00b5L of whole blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA).", [" {\"QIAamp DNA Blood Mask Kit\": 1}\n{\"whole blood samples\": 1}\n{\"200 \u00b5L\": 1}\n{\"DNA\": 1}\n{\"Qiagen\": 1}\n{\"Germantown, MD, USA\": 1}\n{\"USA\": 1}\n{\"Kits\": 1}\n{\"DNA Blood Mini Kit\": 1}\n{\"whole blood\": 1}\n{\"200 \u00b5L\": 1}\n{\"DNA isolation\": 1}\n{\"200 \u00b5L\": 1}\n{\"whole blood\": 1}\n{\"DNA\": 1}\n{\"QIAamp\": 1}\n{\"DNA Blood Mini Kit\": 1}\n{\"whole blood\": 1}\n{\"DNA\": 1}\n{\"Qiagen\": 1}\n{\"Germantown\": 1}\n{\"MD\": 1}\n{\"USA\": 1}\n{\"DNA isolation\": 1}\n{\"whole blood\": 1}\n{\"200 \u00b5L\": 1}\n{\"DNA\": 1}\n{\"QIAamp\": 1}\n{\"DNA Blood Mini Kit\": 1}\n{\"whole blood\": 1}\n{\"DNA\": 1}\n{\"Qiagen\": 1}\n{\"Germantown\": 1}\n{\"MD\": 1}\n{\"USA\": 1}\n{\"DNA isolation\": 1}\n{\"whole blood\": 1}\n{\"200 \u00b5L\": 1}\n{\"DNA\": 1}\n{\"QIAamp\": 1}\n{\"DNA Blood Mini Kit\": 1}\n{\"whole blood\": 1}\n{\"DNA\": 1}\n{\"Qiagen\": 1}\n{\"Germantown\": 1}\n{\"MD\": 1}\n{\"USA\": 1}\n{\"DNA isolation\": 1}\n{\"whole blood\": 1}\n{\"200 \u00b5L\": 1}\n{\"DNA\": 1}\n{\"QIAamp\": 1}\n{\"DNA Blood Mini Kit\": 1}\n{\"whole blood\": 1", {}]], [117, "The identification of genotyping was performed for 4 single-nucleotide polymorphisms (SNPs) in ABCB1, namely C3435T (rs1045642), C1236T (rs1128503), G2677A (rs2032582), and G2677T (rs2032582).", [" {\"ABCB1\": 4, \"single-nucleotide polymorphisms (SNPs)\": 4, \"C3435T (rs1045642)\": 1, \"C1236T (rs1128503)\": 1, \"G2677A (rs2032582)\": 1, \"G2677T (rs2032582)\": 1}\n{\"FREQUENCY\": {\"ABCB1\": 4, \"single-nucleotide polymorphisms (SNPs)\": 4, \"C3435T (rs1045642)\": 1, \"C1236T (rs1128503)\": 1, \"G2677A (rs2032582)\": 1, \"G2677T (rs2032582)\": 1}}", {}]], [118, "Sixteen subjects reported 27 adverse events.", [" {\"Subjects\": 16, \"Adverse Events\": 27}\n{\"Scientific Article\": Frequency: Not specified in the text}\n{\"Pharmacology\": Frequency: Not specified in the text}\n{\"Adverse Events\": 27}\n{\"Article\": Frequency: Not specified in the text}\n{\"Scientific\": Frequency: Not specified in the text}\n{\"Text\": Frequency: Not specified in the text}\n{\"Pharmacology\": Frequency: Not specified in the text}\n{\"Sixteen\": Frequency: 1}\n{\"Subjects\": 16}\n{\"Reported\": Frequency: Not specified in the text}\n{\"27\": Frequency: 1}\n{\"Adverse\": Frequency: Not specified in the text}\n{\"Events\": Frequency: Not specified in the text}\n{\"Described\": Frequency: Not specified in the text}\n{\"Article\": Frequency: Not specified in the text}\n{\"Scientific\": Frequency: Not specified in the text}\n{\"Pharmacology\": Frequency: Not specified in the text}\n{\"Adverse\": Frequency: Not specified in the text}\n{\"Events\": Frequency: Not specified in the text}\n{\"Adverse\": Frequency: 1}\n{\"Adverse\": Frequency: 1}\n{\"Adverse\": Frequency: 1}\n{\"Adverse\": Frequency: 1}\n{\"Adverse\": Frequency: 1}\n{\"Adverse\": Frequency: 1}\n{\"Adverse\": Frequency: 1}\n{\"Adverse\": Frequency: 1}\n{\"Adverse\": Frequency: 1}\n{\"Adverse\": Frequency: 1}\n{\"Adverse\": Frequency: 1}\n{\"Adverse\": Frequency: 1}\n{\"Adverse\": Frequency: 1}\n{\"Adverse\": Frequency: 1}\n{\"Adverse\": Frequency: 1}\n{\"Adverse\": Frequency: 1}\n{\"Adverse\": Frequency: 1}\n{\"Adverse\": Frequency: 1}\n{\"Adverse\": Frequency: 1}\n{\"Adverse\": Frequency: 1}\n{\"Adverse\": Frequency: 1}\n{\"Adverse\":", {"Cohort": ["Sixteen subjects"], "Pathology": ["adverse events"]}]], [119, "All the adverse events were mild in intensity and resolved without any treatment.", [" {\"Pharmacology\": 1, \"Adverse Events\": 1, \"Mild Intensity\": 1, \"Resolved without Treatment\": 1}", {"Pathology": ["adverse events"]}]], [120, "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3.", [" {\"FREQUENCY\": {\"digoxin\": 2, \"Day 1\": 1, \"Day 15\": 1, \"AUC\": 1, \"concomitant administration\": 1, \"GTC\": 1, \"systemic exposure\": 1, \"concentration\u2013time profiles\": 1, \"EC\": 1, \"EGC\": 2, \"ECG\": 1, \"EGCG\": 1, \"pharmacokinetics parameters\": 1}}", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "EC", "EGC", "ECG", "EGCG"], "Parameter": ["AUC"]}]], [121, "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin.", [" {\"ABCB1 genotype\": 1, \"pharmacokinetic alteration\": 1, \"digoxin\": 2, \"GTC\": 1}", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "GTC"], "Parameter": ["AUC"]}]], [122, "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study.", [" {\"GTC\": 1, \"digoxin\": 1}\n{\"FREQUENCY\": {\"coadministration\": 1, \"systemic exposure\": 1, \"study\": 1}}\n{\"digoxin\": {\"coadministration\": 1, \"systemic exposure\": 1, \"study\": 1}}\n{\"GTC\": {\"coadministration\": 1, \"systemic exposure\": 1, \"study\": 1}}", {"Herb name": ["GTC"], "Drug": ["digoxin"]}]], [123, "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables.", [" {\"FREQUENCY\": {\"mean \u00b1 SD\": 1, \"ratios\": 1, \"subject baseline characteristics\": 1, \"start of the study\": 1, \"AUC\": 1}}", {"Herb name": ["catechin"], "Parameter": ["AUC", "AUC"]}]], [124, "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group.", [" {\"Methotrexate\": 2, \"RGE repeated administration group\": 1, \"control group\": 1, \"biliary excretion\": 1, \"urinary excretion\": 1}\n{\"FREQUENCY\": {\"Methotrexate\": 2, \"RGE repeated administration group\": 1, \"control group\": 1, \"biliary excretion\": 1, \"urinary excretion\": 1}}\n\nNote: The frequency count is based on the number of times each entity is mentioned in the text. The entities are directly related to the pharmacological context of the article.", {"Parameter": ["Biliary excretion", "urinary excretion"], "Drug": ["methotrexate"], "Herb name": ["RGE"], "Frequency": ["repeated administration"]}]], [125, "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored.", [" {\"RGE\": 2, \"rats\": 2, \"single or multiple doses\": 1, \"1 or 2 weeks\": 1, \"plasma concentrations\": 1, \"ginsenosides\": 1}\n{\"FREQUENCY\": {\"RGE\": 2, \"rats\": 2, \"single or multiple doses\": 1, \"1 or 2 weeks\": 1, \"plasma concentrations\": 1, \"ginsenosides\": 1}}\n\n(Note: The frequency count is based on the direct mentions of the entities in the provided text. If the context implies a broader usage or relevance, it is not counted here as per the instruction to avoid supplementary information.)", {"Herb name": ["RGE", "ginsenosides"], "Duration": ["for 1 or 2 weeks"]}]], [126, "Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats.", [" {\"RGE\": 1, \"biliary excretion\": 1, \"Mrp2 substrate drug\": 1, \"rats\": 1}\n{\"FREQUENCY\": {\"RGE\": 1, \"biliary excretion\": 1, \"Mrp2 substrate drug\": 1, \"rats\": 1}}\n\n(Note: The frequency count is based on the provided text. If the text were longer or contained more instances of these entities, the frequency count would be adjusted accordingly.)", {"Herb name": ["RGE"], "Target": ["Mrp2"]}]], [127, "However, other ginsenosides, such as Rg3, Re, and Rh1, were not detected in rat plasma despite their high content in RGE (Table 1 and Table 2).", [" {\"Rg3\": 1, \"Re\": 1, \"Rh1\": 1, \"rat plasma\": 1, \"RGE\": 2}\n\nNote: The frequency count is based on the direct mentions of the entities in the provided text. If there were more instances of these entities within the text, the frequency count would increase accordingly. However, based on the given text, the frequency count is as provided above.", {"Herb name": ["ginsenosides", "Rg3", "Re", "Rh1", "RGE"]}]], [128, "Nuclear receptors, such as farnesoid X receptor (FXR, also known as bile acid receptor) and pregnane X receptor (PXR), are known as major regulators of the expression of Bsep and P-gp, respectively [35].", [" {\"FARNESOID_X_RECEPTOR\": 2, \"BILE_ACID_RECEPTOR\": 1, \"PREGNANE_X_RECEPTOR\": 1, \"BSEP\": 1, \"P_GP\": 1}", {"Target": ["farnesoid X receptor (FXR, also known as bile acid receptor)", "pregnane X receptor (PXR)", "Bsep", "P-gp"]}]], [129, "In particular, the beneficial effects of red ginseng products for reducing the symptoms of rheumatoid arthritis have been proven in animals and humans [24,25,26,27,36].", [" {\"Red Ginseng Products\": 1, \"Rheumatoid Arthritis\": 1, \"Animal Studies\": 1, \"Human Studies\": 1}\n\n{\"Rheumatoid Arthritis\": 1}\n\n{\"Red Ginseng Products\": 1}\n\n{\"Animal Studies\": 1}\n\n{\"Human Studies\": 1}\n\n{\"Rheumatoid Arthritis\": 1}\n\n{\"Red Ginseng Products\": 1}\n\n{\"Human Studies\": 1}", {"Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [130, "Therefore, the use of MTX and red ginseng alone or in combination is highly plausible for treatment of rheumatoid arthritis.", [" {\"MTX\": 1, \"red ginseng\": 1, \"combination\": 1, \"treatment\": 1}\n{\"MTX\": {\"FREQUENCY\": 1}, \"red ginseng\": {\"FREQUENCY\": 1}, \"combination\": {\"FREQUENCY\": 1}, \"treatment\": {\"FREQUENCY\": 1}}\n{\"MTX_red ginseng_combination\": {\"FREQUENCY\": 1}, \"MTX_red ginseng_treatment\": {\"FREQUENCY\": 1}, \"red ginseng_combination\": {\"FREQUENCY\": 1}, \"red ginseng_treatment\": {\"FREQUENCY\": 1}}\n{\"rheumatoid arthritis\": {\"FREQUENCY\": 1}}", {"Drug": ["MTX"], "Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [131, "Therefore, in conclusion, this study showed that the herb\u2013drug interactions between red ginseng and MTX occurred via Mrp2 regulation changes in rats, but clinical significance thereof should be determined with follow-up studies.", [" {\"Red Ginseng\": 1, \"MTX\": 1, \"Mrp2\": 1, \"rats\": 1}", {"Herb name": ["red ginseng"], "Drug": ["MTX"], "Target": ["Mrp2"]}]], [132, "The concentration of total RNA was determined by Nano Vue Plus (GE healthcare Korea, Seoul, Korea).", [" {\"GE healthcare Korea\": 1, \"Nano Vue Plus\": 1}", {}]], [133, "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer.", [" {\"liver samples\": 1, \"tissue lysis buffer\": 1}\n{\"total protein\": 1}\n{\"100 mg\": 1}\n{\"liver\": 1}\n{\"100 mg of liver samples\": 1}\n{\"equal volume\": 1}\n{\"tissue lysis buffer\": 1}\n{\"homogenizing\": 1}\n{\"liver samples\": 1}\n{\"100 mg\": 1}\n{\"liver\": 1}\n{\"100 mg of liver samples\": 1}\n{\"equal volume\": 1}\n{\"tissue lysis buffer\": 1}\n{\"homogenizing\": 1}\n{\"liver samples\": 1}\n{\"100 mg\": 1}\n{\"liver\": 1}\n{\"100 mg of liver samples\": 1}\n{\"equal volume\": 1}\n{\"tissue lysis buffer\": 1}\n{\"homogenizing\": 1}\n{\"liver samples\": 1}\n{\"100 mg\": 1}\n{\"liver\": 1}\n{\"100 mg of liver samples\": 1}\n{\"equal volume\": 1}\n{\"tissue lysis buffer\": 1}\n{\"homogenizing\": 1}\n{\"liver samples\": 1}\n{\"100 mg\": 1}\n{\"liver\": 1}\n{\"100 mg of liver samples\": 1}\n{\"equal volume\": 1}\n{\"tissue lysis buffer\": 1}\n{\"homogenizing\": 1}\n{\"liver samples\": 1}\n{\"100 mg\": 1}\n{\"liver\": 1}\n{\"100 mg of liver samples\": 1}\n{\"equal volume\": 1}\n{\"tissue lysis buffer\": 1}\n{\"homogenizing\": 1}\n{\"liver samples\": 1}\n{\"100 mg\": 1}\n{\"liver\": 1}\n{\"100 mg of liver samples\": 1}\n{\"equal volume\": 1}\n{\"tissue lysis buffer\": 1}\n{\"homogenizing\": 1}\n{\"liver samples\": 1}\n{\"10", {}]], [134, "Pharmacokinetic studies started 2 h after the last RGE treatment.", [" {\"RGE treatment\": 1, \"pharmacokinetic studies\": 1, \"2 h\": 1}\n{\"FREQUENCY\": {\"RGE treatment\": 1, \"pharmacokinetic studies\": 1, \"2 h\": 1}}\n\n(Note: The entities \"pharmacokinetic studies\" and \"2 h\" are not direct cited entities but are related to the context of the study. However, they are included here as they are significant to the context of the scientific article.)\n\nIf the instruction is strictly to find only direct cited entities, then the response would be:\n\n{\"RGE treatment\": 1}\n{\"FREQUENCY\": {\"RGE treatment\": 1}}\n\n(Note: \"pharmacokinetic studies\" and \"2 h\" are not directly cited entities but are part of the context. They are not included in the output.)", {"Herb name": ["RGE"]}]], [135, "Sample Availability: Red ginseng extract are available from the authors.", [" {\"Red ginseng extract\": 1, \"authors\": 1}", {"Herb name": ["Red ginseng extract"]}]], [136, "Conceptualization, M.-K.C.", [" {\"FREQUENCY\": {\"Conceptualization\": 1, \"M.-K.C.\": 1}}\n\nNote: In the context of this task, \"Conceptualization\" refers to the process of forming concepts or ideas, and \"M.-K.C.\" could be an author's initials or a specific entity related to the article. However, without additional context, it's assumed to be an entity related to the author. If \"M.-K.C.\" is not an entity but a name, it would not be included in the entity frequency count.", {}]], [137, "Contents of ginsenosides in RGE.", [" {\"Ginsenosides\": 1, \"RGF (Radix Ginseng Flower)\": 1, \"RGE (Radix Ginsenge Extract)\": 1}", {"Herb name": ["ginsenosides", "RGE"]}]], [138, "2016; Bautista et\u00a0al.", [" {\"Bautista et al.\": 1, \"2016\": 1}\n\nNote: In the context of this task, \"cited entities\" refer to the names of researchers, studies, or specific years mentioned in the text. The frequency indicates how many times each entity is mentioned.", {}]], [139, "2014; Dybro et\u00a0al.", [" {\"Dybro et al.\": 1, \"2014\": 1}\n\nNote: In the context of this task, \"cited entities\" refer to the names of researchers, studies, or specific years mentioned in the text. The frequency indicates how many times each entity is mentioned.", {}]], [140, "However, it is unknown whether there is an interaction between AC and DST.", [" {\"AC\": 1, \"DST\": 1}", {"Drug": ["AC"], "Herb name": ["DST"]}]], [141, "; 3.5\u2009\u03bcm) at room temperature.", [" {\"Pharmacology\": 1, \"scientific article\": 1, \"pharmacology\": 1, \"3.5 \u03bcm\": 1, \"room temperature\": 1}\n{\"FREQUENCY\": {\"scientific article\": 1, \"pharmacology\": 2, \"3.5 \u03bcm\": 1, \"room temperature\": 1}}\n{\"Pharmacology-related entities\": [\"Pharmacology\", \"scientific article\", \"pharmacology\", \"3.5 \u03bcm\", \"room temperature\"]}\n{\"Pharmacology-related entities-frequency\": {\"Pharmacology\": 2, \"scientific article\": 1, \"3.5 \u03bcm\": 1, \"room temperature\": 1}}\n{\"Room temperature-related entities\": [\"room temperature\"]}\n{\"Room temperature-related entities-frequency\": {\"room temperature\": 1}}\n{\"3.5 \u03bcm-related entities\": [\"3.5 \u03bcm\"]}\n{\"3.5 \u03bcm-related entities-frequency\": {\"3.5 \u03bcm\": 1}}\n{\"Scientific article-related entities\": [\"scientific article\"]}\n{\"Scientific article-related entities-frequency\": {\"scientific article\": 1}}\n{\"Pharmacology-related entities-context\": \"The cited entities in the context of a scientific article about pharmacology include Pharmacology, scientific article, pharmacology, 3.5 \u03bcm, and room temperature.\"}\n{\"Pharmacology-related entities-context-frequency\": {\"Pharmacology\": 2, \"scientific article\": 1, \"3.5 \u03bcm\": 1, \"room temperature\": 1}}\n{\"Room temperature-related entities-context\": \"Room temperature is mentioned as a condition at room temperature.\"}\n{\"Room temperature-related entities-context-frequency\": {\"room temperature\": 1}}\n{\"3.5 \u03bcm-related entities-context\": \"3.5 \u03bcm refers to the size of a molecule at room temperature.\"}\n{\"3.5 \u03bcm-related entities-context-frequency\": {\"3.5 \u03bcm\":", {}]], [142, "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis.", [" {\"Centrifuge\": 1, \"3500 rpm\": 1, \"10 minutes\": 1, \"supernatant\": 1, \"\u221240 \u00b0C\": 1, \"analysis\": 1}\n{\"Centrifuge\": {\"FREQUENCY\": 1}, \"3500 rpm\": {\"FREQUENCY\": 1}, \"10 minutes\": {\"FREQUENCY\": 1}, \"supernatant\": {\"FREQUENCY\": 1}, \"\u221240 \u00b0C\": {\"FREQUENCY\": 1}, \"analysis\": {\"FREQUENCY\": 1}}\n\n(Note: The entities \"pharmacology\" and \"scientific article\" were not directly mentioned in the text, but the context implies the field of study and the type of document. However, as per the instructions, only words referring to the described entities were listed, hence they are not included in the output.)", {}]], [143, "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC.", [" {\"AC\": 1, \"Rat liver microsomes\": 1, \"C Maximum plasma concentration\": 1, \"C\": 1}\n\nNote: The entities \"AC\" and \"C\" are assumed to refer to the same entity (maximum plasma concentration) based on the context provided. However, if they are considered different entities, the count would be 2 for \"AC\" and 1 for \"C\". The context does not provide enough information to definitively distinguish between the two, so this interpretation is made with the assumption that they refer to the same concept. If they are indeed different, the output would be adjusted accordingly.", {"Drug": ["AC"]}]], [144, "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD.", [" {\"Half-life (t): [frequency]\", \"Experimental values: [frequency]\", \"mean: [frequency]\", \"\u00b1 SD: [frequency]\"}\n\nNote: The frequencies are not provided in the output as this is a template for how the information should be parsed. In a real-world application, you would count the occurrences of these terms in the text of the scientific article. For example, if the term \"half-life (t)\" appeared 10 times, \"mean\" appeared 15 times, and \"\u00b1 SD\" appeared 5 times, the output would be:\n\n{\"Half-life (t): 10\", \"Experimental values: 15\", \"mean: 15\", \"\u00b1 SD: 5\"}", {}]], [145, "The highest recovery was obtained using acetonitrile as a protein precipitant.", [" {\"ACETONITRILE\": 1, \"PROTEIN PRECIPITANT\": 1}", {}]], [146, "In the present study, the selectivity was examined using independent plasma samples from six different rats.", [" {\"RATS\": 1, \"PLASMA\": 1, \"SELECTIVITY\": 1, \"STUDY\": 1}\n\n(Note: The entities \"RATS\" and \"PLASMA\" are not directly mentioned in the text but are inferred from the context of the study. \"SELECTIVITY\" and \"STUDY\" are explicitly mentioned.)", {}]], [147, "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL.", [" {\"AC (Analog-to-Digital Converter)\": 1, \"concentration range\": 1, \"ng/mL (nanograms per milliliter)\": 1}\n\n{\"AC (Analog-to-Digital Converter)\": 1, \"concentration range\": 1, \"ng/mL (nanograms per milliliter)\": 1}\n\n{\"Linearity\": 1}\n\n{\"AC (Analog-to-Digital Converter)\": 1}\n\n{\"1 (unit of concentration)\": 1}\n\n{\"500 (upper limit of concentration range)\": 1}\n\n{\"500 (unit of concentration)\": 1}\n\n{\"concentration range\": 1}\n\n{\"1\u2013500 (range of concentration)\": 1}", {"Drug": ["AC"]}]], [148, "These data indicated that the accuracy and precision of the method were satisfactory.", [" {\"METHODS\": [\"accuracy\", \"precision\", \"method\"]}", {}]], [149, "Its effective plasma drug concentration is close to the toxic concentration, and large individual differences in the effects of the drug have been observed.", [" {\"Pharmacology\": 1, \"Drug Concentration\": 1, \"Toxic Concentration\": 1, \"Plasma\": 1, \"Effects\": 1, \"Individual Differences\": 1}\n{\"FREQUENCY\": {\"Pharmacology\": 1, \"Drug Concentration\": 1, \"Toxic Concentration\": 1, \"Plasma\": 1, \"Effects\": 1, \"Individual Differences\": 1}}\n\n(Note: The frequency count is based on the direct mentions of the entities in the provided text. If the context implies an entity without directly mentioning it, it is not counted. In this case, the entities are directly mentioned, hence the frequency count is as provided.)", {}]], [150, "The results of existing studies are controversial and further in-depth studies are required.", [" {\"PHARMACOLOGY\": 1, \"SCIENTIFIC ARTICLE\": 1, \"EVENTS\": 1, \"FURTHER STUDIES\": 1, \"CONTROVERSIAL\": 1}", {}]], [151, "Most of these reports and studies are on combinations with Western drugs.", [" {\"Western drugs\": 2, \"combinations\": 1, \"studies\": 1, \"reports\": 1}", {}]], [152, "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results.", [" {\"Digoxin\": 2, \"neonates\": 1, \"patients\": 1, \"renal dysfunction\": 1, \"endogenous substances\": 1, \"plasma concentration\": 1}\n{\"FREQUENCY\": {\"Digoxin\": 2, \"neonates\": 1, \"patients\": 1, \"renal dysfunction\": 1, \"endogenous substances\": 1, \"plasma concentration\": 1}}\n\n(Note: The frequency count is based on the direct mentions of the entities in the text provided.)", {"Drug": ["digoxin", "digoxin"], "Pathology": ["patients", "renal dysfunction"]}]], [153, "Based on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows: A.", [" {\"TCM formulations\": 1, \"digoxin\": 1}", {"Drug": ["digoxin"]}]], [154, "In vivo, digoxin was administered intravenously to control rats and citronellal pretreated experimental rats, and in vitro, the transcellular transport of   Single TCM: Single TCM formulations that are capable of inhibiting or downregulating P-gP include Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong), Vernonia amygdalina (Biantaobanjiuju), Tapinanthus sessilifolius, Carica papaya (Mugua) and Ginkgo biloba L. (Yinxing).", [" {\"Digoxin\": 1, \"rats\": 2, \"citronellal\": 1, \"in vivo\": 1, \"intravenously\": 1, \"in vitro\": 1, \"transcellular transport\": 1, \"P-gP\": 1, \"Conioselinum anthriscoides\": 1, \"Chuanxiong\": 1, \"Vernonia amygdalina\": 1, \"Biantaobanjiuju\": 1, \"Tapinanthus sessilifolius\": 1, \"Carica papaya\": 1, \"Mugua\": 1, \"Ginkgo biloba L.\": 1}", {"Drug": ["digoxin"], "Herb name": ["citronellal", "Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong)", "Vernonia amygdalina (Biantaobanjiuju)", "Tapinanthus sessilifolius", "Carica papaya (Mugua)", "Ginkgo biloba L. (Yinxing)"], "Target": ["P-gP"]}]], [155, "Experiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection.", [" {\"Digoxin\": 2, \"mice\": 1, \"AUC\": 1, \"gavage\": 1, \"intravenous injection\": 1}\n{\"Frequency\": {\"Digoxin\": 2, \"mice\": 1, \"AUC\": 1, \"gavage\": 1, \"intravenous injection\": 1}}\n\n(Note: The frequency count is based on the number of times each entity appears in the text.)", {"Parameter": ["AUC"], "Drug": ["digoxin"]}]], [156, "Li Xin et al.", [" {\"LIXIN_NAME\": [1], \"ALICE_NAME\": [1], \"ALICE_ORGANISM\": [1], \"ALICE_PHARMACOLOGICAL_PRODUCT\": [1], \"ALICE_PHARMACOLOGICAL_PRODUCT_IDENTIFIER\": [1], \"ALICE_PHARMACOLOGICAL_PRODUCT_USE\": [1], \"ALICE_PHARMACOLOGICAL_PRODUCT_CLASS\": [1], \"ALICE_PHARMACOLOGICAL_PRODUCT_PURPOSE\": [1], \"ALICE_PHARMACOLOGICAL_PRODUCT_DOSAGE\": [1], \"ALICE_PHARMACOLOGICAL_PRODUCT_DOSAGE_FORM\": [1], \"ALICE_PHARMACOLOGICAL_PRODUCT_DOSAGE_METHOD\": [1], \"ALICE_PHARMACOLOGICAL_PRODUCT_DOSAGE_UNIT\": [1], \"ALICE_PHARMACOLOGICAL_PRODUCT_DOSAGE_TIME\": [1], \"ALICE_PHARMACOLOGICAL_PRODUCT_DOSAGE_DURATION\": [1], \"ALICE_PHARMACOLOGICAL_PRODUCT_DOSAGE_FREQUENCY\": [1], \"ALICE_PHARMACOLOGICAL_PRODUCT_DOSAGE_RATIO\": [1], \"ALICE_PHARMACOLOGICAL_PRODUCT_DOSAGE_RATIO_UNIT\": [1], \"ALICE_PHARMACOLOGICAL_PRODUCT_DOSAGE_RATIO_TIME\": [1], \"ALICE_PHARMACOLOGICAL_PRODUCT_DOSAGE_RATIO_DURATION\": [1], \"ALICE_PHARMACOLOGICAL_PRODUCT_DOSAGE_RATIO_FREQUENCY\": [1], \"ALICE_PHARMACOLOGICAL_PRODUCT_DOSAGE_RATIO_FREQUENCY_TIME\": [1", {}]], [157, "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021).", [" {\"QRS interval prolongation\": 1, \"ventricular precontraction\": 1, \"ventricular tachycardia\": 1, \"ventricular fibrillation\": 1, \"C. pinnatifida Bunge (Shanzha) extract\": 2, \"digoxin-induced arrhythmias\": 2, \"flavonoid glycoside\": 1, \"flavane polymers\": 1, \"digoxin-induced arrhythmias (Li and Huang, 2016)\": 1, \"vascular dilation\": 1, \"blood pressure\": 1, \"heart rhythm\": 1, \"cardiovascular system (Zhang et al., 2021)\": 1}", {"Pathology": ["ventricular precontraction, ventricular tachycardia,", "ventricular fibrillation", "arrhythmia", "arrhythmias", "ventricular arrhythmias", "arrhythmias"], "Herb name": ["C. pinnatifida Bunge (Shanzha)", "C. pinnatifida Bunge (Shanzha)", "flavonoid glycoside", "flavane polymers", "C. pinnatifida Bunge (Shanzha)"], "Drug": ["digoxin", "digoxin", "digoxin"], "Parameter": ["blood pressure", "heart rhythm"]}]], [158, "When the bias of medicine is greater than that of food, it will inevitably affect the balance of qi, blood, yin and yang of the human body (Jia et al., 2021).", [" {\"Jia et al., 2021\": 1}\n\n{\"medicine\": 1}\n\n{\"food\": 1}\n\n{\"balance of qi\": 1}\n\n{\"blood\": 1}\n\n{\"yin and yang\": 1}\n\n{\"human body\": 1}", {}]], [159, "Although a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations.", [" {\"Digoxin\": 1, \"TCM formulations\": 1}\n{\"FREQUENCY\": {\"limited research\": 1}}\n{\"FREQUENCY\": {\"clinical application\": 1}}\n{\"FREQUENCY\": {\"accumulated experience\": 1}}", {"Drug": ["digoxin"]}]], [160, "The composition of TCM formulations is complex.", [" {\"TCM Formulations\": 1, \"Traditional Chinese Medicine (TCM)\": 1, \"composition\": 1}\n{\"Frequency\": {\"TCM Formulations\": 1, \"Traditional Chinese Medicine (TCM)\": 1, \"composition\": 1}}\n\n(Note: The word \"formulations\" in the context of the sentence refers to TCM formulations, hence it is included in the entities.)", {}]], [161, "Therefore, the interactions between TCM formulations and digoxin are difficult to elucidate, and they are easily ignored by physicians.", [" {\"TCM formulations\": 1, \"digoxin\": 2}\n{\"events\": 1}\n{\"physicians\": 1}", {}]], [162, "Many view these medicines as benign because they are of natural origin; however, because their constituents may be metabolized through the same enzymatic pathways as pharmaceutical agents, there is a potential for herb-drug interactions.", [" {\"Pharmaceutical agents\": 1, \"herb-drug interactions\": 1, \"natural origin\": 1}", {}]], [163, "The most important class of enzymes involved in human drug metabolism is cytochrome P450 (P450), which occurs as a superfamily of related monooxygenase forms responsible for oxidative metabolism of xenobiotics and endogenous compounds (Nebert et al., 2013).", [" {\"CYTOCHROM_P450\": 1, \"MONOOXYGENASE\": 1, \"OXIDATIVE_METABOLISM\": 1, \"XENOBIOIETICS\": 1, \"ENDGENOUS_COMPOUNDS\": 1, \"NEBERT_ALT\": 1, \"2013\": 1}\n\nNote: \"Nebert et al., 2013\" is considered an entity referring to the authors and the year of publication, hence \"Nebert_alt\" is used to represent the authors' name and \"2013\" the year.", {"Parameter": ["cytochrome P450 (P450)", "monooxygenase forms"]}]], [164, "Metabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug (Lin and Lu, 1998; Bohnert et al., 2016).", [" {\"FREQUENCY\": {\"Metabolic drug interactions\": 1, \"perpetrator drug\": 1, \"victim drug\": 1, \"Lin and Lu, 1998\": 1, \"Bohnert et al., 2016\": 1}\n\n{\"FREQUENCY\": {\"two or more drugs\": 1}}\n\n{\"FREQUENCY\": {\"alters\": 1}}\n\n{\"FREQUENCY\": {\"systemic levels\": 1}}", {}]], [165, "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline.", [" {\"CAW\": 3, \"drug-metabolizing enzymes\": 1, \"preclinical studies\": 1, \"phase I clinical trials\": 1, \"phase II clinical trials\": 1, \"botanical drug\": 1}\n{\"FREQUENCY\": {\"drug-metabolizing enzymes\": 1, \"preclinical studies\": 1, \"phase I clinical trials\": 1, \"phase II clinical trials\": 1, \"botanical drug\": 1}}", {"Herb name": ["CAW", "CAW"], "Study": ["preclinical studies", "phase II clinical trials"], "Pathology": ["cognitive decline"]}]], [166, "Hepatocytes cultured in this format are responsive to nuclear receptor agonists and maintain important transporter function necessary for proper drug disposition (Yang et al., 2016).", [" {\"Hepatocytes\": 1, \"nuclear receptor agonists\": 1, \"transporter function\": 1, \"drug disposition\": 1, \"Yang et al., 2016\": 1}\n\nNote: The frequency count is based on the direct mentions of the entities in the provided text. If there are multiple instances of the same entity, each instance is counted separately. In this case, each entity is mentioned once.", {"Parameter": ["nuclear receptor"]}]], [167, "C. asiatica Plant Material and Preparation of CAW-R61J.", [" {\"C. asiatica\": 2, \"Plant Material\": 1, \"Preparation of CAW-R61J\": 1}\n\nNote: The frequency count is based on the direct mentions of the entities in the provided text. If there are additional mentions or contexts where these entities are referred to, they are not included in this count.", {"Herb name": ["C. asiatica Plant"]}]], [168, "Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2).", [" {\"OHSU\": 2, \"Oregon Health & Science University (OHSU, Portland, OR)\": 1, \"CAW-R61F\": 1, \"CAW-R61H\": 1, \"filtrates\": 1, \"aliquots\": 1, \"dried CA\": 2}\n{\"FREQUENCY\": {\"OHSU\": 2, \"Oregon Health & Science University (OHSU, Portland, OR)\": 1, \"CAW-R61F\": 1, \"CAW-R61H\": 1, \"filtrates\": 1, \"aliquots\": 1, \"dried CA\": 2}}", {"Amount": ["21.4%", "23.9%"], "Herb name": ["dried CA for CAW-R61F", "dried CA for CAW-R61H"]}]], [169, "DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO.", [" {\"DMSO\": 2, \"CAW-R61J\": 1}\n{\"Dosing solutions\": 1}\n{\"0.1% (v/v)\": 1}\n{\"0.1% DMSO\": 1}\n{\"treatment conditions\": 1}", {"Parameter": ["DMSO", "DMSO"], "Herb name": ["CAW-R61J"], "Amount": ["0.1% (v/v)", "0.1%"]}]], [170, "Plates were thawed at ambient temperature.", [" {\"Thawing Plates\": 1, \"Ambient Temperature\": 1}\n{\"Pharmacology\": 0}\n{\"Scientific Article\": 0}\n{\"Pharmacology Article\": 0}\n{\"Plates\": 1}\n{\"Thawing\": 1}\n{\"Ambient Temperature\": 1}\n{\"Temperature\": 1}\n{\"Thawing Process\": 1}\n{\"Thawing Event\": 1}\n{\"Pharmacology Entity\": 0}\n{\"Scientific Entity\": 0}\n{\"Article Entity\": 0}\n{\"Plate Entity\": 1}\n{\"Thawing Entity\": 1}\n{\"Ambient Temperature Entity\": 1}\n{\"Temperature Entity\": 1}\n{\"Thawing Process Entity\": 1}\n{\"Thawing Event Entity\": 1}\n{\"Pharmacology Citation\": 0}\n{\"Scientific Citation\": 0}\n{\"Article Citation\": 0}\n{\"Plate Citation\": 0}\n{\"Thawing Citation\": 0}\n{\"Ambient Temperature Citation\": 0}\n{\"Temperature Citation\": 0}\n{\"Thawing Process Citation\": 0}\n{\"Thawing Event Citation\": 0}\n{\"Pharmacology Reference\": 0}\n{\"Scientific Reference\": 0}\n{\"Article Reference\": 0}\n{\"Plate Reference\": 0}\n{\"Thawing Reference\": 0}\n{\"Ambient Temperature Reference\": 0}\n{\"Temperature Reference\": 0}\n{\"Thawing Process Reference\": 0}\n{\"Thawing Event Reference\": 0}\n{\"Pharmacology Study\": 0}\n{\"Scientific Study\": 0}\n{\"Article Study\": 0}\n{\"Plate Study\": 0}\n{\"Thawing Study\": 0}\n{\"Ambient Temperature Study\": 0}\n{\"Temperature Study\": 0}\n{\"Thawing Process Study\": 0}\n{\"Thawing Event Study\": 0}\n{\"Pharmacology Research\": 0}\n{\"Scientific Research", {}]], [171, "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH.", [" {\"P450 enzyme\": 1, \"CAW-R61J\": 1, \"IC50 values\": 1, \"NADPH\": 1}\n{\"TDI\": 1, \"P450 enzyme activity\": 1, \"shift in IC50 values\": 1, \"30-minute preincubations\": 1, \"presence and absence\": 1}\n{\"shift in IC50 values\": 1, \"30-minute preincubations\": 1, \"presence and absence of NADPH\": 1}\n{\"P450 enzyme activity\": 1, \"CAW-R61J\": 1, \"NADPH\": 1}\n{\"TDI of P450 enzyme activity\": 1, \"CAW-R61J\": 1, \"shift in IC50 values\": 1, \"30-minute preincubations\": 1, \"presence and absence of NADPH\": 1}\n{\"P450 enzyme activity\": 1, \"CAW-R61J\": 1, \"shift in IC50 values\": 1, \"30-minute preincubations\": 1, \"presence and absence of NADPH\": 1}\n{\"P450 enzyme activity\": 1, \"CAW161J\": 1, \"shift in IC50 values\": 1, \"30-minute preincubations\": 1, \"presence and absence of NADPH\": 1}\n{\"P450 enzyme activity\": 1, \"CAW-R61J\": 1, \"shift in IC50 values\": 1, \"30-minute preincubations\": 1, \"presence and absence of NADPH\": 1}\n{\"P450 enzyme activity\": 1, \"CAW-R61J\": 1, \"shift in IC50 values\": 1, \"30-minute preincubations\": 1, \"presence and absence of NADPH\": 1}\n{\"P450 enzyme activity\": 1, \"CAW-R61", {"Parameter": ["Potential TDI of P450 enzyme activity", "IC50", "NADPH"], "Herb name": ["CAW-R61J"], "Duration": ["30-minute"]}]], [172, "Unless otherwise specified, all results were expressed as the means \u00b1 S.D.", [" {\"Pharmacology Articles\": [frequencies of articles related to pharmacology], \"Scientific Journals\": [frequencies of scientific journals mentioned], \"Researchers\": [frequencies of researchers cited], \"Studies\": [frequencies of studies referenced], \"Drugs\": [frequencies of drugs discussed], \"Drug Names\": [frequencies of specific drug names], \"Dosage\": [frequencies of dosage information], \"Mean \u00b1 SD\": [frequencies of statistical data presented as mean \u00b1 standard deviation], \"Clinical Trials\": [frequencies of clinical trials mentioned], \"Clinical Study Results\": [frequencies of clinical study results cited], \"Pharmacokinetics\": [frequencies of pharmacokinetics terms], \"Pharmacodynamics\": [frequencies of pharmacodynamics terms], \"Drug Interactions\": [frequencies of drug interactions discussed], \"Drug Mechanisms\": [frequencies of drug mechanisms mentioned], \"Drug Side Effects\": [frequencies of drug side effects discussed], \"Drug Efficacy\": [frequencies of drug efficacy information], \"Drug Formulations\": [frequencies of drug formulations discussed], \"Drug Administration Routes\": [frequencies of drug administration routes mentioned], \"Drug Dosage Forms\": [frequencies of drug dosage forms discussed], \"Drug Metabolism\": [frequencies of drug metabolism terms], \"Drug Excretion\": [frequencies of drug excretion terms], \"Drug Toxicity\": [frequencies of drug toxicity information], \"Drug Safety\": [frequencies of drug safety information], \"Drug Development\": [frequencies of drug development processes mentioned], \"Drug Regulation\": [frequencies of drug regulation terms], \"Drug Approval\": [frequencies of drug approval processes mentioned], \"Drug Labeling\": [frequencies of drug labeling information], \"Drug Prescribing\": [frequencies of drug prescribing information], \"Drug Monitoring\": [frequencies of drug monitoring processes], \"Drug Utilization\": [frequencies of drug utilization information], \"D", {}]], [173, "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq.", [" {\"IC50 values\": 1, \"concentration-response\": 1, \"percentage control value\": 1, \"four-parameter sigmoid (Hill) model\": 1, \"eq.\": 1}\n{\"FREQUENCY\": {\"IC50 values\": 1, \"concentration-response\": 1, \"percentage control value\": 1, \"four-parameter sigmoid (Hill) model\": 1, \"eq.\": 1}}\n\n(Note: The \"FREQUENCY\" field is an additional interpretation of the output, indicating the count of each entity mentioned in the text.)", {"Parameter": ["the IC50 values", "the concentration-response (percentage control value)"]}]], [174, "2 above (substituting logEC50 for logIC50).", [" {\"logEC50\": 1, \"logIC50\": 1}", {"Parameter": ["logEC50", "logIC50"]}]], [175, "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA).", [" {\"Prism 8.0.2\": 1, \"GraphPad Software\": 1, \"San Diego, CA\": 1}", {}]], [176, "Object name is dmd.120.090860f1.jpg Fig.", [" {\"FREQUENCY\": {\"dmd.120.090860f1.jpg\": 1, \"pharmacology\": 1, \"scientific article\": 1}}", {}]], [177, "Mean\tS.D.", [" In the provided text, it's not possible to directly extract specific entities or their frequencies without the actual content of the scientific article. However, I can guide you on how to identify and parse cited entities in a scientific article about pharmacology, and how to represent their frequencies in the given format.\n\nTo identify and parse cited entities in a scientific article, you should look for:\n\n1. **Drug names**: These are usually capitalized and may include chemical names or brand names.\n2. **Biological entities**: This includes proteins, genes, and other biological molecules.\n3. **Diseases and conditions**: These are often capitalized and may be accompanied by specific symptoms or diagnostic criteria.\n4. **Measurements**: This includes units of measurement for quantities like dosage, concentration, and response rates.\n\nOnce you've identified these entities in the text, you can represent their frequencies using the provided format. For example, if the article mentions \"Drug A\" 5 times, \"Protein X\" 3 times, and \"Disease Y\" 2 times, you could represent this information as:\n\n```\n{\n  \"Drug A\": 5,\n  \"Protein X\": 3,\n  \"Disease Y\": 2\n}\n```\n\nIf you have the actual content of the article, you can apply this approach to extract and represent the frequencies of the cited entities. Remember, the goal is to identify and count the occurrences of specific entities mentioned in the text. If no information is found for a particular entity, it's appropriate to leave that field empty in your output.", {}]], [178, "Mean\tS.D.", [" In the provided text, it's not possible to directly extract specific entities or their frequencies without the actual content of the scientific article. However, I can guide you on how to identify and parse cited entities in a scientific article about pharmacology, and how to represent their frequencies in the given format.\n\nTo identify and parse cited entities in a scientific article, you should look for:\n\n1. **Drug names**: These are usually capitalized and may include chemical names or brand names.\n2. **Biological entities**: This includes proteins, genes, and other biological molecules.\n3. **Diseases and conditions**: These are often capitalized and may be accompanied by specific symptoms or diagnostic criteria.\n4. **Measurements and units**: This includes dosages, concentrations, and other quantitative data.\n\nOnce you've identified these entities in the text, you can represent their frequencies using the provided format. For example, if the article mentions \"Drug A\" 5 times, \"Protein X\" 3 times, and \"Disease Y\" 2 times, you could represent this information as:\n\n```\n{\n  \"Drug A\": 5,\n  \"Protein X\": 3,\n  \"Disease Y\": 2\n}\n```\n\nIf you have the actual content of the article, you can apply this approach to extract and represent the frequencies of the cited entities. Remember, the goal is to identify and count the occurrences of specific entities mentioned in the text. If no information is found for a particular entity, it's appropriate to leave that field empty in the output.", {}]], [179, "***P < 0.0001.", [" {\"Pharmacology\": 1, \"scientific article\": 1, \"pharmacological entities\": 1, \"cited entities\": 1, \"words\": 1}\n{\"P-value\": 1, \"P < 0.0001\": 1}\n\n(Note: The \"FREQUENCY\" field is counted as 1 for each unique entity mentioned, assuming that each mention is a distinct reference to the entity within the context of the text provided.)", {}]], [180, "; data not shown).", [" In the provided text, without the actual content of the scientific article on pharmacology, it's impossible to identify specific entities or words that refer to them. However, I can guide you on how to approach this task once you have the article content.\n\nTo identify and parse cited entities in a scientific article, you should look for:\n\n1. **Drug names**: These are usually capitalized and may include chemical names or brand names.\n2. **Biological entities**: This includes proteins, genes, and other biological molecules.\n3. **Diseases and conditions**: These are often capitalized and may be accompanied by specific symptoms or diagnostic criteria.\n4. **Organisms**: This includes bacteria, viruses, and other microorganisms.\n5. **Institutions**: Names of universities, research institutes, or pharmaceutical companies.\n6. **Concepts and theories**: Scientific principles, models, or theories.\n\nOnce you have the article content, you can extract the entities and their frequencies as follows:\n\nExample:\n\nArticle content: \"In a recent study, researchers at the University of Pharmacy discovered that Drug X inhibits the growth of Cancer Y. The study, published in the Journal of Pharmacology, involved testing Drug X on various strains of Bacteria Z.\"\n\nParsed entities:\n\n```\n{\n  \"Drug X\": {\"FREQUENCY\": 2},\n  \"Cancer Y\": {\"FREQUENCY\": 1},\n  \"University of Pharmacy\": {\"FREQUENCY\": 1},\n  \"Journal of Pharmacology\": {\"FREQUENCY\": 1},\n  \"Bacteria Z\": {\"FREQUENCY\": 1}\n}\n```\n\nRemember, the actual frequencies will depend on the content of the article.", {}]], [181, "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017).", [" {\"Ring et al.\": 1, \"Suzuki et al.\": 1, \"Emoto et al.\": 1, \"Walsky et al.\": 1, \"VandenBrink et al.\": 1, \"Zhao et al.\": 1, \"Thu et al.\": 1}", {}]], [182, "The strongest reversible inhibition was against CYP2C9 (IC50 330 \u00b5g/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 \u00b5g/ml).", [" {\"CYP2C9\": 1, \"IC50\": 1, \"CYP1A2\": 1, \"CYP2B6\": 1}\n{\"FREQUENCY\": {\"IC50\": 1}}\n\nNote: The frequency count is based on the direct mention of the entities in the text. If the context implies a frequency but does not explicitly state it, it is not included in the frequency count.", {"Target": ["CYP2C9", "CYP1A2", "CYP2B6"], "Parameter": ["IC50", "IC50"], "Amount": ["330 \u00b5g/ml", "> 1000 \u00b5g/ml"]}]], [183, "An external file that holds a picture, illustration, etc.", [" {\"PHARMACOLOGICAL TERMS\": [\"pharmacology\", \"drug\", \"medication\", \"pharmacokinetics\", \"pharmacodynamics\", \"receptor\", \"enzyme\", \"metabolism\", \"absorption\", \"distribution\", \"excretion\", \"bioavailability\", \"half-life\", \"therapeutic window\", \"drug-drug interaction\", \"drug-food interaction\", \"drug resistance\", \"pharmacogenomics\", \"pharmacoeconomics\", \"pharmacotherapy\", \"pharmacodynamics\", \"pharmacokinetics\", \"pharmacological target\", \"pharmacological effect\", \"pharmacological action\", \"pharmacological response\", \"pharmacological efficacy\", \"pharmacological potency\", \"pharmacological selectivity\", \"pharmacological tolerance\", \"pharmacological toxicity\", \"pharmacological safety\", \"pharmacological side effect\", \"pharmacological adverse effect\", \"pharmacological contraindication\", \"pharmacological precaution\", \"pharmacological interaction\", \"pharmacological synergy\", \"pharmacological antagonism\", \"pharmacological agonism\", \"pharmacological inhibition\", \"pharmacological induction\", \"pharmacological potentiation\", \"pharmacological attenuation\", \"pharmacological enhancement\", \"pharmacological modulation\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\",", {}]], [184, "Object name is dmd.120.090860f3.jpg Fig.", [" {\"FREQUENCY\": {\"dmd.120.090860f3.jpg\": 1, \"pharmacology\": 1, \"scientific article\": 1}}", {}]], [185, "Data shown are the means \u00b1 S.D.", [" {\"Pharmacology Articles\": [frequencies of articles related to pharmacology], \"Scientific Journals\": [frequencies of scientific journals mentioned], \"Researchers\": [frequencies of researchers cited], \"Studies\": [frequencies of studies referenced], \"Drugs\": [frequencies of drugs discussed], \"Dosage\": [frequencies of dosage information], \"Mean \u00b1 SD\": [frequencies of mean \u00b1 standard deviation data presented], \"Clinical Trials\": [frequencies of clinical trials mentioned], \"Pharmacokinetics\": [frequencies of pharmacokinetics terms], \"Pharmacodynamics\": [frequencies of pharmacodynamics terms], \"Drug Interactions\": [frequencies of drug interactions discussed], \"Drug Mechanisms\": [frequencies of drug mechanisms mentioned], \"Drug Effects\": [frequencies of drug effects discussed], \"Drug Side Effects\": [frequencies of drug side effects mentioned], \"Drug Efficacy\": [frequencies of drug efficacy discussed], \"Drug Safety\": [frequencies of drug safety discussions], \"Drug Development\": [frequencies of drug development processes mentioned], \"Drug Testing\": [frequencies of drug testing methods mentioned], \"Drug Regulation\": [frequencies of drug regulation topics], \"Drug Formulation\": [frequencies of drug formulation discussions], \"Drug Delivery Systems\": [frequencies of drug delivery systems mentioned], \"Drug Metabolism\": [frequencies of drug metabolism discussions], \"Drug Excretion\": [frequencies of drug excretion discussions], \"Drug Absorption\": [frequencies of drug absorption discussions], \"Drug Distribution\": [frequencies of drug distribution discussions], \"Drug Toxicity\": [frequencies of drug toxicity discussions], \"Drug Interactions\": [frequencies of drug interactions discussed], \"Drug Synergy\": [frequencies of drug synergy discussions], \"Drug Antagonism\": [frequencies of drug antagonism discussions], \"Drug Potency\": [frequencies of drug potency discussions], \"", {}]], [186, "of triplicate determinations.", [" {\"TRIPLET DETERMINATIONS\": 1, \"pharmacology\": 1, \"scientific article\": 1, \"entities\": 1}", {}]], [187, "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9.", [" {\"Purified centelloids\": 1, \"weak inhibitors\": 1, \"human liver microsomes\": 1, \"human P450 forms\": 1, \"CYP2C19\": 1, \"CYP3A4\": 1, \"CYP2D6\": 1, \"CYP2C9\": 1}\n{\"CYP2C19\": \"human P450 forms\", \"CYP3A4\": \"human P450 forms\", \"CYP2D6\": \"human P450 forms\", \"CYP2C9\": \"human P450 forms\"}\n{\"human liver microsomes\": \"weak inhibitors\"}\n{\"Purified centelloids\": \"weak inhibitors\"}", {"Herb name": ["centelloids"], "Parameter": ["P450", "CYP2C19, CYP3A4, CYP2D6, and CYP2C9"]}]], [188, "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract.", [" {\"CAW-R61J\": 1, \"centelloid content\": 1, \"clinical studies\": 1, \"compounds\": 1, \"plasma concentrations\": 1}\n{\"frequencies\": {\"CAW-R61J\": 1, \"centelloid content\": 1, \"clinical studies\": 1, \"compounds\": 1, \"plasma concentrations\": 1}}\n{\"CAW-R61J\": \"1\", \"centelloid content\": \"1\", \"clinical studies\": \"1\", \"compounds\": \"1\", \"plasma concentrations\": \"1\"}", {"Herb name": ["the centelloid content of CAW-R61J"], "Parameter": ["plasma concentrations for these compounds"], "Study": ["clinical studies"]}]], [189, "Ultimately, the clinical relevance of the weak P450 inhibition seen in this study will depend on the IC50 values of the as yet unknown inhibitory CAW-R61J compounds and their in vivo concentration achieved in humans.", [" {\"P450 inhibition\": 1, \"IC50 values\": 1, \"CAW-R61J compounds\": 1, \"in vivo concentration\": 1}\n\nNote: The frequency count is based on the direct mention of these entities in the text. If the context implies the existence of these entities without directly mentioning them, they would not be included in the count. However, in this case, all mentioned entities are directly referred to in the text.", {"Target": ["P450"], "Parameter": ["IC50", "in vivo concentration"], "Herb name": ["CAW-R61J"]}]], [190, "It will also be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes.", [" {\"CA derivatives\": 1, \"phase II drug-metabolizing enzymes\": 1}", {"Herb name": ["CA"], "Parameter": ["phase II drug-metabolizing enzymes"]}]], [191, "Therefore, the tolerability and safety of combination drugs were evaluated in the context of their DDI potential.", [" {\"DDI Potential\": 1, \"combination drugs\": 1, \"tolerability\": 1, \"safety\": 1}\n{\"FREQUENCY\": {\"DDI Potential\": 1, \"combination drugs\": 1, \"tolerability\": 1, \"safety\": 1}}", {}]], [192, "Based on these clinical outcomes, fimasartan can be recommended for patients with hypertension and chronic kidney disease [4,14].", [" {\"fimasartan\": 1, \"hypertension\": 1, \"chronic kidney disease\": 1, \"patients\": 1, \"clinical outcomes\": 1, \"4\": 1, \"14\": 1}\n{\"FREQUENCY\": {\"fimasartan\": 1, \"hypertension\": 1, \"chronic kidney disease\": 1, \"patients\": 1, \"clinical outcomes\": 1, \"4\": 1, \"14\": 1}}\n\nNote: The numbers in the \"FREQUENCY\" field represent the count of each entity mentioned in the text. Since the instruction asks for words referring to the described entities, the count is equal to the number of times each entity is mentioned.", {"Drug": ["fimasartan"], "Pathology": ["hypertension", "chronic kidney disease"]}]], [193, "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA).", [" {\"Fimasartan\": 1, \"fimasartan-amide\": 1, \"amlodipine\": 1, \"hydrochlorothiazide\": 1, \"Agilent 6470 Triple Quadrupole LC-MS/MS system\": 1, \"Agilent\": 1, \"Wilmington, DE, USA\": 1}", {"Drug": ["Fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide"]}]], [194, "Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves.", [" {\"Standard calibration curves\": 1, \"QC samples\": 1, \"low concentration\": 1, \"medium concentration\": 1, \"high concentration\": 1}\n{\"Standard calibration curves\": 1, \"QC samples\": 1, \"low concentration\": 1, \"medium concentration\": 1, \"high concentration\": 1, \"range\": 1}\n{\"low concentration\": 1, \"medium concentration\": 1, \"high concentration\": 1}\n{\"frequences of events\": 3}\n{\"Standard calibration curves\": 1, \"QC samples\": 3, \"low concentration\": 3, \"medium concentration\": 3, \"high concentration\": 3, \"range\": 1}\n{\"frequences of words\": 9}", {}]], [195, "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves.", [" {\"Berberine (IS)\": 1, \"1 \u03bcL\": 1, \"100 \u03bcL\": 1, \"100 \u03bcL reconstituted standard curves\": 1, \"150 \u03bcL acetonitrile\": 1, \"1 ng/mL\": 1}\n{\"Acetonitrile\": 1}\n{\"Standard curves\": 1}\n{\"Liquid volume units\": 3}\n{\"Concentration units\": 1}\n{\"Scientific measurement units\": 2}\n{\"Scientific article\": 1}\n{\"Pharmacology\": 1}\n{\"Scientific article about pharmacology\": 1}\n{\"Cited entities\": 6}\n{\"Events described in text\": 6}\n{\"Frequencies\": 6}\n{\"Scientific article about pharmacology\": \"Pharmacology\"}\n{\"Berberine (IS)\": \"pharmacology\"}\n{\"1 \u03bcL\": \"pharmacology\"}\n{\"100 \u03bcL\": \"pharmacology\"}\n{\"100 \u03bcL reconstituted standard curves\": \"pharmacology\"}\n{\"150 \u03bcL acetonitrile\": \"pharmacology\"}\n{\"1 ng/mL\": \"pharmacology\"}\n{\"Acetonitrile\": \"pharmacology\"}\n{\"Standard curves\": \"pharmacology\"}\n{\"Liquid volume units\": \"pharmacology\"}\n{\"Concentration units\": \"pharmacology\"}\n{\"Scientific measurement units\": \"pharmacology\"}\n{\"Scientific article\": \"pharmacology\"}\n{\"Cited entities\": \"pharmacology\"}\n{\"Events described in text\": \"pharmacology\"}\n{\"Frequencies\": \"pharmacology\"}\n{\"Berberine (IS)\": \"pharmacology\", \"1 \u03bcL\": \"pharmacology\", \"100 \u03bcL\": \"pharmacology\", \"100 \u03bcL reconstituted standard curves\": \"pharmacology\", \"150 \u03bcL acetonitrile\": \"pharmacology\", \"1 ng/mL\": \"pharmacology\", \"Acetonitrile", {}]], [196, "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples).", [" {\"QC samples\": 2, \"autosampler\": 1, \"6 \u00b0C\": 1, \"24 h\": 1}\n{\"post-preparative stability\": 1}\n{\"extracted\": 1}\n{\"untreated QC samples\": 1}", {}]], [197, "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO.", [" {\"FREQUENCY\": {\"fimasartan\": 1, \"amlodipine\": 1, \"hydrochlorothiazide\": 1, \"DMSO\": 1}}\n\n{\"FREQUENCY\": {\"rat\": 1, \"rat in the combination group\": 1, \"group\": 1}}\n\n{\"FREQUENCY\": {\"mg/kg\": 3, \"kg\": 3}}\n\n{\"FREQUENCY\": {\"saline\": 1}}\n\n{\"FREQUENCY\": {\"10%\": 1}}\n\n{\"FREQUENCY\": {\"mixture\": 1}}\n\n{\"FREQUENCY\": {\"dissolved\": 1}}", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"], "Amount": ["3 mg/kg", "5 mg/kg", "5 mg/kg"]}]], [198, "The jejunal segments were then isolated and rinsed using pre-warmed saline.", [" {\"jejunal segments\": 1, \"pre-warmed saline\": 1}\n\nNote: The entities \"jejunal segments\" and \"pre-warmed saline\" are directly mentioned in the text, and their frequency is counted as 1 each. Other entities related to pharmacology or scientific research, such as specific drugs, researchers, or pharmacological terms, are not present in the provided text.", {}]], [199, "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS).", [" {\"AMLodipine\": 1, \"50 \u03bcL\": 1, \"aliquots\": 1, \"150 \u03bcL\": 1, \"acetonitrile\": 1, \"1 ng/mL\": 1, \"berberine (IS)\": 1}\n\n{\"FREQUENCY\": {\"50 \u03bcL\": 1, \"aliquots\": 1, \"150 \u03bcL\": 1, \"acetonitrile\": 1, \"1 ng/mL\": 1, \"berberine (IS)\": 1}}", {"Drug": ["amlodipine"]}]], [200, "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1).", [" {\"Authentic Standards\": 1, \"Product Ion Scan\": 1, \"Figure 1\": 1, \"Q1\": 1, \"Q3\": 1}\n{\"FREQUENCY\": {\"Authentic Standards\": 1, \"Product Ion Scan\": 1, \"Figure 1\": 1, \"Q1\": 1, \"Q3\": 1}}\n\nNote: The frequency count is set to 1 for each entity as per the instruction to count the occurrences of the cited entities in the provided text. If the text had multiple mentions of any of these entities, the frequency count would be adjusted accordingly. However, based on the given text, each entity is mentioned once.", {}]], [201, "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide.", [" {\"FUJI BIOPLATE\": [\"Figure 2\"], \"chromatograms\": [\"chromatograms\"], \"blank matrix\": [\"blank matrix\"], \"fimasartan\": [\"fimasartan\", \"fimasartan-amide\"], \"amlodipine\": [\"amlodipine\"], \"hydrochlorothiazide\": [\"hydrochlorothiazide\"], \"rat plasma samples\": [\"rat plasma samples\"], \"oral administration\": [\"oral administration\"], \"1 h after\": [\"1 h after\"]}\n\n(Note: The frequency for each entity is 1 as they are all mentioned once in the text.)", {"Drug": ["fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide", "fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [202, "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37].", [" {\"QC sample\": 1, \"standard curve sample\": 1, \"analytical process\": 1, \"biological sample\": 1, \"analytical instrument\": 1, \"FDA\": 1, \"EMA\": 1, \"ICH\": 1, \"Guideline\": 1, \"bioanalytical method validation\": 1, \"accuracy\": 2, \"inter-day\": 1, \"intra-day\": 1}", {}]], [203, "These results suggest that fimasartan is an attractive candidate for the treatment of hypertension and suggest the increasing use of fimasartan monotherapy and combination therapy.", [" {\"Fimasartan\": 3, \"hypertension\": 1, \"monotherapy\": 1, \"combination therapy\": 1}\n\nNote: The frequency count is based on the direct mentions of the entities in the provided text. If there are synonyms or related terms used in the text that refer to these entities, they are not included in this count as per the instructions.", {"Drug": ["fimasartan", "fimasartan"], "Pathology": ["hypertension"]}]], [204, "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1).", [" {\"MRM condition\": 1, \"fimasartan\": 1, \"amlodipine\": 1, \"hydrochlorothiazide\": 1, \"product ion mass spectra\": 1}\n{\"fimasartan\": 1, \"amlodipine\": 1, \"hydrochlorothiazide\": 1}\n{\"Figure 1\": 1}\n{\"reports\": 1}", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [205, "and M.P.", [" {\"M.P.\": [1], \"pharmacology\": [2], \"scientific article\": [1], \"cited entities\": [1], \"words\": [1]}\n\n- \"M.P.\" (presumably referring to a person, such as a researcher or author) is mentioned once.\n\n- \"pharmacology\" is mentioned twice, likely referring to the field of study.\n\n- \"scientific article\" is mentioned once, referring to the type of publication.\n\n- \"cited entities\" is mentioned once, referring to the entities being cited in the article.\n\n- \"words\" is mentioned once, referring to the specific words that refer to the described entities.", {}]], [206, "Data represented as mean and CV from five or six independent experiments.", [" {\"Mean\": [\"mean\", \"average\", \"mean value\", \"mean value of\", \"mean value from\", \"mean value of experiments\", \"mean value of five or six\", \"mean value from five or six\", \"mean value from independent experiments\"], \"CV\": [\"coefficient of variation (CV)\", \"CV\", \"coefficient of variation\", \"variation coefficient\", \"variation coefficient from\", \"variation coefficient of\", \"variation coefficient from\", \"variation coefficient from independent experiments\"], \"experiments\": [\"experiment\", \"independent experiment\", \"experimental study\", \"independent experiments\", \"five or six experiments\", \"five or six independent experiments\"]}\n\n{\"FREQUENCY\": {\"mean\": 1, \"CV\": 1, \"experiments\": 1}}", {}]], [207, "However, there are several challenges associated with the chronic nature of HAART administration.", [" {\"HAART\": 1, \"chronic nature\": 1, \"HAART administration\": 1}\n{\"chronic\": 1, \"HAART administration challenges\": 1}\n{\"HAART administration\": 2}\n{\"HAART administration challenges\": 1}\n{\"HAART administration frequency\": 2}\n{\"HAART administration challenges frequency\": 1}\n{\"HAART administration challenges associated\": 1}\n{\"HAART administration challenges associated with\": 1}\n{\"HAART administration challenges associated with chronic\": 1}\n{\"HAART administration challenges associated with chronic nature\": 1}\n{\"HAART administration challenges associated with chronic nature of\": 1}\n{\"HAART administration challenges associated with chronic nature of HAART\": 1}\n{\"HAART administration challenges associated with chronic nature of HAART administration\": 1}\n{\"HAART administration challenges associated with chronic nature of HAART administration\": 1}\n{\"HAART administration challenges associated with chronic nature of HAART administration frequency\": 1}\n{\"HAART administration challenges associated with chronic nature of HAART administration frequency\": 1}\n{\"HAART administration challenges associated with chronic nature of HAART administration frequency of\": 1}\n{\"HAART administration challenges associated with chronic nature of HAART administration frequency of chronic\": 1}\n{\"HAART administration challenges associated with chronic nature of HAART administration frequency of chronic nature\": 1}\n{\"HAART administration challenges associated with chronic nature of HAART administration frequency of chronic nature of\": 1}\n{\"HAART administration challenges associated with chronic nature of HAART administration frequency of chronic nature of HAART\": 1}\n{\"HAART administration challenges associated with chronic nature of HAART administration frequency of chronic nature of HAART administration\": 1}\n{\"HAART administration challenges associated with chronic nature of HAART administration frequency of chronic nature of HAART administration frequency\": 1}\n{\"HAART administration challenges associated with chronic nature of HAART administration frequency of chronic nature of HAART administration frequency of\": 1}\n{\"HAART administration challenges associated with chronic nature of HAART administration frequency of chronic nature of", {"Drug": ["HAART"]}]], [208, "However, attention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].", [" {\"ART\": 2, \"quality of life\": 1, \"people taking ART\": 1}", {"Drug": ["ART"]}]], [209, "EFV and NVP have been associated with a number of side effects including liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia and headache [10].", [" {\"FREQUENCY\": {\"EFV\": 1, \"NVP\": 1, \"liver damage\": 1, \"nausea\": 1, \"vomiting\": 1, \"fever\": 1, \"diarrhoea\": 1, \"dyslipidemia\": 1, \"headache\": 1}}", {"Drug": ["EFV", "NVP"], "Pathology": ["side effects", "liver damage", "nausea", "vomiting", "fever", "diarrhoea", "dyslipidemia", "headache"]}]], [210, "There is substantial evidence supporting the potential of medicinal plants in combating diseases, especially in developing countries [12,13,14,15].", [" {\"Medicinal Plants\": 1, \"Diseases\": 1, \"Developing Countries\": 1}\n{\"Journal Articles\": 1, \"References\": 1}\n{\"Events\": 0}\n{\"Organizations\": 0}\n{\"Products\": 0}\n{\"Publications\": 1}\n{\"Diseases\": 1}\n{\"Countries\": 1}\n{\"Research\": 1}\n{\"Studies\": 1}", {}]], [211, "Although effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.", [" {\"Herbal Medicines\": 1, \"diseases\": 1, \"mechanisms of action\": 1}", {}]], [212, "Genetic polymorphism in CYP2B6 have been implicated in variations in the activity of the enzyme in metabolizing xenobiotics [26].", [" {\"CYP2B6\": 2, \"genetic polymorphism\": 1, \"activity\": 1, \"metabolizing xenobiotics\": 1}\n\nNote: The frequency count is based on the number of times each entity appears in the provided text. The entities are directly mentioned or implied by the context.", {"Target": ["CYP2B6"]}]], [213, "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract.", [" {\"FREQUENCY\": {\"intestinal absorption\": 1, \"plasma concentrations\": 1, \"test compound\": 1, \"bioavailability\": 1, \"herbal extracts\": 1, \"soluble extract\": 1, \"GI tract\": 1}}", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [214, "Note: values are expressed as mg\u00b7kg Structures of the phenolic compounds identified and quantified from crude herbal extracts (1) Caffeic acid; (2) Catechin; (3) Chlorogenic acid; (4) Epicatechin; (5) p-Coumaric acid.", [" {\"PHENOLIC_COMPOUNDS\": [\n  \"caffeic acid\",\n  \"catechin\",\n  \"chlorogenic acid\",\n  \"epicatechin\",\n  \"p-Coumaric acid\"\n],\n\n\"HERBAL_EXTRACTS\": [\"crude herbal extracts\"],\n\n\"QUANTIFICATION_METHODS\": [\"identified\", \"quantified\"]\n}", {"Herb name": ["phenolic compounds", "Caffeic acid", "Catechin", "Chlorogenic acid", "Epicatechin", "p-Coumaric acid"], "Extraction process": ["crude herbal extracts"]}]], [215, "The advantage of phytochemical profiling is that similar drug interacting constituents could be identified in other related herbs that are used for therapeutic purposes and that necessary mechanistic studies are performed on them.", [" {\"Phytochemical profiling\": 1, \"drug interacting constituents\": 1, \"therapeutic herbs\": 1, \"mechanistic studies\": 1}\n{\"Pharmaceutical companies\": \"\", \"Drug names\": \"\", \"Clinical trials\": \"\", \"Pharmacokinetics\": \"\", \"Pharmacodynamics\": \"\", \"Drug targets\": \"\", \"Drug metabolism\": \"\", \"Drug excretion\": \"\", \"Drug absorption\": \"\", \"Drug distribution\": \"\", \"Drug-drug interactions\": \"\", \"Drug-food interactions\": \"\", \"Drug-environment interactions\": \"\", \"Drug-device interactions\": \"\", \"Drug-labeling\": \"\", \"Drug-regulation\": \"\", \"Drug-pricing\": \"\", \"Drug-marketing\": \"\", \"Drug-patents\": \"\", \"Drug-legal issues\": \"\", \"Drug-adverse effects\": \"\", \"Drug-efficacy\": \"\", \"Drug-safety\": \"\", \"Drug-tolerance\": \"\", \"Drug-resistance\": \"\", \"Drug-immunology\": \"\", \"Drug-neurology\": \"\", \"Drug-cardiology\": \"\", \"Drug-endocrinology\": \"\", \"Drug-oncology\": \"\", \"Drug-genetics\": \"\", \"Drug-epigenetics\": \"\", \"Drug-molecular biology\": \"\", \"Drug-biochemistry\": \"\", \"Drug-pharmacology\": \"\", \"Drug-toxicology\": \"\", \"Drug-pharmacokinetics\": \"\", \"Drug-pharmacodynamics\": \"\", \"Drug-metabolism\": \"\", \"Drug-excretion\": \"\", \"Drug-absorption\": \"\", \"Drug-distribution\": \"\", \"Drug-drug interactions\": \"\", \"Drug-food interactions\": \"\", \"Drug-environment interactions\": \"\", \"Drug-device interactions\": \"\", \"Drug-labeling\": \"\", \"Drug-regulation\": \"\", \"Drug-pricing\": \"\", \"Drug-marketing\": \"\", \"Drug-patents\": \"\", \"Drug-legal issues\": \"\", \"Drug-adverse effects\": \"\", \"Drug-efficacy\": \"\", \"Drug", {}]], [216, "The study showed that Launaea taraxacifolia Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6.", [" {\"Launaea taraxacifolia\": 1, \"Hyptis suaveolens\": 1, \"Boerhavia diffusa\": 1, \"Myrothamnus flabellifolius\": 1, \"CYP2B6\": 1}", {"Herb name": ["Launaea taraxacifolia", "Hyptis suaveolens", "Boerhavia diffusa", "Myrothamnus flabellifolius"], "Extraction process": ["extracts"], "Target": ["CYP2B6"]}]], [217, "Ethical approval was obtained from the University of Cape Town Human Research Ethics committee with number HREC REF: 826/2014.", [" {\"University of Cape Town\": 1, \"Human Research Ethics committee\": 1, \"HREC REF: 826/2014\": 1}\n{\"Ethical approval\": 1}\n{\"University of Cape Town Human Research Ethics committee\": 1}\n{\"826/2014\": 1}", {}]], [218, "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated.", [" {\"Material\": [1], \"Extraction process\": [2], \"Supernatant\": [1], \"Solid residue\": [1], \"Purified water\": [1], \"72 hours\": [1], \"room temperature\": [1], \"24 hours\": [1]}\n\nNote: The frequency count is based on the number of times each entity is mentioned in the text.", {"Duration": ["for 72 h"], "Frequency": ["every 24 h"]}]], [219, "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented.", [" {\"Kevin Dzobo\": 1, \"Ambroise Wonkam\": 1, \"Dee Blackhurst\": 1, \"Michelle Skelton\": 1, \"Denis Chopera\": 1}", {}]], [220, "All authors reviewed the final manuscript.", [" {\"AUTHORS\": [\"All\", \"reviewed\", \"final\", \"manuscript\"]}\n{\"TITLE\": [\"pharmacology\"]}\n{\"ACTION\": [\"reviewed\"]}\n{\"FINAL MANUSCRIPT\": 1}\n{\"EVENT\": [\"reviewed\"]}\n{\"PUBLICATION\": 1}\n{\"MANUSCRIPT\": 1}\n{\"ARTICLE\": 1}\n{\"Scientific\": 1}\n{\"PHARMACOLOGY\": 1}\n{\"EVENT\": [\"reviewed\", \"final\"]}\n{\"FREQUENCY\": {\"reviewed\": 2, \"final\": 1}}\n{\"FREQUENCY\": {\"PUBLICATION\": 1}}\n{\"FREQUENCY\": {\"ARTICLE\": 1}}\n{\"FREQUENCY\": {\"Scientific\": 1}}\n{\"FREQUENCY\": {\"PHARMACOLOGY\": 1}}\n{\"FREQUENCY\": {\"AUTHORS\": 1}}\n{\"FREQUENCY\": {\"MANUSCRIPT\": 1}}\n{\"FREQUENCY\": {\"EVENT\": 2}}\n{\"FREQUENCY\": {\"TITLE\": 1}}\n{\"FREQUENCY\": {\"ACTION\": 1}}\n{\"FREQUENCY\": {\"FINAL\": 1}}\n{\"FREQUENCY\": {\"PUBLICATION\": 1}}\n{\"FREQUENCY\": {\"PUBLICATION\": 1}}\n{\"FREQUENCY\": {\"PUBLICATION\": 1}}\n{\"FREQUENCY\": {\"PUBLICATION\": 1}}\n{\"FREQUENCY\": {\"PUBLICATION\": 1}}\n{\"FREQUENCY\": {\"PUBLICATION\": 1}}\n{\"FREQUENCY\": {\"PUBLICATION\": 1}}\n{\"FREQUENCY\": {\"PUBLICATION\": 1}}\n{\"FREQUENCY\": {\"PUBLICATION\": 1}}\n{\"FREQUENCY\": {\"PUBLICATION\": 1}}\n{\"FREQUENCY\": {\"PUBLICATION\": 1}}\n{\"F", {}]], [221, "GGT with five major ingredients also possesses chance of drug interactions when co-administering with other drugs.", [" {\"GGT\": 1, \"major ingredients\": 1, \"drug interactions\": 1, \"co-administering\": 1, \"other drugs\": 1}\n{\"FREQUENCY\": {\"GGT\": 1, \"major ingredients\": 1, \"drug interactions\": 1, \"co-administering\": 1, \"other drugs\": 1}}\n\n(Note: The frequency count is based on the number of times the entities appear in the provided text.)", {"Herb name": ["GGT"]}]], [222, "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between.", [" {\"Treatments\": 3, \"Participants\": 1, \"Washout period\": 7, \"Days\": 1}\n{\"FREQUENCY\": {\"Treatments\": 3, \"Washout period\": 7, \"Days\": 1}}\n\n(Note: The \"Participants\" entity is not explicitly mentioned as a cited entity in the text, but it is implied and thus included in the list. If the instruction strictly requires only explicit mentions, then it would be left empty.)\n\n(Note: The \"FREQUENCY\" field is provided as a JSON object, not a frequency count, since the instruction asks for the frequency of events described in the text, not the frequency of the entities themselves.)", {}]], [223, "Therefore, we applied this dose of GGT in our study.", [" {\"GGT\": 1, \"dose\": 1}\n{\"study\": 1}", {"Herb name": ["GGT"]}]], [224, "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23].", [" {\"AAP dose\": 1, \"1000 mg\": 1, \"1000 mg \u00d7 4 times\": 1, \"8 tablets\": 1, \"common cold\": 1}\n{\"FREQUENCY\": {\"AAP dose\": 1, \"1000 mg\": 1, \"1000 mg \u00d7 4 times\": 1, \"8 tablets\": 1, \"common cold\": 1}}", {"Drug": ["AAP"], "Amount": ["1000 mg", "1000 mg"], "Frequency": ["4 times (8 tablets) per day"], "Pathology": ["common cold"]}]], [225, "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week.", [" {\"AAP 1000 mg once daily\": 1, \"AAP 1000 mg \u00d7 4 times daily\": 1, \"GGT 7680 mg once daily\": 1}\n{\"AAP 1000 mg once daily\": 1, \"AAP 1000 mg \u00d7 4 times daily\": 1, \"GGT 7680 mg once daily\": 1}", {"Drug": ["AAP", "AAP"], "Amount": ["1000 mg", "7680 mg", "1000 mg", "7680 mg"], "Frequency": ["once daily", "once daily", "4 times daily", "once daily"], "Herb name": ["GGT", "GGT"], "Duration": ["week"]}]], [226, "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily.", [" {\"AAP\": 2, \"1000 mg\": 1, \"4 times a day\": 1, \"GGT (7680 mg)\": 1}\n\nNote: The frequency count is based on the number of times the entities appear in the text. The entities are \"AAP,\" \"1000 mg,\" \"4 times a day,\" and \"GGT (7680 mg).\"", {"Drug": ["AAP"], "Frequency": ["once a day", "4 times a day", "daily"], "Amount": ["1000 mg", "7680 mg"], "Herb name": ["GGT"]}]], [227, "and Y.C.P.", [" {\"Y.C.P.\": 1, \"pharmacology\": 1, \"scientific article\": 1, \"cited entities\": 1}", {}]], [228, "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.", [" {\"MODELS\": [1], \"Q.T.T.\": [1], \"H.-m.B.\": [1], \"L.T.N.\": [1], \"J.-w.C.\": [1], \"H.-y.Y.\": [1]}", {}]], [229, "Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP.", [" {\"Non-compartmental analysis (NCA)\": 1, \"pharmacokinetic (PK) parameters\": 1, \"AAP\": 1}\n{\"FREQUENCY\": {\"Non-compartmental analysis (NCA)\": 1, \"pharmacokinetic (PK) parameters\": 1, \"AAP\": 1}}\n\n(Note: The \"FREQUENCY\" field is interpreted as a dictionary with the mentioned entities as keys and their frequencies as values. However, since the instruction asks for a simple count, the dictionary format is used to represent the frequency count.)", {"Drug": ["AAP"]}]], [230, "Single time-point, phenotypic metabolic ratios were used to determine whether long-term supplementation of St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity in elderly subjects.", [" {\"St. John's wort\": 1, \"garlic oil\": 1, \"Panax ginseng\": 1, \"Ginkgo biloba\": 1, \"CYP1A2\": 1, \"CYP2D6\": 1, \"CYP2E1\": 1, \"CYP3A4\": 1}", {"Herb name": ["St. John\u2019s wort", "garlic oil", "Panax ginseng", "Ginkgo biloba"], "Target": ["CYP1A2", "CYP2D6", "CYP2E1", "CYP3A4"]}]], [231, "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age.", [" {\"Prescription Medications\": 1, \"Herbal Supplements\": 2, \"Patients\": 1, \"Individuals\": 1, \"65 years of age\": 1}\n{\"FREQUENCY\": {\"Prescription Medications\": 1, \"Herbal Supplements\": 2, \"Patients\": 1, \"Individuals\": 1, \"65 years of age\": 1}}", {"Study": ["surveys"], "Age": ["greater than 65 years of age"]}]], [232, "Moreover, age-related changes have been observed in the pharmacokinetics of several CYP substrates,[28\u201330] as well as certain CYP enzymes,[29,30] thus the question remains as to whether such effects may extend to botanical supplements and their effect on drug metabolism in the elderly.", [" {\"CYP substrates\": 1, \"CYP enzymes\": 2, \"botanical supplements\": 1, \"drug metabolism\": 1, \"elderly\": 1}", {"Target": ["CYP"]}]], [233, "Adherence to these restrictions was further emphasized five days before each probe drug administration.", [" {\"Probe Drug\": 1, \"drug administration\": 1, \"medication\": 1, \"pharmacology\": 1, \"patients\": 1}\n{\"FREQUENCY\": {\"probe drug administration\": 1}}\n{\"Pharmacology\": 1}", {}]], [234, "Peaks were assigned by a comparison of retention times and ultraviolet absorption spectra.", [" {\"Retention times\": 1, \"Ultraviolet absorption spectra\": 1, \"peaks\": 1, \"comparison\": 1}\n{\"FREQUENCY\": {\"Retention times\": 1, \"Ultraviolet absorption spectra\": 1, \"peaks\": 1, \"comparison\": 1}}\n\n(Note: The \"FREQUENCY\" field is an additional interpretation of the original instruction, indicating the count of each entity mentioned in the text.)", {}]], [235, "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation.", [" {\"Risk of Adverse Events\": [1], \"Study Completion\": [1], \"Investigation\": [1]}\n\n{\"Risk of Adverse Events\": [1], \"Study Completion\": [1], \"Investigation\": [1]}\n\n{\"Risk of Adverse Events\": [1], \"Study Completion\": [1], \"Investigation\": [1]}\n\n{\"Risk of Adverse Events\": [1], \"Study Completion\": [1], \"Investigation\": [1]}\n\n{\"Risk of Adverse Events\": [1], \"Study Completion\": [1], \"Investigation\": [1]}\n\n{\"Risk of Adverse Events\": [1], \"Study Completion\": [1], \"Investigation\": [1]}\n\n{\"Risk of Adverse Events\": [1], \"Study Completion\": [1], \"Investigation\": [1]}\n\n{\"Risk of Adverse Events\": [1], \"Study Completion\": [1], \"Investigation\": [1]}\n\n{\"Risk of Adverse Events\": [1], \"Study Completion\": [1], \"Investigation\": [1]}\n\n{\"Risk of Adverse Events\": [1], \"Study Completion\": [1], \"Investigation\": [1]}\n\n{\"Risk of Adverse Events\": [1], \"Study Completion\": [1], \"Investigation\": [1]}\n\n{\"Risk of Adverse Events\": [1], \"Study Completion\": [1], \"Investigation\": [1]}\n\n{\"Risk of Adverse Events\": [1], \"Study Completion\": [1], \"Investigation\": [1]}\n\n{\"Risk of Adverse Events\": [1], \"Study Completion\": [1], \"Investigation\": [1]}\n\n{\"Risk of Adverse Events\": [1], \"Study Completion\": [1], \"Investigation\": [1]}\n\n{\"Risk of Adverse Events\": [1], \"Study Completion\": [1], \"Investigation\": [1]}\n\n{\"Risk of Adverse Events\": [1], \"Study Comple", {}]], [236, "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation.", [" {\"CYP\": [\"Phenotypic Ratio (CYP)\", \"Supplement\", \"Presupplementation\", \"Postsupplementation\"]}", {}]], [237, "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance.", [" {\"St. John's wort\": 1, \"midazolam\": 1, \"single-time point phenotypic ratio approach\": 1, \"area-under-the-curve\": 1}\n{\"frequencies\": {\"St. John's wort\": 1, \"midazolam\": 1, \"single-time point phenotypic ratio approach\": 1, \"area-under-the-curve\": 1}}\n\nNote: The numbers in the \"frequencies\" field are based on the provided text, where each entity is mentioned once. If the text had multiple mentions of the same entity, the frequency would increase accordingly. For example, if \"midazolam\" was mentioned twice, the frequency would be 2. However, based on the given text, all entities are mentioned once.", {"Herb name": ["St. John\u2019s wort"], "Parameter": ["area-under-the-curve", "clearance"], "Drug": ["midazolam"]}]], [238, "This finding also corroborates the results of an earlier study in young individuals.", [" {\"Young individuals\": 1, \"earlier study\": 1, \"scientific article\": 1, \"pharmacology\": 1}\n\nNote: The entities \"young individuals\" and \"earlier study\" are not direct citations but are inferred from the context of the sentence. If the task strictly requires direct citations, then these may not be included. However, for the purpose of this task, they are considered as entities related to the described entities.", {}]], [239, "[54] Thus, a potential interaction may exist between these agents and St. John\u2019s wort.", [" {\"St. John's wort\": 1, \"agents\": 1}", {"Herb name": ["St. John\u2019s wort"]}]], [240, "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements.", [" {\"CYP2E1\": 2, \"allyl sulfide\": 1, \"garlic supplements\": 1, \"age-related diminution\": 1, \"allyl sulfide content\": 1}\n\nNote: The frequency count is based on the direct mentions of the entities in the text provided. If there were more instances where these entities were referred to indirectly or in different forms, those would not be included in this count.", {"Target": ["CYP2E1"], "Herb name": ["allyl sulfide", "garlic"]}]], [241, "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy.", [" {\"Anticoagulant therapy\": [1, 1], \"elderly patients\": [1]}", {"Drug": ["anticoagulant therapy"]}]], [242, "This interaction appears attributable to the inhibition of platelet activating factor by various ginkgolides.", [" {\"Platelet Activating Factor\": 1, \"ginkgolides\": 1}", {"Target": ["platelet activating factor"], "Herb name": ["ginkgolides"]}]], [243, "[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of phytochemical-mediated effects on CYP isoforms.", [" {\"Ginkgo biloba\": 1, \"herb-drug interactions\": 1, \"phytochemical-mediated effects\": 1, \"CYP isoforms\": 1}\n\n{\"CYP isoforms\": 1}", {"Herb name": ["G. biloba"], "Target": ["CYP"]}]], [244, "Like G. biloba, Panax ginseng appears to have little effect on the activities of the specific CYP isoforms investigated in this study.", [" {\"Ginkgo biloba\": 1, \"Panax ginseng\": 1, \"CYP isoforms\": 1}\n{\"Ginkgo biloba\": {\"FREQUENCY\": 1}, \"Panax ginseng\": {\"FREQUENCY\": 1}, \"CYP isoforms\": {\"FREQUENCY\": 1}}\n\nNote: The entities \"G. biloba\" and \"Panax ginseng\" are derived from the scientific names of the species mentioned in the text. \"CYP isoforms\" refers to the specific Cytochrome P450 enzymes mentioned. These entities are directly cited in the text.", {"Herb name": ["G. biloba", "Panax ginseng"], "Target": ["CYP"]}]], [245, "[62] CYP2C9 is the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme.", [" {\"CYP2C9\": 2, \"warfarin\": 2, \"S-warfarin\": 1, \"ginseng-mediated induction\": 1}\n\nNote: The frequency count is based on the direct mentions of the entities in the provided text. If there were additional mentions of these entities in the full article, the frequency count would be higher. However, based on the given text, this is the count.", {"Target": ["CYP2C9"], "Drug": ["warfarin", "warfarin"], "Study": ["reports"], "Herb name": ["ginseng"]}]], [246, "Therefore, botanical supplements, when taken concomitantly with conventional medications, can give rise to serious herb-drug interactions.", [" {\"Botanical supplements\": 1, \"conventional medications\": 1, \"herb-drug interactions\": 1}\n{\"FREQUENCY\": {\"Botanical supplements\": 1, \"conventional medications\": 1, \"herb-drug interactions\": 1}}", {}]], [247, "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method.", [" {\"HPLC method\": 1, \"plasma quinine\": 1, \"3-hydroxyquinine\": 1}\n{\"blood samples\": 1}\n{\"analyzed\": 1}\n{\"validated\": 1}\n{\"HPLC\": 1}\n{\"HPLC method\": 1}\n{\"HPLC method\": 1} (Note: The frequency is repeated as it refers to the same entity, the HPLC method.)", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [248, "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola.", [" {\"G. kola seeds\": 2, \"phytochemical analysis\": 1, \"benxophenones\": 1, \"xanthones\": 1, \"alkaloids\": 1, \"phenols\": 1, \"tannins\": 1, \"saponins\": 1, \"kolaviron\": 1, \"biflavonoid complex\": 1, \"metallic ions\": 1, \"aluminum\": 1, \"magnesium\": 1, \"calcium\": 1, \"copper\": 1}", {"Herb name": ["G. kola", "benxophenones", "xanthones", "alkaloids", "phenols", "tannins", "saponins", "kolaviron", "biflavonoid complex", "G. kola"], "Herb part": ["seeds"]}]], [249, "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study.", [" {\"G. kola seeds\": 1, \"study\": 1, \"adverse side effects\": 1, \"hypersensitivity\": 1, \"quinine\": 1}\n{\"Pregnancy\": 1, \"breastfeeding\": 1}", {"Pathology": ["Pregnancy", "breastfeeding", "hypersensitivity", "adverse side effects"], "Drug": ["quinine"], "Herb name": ["G. kola"], "Herb part": ["seeds"]}]], [250, "Participants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol.", [" {\"Physician\": 2, \"Healthy\": 1, \"Participants\": 1, \"Certified\": 1, \"Medical history\": 1, \"Clinical examination\": 1, \"Laboratory tests\": 1, \"Informed consent\": 1, \"Study protocol\": 1}\n\n{\"FREQUENCY\": {\"Physician\": 2, \"Healthy\": 1, \"Participants\": 1, \"Certified\": 1, \"Medical history\": 1, \"Clinical examination\": 1, \"Laboratory tests\": 1, \"Informed consent\": 1, \"Study protocol\": 1}}\n\n(Note: The frequency count is based on the direct mentions of the entities in the text provided.)", {"Pathology": ["healthy"]}]], [251, "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England).", [" {\"QUININE SULFATE TABLETS\": 1}\n\n{\"MADERICH LTD\": 1}\n\n{\"SURREY\": 1}\n\n{\"ENGLAND\": 1}\n\n{\"overnight fast\": 1}\n\n{\"single oral dose\": 1}\n\n{\"600 mg\": 1}\n\n{\"subject\": 1}\n\n{\"respective groups\": 1}\n\n{\"first phase\": 1}", {"Amount": ["600 mg"], "Drug": ["quinine sulphate"]}]], [252, "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola.", [" {\n\"Quinine sulphate tablets\": 1,\n\"G. kola\": 1,\n\"venous blood samples\": 1,\n\"heparinised tubes\": 1,\n\"time zero\": 1,\n\"participant\": 1\n}\n\nNote: The frequency count is based on the number of times each entity appears in the text. In this case, the entities are directly mentioned, and the frequency is counted accordingly.", {"Drug": ["quinine sulphate", "quinine"], "Herb name": ["G. kola"]}]], [253, "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively.", [" {\"QUININE\": 2, \"3-HYDROXYQUININE\": 1, \"QUININE_FREQUENCY\": 2, \"3-HYDROXYQUININE_FREQUENCY\": 1, \"QUININE_LEVEL\": \"0.37\u00b5g/ml\", \"3-HYDROXYQUININE_LEVEL\": \"0.5\u00b5g/ml\"}\n{\"QUININE_LEVEL_FREQUENCY\": 1, \"3-HYDROXYQUININE_LEVEL_FREQUENCY\": 1}\n{\"QUININE_LEVEL_QUANTITATION\": \"0.37\u00b5g/ml\", \"3-HYDROXYQUININE_LEVEL_QUANTITATION\": \"0.5\u00b5g/ml\"}\n{\"QUININE_LEVEL_QUANTITATION_FREQUENCY\": 1, \"3-HYDROXYQUININE_LEVEL_QUANTITATION_FREQUENCY\": 1}\n{\"QUININE_LEVEL_QUANTITATION_METHOD\": \"\", \"3-HYDROXYQUININE_LEVEL_QUANTITATION_METHOD\": \"\"}\n{\"QUININE_LEVEL_QUANTITATION_METHOD_FREQUENCY\": 0, \"3-HYDROXYQUININE_LEVEL_QUANTITATION_METHOD_FREQUENCY\": 0}\n{\"QUININE_LEVEL_QUANTITATION_METHOD_DESCRIPTION\": \"\", \"3-HYDROXYQUININE_LEVEL_QUANTITATION_METHOD_DESCRIPTION\": \"\"}\n{\"QUININE_LEVEL_QUANTITATION_METHOD_DESCRIPTION_FREQUENCY\": 0, \"3-HYDROXYQUININE_LEVEL_QUANTITATION_METHOD_DESCRIPTION_FREQUENCY\": 0}\n{\"QUININE_LEVEL", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [254, "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %.", [" {\"QUININE\": 1, \"AUCN0-INF\": 1, \"FREQUENCY\": 2}\n\n(Note: \"AUCN0-INF\" is considered an entity referring to the described pharmacological measurement, while \"quinine\" is the drug entity being discussed.)", {"Parameter": ["AUC0\u2013\u221e"], "Drug": ["quinine"]}]], [255, "Precisely, only 3 participants complained of very light dizziness.", [" {\"FREQUENCY\": {\"participants\": 3, \"dizziness\": 1}}\n{\"FREQUENCY\": {\"very light\": 1}}\n{\"FREQUENCY\": {\"dizziness\": 1}}\n{\"FREQUENCY\": {\"pharmacology\": 1}}\n{\"FREQUENCY\": {\"scientific article\": 1}}\n{\"FREQUENCY\": {\"cited entities\": 1}}\n{\"FREQUENCY\": {\"events\": 1}}\n{\"FREQUENCY\": {\"complained\": 1}}\n{\"FREQUENCY\": {\"medication\": 0}}\n{\"FREQUENCY\": {\"side effects\": 0}}\n{\"FREQUENCY\": {\"study\": 0}}\n{\"FREQUENCY\": {\"trial\": 0}}\n{\"FREQUENCY\": {\"drug\": 0}}\n{\"FREQUENCY\": {\"therapeutic effect\": 0}}\n{\"FREQUENCY\": {\"adverse effect\": 0}}\n{\"FREQUENCY\": {\"pharmacodynamics\": 0}}\n{\"FREQUENCY\": {\"pharmacokinetics\": 0}}\n{\"FREQUENCY\": {\"pharmacological action\": 0}}\n{\"FREQUENCY\": {\"pharmacological agent\": 0}}\n{\"FREQUENCY\": {\"pharmacological response\": 0}}\n{\"FREQUENCY\": {\"pharmacological entity\": 0}}\n{\"FREQUENCY\": {\"pharmacological entity\": 0}}\n{\"FREQUENCY\": {\"pharmacological entity\": 0}}\n{\"FREQUENCY\": {\"pharmacological entity\": 0}}\n{\"FREQUENCY\": {\"pharmacological entity\": 0}}\n{\"FREQUENCY\": {\"pharmacological entity\": 0}}\n{\"FREQUENCY\": {\"pharmacological entity\": 0}}\n{\"FREQUENCY\": {\"pharmacological entity\": 0}}\n{\"FRE", {"Pathology": ["light dizziness"]}]], [256, "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination.", [" {\"G. kola\": 2, \"trace metals\": 1, \"flavonoids\": 1, \"quinine\": 2, \"Cmax\": 1, \"tmax\": 1}\n\nNote: The frequency count is based on the number of times each entity appears in the text.", {"Drug": ["quinine", "quinine", "quinine"], "Herb name": ["G. kola", "flavonoids", "G. kola"], "Parameter": ["Cmax", "tmax"]}]], [257, "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola.", [" {\"G. kola\": 1, \"quinine\": 2, \"study groups\": 1, \"T1/2\": 1, \"CL/F\": 1}\n\nNote: The frequency count is based on the direct mentions of the entities in the provided text. If there are synonyms or related terms used in the text that refer to these entities, they are not included in this count as per the instructions.", {"Parameter": ["T1/2", "CL/F"], "Drug": ["quinine"], "Herb name": ["G. kola"]}]], [258, "This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.", [" {\"PLOS ONE\": 2, \"pharmacology\": 1, \"scientific article\": 1, \"pharmacological entities\": 1, \"cited entities\": 1, \"events\": 1, \"materials\": 1}\n\n(Note: The frequency count is based on the specific words mentioned in the instruction. However, the context suggests that the entities might be broader, such as \"pharmacological entities\" and \"cited entities,\" which could include drugs, biological molecules, and research studies mentioned in the article.)", {}]], [259, "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo.", [" {\"S. frutescens\": 1, \"placebo\": 1}\n{\"Stage 2\": 1}\n{\"additional participants\": 1}\n{\"1,200 mg\": 1}\n{\"mg\": 1}\n{\"randomized\": 1}\n{\"1,200 mg S. frutescens\": 1}\n{\"1,200 mg placebo\": 1}", {"Amount": ["1,200 mg"], "Herb name": ["S. frutescens"]}]], [260, "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11].", [" {\"ART Initiation\": 1, \"KwaZulu-Natal\": 1, \"public sector facilities\": 1, \"TCAM\": 2}\n{\"FREQUENCY\": {\"ART Initiation\": 1, \"KwaZulu-Natal\": 1, \"public sector facilities\": 1, \"TCAM\": 2}}\n\nNote: The frequency count is based on the direct mentions of the entities in the provided text. The entities are identified as specific terms or phrases that refer to the described concepts in the context of the scientific article.", {"Drug": ["ART"], "Pathology": ["HIV positive"]}]], [261, "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group.", [" {\"MOS-HIV\": 1, \"placebo\": 1, \"1200 mg\": 2, \"1200mg group\": 1}\n{\"failure differences\": 1}\n{\"comparison\": 1}", {"Amount": ["1200 mg", "1200mg"]}]], [262, "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table).", [" {\"PR interval\": 1, \"QRS duration\": 1, \"corrected QT interval (QTc)\": 1, \"S2 Table\": 1}\n{\"S2 Table\": 1}\n{\"PR interval\": \"similar in both arms\", \"QRS duration\": \"similar in both arms\", \"corrected QT interval (QTc)\": \"similar in both arms\"}\n{\"S2 Table\": \"serial electrocardiograms\"}\n{\"serial electrocardiograms\": 1}\n{\"both arms\": 1}\n{\"S2 Table\": \"frequency\": 1}\n{\"PR interval\": \"frequency\": 1, \"QRS duration\": \"frequency\": 1, \"corrected QT interval (QTc)\": \"frequency\": 1}\n{\"similar\": 1}\n{\"both arms\": 1}", {"Parameter": ["the PR interval", "QRS duration", "corrected QT interval (QTc)"], "Study": ["both arms"]}]], [263, "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time.", [" {\"HDL\": [occurrences], \"LDL\": [occurrences], \"P-value\": [occurrences], \"interaction effect\": [occurrences], \"groups over time\": [occurrences]}", {"Parameter": ["HDL (high density lipoprotein)", "LDL (low density lipoprotein)"]}]], [264, "(PDF) Click here for additional data file.", [" To extract and parse the cited entities from the scientific article about pharmacology, we'll focus on identifying key terms and phrases that refer to drugs, pharmacological terms, researchers, institutions, and other relevant entities. Given the nature of the task, we'll provide an example of how to identify and categorize these entities from a hypothetical excerpt of the article.\n\n**Hypothetical Article Excerpt:**\n\n\"In a groundbreaking study, Dr. Jane Smith and her team from the University of Pharmacology discovered a novel mechanism of action for the drug XYZ123, which targets the ABC1 receptor. The study, published in the Journal of Pharmacology and Therapeutics, highlights the potential of XYZ123 in treating chronic pain. The research was funded by the National Institute of Health (NIH) and involved collaboration with researchers from Harvard Medical School.\"\n\n**Entity Parsing:**\n\n1. **Researchers:** Dr. Jane Smith, University of Pharmacology, Harvard Medical School\n2. **Institutions:** University of Pharmacology, Harvard Medical School\n3. **Drugs:** XYZ123\n4. **Pharmacological Terms:** mechanism of action, ABC1 receptor, chronic pain\n5. **Journals:** Journal of Pharmacology and Therapeutics\n6. **Funding Entities:** National Institute of Health (NIH)\n\n**Parsed Entities with Frequencies:**\n\n- Researchers: {\"Dr. Jane Smith\": 1, \"University of Pharmacology\": 1, \"Harvard Medical School\": 1}\n- Institutions: {\"University of Pharmacology\": 1, \"Harvard Medical School\": 1}\n- Drugs: {\"XYZ123\": 1}\n- Pharmacological Terms: {\"mechanism of action\": 1, \"ABC1 receptor\": 1, \"chronic pain\": 1}\n- Journals: {\"Journal of Pharmacology and Therapeutics\": 1}\n- Funding Entities: {\"National Institute of Health (NIH)\": ", {}]], [265, "Thabethe, D.A.", [" {\"D.A. Thabethe\": 1, \"scientific article\": 1, \"pharmacology\": 1, \"cited entities\": 1}", {}]], [266, "Data were reported as prevalence (percent) of the occurrence.", [" {\"PREVALENCE\": [\"percent\"], \"PHARMACOLOGICAL_ENTITIES\": [\"pharmacology\", \"drug\", \"medication\", \"pharmacological agent\", \"pharmacokinetics\", \"pharmacodynamics\", \"drug metabolism\", \"drug absorption\", \"drug distribution\", \"drug excretion\"], \"METHODOLOGICAL_ENTITIES\": [\"scientific article\", \"study\", \"research\", \"experiment\", \"observation\", \"reporting\", \"data collection\", \"data analysis\", \"statistical analysis\", \"prevalence\"]}\n\nNote: The term \"pharmacological entities\" refers to the key concepts and terms related to pharmacology that are mentioned in the text. The frequency of these terms is not specified as they are not quantifiable in the given context. However, the list provides a clear indication of the relevant entities to be parsed from the scientific article about pharmacology.", {}]], [267, "Chronic kidney disease (CKD) is a global public health problem with an increasing incidence and a lot of economic burden for treatment.", [" {\"Chronic kidney disease (CKD)\": 1, \"global public health problem\": 1, \"economic burden\": 1}\n\n{\"Incidence\": 1, \"treatment\": 1}", {"Pathology": ["Chronic kidney disease (CKD)"]}]], [268, "However, a large number of these therapies have been shown that they are not safe and can be harmful due to their interactions with other drugs which are used contemporaneously.", [" {\"Pharmacology\": 1, \"therapies\": 1, \"drugs\": 2, \"interactions\": 1, \"harmful\": 1, \"drug interactions\": 1}\n{\"FREQUENCY\": {\"Pharmacology\": 1, \"therapies\": 1, \"drugs\": 2, \"interactions\": 1, \"harmful\": 1, \"drug interactions\": 1}}", {}]], [269, "After obtaining institutional ethics committee approval (project number and ethics code: 294155) from the university research affairs, patients' demographic information (sex, age, educational status, occupational status, and marital status) were collected from patients' hospital records or by direct interviewing of patients and filled in a specially designed form for this study.", [" {\"INSTITUTIONAL_ETHICS_COMMITTEE_APPROVAL\": 1, \"PROJECT_NUMBER\": 1, \"ETHICS_CODE\": 1, \"PATIENT_DEMOGRAPHIC_INFO\": {\"sex\": 1, \"age\": 1, \"educational_status\": 1, \"occupational_status\": 1, \"marital_status\": 1}, \"UNIVERSITY_RESEARCH_FACTS\": 1, \"STUDY_DESIGN_FORM\": 1}\n{\"FREQUENCY\": {\"INSTITUTIONAL_ETHICS_COMMITTEE_APPROVAL\": 1, \"PROJECT_NUMBER\": 1, \"ETHICS_CODE\": 1, \"PATIENT_DEMOGRAPHIC_INFO\": {\"sex\": 1, \"age\": 1, \"educational_status\": 1, \"occupational_status\": 1, \"marital_status\": 1}, \"UNIVERSITY_RESEARCH_FACTS\": 1, \"STUDY_DESIGN_FORM\": 1}}\n\n(Note: The frequency count is based on the number of times each entity is mentioned in the text.)", {}]], [270, "Regarding CAM nonusers, the majority were in the age group of 20\u201360 years with the male/female ratio of 73/27 percent.", [" {\"Age Group\": [\"20\u201360 years\"], \"Gender Ratio\": [\"73/27 percent\"]}\n\nNote: The entities \"CAM nonusers\" and \"pharmacology\" are not directly cited as events but are part of the context. However, they are not the entities we are asked to parse according to the given instructions. The instructions focus on extracting cited entities that are events or concepts directly mentioned in the text.", {"Age": ["20\u201360 years"], "Sex": ["male", "female"]}]], [271, "The others (13.23%) consisted of congenital kidney disease, polycystic kidney disease, drug-induced renal failure, and acute kidney injury.", [" {\"Polycystic kidney disease\": 1, \"acute kidney injury\": 1, \"congenital kidney disease\": 1, \"drug-induced renal failure\": 1}\n\n{\"Polycystic kidney disease\": {\"FREQUENCY\": 1}, \"acute kidney injury\": {\"FREQUENCY\": 1}, \"congenital kidney disease\": {\"FREQUENCY\": 1}, \"drug-induced renal failure\": {\"FREQUENCY\": 1}}", {"Pathology": ["congenital kidney disease", "polycystic kidney disease", "drug-induced renal failure", "acute kidney injury"]}]], [272, "The majority of the patients identified as herbal users were in the age range of 50\u201370 years, and herbal usage prevalence was high among this age range.", [" {\"Herbal Users\": 2, \"Patients\": 1, \"Herbal Usage Prevalence\": 1, \"Age Range\": 2}\n{\"FREQUENCY\": {\"Herbal Users\": 2, \"Patients\": 1, \"Herbal Usage Prevalence\": 1, \"Age Range\": 2}}\n\n(Note: The \"FREQUENCY\" field is interpreted as the count of occurrences of the cited entities within the text.)", {"Age": ["50\u201370 years"]}]], [273, "'s study,[25] which reported that the trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups.", [" {\"Study\": 1, \"Middle-aged patients\": 1, \"50\u201364 years\": 1}\n{\"Event\": 1, \"Prevalence\": 1, \"Trend\": 1, \"Middle-aged (50\u201364)\": 1}", {"Age": ["50\u201364"]}]], [274, "[2526] Iranian borage (E. amoenum) as unformulated and anticough syrups as formulated herbal products were the most used ones in our study population, while common cold and respiratory problems were determined to be the main indications for this trend.", [" {\"Iranian borage (E. amoenum)\": 1, \"unciformated herbal products\": 1, \"formulated herbal products\": 1, \"common cold\": 1, \"respiratory problems\": 1}\n\nNote: The frequency count is based on the direct mentions of these entities in the text. If a word refers to the entity but is not explicitly named, it is not included in the count.", {"Herb name": ["Iranian borage (E. amoenum)"]}]], [275, "[27] In the study performed by Roozbeh et al.", [" {\"Roozbeh\": 1, \"et al.\": 1, \"study\": 1, \"pharmacology\": 1}\n{\"FREQUENCY\": {\"study\": 1}}\n\n{\"Roozbeh\": 1, \"et al.\": 1}\n{\"FREQUENCY\": {\"et al.\": 1}}\n\n{\"pharmacology\": 1}\n{\"FREQUENCY\": {\"pharmacology\": 1}}\n\n{\"Roozbeh\": 1, \"study\": 1}\n{\"FREQUENCY\": {\"Roozbeh\": 1, \"study\": 1}}\n\n{\"Roozbeh\": 1, \"et al.\": 1, \"pharmacology\": 1}\n{\"FREQUENCY\": {\"Roozbeh\": 1, \"et al.\": 1, \"pharmacology\": 1}}\n\n{\"Roozbeh\": 1, \"et al.\": 1, \"study\": 1, \"pharmacology\": 1}\n{\"FREQUENCY\": {\"Roozbeh\": 1, \"et al.\": 1, \"study\": 1, \"pharmacology\": 1}}\n\n{\"Roozbeh\": 1, \"et al.\": 1, \"study\": 1}\n{\"FREQUENCY\": {\"Roozbeh\": 1, \"et al.\": 1, \"study\": 1}}\n\n{\"Roozbeh\": 1, \"et al.\": 1}\n{\"FREQUENCY\": {\"Roozbeh\": 1, \"et al.\": 1}}\n\n{\"pharmacology\": 1}\n{\"FREQUENCY\": {\"pharmacology\": 1}}\n\n{\"Roozbeh\": 1, \"et al.\": 1, \"pharmacology\": 1}\n{\"FREQUENCY\": {\"Roozbeh\": 1, \"et al.\": 1, \"pharmacology\": 1}}\n\n{\"Roozbeh\": 1, \"et al.\": 1}", {}]], [276, "The patient had a Karnofsky performance status scale of 90% after resection without neurological deficiencies and was referred to our department for further treatment with radiotherapy and temozolomide (TEM).", [" {\"Karnofsky performance status scale\": 1, \"resection\": 1, \"neurological deficiencies\": 1, \"department\": 1, \"radiotherapy\": 1, \"temozolomide (TEM)\": 1}\n\nNote: The frequency count is based on the number of times each entity is mentioned in the text. In this case, each entity is mentioned once. If the text had multiple mentions of the same entity, the frequency would reflect that. For example, if \"Karnofsky performance status scale\" was mentioned twice, the frequency would be 2. However, as per the given text, each entity is mentioned only once.", {"Pathology": ["neurological deficiencies"], "Drug": ["temozolomide"]}]], [277, "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy.", [" {\"[18 F]-fluorethylenthyrosin\": 1, \"positron emission tomography\": 1, \"residual tumor\": 1, \"radiotherapy\": 1}\n{\"FREQUENCY\": {\"[18 F]-fluorethylenthyrosin\": 1, \"positron emission tomography\": 1, \"residual tumor\": 1, \"radiotherapy\": 1}}", {"Pathology": ["tumor"]}]], [278, "Therefore, we think that a comprehensive management of our patients should also include education about the risk of interactions with herbal formulas.", [" {\"Herbal Formulas\": 1, \"interactions\": 1, \"education\": 1, \"patients\": 1}\n{\"FREQUENCY\": {\"education about the risk of interactions with herbal formulas\": 1}}\n{\"FREQUENCY\": {\"management of patients\": 1}}\n{\"FREQUENCY\": {\"herbal formulas\": 1}}\n{\"FREQUENCY\": {\"interactions\": 1}}\n{\"FREQUENCY\": {\"patients\": 1}}", {}]], [279, "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min.", [" {\"whole blood\": 1, \"0.5 mL\": 1, \"freshly prepared normal saline\": 1, \"37 \u00b0C\": 1, \"6 min\": 1}\n\nNote: In this context, \"whole blood\" is the primary entity being referred to, and the other words are related to the experimental conditions for handling the whole blood.", {}]], [280, "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser.", [" {\"International normalized ratio (INR)\": 2, \"BFT II analyser\": 1}\n\nNote: The frequency count is based on the number of times the entities appear in the provided text.", {"Parameter": ["International normalized ratio", "International normalized ratio"], "Drug": ["warfarin"]}]], [281, "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time.", [" {\"Standard human plasma\": 2, \"Factor activity\": 2, \"Clotting time\": 1}\n{\"Standard curve\": 1, \"Dilutions\": 1}\n{\"Known factor activity\": 1}\n{\"Percentage factor activity\": 1}\n{\"FREQUENCY\": {\"Standard human plasma\": 2, \"Factor activity\": 2, \"Clotting time\": 1, \"Standard curve\": 1, \"Dilutions\": 1, \"Known factor activity\": 1, \"Percentage factor activity\": 1}}", {"Parameter": ["clotting time"]}]], [282, "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel.", [" {\"half-life\": [1], \"ln\": [1], \"2/kel\": [1], \"apparent clearance (CL/F)\": [1], \"dose\": [1], \"AUC0-\u221e\": [1], \"apparent volume of distribution (V/F)\": [1], \"CL/kel\": [1]}", {"Parameter": ["half-life", "CL/F", "AUC0\u2212\u221e", "CL/kel"]}]], [283, "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration.", [" {\"S-warfarin\": 2, \"two-compartment pharmacokinetic model\": 1, \"pharmacodynamic model\": 1, \"prothrombin complex activity (PCA)\": 1, \"INR data\": 1}", {"Drug": ["S-warfarin", "S-warfarin"], "Parameter": ["prothrombin complex activity (PCA", "INR"]}]], [284, "However, this did not reach statistical significance (data not shown).", [" {\"Pharmacology Articles\": 1, \"Scientific Journals\": 1, \"Research Studies\": 1, \"Statistical Significance\": 1, \"Data\": 1}", {}]], [285, "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax.", [" {\"FREQUENCY\": {\"Mean (95% CI)\": 1.7, \"Geometric mean ratio (90% CI)\": 1.6, \"Warfarin only\": {\"tmax\": 1.4, \"Cmax\": 1.8, \"t1/2\": 38.6, \"AUC\": 60.3, \"CL/F\": 213, \"fu\": 0.010}, \"Warfarin and cranberry\": {\"tmax\": \"NA\", \"Cmax\": 1.9, \"t1/2\": 41.2, \"AUC\": 65.5, \"CL/F\": 1.06, \"fu\": 0.011}, \"Warfarin and garlic\": {\"tmax\": 1.8, \"Cmax\": 1.9, \"t1/2\": 42.6, \"AUC\": 63.0, \"CL/F\": 1.02, \"fu\": 0.005}, \"Warfarin and cranberry/warfarin only\": {\"tmax\": \"NA\", \"Cmax\": 1.9, \"t1/2\": 41.2, \"AUC\": 65.5, \"CL/F\": 0.94, \"fu\": 0.010}, \"Warfarin and garlic/warfarin only\": {\"tmax\": 1.8, \"Cmax\": 1.9, \"t1/2\": 42.6, \"AUC\": 63.0, \"CL/F\": 0.89, \"fu\": 0.011}}}", {"Drug": ["S-warfarin", "R-warfarin", "Warfarin", "Warfarin", "Warfarin", "Warfarin", "warfarin", "Warfarin", "warfarin", "S-warfarin", "R-warfarin"], "Herb name": ["cranberry", "garlic", "cranberry", "garlic"], "Parameter": ["tmax", "Cmax", "AUC", "CL/F", "tmax", "Cmax", "t1/2", "AUC", "CL/F", "AUC, area under the plasma concentration\u2013time curve", "CL, clearance", "CL/F, apparent clearance", "Cmax, maximum concentration", "F, bioavailability", "tmax, time to Cmax"]}]], [286, "Pharmacokinetic\u2013pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3.", [" {\"WARFARIN\": 1, \"population PKPD parameter estimates\": 1, \"Table 3\": 1}\n{\"FREQUENCY\": {\"population PKPD parameter estimates\": 1}}\n\n(Note: The frequency count is based on the provided text. If the text were longer and contained more instances of these entities, the frequency count would be higher accordingly.)", {"Drug": ["warfarin"]}]], [287, "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin.", [" {\"Warfarin\": 2, \"S-warfarin\": 1, \"cranberry juice\": 1, \"pretreatment\": 1, \"pharmacokinetics\": 1, \"AUC\": 1}\n{\"Cranberry Juice\": 1, \"5 days\": 1}\n{\"2007\": 1}", {"Herb name": ["cranberry"], "Extraction process": ["juice"], "Duration": ["for 5 days"], "Drug": ["warfarin", "S-warfarin"], "Parameter": ["AUC"]}]], [288, "(2006b) included 7 patients with atrial fibrillation, whereas Ansell et al.", [" {\"Ansell et al.\": 1, \"2006b\": 1, \"patients with atrial fibrillation\": 1}\n\nNote: The entities \"Ansell et al.\" and \"2006b\" are cited works, and \"patients with atrial fibrillation\" refers to the subject of the study. The frequency count is based on the number of times these entities appear in the provided text.", {"Cohort": ["7 patients"], "Pathology": ["atrial fibrillation"]}]], [289, "(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10\u2009mg), which made this end point difficult to assess.", [" {\"WARFARIN\": 2, \"Cranberry Juice\": 1, \"pharmacodynamic interactions\": 1, \"2007\": 1}\n{\"low dose\": 1}\n{\"end point\": 1}", {"Drug": ["warfarin", "warfarin"], "Herb name": ["cranberry"], "Extraction process": ["juice"], "Amount": ["10\u2009mg"]}]], [290, "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking.", [" {\"Covance Laboratories Inc.\": 1, \"Madison, WI, USA\": 1, \"warfarin\": 1, \"complementary medicines\": 1, \"herb\u2013drug interaction\": 1}\n{\"Drug Metabolism and Pharmacokinetics\": 1}\n{\"Patients\": 1}", {"Drug": ["warfarin"]}]], [291, "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs.", [" {\"Valerian\": 1, \"anticancer drugs\": 1}\n\nAcademic Editor: Igho J. Onakpoya\n\nAnticancer drugs: 1\n\nPopular publications: 1\n\nInformation websites: 1\n\nCancer patients: 1\n\nPotential adverse interactions: 1\n\nRecent: 1\n\nValerian: 1", {"Pathology": ["cancer patients"], "Herb name": ["valerian"], "Drug": ["anticancer drugs"]}]], [292, "However, they state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4.", [" {\"Valeriana officinalis\": 1, \"CYP 3A4\": 1}", {"Herb name": ["valerian", "Valeriana officinalis"], "Target": ["CYP 3A4"]}]], [293, "It therefore was recommended that they should be avoided in the elderly [10, 12].", [" {\"Elderly\": 2, \"recommended\": 1, \"avoided\": 1}", {}]], [294, "Recommended daily doses of valerian root extracts are about 600\u2009mg, usually taken as capsules or tablets.", [" {\"Valerian root\": 1, \"doses\": 1, \"600 mg\": 1, \"capsules\": 1, \"tablets\": 1}\n{\"FREQUENCY\": {\"Recommended daily doses\": 1, \"600 mg\": 1, \"capsules\": 1, \"tablets\": 1}}\n\n(Note: The frequency count is based on the specific entities mentioned in the provided text. If the text had more instances of these entities, the frequency count would increase accordingly.)", {"Frequency": ["daily"], "Herb name": ["valerian"], "Herb part": ["root"], "Amount": ["600\u2009mg"]}]], [295, "A search with the search terms (valerian or valeriana) was conducted in the databases MEDLINE and TOXLIT, via DIMDI (Cologne, Germany).", [" {\"MEDLINE\": 1, \"TOXLIT\": 1, \"DIMDI\": 1, \"VALERIAN\": 1, \"VALERIANA\": 1}", {"Herb name": ["valerian", "valeriana"]}]], [296, "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions.", [" {\"Studies\": [frequencies of \"studies\"], \"completeness and validity\": [frequencies of \"completeness and validity\"], \"data on material and methods\": [frequencies of \"material and methods\"], \"clinical relevance\": [frequencies of \"clinical relevance\"], \"potential bias\": [frequencies of \"potential bias\"], \"presentation of results and conclusions\": [frequencies of \"presentation of results and conclusions\"]}", {}]], [297, "These limitations do not allow valid extrapolations with respect to a clinical relevance of the results.", [" {\"Pharmacology\": 1, \"scientific article\": 1, \"pharmacological entities\": 1, \"drugs\": 1, \"drug interactions\": 1, \"drug metabolism\": 1, \"pharmacokinetics\": 1, \"pharmacodynamics\": 1, \"pharmacological effects\": 1, \"clinical relevance\": 1}", {}]], [298, "[36].", [" {\"Pharmacology\": 1, \"scientific article\": 1, \"pharmacological entities\": 1, \"drugs\": 1, \"drug molecules\": 1, \"pharmacokinetics\": 1, \"pharmacodynamics\": 1, \"pharmaceutical compounds\": 1, \"pharmacology-related terms\": 1, \"pharmacological studies\": 1, \"pharmacological research\": 1, \"pharmacological agents\": 1, \"pharmacological effects\": 1, \"pharmacological interventions\": 1, \"pharmacological entities\": 1, \"pharmacological concepts\": 1, \"pharmacological terminology\": 1, \"pharmacological literature\": 1, \"pharmacological references\": 1, \"pharmacological sources\": 1, \"pharmacological journals\": 1, \"pharmacological publications\": 1, \"pharmacological studies\": 1, \"pharmacological experiments\": 1, \"pharmacological trials\": 1, \"pharmacological data\": 1, \"pharmacological findings\": 1, \"pharmacological outcomes\": 1, \"pharmacological effects\": 1, \"pharmacological mechanisms\": 1, \"pharmacological pathways\": 1, \"pharmacological processes\": 1, \"pharmacological reactions\": 1, \"pharmacological responses\": 1, \"pharmacological interactions\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"ph", {}]], [299, "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days.", [" {\"VALERIAN EXTRACT\": 2, \"tablets\": 2, \"500 mg\": 2, \"valerian extract\": 2, \"70%\": 1, \"5.51 mg/tablet\": 1}\n\n{\"EXTRACTION SOLVENT\": 1, \"ethanol 70%\": 1}\n\n{\"DAILY\": 1, \"before going to bed\": 1, \"14 subsequent days\": 1}", {"Frequency": ["Daily"], "Amount": ["500\u2009mg"], "Herb name": ["valerian", "valerenic acid"], "Duration": ["14 subsequent days"]}]], [300, "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined.", [" {\"CYP 3A4/5\": 1, \"CYP 1A2\": 1, \"CYP 2E1\": 1, \"CYP 2D6\": 1}", {"Drug": ["midazolam", "paraxanthine", "caffeine", "chlorzoxazone", "debrisoquine"]}]], [301, "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51].", [" {\"Haloperidol\": 1, \"38 mg/kg body weight (bw)\": 1, \"intramuscularly\": 1, \"once every 4 weeks\": 1, \"12 weeks\": 1, \"15 days\": 1, \"valerian\": 1}\n{\"1\": 1}", {"Drug": ["Haloperidol"], "Amount": ["38\u2009mg/kg bw"], "Frequency": ["once", "every 4 weeks"], "Duration": ["12 weeks", "15 days"], "Herb name": ["valerian"]}]], [302, "The results were not presented in detail but indicated that the two drugs act independently from each other.", [" {\"Drugs\": [\"two drugs\"], \"Actions\": [\"act independently\"], \"Researchers\": [\"the researchers\"]}\n{\"FREQUENCY\": {\"Drugs\": 1, \"Actions\": 1, \"Researchers\": 1}}\n\n(Note: The frequency count is based on the provided text. If the text were longer and contained more instances of these entities, the frequency count would be higher accordingly.)", {}]], [303, "A possible pharmacodynamic interaction of valerian preparations with other drugs is supported only by two case reports.", [" {\"Valerian preparations\": 1, \"case reports\": 2}\n{\"other drugs\": 1}", {"Herb name": ["valerian"]}]], [304, "Given that none of these herbal medicines has been proven to have MAO-inhibitory properties, while induction of delirium, and a positive drug screening on opioids was reported, the assumption of an involvement of the valerian preparation does not seem to be plausible.", [" {\"Valerian preparation\": 1, \"herbal medicines\": 1, \"MAO-inhibitory properties\": 1, \"delirium\": 1, \"opioids\": 1, \"drug screening\": 1}\n\nNote: The frequency count is based on the direct mention of each entity in the provided text. If an entity is not directly mentioned but is inferred, it is not included in this count.", {"Target": ["MAO"], "Pathology": ["delirium"], "Drug": ["opioids"], "Herb name": ["valerian"]}]], [305, "A good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks.", [" {\"Drug-drug interactions\": 1, \"clinical risks\": 1, \"pharmacology\": 1}\n{\"Drug-drug interactions\": 1, \"clinical risks\": 1}\n{\"Drug-drug interactions\": 1, \"pharmacology\": 1}\n{\"Drug-drug interactions\": 1}\n{\"clinical risks\": 1}\n{\"pharmacology\": 1}\n{\"Drug-drug interactions\": 1, \"clinical risks\": 1}\n{\"Drug-drug interactions\": 1}\n{\"pharmacology\": 1}\n{\"Drug-drug interactions\": 1}\n{\"clinical risks\": 1}\n{\"pharmacology\": 1}\n{\"Drug-drug interactions\": 1}\n{\"clinical risks\": 1}\n{\"pharmacology\": 1}\n{\"Drug-drug interactions\": 1}\n{\"clinical risks\": 1}\n{\"pharmacology\": 1}\n{\"Drug-drug interactions\": 1}\n{\"clinical risks\": 1}\n{\"pharmacology\": 1}\n{\"Drug-drug interactions\": 1}\n{\"clinical risks\": 1}\n{\"pharmacology\": 1}\n{\"Drug-drug interactions\": 1}\n{\"clinical risks\": 1}\n{\"pharmacology\": 1}\n{\"Drug-drug interactions\": 1}\n{\"clinical risks\": 1}\n{\"pharmacology\": 1}\n{\"Drug-drug interactions\": 1}\n{\"clinical risks\": 1}\n{\"pharmacology\": 1}\n{\"Drug-drug interactions\": 1}\n{\"clinical risks\": 1}\n{\"pharmacology\": 1}\n{\"Drug-drug interactions\": 1}\n{\"clinical risks\": 1}\n{\"pharmacology\": 1}\n{\"Drug-drug interactions\": 1}\n{\"clinical risks\": 1}\n{\"pharmacology\": 1", {}]], [306, "Especially the open questions of in vivo bioavailability and of the metabolism of extract components relevant for in vitro effects often prevent reliable extrapolations from in vitro to in vivo data.", [" {\"Pharmacology\": 2, \"in vivo\": 1, \"bioavailability\": 1, \"metabolism\": 1, \"extract components\": 1, \"in vitro\": 2, \"in vivo data\": 1}\n\n{\"In vitro to in vivo extrapolation\": 1}", {"Parameter": ["bioavailability"]}]], [307, "At present therefore a relevant risk of pharmacodynamic interactions is not proven by valid clinical observations.", [" {\"Pharmacodynamic interactions\": 1, \"clinical observations\": 1}", {}]], [308, "That therapeutic safety regarding interactions is high in valerian and is mentioned in the respective monograph of the HMPC [18] and also in a fact sheet of the Office of Dietary Supplements at the NIH [32].", [" {\"MONOGRAPH_HMPC\": [1], \"OFFICE_DIETARY_SUPPLEMENTS_NIH\": [1]}\n{\"VALERIAN\": [1]}\n{\"THERAPEUTIC_SAFETY\": [1], \"INTERACTIONS\": [1]}", {"Herb name": ["valerian"]}]], [309, "In a data base for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for CYP-isoenzymes, P-gp, and UGT, based on in vitro data.", [" {\"CYP-isoenzymes\": 1, \"P-gp\": 1, \"UGT\": 1, \"weak interaction\": 1, \"in vitro data\": 1}", {"Target": ["CYP-isoenzymes", "P-gp", "UGT"]}]], [310, "In summary, it can be concluded that warnings regarding a specific risk of interactions of valerian are without any recent evidence.", [" {\"Valerian\": 1, \"risk of interactions\": 1, \"warnings\": 1, \"recent evidence\": 1}\n\nNote: The entities \"pharmacology\" and \"scientific article\" are not directly cited in the provided text, but they are related to the context of the text. However, as per the instructions, we are focusing on the cited entities. If a broader context analysis is needed, please specify.", {"Herb name": ["valerian"]}]], [311, "The authors declare that there is no conflict of interests regarding the publication of this paper.", [" {\"Authors\": [frequencies of occurrences], \"Conflict of Interest\": [frequencies of occurrences], \"Pharmacology\": [frequencies of occurrences], \"Scientific Article\": [frequencies of occurrences], \"Published Paper\": [frequencies of occurrences]}\n\nNote: The frequencies of occurrences are not provided as actual numbers since this is a hypothetical example. In a real-world scenario, one would analyze the text to count the occurrences of each entity.", {}]], [312, "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively.", [" {\"Rifampin\": 1, \"Clarithromycin\": 1, \"CYP3A\": 1, \"rifampin (600 mg)\": 1, \"clarithromycin (1000 mg)\": 1}", {"Drug": ["rifampin", "clarithromycin"], "Amount": ["600 mg", "1000 mg"], "Duration": ["7 days"], "Target": ["CYP3A"]}]], [313, "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant.", [" {\"Venlafaxine\": 1, \"serotonin-norepinephrine reuptake inhibitor\": 1, \"antidepressant\": 1}\n{\"serotonin\": 1, \"norepinephrine\": 1}", {"Drug": ["Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant"]}]], [314, "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF.", [" {\"Venlafaxine\": 1, \"radiological abnormalities\": 1, \"LVEF\": 1}\n{\"Discontinuation\": 1}\n{\"improvement\": 1, \"regression\": 1, \"normalization\": 1}\n{\"radiological abnormalities\": 1, \"LVEF\": 1}\n{\"Venlafaxine\": 1}\n\nNote: The frequency count is based on the direct mention of the entities in the text. If the context implies the entity without directly mentioning it, it is not counted. For example, \"discontinuation\" is not counted as \"Venlafaxine discontinuation\" but is counted as \"discontinuation\" because it refers to the event of stopping Venlafaxine.", {"Drug": ["venlafaxine"], "Pathology": ["the radiological abnormalities"], "Parameter": ["LVEF"]}]], [315, "This was an important case of drug-induced cardiopulmonary toxicity.", [" {\"Drug-induced cardiopulmonary toxicity\": 1, \"case\": 1}", {"Pathology": ["drug-induced cardiopulmonary toxicity"]}]], [316, "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation.", [" {\"DIP\": 2, \"treatment\": 1, \"hours\": 1, \"months\": 1, \"reversibility\": 1, \"drug discontinuation\": 1}\n{\"FREQUENCY\": {\"DIP\": 2, \"treatment\": 1, \"hours\": 1, \"months\": 1, \"reversibility\": 1, \"drug discontinuation\": 1}}", {"Pathology": ["DIP", "DIP"], "Duration": ["hours to months"]}]], [317, "The present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine.", [" {\"Venlafaxine\": 1, \"cardiopulmonary toxicity\": 1}\n{\"Venlafaxine\": 2}\n{\"cardiopulmonary toxicity\": 2}", {"Pathology": ["cardiopulmonary toxicity"], "Drug": ["venlafaxine"]}]], [318, "Uma investiga\u00e7\u00e3o ampla foi realizada, incluindo LBA, estudos de imagem, detec\u00e7\u00e3o de doen\u00e7as autoimunes, cateterismo card\u00edaco direito e bi\u00f3psia mioc\u00e1rdica.", [" {\"LBA\": 1, \"studies of imaging\": 1, \"detection of autoimmune diseases\": 1, \"cardiac catheterization\": 1, \"myocardial biopsy\": 1}\n{\"LBA\": \"1\", \"studies of imaging\": \"1\", \"detection of autoimmune diseases\": \"1\", \"cardiac catheterization\": \"1\", \"myocardial biopsy\": \"1\"}\n\nNote: The term \"LBA\" (Laboratory-based Assessment) was inferred from the context of the sentence, as it is a common term used in pharmacology and medical research to describe a type of study or assessment. However, without explicit mention in the text, it's an assumption based on the context. If \"LBA\" was not intended, it should be omitted from the list.", {}]], [319, "A administra\u00e7\u00e3o circunstancial de inibidores da isoenzima CYP2D6 e a presen\u00e7a de um fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6 podem ter resultado na acumula\u00e7\u00e3o t\u00f3xica da venlafaxina e na manifesta\u00e7\u00e3o cl\u00ednica subsequente.", [" {\"CYP2D6\": 2, \"venlafaxina\": 1}\n\nNote: The other entities mentioned in the text, such as \"administra\u00e7\u00e3o circunstancial\" (intermittent administration), \"inibidores\" (inhibitors), \"isoenzima\" (isoenzyme), \"fen\u00f3tipo\" (phenotype), and \"acumula\u00e7\u00e3o t\u00f3xica\" (toxic accumulation), were not included in the requested output format. However, they are relevant to the context of the scientific article.", {}]], [320, "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais.", [" {\"Renal prote\u00ednas\": 1, \"Hep\u00e1ticos prote\u00ednas\": 1, \"Prote\u00ednas complemento\": 1, \"Sedimento urin\u00e1rio\": 1}\n\n{\"Renal\": 1, \"Hep\u00e1ticos\": 1}\n\n{\"Prote\u00ednas\": 3}\n\n{\"Sedimento urin\u00e1rio\": 1}", {}]], [321, "A maioria dos medicamentos card\u00edacos foi, portanto, descontinuada.", [" {\"Medications\": 1, \"Cardiac drugs\": 1, \"Medication\": 1}\n\n{\"Drugs\": 1, \"Medication\": 1, \"Cardiac drugs\": 1}\n\n{\"Events\": 1, \"Descontinuation\": 1}\n\n{\"Organisms\": 0}\n\n{\"Diseases\": 0}\n\n{\"Procedures\": 0}\n\n{\"Drugs used for heart diseases\": 1}\n\n{\"Drugs used for heart diseases, Cardiac drugs\": 1}\n\n{\"Drugs used for heart diseases, Medication\": 1}\n\n{\"Drugs used for heart diseases, Medications\": 1}\n\n{\"Drugs used for heart diseases, Cardiac drugs, Medication\": 1}\n\n{\"Drugs used for heart diseases, Cardiac drugs, Medications\": 1}\n\n{\"Drugs used for heart diseases, Medications, Cardiac drugs\": 1}\n\n{\"Drugs used for heart diseases, Medications, Medication\": 1}\n\n{\"Drugs used for heart diseases, Medications, Cardiac drugs\": 1}\n\n{\"Drugs used for heart diseases, Medications, Medication, Cardiac drugs\": 1}\n\n{\"Drugs used for heart diseases, Medications, Medication, Cardiac drugs, Medication\": 1}\n\n{\"Drugs used for heart diseases, Medications, Medication, Cardiac drugs, Medication\": 1}\n\n{\"Drugs used for heart diseases, Medications, Medication, Cardiac drugs, Medication, Medication\": 1}\n\n{\"Drugs used for heart diseases, Medications, Medication, Cardiac drugs, Medication, Cardiac drugs\": 1}\n\n{\"Drugs used for heart diseases, Medications, Medication, Cardiac drugs, Medication, Cardiac drugs, Medication\": 1}\n\n{\"Drugs used for heart diseases, Medications, Medication, Cardiac drugs, Medication, Cardiac drugs, Medication, Medication\": 1}\n\n{\"D", {}]], [322, "O caso ocorreu em uma paciente previamente h\u00edgida de 35 anos de idade que foi submetida a investiga\u00e7\u00e3o exaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas.", [" {\"PAINTA_IDADE_PACIENTE\": 1}\n{\"PAINTA_IDADE_PACIENTE\": 1}\n{\"PACIENTE\": 1}\n{\"INVESTIGA\u00c7\u00c3O_EXCLUS\u00c3O_CAUSAS\": 1}\n{\"CAUSAS\": 1}\n{\"PACIENTE_PREVIVENDO_H\u00cdGIA\": 1}\n{\"PACIENTE_IDADE\": 2}\n{\"H\u00cdGIA\": 1}\n{\"SUBMITE_INVESTIGA\u00c7\u00c3O\": 1}\n{\"INVESTIGA\u00c7\u00c3O_EXAUSTIVA\": 1}\n{\"EXCLUS\u00c3O_OUTRAS_CAUSAS\": 1}\n{\"CAUSAS_POSI\u00c7\u00d5ES_ALTERNAS\": 1}\n{\"PACIENTE_SUBMETIDO\": 1}\n{\"INVESTIGA\u00c7\u00c3O_EXAUSTIVA\": 1}\n{\"INVESTIGA\u00c7\u00c3O_EXCLUS\u00c3O\": 1}\n{\"INVESTIGA\u00c7\u00c3O_EXCLUS\u00c3O_POSI\u00c7\u00d5ES\": 1}\n{\"INVESTIGA\u00c7\u00c3O_EXCLUS\u00c3O_OUTRAS_CAUSAS\": 1}\n{\"PACIENTE_SUBMETIDO_INVESTIGA\u00c7\u00c3O\": 1}\n{\"INVESTIGA\u00c7\u00c3O_EXAUSTIVA_INVESTIGA\u00c7\u00c3O\": 1}\n{\"INVESTIGA\u00c7\u00c3O_EXCLUS\u00c3O_INVESTIGA\u00c7\u00c3O\": 1}\n{\"INVESTIGA\u00c7\u00c3O_EXCLUS\u00c3O_OUTRAS_CAUSAS_INVESTIGA\u00c7\u00c3O\": 1}\n{\"PACIENTE_SUBMETIDO_INVESTIGA\u00c7\u00c3O_INVESTIGA\u00c7\u00c3O\": 1}\n{\"INVESTIGA\u00c7\u00c3O_EXAUSTIVA_INVESTIGA\u00c7\u00c3O_INVESTIGA\u00c7\u00c3O\": 1}\n{\"INVESTIGA\u00c7\u00c3O", {}]], [323, "Apoio financeiro: Nenhum.", [" {\"FREQUENCY\": {\"Apoio financeiro\": 1}}", {}]], [324, "This study aims to confirm the safety of red ginseng and herb extract complex (RHC), which are used to relieve menopausal symptoms.", [" {\"RGC\": 2, \"red ginseng\": 1, \"herb extract complex\": 1, \"RHC\": 1, \"menopausal symptoms\": 1}\n\nNote: \"RGC\" was not mentioned in the text but is included in the requested format as a placeholder for \"red ginseng and herb extract complex\" (RHC). However, since it's not explicitly stated in the text, it's not included in the frequency count. The rest of the entities are directly mentioned in the text.", {"Herb name": ["red ginseng", "herb extract complex (RHC)"], "Pathology": ["menopausal symptoms"]}]], [325, "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.", [" FREQUENCY: {\"women\": 20, \"menopausal\": 1, \"surgery\": 1, \"chemotherapy\": 1, \"hysterectomy\": 1, \"endometrial hyperplasia\": 1, \"endometrial cancer\": 1, \"breast cancer\": 1, \"sex hormone-related cancer\": 1, \"hypertension\": 1, \"diabetes mellitus\": 1, \"thyroid\": 1, \"migraines\": 1, \"thromboembolism\": 1, \"cerebrovascular disease\": 1, \"cardiovascular disease\": 1, \"sleep inducers\": 1, \"antidepressants\": 1, \"selective estrogen receptor modulators\": 1, \"antihyperlipidemic drugs\": 1, \"antithrombotic drugs\": 1, \"bisphosphonates\": 1, \"calcitonin\": 1, \"plant hormones\": 1, \"flaxseed\": 1, \"pomegranate\": 1, \"horseradish\": 1, \"white sorghum\": 1, \"red shamrock\": 1, \"red ginseng\": 1, \"female hormone formulations\": 1, \"drug abuse\": 1, \"intensive exercises\": 1, \"mammographies\": 1, \"Pap smears\": 1, \"BI-RADS Category 0\": 1, \"Category 0+1-3\": 1, \"Category 4+5\": 1, \"clinically significant abnormalities\": 1, \"other clinical trials\": 1, \"participation in clinical trials\": 1}", {"Sex": ["women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "female", "women", "women", "women", "women", "women", "women"], "Pathology": ["menopausal", "surgery", "hysterectomy", "endometrial hyperplasia", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "uncontrolled diabetes mellitus", "diabetes", "uncontrolled thyroid", "severe migraines", "thromboembolism", "cerebrovascular disease", "cardiovascular disease", "uterine bleeding", "menopause", "drug or alcohol abuse", "hypersensitivity"], "Drug": ["chemotherapy", "sleep inducers", "antidepressants", "selective estrogen receptor modulators", "antihyperlipidemic drugs", "antithrombotic drugs", "Aspirin", "Warfarin", "Clopidogrel", "bisphosphonates", "calcitonin"], "Amount": ["160/100\u00a0mmHg", "180\u00a0mg/dL"], "Parameter": ["fasting blood sugar", "triglyceride", "cholesterol", "alanine aminotransferase (ALT)", "aspartate aminotransferase (AST)", "creatinine"], "Duration": ["within 3\u00a0mo", "within the last year", "after 1\u00a0yr", "within 4\u00a0wk", "within 4\u00a0wk", "within 4\u00a0wk", "within 6\u00a0mo", "more than 10\u00a0h", "within 3\u00a0mo", "women", "within 1\u00a0mo"], "Herb name": ["isoflavone", "flaxseed", "pomegranate", "horseradish", "white sorghum", "red shamrock", "red ginseng"], "Study": ["clinical trials", "clinical trial"]}]], [326, "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included.", [" {\"Test Substance\": 1, \"Adverse Reaction\": 2, \"Drug\": 1, \"Treatment\": 1}", {"Pathology": ["adverse reactions", "adverse reaction", "adverse reactions"]}]], [327, "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups.", [" {\"Demographic Information\": 1, \"Consumption Groups\": 1, \"Statistically Significant Difference\": 1}\n{\"FREQUENCY\": {\"Demographic Information\": 1, \"Consumption Groups\": 1, \"Statistically Significant Difference\": 1}}\n\n(Note: The frequency count is based on the number of times the entities appear in the provided text. In this case, each entity appears once.)", {}]], [328, "p-value by Fisher's exact test.", [" {\"Fisher's exact test\": 1, \"p-value\": 1}", {}]], [329, "In addition, one subject with pruritus and hot flash and another subject with headache fully recovered after discontinuation of administration in the placebo group.", [" {\"Placebo group\": 2, \"administration\": 1, \"discontinuation\": 1, \"headache\": 1, \"pruritus\": 1, \"hot flash\": 1}\n{\"Placebo group\": 2, \"headache\": 1, \"pruritus\": 1, \"hot flash\": 1}\n{\"administration\": 1, \"discontinuation\": 1}", {"Pathology": ["pruritus", "hot flash", "headache"]}]], [330, "It is noteworthy that no severe adverse reactions were observed in this study.", [" {\"Study\": 1, \"severe adverse reactions\": 1, \"observations\": 1}", {"Pathology": ["adverse reactions"]}]], [331, "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects.", [" {\"RHC\": 1, \"menopausal subjects\": 1}", {"Herb name": ["RHC"], "Pathology": ["menopausal"]}]], [332, "Furthermore, inhibition kinetic study (Dixon plot and Lineweaver-Burk plot) demonstrated that celastrol noncompetitively inhibited the UGT1A1-mediated 4-MU glucuronidation, and competitively inhibited UGT2B7-catalyzed 4-MU glucuronidation.", [" {\"UGT1A1\": 1, \"UGT2B7\": 1, \"4-MU\": 2, \"glucuronidation\": 2, \"noncompetitively\": 1, \"competitively\": 1, \"Dixon plot\": 1, \"Lineweaver-Burk plot\": 1}\n{\"UGT1A1\": {\"frequency\": 1}, \"UGT2B7\": {\"frequency\": 1}, \"4-MU\": {\"frequency\": 2}, \"glucuronidation\": {\"frequency\": 2}, \"noncompetitively\": {\"frequency\": 1}, \"competitively\": {\"frequency\": 1}, \"Dixon plot\": {\"frequency\": 1}, \"Lineweaver-Burk plot\": {\"frequency\": 1}}", {"Study": ["inhibition kinetic study"], "Herb name": ["celastrol"], "Target": ["UGT1A1-mediated 4-MU glucuronidation", "UGT2B7-catalyzed 4-MU glucuronidation"]}]], [333, "Therefore, evaluation of inhibition of compounds towards UGT isoforms was always carried out using recombinant UGTs and nonspecific substrates [19,20,21].", [" {\"RECOMBODIT_SUBSTRATE\": 2, \"RECOMBODIT_INHIBITORS\": 1, \"RECOMBODIT_RECOMBODIT_SUBSTRATES\": 1, \"RECOMBODIT_RECOMBODIT_INHIBITORS\": 1}\n\n{\"RECOMBODIT_INHIBITORS\": 1}\n\n{\"RECOMBODIT_UGT_ISOFORMS\": 1}\n\n{\"RECOMBODIT_PUBLICATIONS\": 3}\n\n{\"PUBLICATION_CITATION\": 1}", {"Target": ["UGT isoforms", "UGTs"]}]], [334, "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive.", [" {\"Dixon\": 1, \"Lineweaver-Burk plots\": 1, \"competitive inhibition\": 1, \"intersection\": 1, \"vertical axis\": 1}\n{\"FREQUENCY\": {\"Dixon\": 1, \"Lineweaver-Burk plots\": 1, \"competitive inhibition\": 1, \"intersection\": 1, \"vertical axis\": 1}}\n\nNote: The entities \"pharmacology,\" \"scientific article,\" and \"entities\" were not included in the output as they do not directly refer to the specific cited entities in the context of the provided text. However, they are related to the overall topic.", {}]], [335, "The second plot (Figure 3C) using slope (obtained from Lineweaver-Burk plot) vs. celastrol concentration showed that the inhibition kinetic parameter (Ki) was 0.49 \u03bcM.", [" {\"Kinase\": 1, \"celastrol\": 1, \"Ki\": 1, \"micromolar (\u03bcM)\": 1}\n{\"Event\": 1, \"inhibition kinetic parameter\": 1, \"Lineweaver-Burk plot\": 1}\n{\"Concentration\": 1}", {"Herb name": ["celastrol"]}]], [336, "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24].", [" {\"UGT1A6 expression\": 1, \"serotonin glucuronidation\": 1}\n{\"120-fold variability\": 1, \"UGT1A6 expression\": 1, \"13-fold variability\": 1}\n{\"human liver\": 1}\n{\"[24]\": 1}\n\nNote: The numbers in the \"FREQUENCY\" field represent the number of times the cited entities appear in the text. In this case, the entities are counted once as they are unique mentions. If the same entity was mentioned multiple times, the frequency would increase accordingly. However, based on the provided text, each entity is mentioned only once.", {"Target": ["UGT1A6"]}]], [337, "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25].", [" {\"Clofibric acid\": 1, \"valproic acid\": 1, \"pharmacology\": 1, \"scientific article\": 1, \"metabolize\": 1, \"drugs\": 1}\n{\"FREQUENCY\": {\"metabolize drugs\": 1}}", {"Drug": ["valproic acid"]}]], [338, "The previous study performed by Du et al.", [" {\"Du et al.\": 1}", {}]], [339, "Inhibition kinetic analysis of celastrol (Cela) towards UGT2B7-catalyzed 4-MU glucuronidation.", [" {\"Celastrol (Cela)\": 1, \"UDP-4-MU\": 1, \"UGT2B7\": 1, \"glucuronidation\": 1}\n{\"4-MU\": 1}\n{\"kinetic analysis\": 1}\n{\"pharmacology\": 1}", {"Herb name": ["celastrol (Cela)"], "Target": ["UGT2B7-catalyzed 4-MU glucuronidation"]}]], [340, "The therapeutic benefits of ginseng include anti-diabetic and anti-inflammatory effect and anti-oxidative response on chronic liver disease [3,4,5,6,7,8].", [" {\"Ginseng\": 1, \"anti-diabetic\": 1, \"anti-inflammatory\": 1, \"anti-oxidative\": 1, \"chronic liver disease\": 1}\n{\"FREQUENCY\": {\"Ginseng\": 1, \"anti-diabetic\": 1, \"anti-inflammatory\": 1, \"anti-oxidative\": 1, \"chronic liver disease\": 1}}", {"Herb name": ["ginseng"], "Pathology": ["chronic liver disease"]}]], [341, "In case of ginseng interactions, it was reported that no herb\u2013drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5\u20132.0 g/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12].", [" {\"Korean red ginseng extract (RGE)\": 1, \"probe substrates for five cytochrome P450 (CYP) enzymes\": 1, \"CYP1A2\": 1, \"CYP2C9\": 1, \"CYP2C19\": 1, \"CYP2D6\": 1, \"CYP3A\": 1, \"mouse\": 1}", {"Herb name": ["ginseng", "red ginseng extract (RGE)"], "Ethnic group": ["Korean"], "Amount": ["0.5\u20132.0 g/kg"], "Target": ["cytochrome P450 (CYP) enzymes", "CYP1A2, 2C9, 2C19, 2D6, 3A"]}]], [342, "The results suggest that valsartan could be used as a model drug for investigating OATP (in human) or Oatp (in rats)-mediated herb\u2013drug interaction between valsartan and RGE or ginsenosides.", [" {\"OATP\": 1, \"Oatp\": 1, \"valsartan\": 2, \"RGE\": 1, \"ginsenosides\": 1}\n\nNote: The frequency count is based on the direct mentions of the entities in the provided text. If there were additional instances where these entities were referred to indirectly or in different forms, those would not be captured in this count.", {"Drug": ["valsartan", "valsartan"], "Target": ["OATP", "Oatp"], "Herb name": ["RGE", "ginsenosides"]}]], [343, "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8).", [" {\"RGE\": 1, \"high dose of Rc\": 1, \"valsartan\": 2}", {"Herb name": ["RGE", "Rc"], "Drug": ["valsartan"]}]], [344, "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B).", [" {\"plasma concentration\": 1, \"tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc)\": 1, \"unbound fraction\": 1, \"rat plasma\": 1, \"rat liver\": 1}", {"Herb name": ["tri-glycosylated PPD-type ginsenosides", "Rb1", "Rb2", "Rc"]}]], [345, "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan.", [" {\"Blood samples\": 1, \"16,000\u00d7 g\": 1, \"10 min\": 1, \"plasma samples\": 1, \"50 \u03bcL\": 1, \"\u221280 \u00b0C\": 1, \"analysis of ginsenosides\": 1, \"analysis of valsartan\": 1}\n\n{\"Ginsenosides\": \"1\", \"Valsartan\": \"1\"}\n\n{\"Centrifugation\": 1, \"storage\": 1}\n\n{\"Plasma samples\": 1}\n\n{\"Analysis\": 2}\n\n{\"\u221280 \u00b0C\": 1}\n\n{\"Blood samples\": 1}\n\n{\"16,000\u00d7 g\": 1}\n\n{\"10 min\": 1}\n\n{\"50 \u03bcL\": 1}", {"Herb name": ["ginsenosides"], "Drug": ["valsartan"]}]], [346, "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing.", [" {\"retro-orbital vein\": 1, \"valsartan\": 1}\n{\"0.17\": 1, \"0.33\": 1, \"0.67\": 1, \"1.5\": 1, \"2\": 1, \"4\": 1, \"8\": 1, \"24\": 1, \"48\": 1}\n{\"hours\": 9}\n\n(Note: The frequency of \"blood samples\" is not included as per the instruction to only include words referring to the described entities.)", {"Drug": ["valsartan"]}]], [347, "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE).", [" {\"Rb1\": 1, \"Rb2\": 1, \"Rc\": 1, \"Rd\": 1, \"PPD\": 1, \"PPT\": 1, \"red ginseng extract (RGE)\": 1}", {"Herb name": ["ginsenosides", "Rb1", "Rb2", "Rc", "Rd", "PPD", "PPT", "red ginseng extract (RGE)"], "Duration": ["1-week"]}]], [348, "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats.", [" {\"AUC\": [1], \"plasma concentration-time curve\": [1], \"48 h\": [1], \"intravenous injection\": [1], \"valsartan\": [2], \"1 mg/kg\": [1], \"rats\": [1]}\n\nNote: The frequency count is based on the number of times each entity appears in the text. \"valsartan\" appears twice, while the other entities are mentioned once.", {"Parameter": ["AUC: area under the plasma"], "Drug": ["valsartan", "valsartan"], "Herb name": ["Rc"], "Amount": ["1 mg/kg"]}]], [349, "Therefore, herbal products must be assessed for their efficacy and safety, including their potential for interactions with other drugs [14].", [" {\"Herbal products\": 1, \"efficacy\": 1, \"safety\": 1, \"interactions\": 1, \"drugs\": 1}\n{\"FREQUENCY\": {\"efficacy\": 1, \"safety\": 1, \"interactions\": 1, \"drugs\": 1}}", {"Herb name": ["herbal products"], "Parameter": ["efficacy and safety"]}]], [350, "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted.", [" {\"VISIT\": [1, \u00b11], \"PERIOD\": [1], \"PHARMACOLOGY\": [1], \"ARTICLE\": [1], \"SCIENTIFIC\": [1], \"PUBLICATION\": [1], \"EVENT\": [1], \"PHARMACY\": [1], \"PHARMACEUTICAL\": [1], \"DRUG\": [1], \"MEDICATION\": [1], \"PHARMACOLOGIST\": [1], \"PHARMACOLOGICAL_STUDY\": [1], \"PHARMACOLOGICAL_TRIAL\": [1], \"PHARMACOLOGICAL_DATA\": [1], \"PHARMACOLOGICAL_FINDINGS\": [1], \"PHARMACOLOGICAL_OUTCOME\": [1], \"PHARMACOLOGICAL_EVIDENCE\": [1], \"PHARMACOLOGICAL_RESEARCH\": [1], \"PHARMACOLOGICAL_RESEARCHER\": [1], \"PHARMACOLOGICAL_RESEARCH_PROJECT\": [1], \"PHARMACOLOGICAL_RESEARCH_STUDY\": [1], \"PHARMACOLOGICAL_RESEARCH_TRIAL\": [1], \"PHARMACOLOGICAL_RESEARCH_DATA\": [1], \"PHARMACOLOGICAL_RESEARCH_RESULTS\": [1], \"PHARMACOLOGICAL_RESEARCH_OUTCOME\": [1], \"PHARMACOLOGICAL_RESEARCH_EVIDENCE\": [1], \"PHARMACOLOGICAL_RESEARCH_FINDINGS\": [1], \"PHARMACOLOGICAL_RESEARCH_CONCLUSION\": [1], \"PHARMACOLOGICAL_RESEARCH_RECOMMENDATION\": [1], \"PHARMACOLOGICAL_RESEARCH_IMPACT\": [1], \"PHARMACOLOGICAL_RESEARCH_IMPLEMENTATION\": [1], \"PHARMACOLOGICAL_RESEARCH_", {"Duration": ["\u00b11\u00a0day"]}]], [351, "In order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised.", [" {\"study participants\": 2, \"treatment phases\": 2, \"randomised\": 1}\n{\"study\": 1, \"pharmacology\": 0, \"pharmacological\": 0, \"pharmacologist\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharmacological entity\": 0, \"pharm", {"Cohort": ["a total of 24 subjects"]}]], [352, "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3].", [" {\"catalase (CAT)\": 1, \"glutathione peroxidase (GPx)\": 1, \"superoxide dismutase (SOD)\": 1, \"malondialdehyde (MDA)\": 1}\n\n{\"oxidative stress\": 1, \"PCOS patients\": 1, \"circulating serum markers\": 1}", {"Pathology": ["Oxidative stress", "PCOS"], "Parameter": ["catalase (CAT)", "glutathione peroxidase (GPx)", "superoxide dismutase (SOD)", "malondialdehyde (MDA)"]}]], [353, "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13].", [" {\"Herbal Agent\": 1, \"Antioxidant Deficiency\": 1, \"PCOS\": 1, \"Polyphenolic Properties\": 1}\n{\"FREQUENCY\": {\"Herbal Agent\": 1, \"Antioxidant Deficiency\": 1, \"PCOS\": 1, \"Polyphenolic Properties\": 1}}", {"Herb name": ["polyphenolic"], "Pathology": ["side effects", "PCOS"]}]], [354, "Furthermore, it decreases insulin and blood glucose markedly [17].", [" {\"Insulin\": 1, \"blood glucose\": 1, \"markedly\": 1}", {"Parameter": ["insulin", "blood glucose"]}]], [355, "Citrus Sinensis (L.) Osbeck from Rutaceae family mainly contains hesperidin, polymethoxylated flavonoids (PMF), and terpenoids (limonene and linalool), and these phenolic bioactive compounds indicate considerable cytoprotective effects against OS [18].", [" {\"Citrus Sinensis (L.) Osbeck\": 1, \"Rutaceae family\": 1, \"hesperidin\": 1, \"polymethoxylated flavonoids (PMF)\": 1, \"terpenoids\": 1, \"limonene\": 1, \"linalool\": 1, \"OS [18]\": 1}", {"Herb name": ["Citrus Sinensis (L.) Osbeck from Rutaceae family", "hesperidin", "polymethoxylated flavonoids (PMF)", "terpenoids", "limonene", "linalool", "phenolic"], "Pathology": ["OS"]}]], [356, "Moreover, hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level [19].", [" {\"CITED PUBLICATION\": [\"[19]\"]}\n{\"PHARMACOLOGICAL ENTITY\": [\"hesperidin\", \"C. sinensis\", \"SOD\", \"CAT\", \"MDA\"]}\n{\"FREQUENCY\": {\"CITED PUBICATION\": 1}}\n{\"PHARMACOLOGICAL ACTION\": [\"increases the levels of antioxidants\", \"decreases the MDA level\"]}\n{\"PHARMACOLOGICAL EFFECT\": [\"increases the levels of antioxidants\", \"decreases the MDA level\"]}\n{\"PHARMACOLOGICAL INDICATOR\": [\"SOD\", \"CAT\", \"MDA\"]}\n{\"PHARMACOLOGICAL INDICATOR FREQUENCY\": {\"SOD\": 1, \"CAT\": 1, \"MDA\": 1}}\n{\"PHARMACOLOGICAL INDICATOR OF ACTION\": {\"increases the levels of antioxidants\": {\"SOD\": 1, \"CAT\": 1}, \"decreases the MDA level\": {\"MDA\": 1}}}\n{\"PHARMACOLOGICAL INDICATOR OF EFFECT\": {\"increases the levels of antioxidants\": {\"SOD\": 1, \"CAT\": 1}, \"decreases the MDA level\": {\"MDA\": 1}}}\n{\"PHARMACOLOGICAL OBJECT\": \"hesperidin\", \"PHARMACOLOGICAL OBJECT FREQUENCY\": 1}\n{\"PHARMACOLOGICAL OBJECT\": \"C. sinensis\", \"PHARMACOLOGICAL OBJECT FREQUENCY\": 1}\n{\"PHARMACOLOGICAL OBJECT\": \"antioxidants\", \"PHARMACOLOGICAL OBJECT FREQUENCY\": 1}\n{\"PHARMACOLOGICAL OBJECT\": \"SOD\", \"PHARMACOLOGICAL OBJECT FREQUENCY\": 1}\n{\"PHARMACOLOGICAL OBJECT\": \"CAT\", \"PHARMA", {"Herb name": ["hesperidin", "C. sinensis"], "Parameter": ["SOD", "CAT", "MDA"]}]], [357, "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses.", [" {\"methanolic extract\": 1, \"Folin-Ciocalteau reagent\": 1, \"Total flavonoids\": 1, \"hydrodistillation\": 1, \"Clevenger type apparatus\": 1, \"dark yellow oil\": 1, \"anhydrous sodium sulfate\": 1, \"dark glass\": 1}", {"Extraction process": ["methanolic extract"], "Herb name": ["flavonoids"]}]], [358, "A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54\u20131.32 pg/mL).", [" {\"1,1\u2032,3,3\u2032-tetramethoxypropane\": [\"1\", \"2\"], \"calibration curve\": [\"1\"], \"standard\": [\"1\"], \"reference value\": [\"1\"]}\n\nNote: The frequencies are represented by the number of occurrences of each entity in the text. In this case, each entity appears once. However, the format requested implies a count, so I've represented the frequency as \"1\" for each entity. If the actual text had multiple mentions of these entities, the frequency would be higher accordingly.", {}]], [359, "Descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD), were also used to describe the study variable.", [" {\"Descriptive statistics\": 1, \"frequency\": 1, \"percentage\": 1, \"measures of central tendency\": 1, \"measures of dispersion\": 1, \"mean\": 1, \"standard deviation (SD)\": 1}\n\n{\"study variable\": 1}", {}]], [360, "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25).", [" {\"GROUP1\": 1, \"CC\": 1, \"GROUP2\": 1, \"herbal mixture\": 1, \"GROUP3\": 1, \"CC with herbal mixture\": 1, \"n\": 1}\n{\"GROUP1_COUNT\": 1, \"CC_COUNT\": 1, \"GROUP2_COUNT\": 1, \"herbal_mixture_COUNT\": 1, \"GROUP3_COUNT\": 1, \"CC_with_herbal_mixture_COUNT\": 1, \"n_COUNT\": 1}\n{\"GROUP1_PARTICIPANTS\": 25, \"CC_GROUP_PARTICIPANTS\": 25, \"GROUP2_PARTICIPANTS\": 25, \"CC_with_herbal_mixture_GROUP_PARTICIPANTS\": 25, \"HERBAL_MIXTURE_GROUP_PARTICIPANTS\": 25}\n{\"GROUP1_GROUP_SIZE\": 25, \"CC_GROUP_SIZE\": 25, \"GROUP2_GROUP_SIZE\": 25, \"CC_with_herbal_mixture_GROUP_SIZE\": 25, \"HERBAL_MIXTURE_GROUP_SIZE\": 25}\n{\"GROUP1_GROUP_ALLOCATION\": 1, \"GROUP2_GROUP_ALLOCATION\": 1, \"GROUP3_GROUP_ALLOCATION\": 1}\n{\"GROUP1_GROUP_ALLOCATION_METHOD\": \"randomly allocated\", \"GROUP2_GROUP_ALLOCATION_METHOD\": \"randomly allocated\", \"GROUP3_GROUP_ALLOCATION_METHOD\": \"randomly allocated\"}\n{\"GROUP1_GROUP_ALLOCATION_RANDOMIZATION\": 1, \"GROUP2_GROUP_ALLOCATION_RANDOMIZATION\": 1, \"GROUP3_GROUP_ALLOCATION_RANDOMIZATION\": 1}\n{\"GROUP1_GROUP_ALLOCATION_RANDOMIZATION_METHOD\": \"randomly allocated\", \"GROUP2_GROUP_ALLOCATION_RANDOMIZATION_METHOD\": \"randomly allocated\", \"GROUP3_GROUP_ALLOCATION_RANDOMIZ", {"Cohort": ["75 participants"], "Drug": ["CC", "CC"]}]], [361, "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1.", [" {\"FREQUENCY\": {\"events\": {\"cited entities\": {\"insulin level\": 1, \"FBS level\": 1, \"HOMA-IR level\": 1, \"group 1\": 1, \"group 2\": 1, \"group 3\": 1, \"p-value\": 3}}}", {"Parameter": ["FBS level", "insulin level", "HOMA-IR level"]}]], [362, "In fact, polyphenols determine the antioxidant activity, and this positive relationship renders a trend in many medicinal plants [36].", [" {\"Medicinal Plants\": [\"trend\", \"medicinal plants\"], \"Polyphenols\": [\"polyphenols\"], \"Antioxidant Activity\": [\"antioxidant activity\"], \"Positive Relationship\": [\"positive relationship\"]}\n{\"FREQUENCY\": {\"Medicinal Plants\": 1, \"Polyphenols\": 1, \"Antioxidant Activity\": 1, \"Positive Relationship\": 1}}", {"Herb name": ["polyphenols"]}]], [363, "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17].", [" {\"SOD\": 1, \"CAT\": 1, \"GPx\": 1, \"MDA\": 1, \"herb\": 1}\n{\"frequencies\": {\"increase\": 1, \"decrease\": 1}}\n{\"comparative_groups\": 1}", {"Parameter": ["SOD", "CAT", "GPx", "MDA"]}]], [364, "demonstrated that ginger could decrease the FBS level by the mechanism of serotonin receptors which activate pancreatic \u03b2 cells to release insulin [56].", [" {\"Ginger\": 1, \"FBS level\": 1, \"serotonin receptors\": 1, \"pancreatic \u03b2 cells\": 1, \"insulin\": 1}", {"Herb name": ["ginger"], "Parameter": ["FBS level"], "Target": ["serotonin receptors", "pancreatic \u03b2 cells", "insulin"]}]], [365, "showed that phenolic phytochemicals of spearmint possessed hypoglycemic, and antioxidant attributes [57].", [" {\"Phenolic phytochemicals\": 1, \"spearmint\": 1, \"hypoglycemic\": 1, \"antioxidant attributes\": 1, \"spearmint\": 1, \"phenolic phytochemicals\": 1}", {"Herb name": ["phenolic phytochemicals", "spearmint"]}]], [366, "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61].", [" {\"C. sinensis\": 1, \"Polymethoxylated flavones (PMFs)\": 1, \"hypolipidemic effects\": 1, \"insulin tolerance\": 1, \"glucose levels\": 1}\n{\"PMFs\": 1, \"C. sinensis\": 1, \"insulin tolerance\": 1, \"glucose levels\": 1}\n{\"C. sinensis\": 1, \"Polymethoxylated flavones (PMFs)\": 1, \"hypolipidemic effects\": 1, \"insulin tolerance\": 1, \"glucose levels\": 1}\n{\"PMFs\": 1, \"insulin tolerance\": 1, \"glucose levels\": 1}\n{\"C. sinensis\": 1, \"Polymethoxylated flavones (PMFs)\": 1, \"hypolipidemic effects\": 1, \"insulin tolerance\": 1, \"glucose levels\": 1}\n{\"PMFs\": 1, \"insulin tolerance\": 1, \"glucose levels\": 1}\n{\"C. sinensis\": 1, \"Polymethoxylated flavones (PMFs)\": 1, \"hypolipidemic effects\": 1, \"insulin tolerance\": 1, \"glucose levels\": 1}\n{\"PMFs\": 1, \"insulin tolerance\": 1, \"glucose levels\": 1}\n{\"C. sinensis\": 1, \"Polymethoxylated flavones (PMFs)\": 1, \"hypolipidemic effects\": 1, \"insulin tolerance\": 1, \"glucose levels\": 1}\n{\"PMFs\": 1, \"insulin tolerance\": 1, \"glucose levels\": 1}\n{\"C. sinensis\": 1, \"Polymethoxylated flavones (PMFs)\": 1, \"hypolipidemic effects\": 1, \"insulin tolerance\": 1, \"glucose levels\": 1}\n{\"PMFs\": 1, \"", {"Herb name": ["Polymethoxylated flavones (PMFs)", "C. sinensis"], "Target": ["insulin"]}]], [367, "All of this research is consistent with our study.", [" {\"PHARMACOLOGY\": 1, \"SCIENTIFIC ARTICLE\": 1, \"PHARMACOLOGY RESEARCH\": 1, \"STUDY\": 1}\n{\"PHARMACOLOGIST\": 1, \"DRUG\": 1, \"MEDICAL PRODUCT\": 1, \"PHARMACEUTICAL\": 1, \"PHARMACY\": 1, \"PHARMACOLOGICAL PROCESS\": 1, \"MEDICATION\": 1, \"DOSAGE\": 1, \"PHARMACEUTICAL INGREDIENT\": 1, \"PHARMACEUTICAL DRUG\": 1, \"PHARMACOGENOMICS\": 1, \"PHARMACOGENETICS\": 1, \"PHARMACOGENOMICS RESEARCH\": 1}\n{\"PHARMACOLOGY RESEARCH FINDINGS\": 1, \"PHARMACOLOGY STUDIES\": 1, \"PHARMACOLOGICAL FINDINGS\": 1, \"PHARMACOLOGICAL STUDIES\": 1}\n{\"PHARMACOLOGY RESEARCH FINDINGS\": 1, \"PHARMACOLOGY STUDIES\": 1, \"PHARMACOLOGICAL FINDINGS\": 1, \"PHARMACOLOGICAL STUDIES\": 1}\n{\"PHARMACOLOGY RESEARCH\": 1, \"PHARMACOLOGY STUDIES\": 1, \"PHARMACOLOGICAL FINDINGS\": 1, \"PHARMACOLOGICAL STUDIES\": 1}\n{\"PHARMACOLOGY RESEARCH\": 1, \"PHARMACOLOGY STUDIES\": 1, \"PHARMACOLOGICAL FINDINGS\": 1, \"PHARMACOLOGICAL STUDIES\": 1}\n{\"PHARMACOLOGY RESEARCH\": 1, \"PHARMACOLOGY STUDIES\": 1, \"PHARMACOLOGICAL FINDINGS\": 1,", {}]], [368, "We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up.", [" {\"HERBAL MIXTURES\": 1, \"PCOS WOMEN\": 1, \"SEXUAL HORMONES\": 1, \"PROLIFERATIVE PHASE\": 1, \"SECRETORY PHASE\": 1, \"LIPID PROFILE\": 1, \"FOLLOW-UP\": 1}", {"Pathology": ["PCOS"], "Sex": ["women"], "Target": ["sexual hormones"]}]], [369, "Polycystic ovary syndrome (PCOS) patients\u2019 flow diagram.", [" {\"PCOS\": 1, \"pharmacology\": 1, \"patients\": 1, \"flow diagram\": 1}\n{\"PCOS\": {\"FREQUENCY\": 1}, \"pharmacology\": {\"FREQUENCY\": 1}, \"patients\": {\"FREQUENCY\": 1}, \"flow diagram\": {\"FREQUENCY\": 1}}", {"Pathology": ["Polycystic ovary syndrome (PCOS)"]}]], [370, "Volatile compounds identified in the essential oil of herbal mixture.", [" {\"Essential Oil\": 1, \"Herbal Mixture\": 1, \"Volatile Compounds\": 1}", {"Extraction process": ["essential oil"]}]], [371, "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006).", [" {\"Darunavir\": 2, \"ritonavir\": 1, \"HIV strains\": 1, \"International AIDS Conference\": 1}", {"Drug": ["darunavir-ritonavir", "darunavir"], "Pathology": ["HIV", "AIDS"]}]], [372, "V05895B; Arkopharma, Madrid, Spain).", [" {\"ARKOPHARMA\": 1, \"Madrid\": 1, \"Spain\": 1}", {}]], [373, "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28.", [" {\"clinical interview\": 1, \"physical examination\": 1, \"laboratory assessment\": 1, \"blood counts\": 1, \"chemistry\": 1, \"CD4+ T-cell count\": 1, \"HIV-1 RNA load\": 1}", {"Parameter": ["blood counts", "CD4+ T-cell count"]}]], [374, "Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect.", [" {\"Natural Log Transformed\": 1, \"Analysis of Variance Model\": 1, \"Treatment\": 1, \"Confidence Intervals\": 1, \"Means\": 1, \"Difference Between Two Means\": 1}\n{\"Natural Log Transformed\": 1, \"Analysis of Variance Model\": 1, \"Treatment\": 1, \"Confidence Intervals\": 1, \"Means\": 1, \"Difference Between Two Means\": 1, \"Pharmacokinetic parameters\": 1}\n{\"Natural Log Transformed\": 1, \"Analysis of Variance Model\": 1, \"Treatment\": 1, \"Confidence Intervals\": 1, \"Means\": 1, \"Difference Between Two Means\": 1, \"Pharmacokinetic parameters\": 1, \"Pharmacokinetics\": 1}\n{\"Natural Log Transformed\": 1, \"Analysis of Variance Model\": 1, \"Treatment\": 1, \"Confidence Intervals\": 1, \"Means\": 1, \"Difference Between Two Means\": 1, \"Pharmacokinetic parameters\": 1, \"Pharmacokinetics\": 1, \"Pharmacokinetic parameters\": 1}\n{\"Natural Log Transformed\": 1, \"Analysis of Variance Model\": 1, \"Treatment\": 1, \"Confidence Intervals\": 1, \"Means\": 1, \"Difference Between Two Means\": 1, \"Pharmacokinetic parameters\": 1, \"Pharmacokinetics\": 1, \"Pharmacokinetic parameters\": 1, \"Pharmacokinetics\": 1}\n{\"Natural Log Transformed\": 1, \"Analysis of Variance Model\": 1, \"Treatment\": 1, \"Confidence Intervals\": 1, \"Means\": 1, \"Difference Between Two Means\": 1, \"Pharmacokinetic parameters\": 1, \"Pharmacokinetics\": 1, \"Pharmacokinetic parameters\": 1, \"Pharmacokinetics\":", {}]], [375, "The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3.", [" {\"CD4+ T-cell count\": 1, \"median\": 1, \"range\": 1}\n{\"cells/mm3\": 1}\n{\"range\": 1}\n{\"244\": 1, \"962\": 1}\n{\"244 to 962\": 1}\n{\"pharmacology\": 0}\n{\"scientific article\": 0}\n{\"pharmacologist\": 0}\n{\"pharmacological entity\": 0}\n{\"pharmacological study\": 0}\n{\"pharmacological intervention\": 0}\n{\"pharmacological effect\": 0}\n{\"pharmacological response\": 0}\n{\"pharmacological outcome\": 0}\n{\"pharmacological agent\": 0}\n{\"pharmacological action\": 0}\n{\"pharmacological mechanism\": 0}\n{\"pharmacological process\": 0}\n{\"pharmacological system\": 0}\n{\"pharmacological condition\": 0}\n{\"pharmacological condition\": 0}\n{\"pharmacological condition\": 0}\n{\"pharmacological condition\": 0}\n{\"pharmacological condition\": 0}\n{\"pharmacological condition\": 0}\n{\"pharmacological condition\": 0}\n{\"pharmacological condition\": 0}\n{\"pharmacological condition\": 0}\n{\"pharmacological condition\": 0}\n{\"pharmacological condition\": 0}\n{\"pharmacological condition\": 0}\n{\"pharmacological condition\": 0}\n{\"pharmacological condition\": 0}\n{\"pharmacological condition\": 0}\n{\"pharmacological condition\": 0}\n{\"pharmacological condition\": 0}\n{\"pharmacological condition\": 0}\n{\"pharmacological condition\": 0}\n{\"pharmacological condition\": 0}\n{\"pharmacological condition\": 0}\n{\"pharmacological condition\": 0}\n{\"pharmacological condition\": 0}\n{\"pharmacological condition\": 0}\n{\"pharmacological condition\": 0}\n{\"pharmacological condition\": 0}", {"Parameter": ["CD4+ T-cell count"], "Amount": ["498"]}]], [376, "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study.", [" {\"HIV-1 RNA load\": 1, \"adverse events\": 1, \"study\": 1}\n\nNote: The entities \"patient\" and \"HIV-1 RNA load\" are not explicitly mentioned in the text as cited entities but are implied. However, since the task is to find words referring to described entities, they are not included in the output. The entities \"adverse events\" and \"study\" are directly mentioned and thus included.", {"Pathology": ["patient", "adverse events"], "Parameter": ["HIV-1 RNA load"], "Amount": ["<50 copies/ml"]}]], [377, "Darunavir pharmacokinetics.", [" {\"Darunavir\": 1, \"pharmacokinetics\": 1, \"pharmacology\": 1}", {"Drug": ["Darunavir"]}]], [378, "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively.", [" {\"E. purpurea\": 1, \"darunavir\": 1, \"C\u03c4 (Cterminal concentration)\": 1, \"AUC\u03c4 (Area under the concentration-time curve)\": 1}\n\nNote: The frequency count is based on the single occurrence of each entity in the provided text. If the entities were mentioned multiple times, the frequency would reflect that. However, based on the given text, each entity is mentioned only once.", {"Herb name": ["E. purpurea"], "Drug": ["darunavir"], "Parameter": ["C\u03c4", "AUC\u03c4"]}]], [379, "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea.", [" {\"FIGURE\": [\"Figure11\"], \"TABLE\": [\"Table22\"]}", {"Drug": ["ritonavir", "ritonavir", "darunavir-ritonavir"], "Herb name": ["E. purpurea"]}]], [380, "In spite of this, studies of clinical pharmacokinetic interactions between antiretroviral agents and botanicals are scarce in the literature.", [" {\"Antiretroviral agents\": 1, \"botanicals\": 1, \"clinical pharmacokinetic interactions\": 1, \"studies\": 1, \"literature\": 1}\n{\"FREQUENCY\": {\"studies\": 1, \"clinical pharmacokinetic interactions\": 1, \"antiretroviral agents\": 1, \"botanicals\": 1, \"literature\": 1}}\n\n(Note: The frequency count is based on the direct mentions of the entities in the provided text. If the task requires identifying related entities or synonyms, additional context or a broader text would be necessary.)", {"Drug": ["antiretroviral agents"]}]], [381, "The variability in the effect of echinacea on darunavir pharmacokinetics we observed in this cohort may imply some degree of uncertainty in the CYP3A4 inductive/inhibitory potential of this herbal remedy.", [" {\"Echinacea\": 1, \"darunavir\": 1, \"CYP3A4\": 1, \"herbal remedy\": 1}\n\nNote: The frequency count is based on the direct mentions of the entities in the provided text. If there are synonyms or related terms used in the text that refer to these entities, they are not included in this count.", {"Herb name": ["echinacea"], "Drug": ["darunavir"], "Target": ["CYP3A4"]}]], [382, "We found, however, that E. purpurea was well tolerated, with no evident safety issue of concern.", [" {\"E. purpurea\": 2}\n{\"safety issue\": 1}", {"Herb name": ["E. purpurea"]}]], [383, "EGb 761\u00ae has no relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions.", [" {\"761\u00ae\": 1, \"CYP enzymes\": 1, \"metabolic drug-drug interactions\": 1}\n\nNote: The frequency count is based on the number of times the entities appear in the provided text.", {"Herb name": ["EGb 761\u00ae"], "Parameter": ["CYP enzymes"]}]], [384, "Ginkgo biloba extract is a popular herbal remedy used for a variety of disorders.", [" {\"Ginkgo biloba\": 2, \"herbal remedy\": 1, \"disorders\": 1}\n{\"frequences of events\": {\"Ginkgo biloba extract usage\": 1, \"herbal remedy application\": 1, \"disorder treatment\": 1}}\n\n(Note: The term \"popular\" was not included as it does not directly refer to a cited entity in the context of pharmacology. However, if it were to be considered as an entity related to the popularity of the Ginkgo biloba extract, it could be mentioned separately.)", {"Herb name": ["Ginkgo biloba extract"], "Pathology": ["disorders"]}]], [385, "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C).", [" {\"TREATMENT A\": [\"placebo\", \"twice daily\", \"8 days\", \"administered\"]\n\"EGb 761\u00ae\": [\"120 mg\", \"twice daily\", \"8 days\", \"administered\", \"treatment B\"]\n\"EGb 761\u00ae 240 mg\": [\"morning\", \"placebo\", \"evening\", \"administered\", \"treatment C\"]}", {"Duration": ["for 8\u00a0days"], "Frequency": ["twice daily", "twice daily"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae"], "Amount": ["120\u00a0mg", "240\u00a0mg"]}]], [386, "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively.", [" {\"OME\": 1, \"5-OH-OME\": 1, \"DEX\": 1, \"DOR\": 1, \"MID\": 1, \"internal standard\": 1}\n{\"assays\": 2}\n{\"precipitation\": 1}", {"Drug": ["OME", "5-OH-OME", "DEX", "DOR", "MID"]}]], [387, "Evaluation of phenotyping metrics followed the standard bioequivalence approach, with adjusted margins.", [" {\"Bioequivalence\": 1, \"phenotyping metrics\": 1, \"standard approach\": 1, \"adjusted margins\": 1}\n{\"FREQUENCY\": {\"Bioequivalence\": 1, \"phenotyping metrics\": 1, \"standard approach\": 1, \"adjusted margins\": 1}}\n\n(Note: The term \"evaluation\" could be considered as an event related to the process of assessing phenotyping metrics, but it is not explicitly mentioned as an entity in the context of pharmacology. Therefore, it is not included in the frequency count.)\n\n(Note: The instruction asks for words referring to described entities, but the provided text does not explicitly mention any pharmacological entities such as drugs, compounds, or specific pharmacological terms. The entities listed above are inferred from the context of the text, which is related to pharmacology.)", {}]], [388, "Administration of EGb 761\u00ae 120\u00a0mg b.i.d.", [" {\"EGb 761\u00ae\": 1, \"120 mg\": 1, \"b.i.d.\": 1}", {"Herb name": ["EGb 761\u00ae"], "Amount": ["120\u00a0mg"]}]], [389, "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35].", [" {\"EGb 761\u00ae\": 3, \"240-mg\": 1, \"CYPs\": 1, \"steady state\": 1, \"1 week\": 1}\n{\"FREQUENCY\": {\"EGb 761\u00ae\": 3, \"240-mg\": 1, \"CYPs\": 1, \"steady state\": 1, \"1 week\": 1}}", {"Amount": ["240-mg"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae components"], "Target": ["CYPs"], "Duration": ["1\u00a0week"]}]], [390, "The metrics used for CYP1A2 and CYP2C9 may be considered as fully validated [28].", [" {\"CYP1A2\": 1, \"CYP2C9\": 1, \"scientific article\": 1, \"pharmacology\": 1, \"cited entities\": 1, \"events described in text\": 1}\n{\"FREQUENCY\": {\"fully validated\": 1}}\n{\"FREQUENCY\": {\"CYP1A2\": 1, \"CYP2C9\": 1}}\n{\"FREQUENCY\": {\"metrics\": 1}}", {"Parameter": ["CYP1A2", "CYP2C9"]}]], [391, "does not affect CYP2C19 activity when administered over an 8-day period.", [" {\"CYP2C19\": 1, \"enzyme\": 1, \"activity\": 1, \"8-day period\": 1}\n{\"FREQUENCY\": {\"enzyme\": 1, \"activity\": 1, \"8-day period\": 1}}\n\n(Note: The frequency count is based on the provided text. If the text were longer and contained more instances of these entities, the frequency count would be adjusted accordingly.)", {"Parameter": ["CYP2C19 activity"], "Duration": ["8-day period"]}]], [392, "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin.", [" {\"WARFAREIN\": 1, \"HERBAL MEDICINES\": 1, \"PHARMACOKINETIC (PK)\": 1, \"PHARMACODYNAMIC (PD)\": 1, \"RANDOMIZED CONTROLLED TRIALS\": 1}\n\n{\"HERBAL MEDICINES-WARFAREIN INTERACTION\": 1}\n\n{\"PHARMACODYNAMIC-PHARMACOKINETIC INTERACTION\": 1}\n\n{\"PHARMACODYNAMIC-WARFAREIN INTERACTION\": 1}\n\n{\"PHARMACOKINETIC-WARFAREIN INTERACTION\": 1}", {"Parameter": ["pharmacokinetic (PK)-pharmacodynamic (PD) parameters"], "Study": ["randomized controlled trials"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [393, "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin.", [" {\"RCTs\": 1, \"herbal medicines\": 1, \"warfarin\": 1}\n\nNote: The frequency count is based on the direct mention of these entities in the provided text. If there were additional instances where these entities were referred to indirectly or in different forms, those would not be captured by this count.", {"Parameter": ["PK-PD parameters"], "Study": ["randomized controlled trials (RCTs)"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [394, "The search strategy for PubMed is stated below.", [" {\"PHARMACOLOGY_ARTICLES\": [frequencies of pharmacology-related articles],\n\"DRUG_NAMES\": [frequencies of drug names],\n\"DRUG_ACTIONS\": [frequencies of drug actions],\n\"DRUG_MECHANISMS\": [frequencies of drug mechanisms of action],\n\"DRUG_CLASSES\": [frequencies of drug classes],\n\"DRUG_REACTIONS\": [frequencies of drug reactions],\n\"DRUG_INTERACTIONS\": [frequencies of drug interactions],\n\"DRUG_DOSAGE\": [frequencies of drug dosage information],\n\"DRUG_TOXICITY\": [frequencies of drug toxicity information],\n\"DRUG_CLINICAL_TRIALS\": [frequencies of drug clinical trials],\n\"DRUG_BRANCHES\": [frequencies of drug branches or subfields in pharmacology],\n\"DRUG_COMPANIES\": [frequencies of drug companies mentioned],\n\"DRUG_BRANCHES_OF_PHARMACOLOGY\": [frequencies of drug branches or subfields in pharmacology],\n\"DRUG_CLINICAL_TRIAL_IDS\": [frequencies of drug clinical trial identifiers],\n\"PUBMED_SEARCH_STRATEGIES\": [frequencies of PubMed search strategies mentioned}", {}]], [395, "Type of participant.", [" {\"PHARMACOLOGICAL AGENTS\": [\"drug\", \"medication\", \"pharmacological agent\", \"compound\", \"substance\"], \"PHARMACOLOGY\": [\"pharmacology\", \"pharmacological process\", \"drug action\", \"drug metabolism\", \"drug absorption\"], \"RESEARCHERS\": [\"scientists\", \"researchers\", \"students\", \"pharmacologists\"], \"ARTICLES\": [\"scientific article\", \"research paper\", \"study\", \"review\", \"article\"], \"JOURNALS\": [\"Journal of Pharmacology\", \"Pharmacological Research\", \"Clinical Pharmacology and Therapeutics\", \"Drug Metabolism and Disposition\"], \"PLACE\": [\"laboratory\", \"research facility\", \"university\"], \"TIME\": [\"recent\", \"historical\", \"long-term\"], \"METHODS\": [\"experimental\", \"clinical\", \"observational\", \"epidemiological\", \"statistical\"], \"OUTCOMES\": [\"effectiveness\", \"efficacy\", \"side effects\", \"toxicity\", \"pharmacokinetics\", \"pharmacodynamics\"], \"DOSAGE\": [\"dose\", \"dosage\", \"dosage range\", \"dosage regimen\"], \"DURATION\": [\"short-term\", \"long-term\", \"acute\", \"chronic\"], \"DRUG NAMES\": [\"drug X\", \"drug Y\", \"drug Z\"], \"DRUG CATEGORIES\": [\"antibiotic\", \"antiviral\", \"antifungal\", \"antiparasitic\", \"anticancer\", \"antihypertensive\", \"antidiabetic\", \"antidepressant\", \"antipsychotic\", \"antihistamine\"], \"DRUG ACTIONS\": [\"agonist\", \"antagonist\", \"inhibitor\", \"activator\", \"blocker\", \"reuptake inhibitor\", \"metabolic inhibitor\"], \"DRUG METABOLISM\": [\"liver\", \"kidney\", \"gut\", \"cytochrome P450 enzymes\", \"P-glycoprotein\"], \"DRUG", {}]], [396, "An herb was defined as a product or an extract originating from a single botanical source.", [" {\"Botanical Source\": [1], \"Product\": [1], \"Extract\": [1]}", {}]], [397, "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers.", [" {\"STUDY SELECTION CRITERIA\": [\"standard eligibility inclusion criteria\", \"two reviewers\"]}\n\n{\"PHARMACOLOGICAL TERMS\": [\"pharmacology\", \"pharmacotherapy\", \"drug\", \"therapy\", \"pharmacological\", \"pharmacokinetics\", \"pharmacodynamics\"]}\n\n{\"RESEARCHER FAMILIES\": []}\n\n{\"MEDICAL TERMS\": [\"study\", \"articles\", \"scientific\", \"pharmacology\"]}\n\n{\"MEDICAL EVENTS\": [\"pharmacological entities\"]}\n\n{\"MEDICAL EVENTS\": [\"pharmacological entities\", \"pharmacokinetics\", \"pharmacodynamics\"]}\n\n{\"MEDICAL EVENTS\": [\"pharmacotherapy\"]}\n\n{\"MEDICAL EVENTS\": [\"drug\"]}\n\n{\"MEDICAL EVENTS\": [\"therapy\"]}\n\n{\"MEDICAL EVENTS\": [\"eligibility inclusion criteria\"]}\n\n{\"MEDICAL EVENTS\": [\"reviewers\"]}\n\n{\"MEDICAL EVENTS\": [\"study selection\"]}\n\n{\"MEDICAL EVENTS\": [\"data extraction\"]}\n\n{\"MEDICAL EVENTS\": [\"pharmacology\"]}\n\n{\"MEDICAL EVENTS\": [\"pharmacology\", \"pharmacotherapy\", \"pharmacokinetics\", \"pharmacodynamics\"]}\n\n{\"MEDICAL EVENTS\": [\"pharmacotherapy\", \"pharmacokinetics\", \"pharmacodynamics\"]}\n\n{\"MEDICAL EVENTS\": [\"pharmacokinetics\", \"pharmacodynamics\"]}\n\n{\"MEDICAL EVENTS\": [\"pharmacokinetics\", \"pharmacodynamics\"]}\n\n{\"MEDICAL EVENTS\": [\"pharmacokinetics\", \"pharmacodynamics\"]}\n\n{\"MEDICAL EVENTS\": [\"pharmac", {}]], [398, "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2.", [" {\"Table 2\": 1, \"RCTs\": 1, \"herbal preparations\": 1, \"bioanalytical data\": 1, \"composition\": 1, \"extraction method\": 1, \"summarized\": 1}\n{\"FREQUENCY\": {\"Table 2\": 1, \"RCTs\": 1, \"herbal preparations\": 1, \"bioanalytical data\": 1, \"composition\": 1, \"extraction method\": 1, \"summarized\": 1}}\n{\"FREQUENCY\": {\"Table 2\": 1, \"RCTs\": 1, \"herbal preparations\": 1, \"bioanalytical data\": 1, \"composition\": 1, \"extraction method\": 1, \"summarized\": 1}}\n{\"FREQUENCY\": {\"Table 2\": 1, \"RCTs\": 1, \"herbal preparations\": 1, \"bioanalytical data\": 1, \"composition\": 1, \"extraction method\": 1, \"summarized\": 1}}\n{\"FREQUENCY\": {\"Table 2\": 1, \"RCTs\": 1, \"herbal preparations\": 1, \"bioanalytical data\": 1, \"composition\": 1, \"extraction method\": 1, \"summarized\": 1}}\n{\"FREQUENCY\": {\"Table 2\": 1, \"RCTs\": 1, \"herbal preparations\": 1, \"bioanalytical data\": 1, \"composition\": 1, \"extraction method\": 1, \"summarized\": 1}}\n{\"FREQUENCY\": {\"Table 2\": 1, \"RCTs\": 1, \"herbal preparations\": 1, \"bioanalytical data\": 1, \"composition\": 1, \"extraction method\": 1, \"summarized\": 1}}\n{\"FREQUENCY\": {\"Table 2\": 1, \"RCTs\": 1, \"herbal preparations\": 1, \"bioanalytical data\": 1, \"composition\": 1, \"", {"Herb name": ["herbal preparations"], "Study": ["RCTs"]}]], [399, "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal.", [" {\"TRIALS\": [\"trials [21\u201324, 26, 28, 29]\"]}\n{\"PARTICIPANTS\": [\"participants\"]}\n{\"WITHDRAWAL\": [\"attrition\", \"withdrawal\", \"number and reasons for withdrawal\"]}\n{\"REASONS\": [\"reasons for withdrawal\"]}\n{\"NUMBER\": [\"number and\"]}\n{\"REASONS FOR WITHDRAWAL\": [\"reasons for withdrawal\"]}\n{\"REPORTING\": [\"reported detailed information\"]}\n{\"DETAILED INFORMATION\": [\"detailed information\"]}\n{\"REASONS FOR WITHDRAWAL\": [\"reasons for withdrawal\"]}\n{\"REASONS FOR WITHDRAWAL\": [\"reasons for withdrawal\"]}\n{\"REASONS FOR WITHDRAWAL\": [\"reasons for withdrawal\"]}\n{\"REASONS FOR WITHDRAWAL\": [\"reasons for withdrawal\"]}\n{\"REASONS FOR WITHDRAWAL\": [\"reasons for withdrawal\"]}\n{\"REASONS FOR WITHDRAWAL\": [\"reasons for withdrawal\"]}\n{\"REASONS FOR WITHDRAWAL\": [\"reasons for withdrawal\"]}\n{\"REASONS FOR WITHDRAWAL\": [\"reasons for withdrawal\"]}\n{\"REASONS FOR WITHDRAWAL\": [\"reasons for withdrawal\"]}\n{\"REASONS FOR WITHDRAWAL\": [\"reasons for withdrawal\"]}\n{\"REASONS FOR WITHDRAWAL\": [\"reasons for withdrawal\"]}\n{\"REASONS FOR WITHDRAWAL\": [\"reasons for withdrawal\"]}\n{\"REASONS FOR WITHDRAWAL\": [\"reasons for withdrawal\"]}\n{\"REASONS FOR WITHDRAWAL\": [\"reasons for withdrawal\"]}\n{\"REASONS FOR WITHDRAWAL\": [\"reasons for withdrawal\"]}\n{\"REASONS FOR WITHDRAWAL\": [\"reasons for withdrawal\"]}\n{\"REASONS FOR WITHDRAWAL\": [\"reasons for withdrawal\"]}\n{\"REASONS FOR WITHDRA", {"Study": ["trials"]}]], [400, "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias.", [" {\"marked circle\": [1, 2, 3]}", {}]], [401, "Based on the two CONSORT statements, the reporting percentage for each of the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%.", [" {\"CONSORT statement\": 2, \"reporting percentage\": 4, \"articles\": 1, \"mean percentage\": 1}\n\n{\"FREQUENCY\": {\"reporting percentage\": 4, \"articles\": 1, \"mean percentage\": 1}}\n\n{\"FREQUENCY\": {\"CONSORT statement\": 2}}\n\n{\"FREQUENCY\": {\"mean percentage\": 1}}\n\n{\"FREQUENCY\": {\"reporting percentage\": 4}}\n\n{\"FREQUENCY\": {\"articles\": 1}}\n\n{\"FREQUENCY\": {\"36.5%\": 1, \"61.5%\": 1}}\n\n{\"FREQUENCY\": {\"mean percentage\": 1}}\n\n{\"FREQUENCY\": {\"45.6%\": 1}}", {}]], [402, "All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study.", [" {\"WARFARIN\": 1, \"HERBAL MEDICINES\": 1, \"PD INTERACTIONS\": 1, \"STUDIES\": 1}\n{\"WARFARIN\": 1, \"HERBAL MEDICINES\": 1, \"PD INTERACTIONS\": 1, \"STUDIES\": 1}\n{\"WARFARIN\": 1, \"HERBAL MEDICINES\": 1, \"PD INTERACTIONS\": 1, \"PARAMETERS\": 1}\n{\"WARFARIN\": 1, \"HERBAL MEDICINES\": 1, \"PARAMETERS\": 1, \"STUDIES\": 1}\n{\"WARFARIN\": 1, \"HERBAL MEDICINES\": 1, \"PARAMETERS\": 1, \"STUDIES\": 1}\n{\"WARFARIN\": 1, \"HERBAL MEDICINES\": 1, \"PARAMETERS\": 1, \"STUDIES\": 1}\n{\"WARFARIN\": 1, \"HERBAL MEDICINES\": 1, \"PARAMETERS\": 1, \"STUDIES\": 1}\n{\"WARFARIN\": 1, \"HERBAL MEDICINES\": 1, \"PARAMETERS\": 1, \"STUDIES\": 1}\n{\"WARFARIN\": 1, \"HERBAL MEDICINES\": 1, \"PARAMETERS\": 1, \"STUDIES\": 1}\n{\"WARFARIN\": 1, \"HERBAL MEDICINES\": 1, \"PARAMETERS\": 1, \"STUDIES\": 1}\n{\"WARFARIN\": 1, \"HERBAL MEDICINES\": 1, \"PARAMETERS\": 1, \"STUDIES\": 1}\n{\"WARFARIN\": 1, \"HERBAL MEDICINES\": 1, \"PARAMETERS\": 1, \"STUDIES\": 1}\n{\"WARFAR", {"Drug": ["warfarin"], "Herb name": ["herbal medicines"]}]], [403, "These relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship.", [" {\"Warfarin\": 2, \"herb-warfarin interaction\": 1, \"case reports\": 1}\n{\"FREQUENCY\": {\"Warfarin\": 2, \"herb-warfarin interaction\": 1, \"case reports\": 1}}", {"Study": ["case reports"], "Herb name": ["herb"], "Drug": ["warfarin"]}]], [404, "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40].", [" {\"Case Reports\": 1, \"Studies\": 1, \"Limitations\": 1, \"Misleading Conclusions\": 1, \"Reasons\": 1, \"39\": 1, \"40\": 1}\n{\"FREQUENCY\": {\"Case Reports\": 1, \"Studies\": 1, \"Limitations\": 1, \"Misleading Conclusions\": 1, \"Reasons\": 1, \"39\": 1, \"40\": 1}}", {"Study": ["case reports"]}]], [405, "However, an in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47].", [" {\"Echinacea\": 1, \"in vivo study\": 1, \"significant effect\": 1, \"metabolism\": 2, \"drugs\": 1, \"metabolized by\": 1, \"CYP2C9\": 1}\n{\"CYP2C9\": {\"FREQUENCY\": 1}}", {"Study": ["in vivo study"], "Herb name": ["echinacea"], "Parameter": ["CYP2C9"]}]], [406, "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48].", [" {\"Gingko Biloba\": 2, \"CYP enzyme activity\": 1, \"liver\": 1, \"hepatic damage\": 1, \"in vivo study\": 1, \"dose-dependent manner\": 1}\n{\"FREQUENCY\": {\"Gingko Biloba\": 2, \"CYP enzyme activity\": 1, \"liver\": 1, \"hepatic damage\": 1, \"in vivo study\": 1, \"dose-dependent manner\": 1}}", {"Study": ["in vivo study"], "Herb name": ["gingko"], "Parameter": ["CYP enzyme activity"]}]], [407, "However, no studies were reported these data.", [" {\"Studies\": 0, \"Authors\": \"\", \"Journal Names\": \"\", \"Pharmacological Subjects\": \"\", \"Drugs\": \"\", \"Diseases/Conditions\": \"\", \"Years\": \"\"}\n\n{\"Studies\": \"0\", \"Authors\": \"\", \"Journal Names\": \"\", \"Pharmacological Subjects\": \"pharmacology\", \"Drugs\": \"\", \"Diseases/Conditions\": \"\", \"Years\": \"\"}\n\n(Note: The provided text does not mention specific authors, journal names, drugs, diseases/conditions, or years, hence those fields are left empty. However, the term \"pharmacology\" is mentioned, which is a pharmacological subject.)", {}]], [408, "(DOCX) Click here for additional data file.", [" {\"PHARMACOLOGY_ARTICLE\": 1, \"SCIENTIFIC_ARTICLE\": 1, \"PHARMACOLOGY\": 1, \"PHARMACOLOGIST\": 1, \"PHARMACEUTICAL_PRODUCT\": 1, \"DRUG\": 1, \"DRUG_NAME\": 1, \"DRUG_ACTION\": 1, \"DRUG_REACTION\": 1, \"DRUG_DOSAGE\": 1, \"DRUG_MEDICATION\": 1, \"DRUG_CLINICAL_TRIAL\": 1, \"DRUG_TOXICITY\": 1, \"DRUG_INTERACTION\": 1, \"DRUG_METABOLISM\": 1, \"DRUG_PHARMACOLOGY\": 1, \"DRUG_PHARMACEUTICAL_PRODUCT\": 1, \"DRUG_CLINICAL_STUDY\": 1, \"DRUG_CLINICAL_TRIAL_STUDY\": 1, \"DRUG_CLINICAL_TRIAL_RESULT\": 1, \"DRUG_CLINICAL_TRIAL_OUTCOME\": 1, \"DRUG_CLINICAL_TRIAL_CONCLUSION\": 1, \"DRUG_CLINICAL_TRIAL_RECOMMENDATION\": 1, \"DRUG_CLINICAL_TRIAL_RESEARCH\": 1, \"DRUG_CLINICAL_TRIAL_RESEARCH_FINDINGS\": 1, \"DRUG_CLINICAL_TRIAL_RESEARCH_CONCLUSION\": 1, \"DRUG_CLINICAL_TRIAL_RESEARCH_RECOMMENDATION\": 1, \"DRUG_CLINICAL_TRIAL_RESEARCH_IMPACT\": 1, \"DRUG_CLINICAL_TRIAL_RESEARCH_IMPACT_ON_PATIENT\": 1, \"DRUG_CLINICAL_TRIAL_RESEARCH_IMPACT_ON_HEALTHCA", {}]], [409, "She had no history of warfarin use, but warfarin was detected in her blood serum analysis.", [" {\"WARFARIN\": 2}", {"Drug": ["warfarin", "warfarin"]}]], [410, "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven.", [" {\"prothrombin time\": 1, \"activated partial thromboplastin time\": 1, \"international normalized ratio\": 1}\n{\"FREQUENCY\": {\"prothrombin time\": 1, \"activated partial thromboplastin time\": 1, \"international normalized ratio\": 1}}", {"Parameter": ["prothrombin time (PT)", "activated partial thromboplastin time (aPTT)", "international normalized ratio (INR)"], "Amount": ["more than 37 seconds", "more than 70 seconds", "greater than seven"]}]], [411, "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6).", [" {\"WARFAREIN\": 1, \"SUPER-WARFAREIN\": 1, \"DISEMATIZED INTRAVASCULAR COAGULATION (DIC)\": 1, \"VITAMIN K MALABSORPTION\": 1, \"PATHOLOGIC INHIBITORS OF COAGULATION\": 1}", {"Pathology": ["coagulopathy", "disseminated intravascular coagulation (DIC)", "vitamin K malabsorption", "pathologic inhibitors of coagulation"], "Drug": ["warfarin", "super-warfarin"]}]], [412, "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment.", [" {\"WSU Institutional Review Board\": 1, \"study protocol\": 1, \"consent form\": 1, \"subject enrollment\": 1}\n{\"Frequency\": {\"WSU Institutional Review Board\": 1, \"study protocol\": 1, \"consent form\": 1, \"subject enrollment\": 1}}\n\n(Note: The entities \"study protocol\" and \"consent form\" are not explicitly mentioned as cited entities in the text, but they are directly related to the described entities and activities. However, strictly following the instruction, they are not listed as separate entities. If the task is to identify only direct mentions of cited entities, then they are not included in the output.)\n\n(Note: The instruction asks for words referring to described entities, but the provided text does not contain such words. The entities listed above are inferred from the context of the text. If the instruction is strictly to identify direct mentions of cited entities, then the output would be empty for these entities.)", {}]], [413, "Vital signs (blood pressure, pulse, oxygen saturation) were obtained on every study day.", [" {\"Vital signs\": 1, \"blood pressure\": 1, \"pulse\": 1, \"oxygen saturation\": 1}\n{\"FREQUENCY\": {\"Vital signs\": 1, \"blood pressure\": 1, \"pulse\": 1, \"oxygen saturation\": 1}}", {"Parameter": ["Vital signs (blood pressure, pulse, oxygen saturation)"], "Frequency": ["every study day"]}]], [414, "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable.", [" {\"Siliphos\": 1, \"blister pack\": 1, \"pill diary\": 1, \"time of administration\": 1, \"beverage\": 1, \"volume used to aid swallowing\": 1, \"adverse events\": 1}", {"Herb name": ["Siliphos"], "Parameter": ["approximate volume used to aid swallowing"], "Pathology": ["adverse events"]}]], [415, "The terminal elimination rate constant (\u03bb All statistical analyses were conducted using SAS (v. 9.2; SAS Institute).", [" {\"SAS Institute\": 1, \"statistical analyses\": 1, \"SAS (v. 9.2)\": 1, \"terminal elimination rate constant (\u03bb)\": 1, \"pharmacology\": 1}\n{\"SAS Institute\": 1, \"SAS (v. 9.2)\": 1, \"statistical analyses\": 1, \"terminal elimination rate constant (\u03bb)\": 1, \"pharmacology\": 1}\n{\"SAS Institute\": 1, \"SAS (v. 9.2)\": 1, \"statistical analyses\": 1, \"terminal elimination rate constant (\u03bb)\": 1}\n{\"SAS Institute\": 1, \"SAS (v. 9.2)\": 1, \"statistical analyses\": 1, \"terminal elimination rate constant (\u03bb)\": 1, \"pharmacology\": 1}\n{\"SAS Institute\": 1, \"SAS (v. 9.2)\": 1, \"statistical analyses\": 1, \"terminal elimination rate constant (\u03bb)\": 1}\n{\"SAS Institute\": 1, \"SAS (v. 9.2)\": 1, \"statistical analyses\": 1, \"terminal elimination rate constant (\u03bb)\": 1, \"pharmacology\": 1}\n{\"SAS Institute\": 1, \"SAS (v. 9.2)\": 1, \"statistical analyses\": 1, \"terminal elimination rate constant (\u03bb)\": 1}\n{\"SAS Institute\": 1, \"SAS (v. 9.2)\": 1, \"statistical analyses\": 1, \"terminal elimination rate constant (\u03bb)\": 1, \"pharmacology\": 1}\n{\"SAS Institute\": 1, \"SAS (v. 9.2)\": 1, \"statistical analyses\": 1, \"terminal elimination rate constant (\u03bb)\": 1}\n{\"SAS Institute\": 1, \"SAS (v. 9.2)\": 1, \"statist", {}]], [416, "This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms.", [" {\"Herbal products\": 2, \"ADME processes\": 1, \"herb\u2013drug interactions\": 1}", {"Herb name": ["herbal products"], "Parameter": ["ADME processes"]}]], [417, "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction.", [" {\"Silibinin\": 1, \"model herbal product\": 1, \"perpetrator\": 1, \"herbal product\": 1, \"glucuronidation\": 1, \"intestinal glucuronidation\": 1, \"human pharmacokinetic data\": 1, \"in vitro inhibitory potency\": 1, \"raloxifene\": 1}", {"Herb name": ["Silibinin", "herbal product", "silibinin"], "Parameter": ["intestinal glucuronidation"], "Drug": ["raloxifene"]}]], [418, "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential.", [" {\"Scientific Article\": 1, \"Pharmacology\": 1, \"cited entities\": {\"scientific article\": 1, \"pharmacology\": 1, \"silibinin\": 1, \"predosing\": 1, \"raloxifene\": 1, \"multiple dosing\": 1, \"interaction potential\": 1}}\n{\"FREQUENCY\": {\"scientific article\": 1, \"pharmacology\": 1, \"silibinin\": 1, \"predosing\": 1, \"raloxifene\": 1, \"multiple dosing\": 1, \"interaction potential\": 1}}\n{\"study designs\": 1, \"silibinin\": 1, \"predosing\": 1, \"raloxifene\": 1, \"multiple dosing\": 1}\n{\"interaction potential\": 1}", {"Herb name": ["silibinin"], "Frequency": ["multiple dosing"], "Drug": ["raloxifene"]}]], [419, "Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development.", [" {\"Drug molecules\": 1, \"oxidative metabolism\": 1, \"conjugative metabolism\": 1, \"drug development\": 1}\n\nNote: The entities \"pharmacology\" and \"scientific article\" are not directly mentioned in the text but are implied in the context of the topic. However, since the task is to find words referring to the described entities, they are not included in the output.", {}]], [420, "Supporting Information Click here for additional data file.", [" {\"PHARMACOLOGY_ARTICLE\": 1,\n\n\"Scientific_Article\": 1,\n\n\"Pharmacology\": 1,\n\n\"Cited_Entities\": 1,\n\n\"Cited_Words\": 1,\n\n\"Events\": 1,\n\n\"Studies\": 1,\n\n\"Research\": 1,\n\n\"Drugs\": 1,\n\n\"Drug_Names\": 1,\n\n\"Drug_Classifications\": 1,\n\n\"Drug_Mechanisms\": 1,\n\n\"Drug_Effects\": 1,\n\n\"Drug_Side_Effects\": 1,\n\n\"Drug_Interactions\": 1,\n\n\"Drug_Dosage\": 1,\n\n\"Drug_Administration\": 1,\n\n\"Drug_Distribution\": 1,\n\n\"Drug_Metabolism\": 1,\n\n\"Drug_Excretion\": 1,\n\n\"Clinical_Trials\": 1,\n\n\"Clinical_Studies\": 1,\n\n\"Clinical_Data\": 1,\n\n\"Clinical_Outcomes\": 1,\n\n\"Clinical_Parameters\": 1,\n\n\"Clinical_Endpoints\": 1,\n\n\"Clinical_Significance\": 1,\n\n\"Clinical_Relevance\": 1,\n\n\"Clinical_Applications\": 1,\n\n\"Clinical_Implications\": 1,\n\n\"Clinical_Trials_Data\": 1,\n\n\"Clinical_Trial_Results\": 1,\n\n\"Clinical_Trial_Design\": 1,\n\n\"Clinical_Trial_Phases\": 1,\n\n\"Clinical_Trial_Regulations\": 1,\n\n\"Clinical_Trial_Ethics\": 1,\n\n\"Clinical_Trial_Statistics\": 1,\n\n\"Clinical_Trial_Analysis\": 1,\n\n\"Clinical_Trial_Conclusions\": 1,", {}]], [421, "Curcumin commercially available as pure powder capsule (95%) was obtained from Quality Supplements and Vitamins (Fort Lauderdale, FL, USA).", [" {\"Curcumin\": 1, \"pure powder capsule\": 1, \"95%\": 1, \"Quality Supplements\": 1, \"Vitamins\": 1, \"Fort Lauderdale, FL, USA\": 1}\n{\"FREQUENCY\": {\"Curcumin\": 1, \"pure powder capsule\": 1, \"95%\": 1, \"Quality Supplements\": 1, \"Vitamins\": 1, \"Fort Lauderdale, FL, USA\": 1}}\n\n(Note: The frequency count is based on the specific phrases and entities mentioned in the provided text.)", {"Herb name": ["Curcumin"]}]], [422, "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control.", [" {\"Curcumin\": 1, \"Gliclazide\": 2, \"Blood glucose reduction\": 1, \"normal rats\": 1, \"rabbits\": 1}\n\n{\"FREQUENCY\": {\"Curcumin\": 1, \"Gliclazide\": 2, \"Blood glucose reduction\": 1, \"normal rats\": 1, \"rabbits\": 1}}", {"Herb name": ["curcumin"], "Drug": ["gliclazide", "gliclazide"]}]], [423, "This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier.", [" {\"Curcumin\": 1, \"pharmacology\": 1, \"scientific article\": 1, \"mechanisms\": 1, \"effect\": 1}\n{\"FREQUENCY\": {\"Curcumin\": 1, \"pharmacology\": 1, \"scientific article\": 1, \"mechanisms\": 1, \"effect\": 1}}\n{\"Curcumin\": {\"first_mention\": \"This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier.\"}, \"pharmacology\": {\"first_mention\": \"This is a scientific article about pharmacology.\"}, \"scientific article\": {\"first_mention\": \"This is a scientific article about pharmacology.\"}, \"mechanisms\": {\"first_mention\": \"This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier.\"}, \"effect\": {\"first_mention\": \"This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier.\"}}", {"Herb name": ["curcumin"]}]], [424, "Traditional Chinese medicine accounted for most of the interactions (n = 17), followed by food (n = 10), dietary supplements (n = 3), and other herbs/botanicals (n = 3).", [" {\"Traditional Chinese medicine\": 1, \"interactions\": 1, \"food\": 1, \"dietary supplements\": 1, \"other herbs/botanicals\": 1}\n{\"n\": 1}", {"Ethnic group": ["Chinese"]}]], [425, "Despite its clinical popularity, CBZ possesses several pharmacokinetic properties which make it prone to interaction with coadministered substances, including drugs, herbal products, and food [7].", [" {\"CBZ\": 2, \"pharmacokinetic properties\": 1, \"interaction\": 1, \"coadministered substances\": 1, \"drugs\": 1, \"herbal products\": 1, \"food\": 1}\n{\"FREQUENCY\": {\"pharmacokinetic properties\": 1, \"interaction\": 1, \"coadministered substances\": 1, \"drugs\": 1, \"herbal products\": 1, \"food\": 1}}", {"Drug": ["CBZ"]}]], [426, "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions.", [" {\"CBZ\": 2, \"systematic review\": 1, \"healthcare professionals\": 1, \"decision-making\": 1}\n\nNote: The frequency count is based on the direct mentions of the entities in the provided text. If there are synonyms or related terms used in the context, they are not included in this count as per the instruction to only list words referring to the described entities.", {"Drug": ["CBZ"]}]], [427, "2012), Cochrane Database of Systematic Reviews (2005\u2013Dec.", [" {\"Cochrane Database of Systematic Reviews\": 1, \"2005\": 1, \"December\": 1, \"2012\": 1}\n\nNote: The frequency count is based on the direct mentions of the entities in the provided text. If there were additional mentions of these entities in the full article, the frequency count would be higher. However, based on the given text, this is the frequency of each entity mentioned.", {}]], [428, "2012).", [" {\"2012\": 1, \"pharmacology\": 2, \"scientific article\": 1, \"cited entities\": 1}", {}]], [429, "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365].", [" {\"Honey\": 1, \"orally bioavailable\": 1, \"Clobazam (CBZ)\": 2, \"pharmacokinetic parameters\": 1, \"human\": 1}\n{\"FREQUENCY\": {\"Honey\": 1, \"orally bioavailable\": 1, \"Clobazam (CBZ)\": 2, \"pharmacokinetic parameters\": 1, \"human\": 1}}", {"Parameter": ["oral bioavailability"], "Drug": ["CBZ", "CBZ"]}]], [430, "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70].", [" {\"FOLINIC ACID\": 1, \"CBZ\": 2, \"plasma level\": 1, \"rats\": 1, \"nicotinamide\": 1, \"children with epilepsy\": 1}", {"Drug": ["CBZ", "folinic acid", "CBZ", "nicotinamide", "CBZ"], "Parameter": ["clearance"], "Cohort": ["two children"], "Pathology": ["epilepsy"]}]], [431, "Patients on antiepileptic therapy are usually on a long-term basis.", [" {\"Antiepileptic drugs\": 1, \"Patients\": 1, \"therapy\": 1}\n{\"FREQUENCY\": {\"long-term basis\": 1}}\n\n(Note: The entities \"antiepileptic drugs\" and \"therapy\" are inferred from the context of the sentence, as the specific names of the drugs are not mentioned. \"Patients\" is directly mentioned.)", {"Pathology": ["Patients"], "Drug": ["antiepileptic therapy"]}]], [432, "In order to achieve a comprehensive literature search, a total of eleven databases were searched.", [" {\"DATABASES\": [\"eleven databases\"]}\n\n{\"PHARMACOLOGY_TERMS\": [\"pharmacology\"]}\n\n{\"PHARMACEUTICAL_ENTITIES\": [\"pharmacology\", \"medicine\", \"drugs\", \"pharmacokinetics\", \"pharmacodynamics\", \"drug action\", \"drug metabolism\", \"drug absorption\", \"drug distribution\", \"drug excretion\"]}\n\n{\"SPECIALTY_FIELDS\": [\"literature search\"]}\n\n{\"EVENTS\": [\"comprehensive literature search\"]}\n\n{\"FREQUENCY\": {\"DATABASES\": 1}}", {}]], [433, "These included two conventional databases (EMBASE and MEDLINE), five other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, and SciFinder Scholar) four Chinese databases.", [" {\"EMBASE\": 1, \"MEDLINE\": 1, \"AMED\": 1, \"CINAHL Plus\": 1, \"Cochrane Database of Systematic Reviews\": 1, \"CENTRAL\": 1, \"SciFinder Scholar\": 1, \"Chinese databases\": 1}", {"Ethnic group": ["Chinese"]}]], [434, "Ispaghula husk, septilin, soybean and Xiao-cha-hu-tang reduced the plasma level of CBZ by affecting its gastric absorption.", [" {\"Ispaghula husk\": 1, \"septilin\": 1, \"soybean\": 1, \"Xiao-cha-hu-tang\": 1, \"plasma level of CBZ\": 1, \"gastric absorption\": 1}\n{\"FREQUENCY\": {\"Ispaghula husk\": 1, \"septilin\": 1, \"soybean\": 1, \"Xiao-cha-hu-tang\": 1, \"plasma level of CBZ\": 1, \"gastric absorption\": 1}}", {"Herb name": ["Ispaghula husk", "septilin", "soybean", "Xiao-cha-hu-tang"], "Drug": ["CBZ"]}]], [435, "Caution should also be paid for beverage containing alcohol.", [" {\"Alcoholic Beverages\": 1, \"Pharmacology\": 1, \"Scientific Article\": 1, \"Cited Entities\": 1}", {}]], [436, "In a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects including dizziness, blurred vision, skin rash, and nausea in patients with major depression or bipolar disorder.", [" {\"Xiao-yao-san\": 1, \"CBZ-related side effects\": 1, \"dizziness\": 1, \"blurred vision\": 1, \"skin rash\": 1, \"nausea\": 1, \"major depression\": 1, \"bipolar disorder\": 1}", {"Study": ["a randomized double-blinded control trial"], "Herb name": ["Xiao-yao-san"], "Drug": ["CBZ"], "Pathology": ["dizziness", "blurred vision", "skin rash", "nausea", "major depression", "bipolar disorder"]}]], [437, "Composition of individual herbs in the included herbal formulae.", [" {\"HERBAL_FORMULAE\": [\"composition of individual herbs\", \"included herbal formulae\"]}", {}]], [438, "Fifty percent of the informants used herbal medicines alongside their prescription drugs.", [" {\"Herbal medicines\": 1, \"prescription drugs\": 1}\n{\"FREQUENCY\": {\"Herbal medicines\": 1, \"prescription drugs\": 1}}\n\n(Note: The frequency count is based on the single occurrence of each entity in the provided text.)\n\nIf the text had more instances, the frequency count would reflect those additional occurrences. For example, if the text mentioned \"herbal medicines\" twice, the frequency count for \"Herbal medicines\" would be 2. However, based on the given text, the frequency count is as shown above.", {}]], [439, "In identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of patients' use of herbal medicines.", [" {\"Herbal Medicines\": 1, \"Healthcare Professionals\": 1, \"Proactive Monitoring\": 1}\n{\"Herbal Medicines\": 1, \"Healthcare Professionals\": 1, \"Proactive Monitoring\": 1}\n{\"Herbal Medicines\": 1, \"Patients\": 1}\n{\"Interactions\": 1}\n{\"Monitoring\": 1}\n{\"Promotion\": 1}\n{\"Use\": 1}\n{\"Healthcare Professionals\": 1}\n{\"Patients\": 1}\n{\"Herbal Medicines\": 1}\n{\"Proactive Monitoring\": 1}\n{\"Healthcare Professionals\": 1}\n{\"Patients\": 1}\n{\"Herbal Medicines\": 1}\n{\"Interactions\": 1}\n{\"Healthcare Professionals\": 1}\n{\"Patients\": 1}\n{\"Proactive Monitoring\": 1}\n{\"Healthcare Professionals\": 1}\n{\"Patients\": 1}\n{\"Herbal Medicines\": 1}\n{\"Interactions\": 1}\n{\"Healthcare Professionals\": 1}\n{\"Patients\": 1}\n{\"Proactive Monitoring\": 1}\n{\"Healthcare Professionals\": 1}\n{\"Patients\": 1}\n{\"Herbal Medicines\": 1}\n{\"Interactions\": 1}\n{\"Healthcare Professionals\": 1}\n{\"Patients\": 1}\n{\"Proactive Monitoring\": 1}\n{\"Healthcare Professionals\": 1}\n{\"Patients\": 1}\n{\"Herbal Medicines\": 1}\n{\"Interactions\": 1}\n{\"Healthcare Professionals\": 1}\n{\"Patients\": 1}\n{\"Proactive Monitoring\": 1}\n{\"Healthcare Professionals\": 1}\n{\"Patients\": 1}\n{\"Herbal Medicines\": 1}\n{\"Interactions\": 1}\n{\"Healthcare Professionals\": 1}\n{\"Patients\": 1}\n{\"Proactive Monitoring\": 1}\n{\"Healthcare Professionals\": 1}\n{\"Patients", {}]], [440, "A significant relationship between variables was identified if p < 0.05.", [" {\"p-value\": [1], \"variables\": [1], \"significance level\": [1]}", {}]], [441, "A summary of the background characteristics of the interviewed patients is given in Table 1.", [" {\"FREQUENCY\": {\"Table 1\": 1, \"summary\": 1, \"interviewed patients\": 1, \"background characteristics\": 1}}\n\n{\"ENTITY\": \"Table 1\", \"FREQUENCY\": 1}\n\n{\"ENTITY\": \"summary\", \"FREQUENCY\": 1}\n\n{\"ENTITY\": \"interviewed patients\", \"FREQUENCY\": 1}\n\n{\"ENTITY\": \"background characteristics\", \"FREQUENCY\": 1}", {}]], [442, "This is possibly because the highest number of patients with type-2 diabetes fell within that age group.", [" {\"Type-2 diabetes\": 1, \"age group\": 1}", {"Pathology": ["type-2 diabetes"]}]], [443, "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents.", [" {\"Pharmacological Management\": [1], \"Patients\": [1], \"Hypoglycaemic Agents\": [1]}\n\n{\"Hypoglycaemic Agents\": [1], \"Patients\": [1]}\n\n{\"Pharmacological Management\": [1], \"Hypoglycaemic Agents\": [1]}\n\n{\"Pharmacological Management\": [1], \"Patients\": [1]}\n\n{\"Hypoglycaemic Agents\": [1]}\n\n{\"Pharmacological Management\": [1], \"Patients\": [1]}\n\n{\"Pharmacological Management\": [1], \"Hypoglycaemic Agents\": [1]}\n\n{\"Pharmacological Management\": [1], \"Patients\": [1]}\n\n{\"Pharmacological Management\": [1], \"Hypoglycaemic Agents\": [1]}\n\n{\"Pharmacological Management\": [1], \"Patients\": [1]}\n\n{\"Pharmacological Management\": [1], \"Hypoglycaemic Agents\": [1]}\n\n{\"Pharmacological Management\": [1], \"Patients\": [1]}\n\n{\"Pharmacological Management\": [1], \"Hypoglycaemic Agents\": [1]}\n\n{\"Pharmacological Management\": [1], \"Patients\": [1]}\n\n{\"Pharmacological Management\": [1], \"Hypoglycaemic Agents\": [1]}\n\n{\"Pharmacological Management\": [1], \"Patients\": [1]}\n\n{\"Pharmacological Management\": [1], \"Hypoglycaemic Agents\": [1]}\n\n{\"Pharmacological Management\": [1], \"Patients\": [1]}\n\n{\"Pharmacological Management\": [1], \"Hypoglycaemic Agents\": [1]}\n\n{\"Pharmacological Management\": [1], \"Patients\": [1]}\n\n{\"Pharmacological Management\": [1], \"Hypoglycaemic Agents\": [1]}\n\n{\"Pharmacological Management\": [1], \"Patients\": [1]}\n\n{\"Pharmacological Management\": [1], \"Hypoglyca", {"Drug": ["hypoglycaemic agents"]}]], [444, "For all of the 12 identified plants, pharmacological evidence validating their traditional use in diabetes management have been published.", [" {\"Plants\": [12], \"Pharmacological evidence\": [1], \"Diabetes management\": [1]}\n{\"FREQUENCY\": {\"Plants\": 12, \"Pharmacological evidence\": 1, \"Diabetes management\": 1}}", {"Pathology": ["diabetes"]}]], [445, "An analysis of the drugs commonly prescribed to patients with diabetes show that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions.", [" {\"Drugs\": [\"drugs commonly prescribed to patients with diabetes\"], \"Pharmacokinetic parameters\": [\"pharmacokinetic parameters commonly implicated in drug interactions\"], \"Patients\": [\"patients with diabetes\"]}\n\nNote: The terms \"substrates\" and \"modulators\" may also refer to specific drugs, but without explicit mention of specific drug names, they are categorized under the broader term \"Drugs\".", {"Pathology": ["diabetes"]}]], [446, "Healthcare practitioners who are aware of their patients' use of herbal medicines and its identity can more easily monitor them for any possible interactions using available information, such as that presented in Tables 3, 4.", [" {\"Healthcare practitioners\": 1, \"patients' use of herbal medicines\": 1, \"possible interactions\": 1, \"Tables 3, 4\": 2}\n{\"T\": 1, \"herbal medicines\": 1, \"Tables\": 2}", {}]], [447, "Herb\u2013drug interactions strongly challenge the clinical combined application of herbs and drugs.", [" {\"Herb\": 1, \"drug\": 1, \"interactions\": 1, \"clinical\": 1, \"application\": 1}\n{\"Herb\": 1, \"drug\": 1}\n{\"interactions\": 1}\n{\"clinical\": 1, \"application\": 1}", {}]], [448, "Herbs have been used for primary health care for thousands of years before the advent of modern medicines.", [" {\"HERBS\": 1, \"primary health care\": 1, \"modern medicines\": 1}\n{\"FREQUENCY\": {\"HERBS\": 1, \"primary health care\": 1, \"modern medicines\": 1}}\n\n(Note: The entities \"primary health care\" and \"modern medicines\" are not strictly pharmacological entities but are included here as they are relevant to the context of the article. If the focus is strictly on pharmacological entities, they may be excluded.)", {"Herb name": ["Herbs"], "Duration": ["for thousands of years"]}]], [449, "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7].", [" {\"HepaRG cell line\": 1, \"hepatocellular carcinoma\": 1, \"liver-specific enzymes\": 1}\n{\"5\": 1, \"6\": 1, \"7\": 1}\n\n(Note: The numbers in brackets are the frequencies of the cited entities in the text.)", {"Pathology": ["carcinoma"], "Parameter": ["liver-specific enzymes"]}]], [450, "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12].", [" {\"Aspirin\": 1, \"administration\": 1, \"body\": 1, \"elimination half-life\": 1, \"15 min\": 1, \"11,12\": 2}\n\n{\"Aspirin\": {\"FREQUENCY\": 1}, \"administration\": {\"FREQUENCY\": 1}, \"body\": {\"FREQUENCY\": 1}, \"elimination half-life\": {\"FREQUENCY\": 1}, \"15 min\": {\"FREQUENCY\": 1}, \"11,12\": {\"FREQUENCY\": 2}}\n\n{\"Aspirin\": {\"FREQUENCY\": 1}, \"administration\": {\"FREQUENCY\": 1}, \"body\": {\"FREQUENCY\": 1}, \"elimination half-life\": {\"FREQUENCY\": 1}, \"15 min\": {\"FREQUENCY\": 1}, \"11,12\": {\"FREQUENCY\": 2}}\n\n{\"Aspirin\": {\"FREQUENCY\": 1}, \"administration\": {\"FREQUENCY\": 1}, \"body\": {\"FREQUENCY\": 1}, \"elimination half-life\": {\"FREQUENCY\": 1}, \"15 min\": {\"FREQUENCY\": 1}, \"11,12\": {\"FREQUENCY\": 2}}\n\n{\"Aspirin\": {\"FREQUENCY\": 1}, \"administration\": {\"FREQUENCY\": 1}, \"body\": {\"FREQUENCY\": 1}, \"elimination half-life\": {\"FREQUENCY\": 1}, \"15 min\": {\"FREQUENCY\": 1}, \"11,12\": {\"FREQUENCY\": 2}}\n\n{\"Aspirin\": {\"FREQUENCY\": 1}, \"administration\": {\"FREQUENCY\": 1}, \"body\": {\"FREQUENCY\": 1}, \"elimination half-life\": {\"", {"Drug": ["aspirin"], "Parameter": ["an elimination half-life"], "Duration": ["15 min"]}]], [451, "A total of 22 compounds were identified or tentatively identified (Figure 1).", [" {\"Compounds\": 22, \"Identified_or_tentatively_identified\": 22, \"Figure_1\": 1}\n\n{\"Figure\": 1}\n\n{\"Events\": \"identified or tentatively identified\"}", {}]], [452, "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL).", [" {\"BNPP\": 1, \"PNS\": 1}", {"Parameter": ["BNPP"], "Amount": ["68 \u00b5g/mL", "150 \u00b5g/mL"], "Herb name": ["PNS"]}]], [453, "Liver drug enzymes are the common sites of drug interaction in human.", [" {\"Liver drug enzymes\": 1, \"drug interaction\": 1, \"human\": 1}", {"Parameter": ["Liver drug enzymes"]}]], [454, "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).", [" {\"Ultimate 3000 UPLC system\": 1, \"LTQ-Orbitrap Elite mass spectrometer\": 1, \"Thermo Fisher Scientific\": 2, \"notoginsenoside R\": 1, \"UPLC-MS/MS analysis\": 1}", {"Herb name": ["PNS", "notoginsenoside R"]}]], [455, "The influence test for PON was conducted by the method of Furlong et al.", [" {\"Furlong et al.\": 1}\n\n{\"PON\": 2}", {"Parameter": ["PON"]}]], [456, "Briefly, 2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China).", [" {\"TOTAL RNA\": 1, \"Trizol\": 1}\n{\"cells\": 1}\n{\"CW0581\": 1}\n{\"CWbio\": 1}\n{\"Beijing\": 1}\n{\"China\": 1}", {"Amount": ["2 \u00d7 10"], "Parameter": ["Total RNA"]}]], [457, "The present work provides an insight into the mechanism exploration governing HDI between aspirin and PNS.", [" {\"Aspirin\": 1, \"Pharmacology\": 1, \"Pain Neuromodulation System (PNS)\": 1}\n\n(Note: The frequency count is based on the direct mentions of the entities in the provided text. If there are more instances or related terms that refer to these entities, they are not included in this count.)", {"Drug": ["aspirin"], "Herb name": ["PNS"]}]], [458, "conceived and designed the whole experiments.", [" {\"FREQUENCY\": {\"experiments\": 1, \"conceived\": 1, \"designed\": 1, \"whole experiments\": 1}}\n\n{\"FREQUENCY\": {\"authors\": 1}}\n\n{\"FREQUENCY\": {\"scientific article\": 1}}\n\n{\"FREQUENCY\": {\"pharmacology\": 1}}\n\n{\"FREQUENCY\": {\"cited entities\": 1}}\n\n{\"FREQUENCY\": {\"events\": 1}}", {}]], [459, "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively).", [" {\"Control Group\": [1], \"Experimental Group\": [1], \"Significant Difference\": [1], \"p-value\": [2], \"Statistical Significance\": [1]}\n\n- \"Control Group\": [1]\n- \"Experimental Group\": [1]\n- \"Significant Difference\": [1]\n- \"p-value\": [2]\n- \"Statistical Significance\": [1]", {}]], [460, "However, there is hardly any data on the pharmacological safety of these two herbal medicines.", [" {\"Herbal Medicines\": 2, \"Pharmacological Safety\": 1, \"Data\": 1}\n{\"FREQUENCY\": {\"Pharmacological Safety\": 1, \"Data\": 1}}\n\n(\"Herbal Medicines\" and \"Pharmacological Safety\" are entities referring to the described entities in the text, while \"Data\" refers to the information or lack thereof.)", {}]], [461, "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates.", [" {\"cytochrome P450 enzymes (CYPs)\": 1, \"commercial kits\": 1, \"drug transporters\": 1, \"fluorescent probe substrates\": 1}\n\n{\"cytochrome P450 enzymes (CYPs)\": \"FREQUENCENCE: 1\", \"commercial kits\": \"FREQUENCENCE: 1\", \"drug transporters\": \"FREQUENCENCE: 1\", \"fluorescent probe substrates\": \"FREQUENCENCE: 1\"}", {"Target": ["cytochrome P450 enzymes (CYPs)"]}]], [462, "Neither Samento nor Banderol increased intracellular calcein fluorescence in L-MDR1 cells over-expressing human P-glycoprotein (P-gp), indicating lack of P-gp inhibition (data not shown).", [" {\"L-MDR1 cells\": 1, \"human P-glycoprotein (P-gp)\": 2}\n{\"Samento\": 1, \"Banderol\": 1}", {"Herb name": ["Samento", "Banderol"], "Target": ["P-glycoprotein (P-gp)", "P-gp"]}]], [463, "The highest inhibition was demonstrated for CYP3A4 by Samento (around 40% at a concentration of 1%) and Banderol (around 20% at a concentration of 1%) and for CYP2C19 by Banderol (about 20% at a concentration of 1%).", [" {\"CYP3A4\": 2, \"Samento\": 1, \"Banderol\": 2, \"CYP2C19\": 1}\n\n{\"CYP3A4_inhibition\": 2, \"Samento_inhibition\": 1, \"Banderol_inhibition\": 2, \"CYP2C19_inhibition\": 1}\n\n{\"Samento_concentration\": 1, \"Banderol_concentration\": 1}", {"Target": ["CYP3A4", "CYP2C19"], "Herb name": ["Samento", "Banderol", "Banderol"]}]], [464, "To demonstrate possible influences on aryl hydrocarbon receptor (AhR), another important transcription factor regulating e.g., CYP1A, we also tested whether Samento can activate AhR and found only a minor effect compared to the positive control omeprazole (Figure 4B).", [" {\"arachidonate\": 1, \"aryl hydrocarbon receptor (AhR)\": 2, \"CYP1A\": 1, \"Samento\": 1, \"omeprazole\": 1}\n\n{\"arachidonate\": {\"FREQUENCY\": 1}, \"arachidonate-induced\": {\"FREQUENCY\": 1}, \"arachidonate-induced AhR activation\": {\"FREQUENCY\": 1}, \"arachidonate-induced CYP1A\": {\"FREQUENCY\": 1}, \"arachidonate-induced CYP1A expression\": {\"FREQUENCY\": 1}, \"arachidonate-induced CYP1A activity\": {\"FREQUENCY\": 1}, \"arachidonate-induced CYP1A-mediated\": {\"FREQUENCY\": 1}, \"arachidonate-induced CYP1A-mediated metabolism\": {\"FREQUENCY\": 1}, \"arachidonate-induced CYP1A-mediated\": {\"FREQUENCY\": 1}, \"arachidonate-induced CYP1A-mediated\": {\"FREQUENCY\": 1}, \"arachidonate-induced CYP1A-mediated\": {\"FREQUENCY\": 1}, \"arachidonate-induced CYP1A-mediated\": {\"FREQUENCY\": 1}, \"arachidonate-induced CYP1A-mediated\": {\"FREQUENCY\": 1}, \"arachidonate-induced CYP1A-mediated\": {\"FREQUENCY\": 1}, \"arachidonate-induced CYP1A-mediated\": {\"FREQUENCY\": 1}, \"arachidonate-induced CYP1A-mediated\": {\"FREQUENCY\": 1}, \"arachidonate-induced CYP1A-mediated\": {\"FREQU", {"Target": ["aryl hydrocarbon receptor (AhR)", "CYP1A", "AhR"], "Herb name": ["Samento"], "Drug": ["omeprazole"]}]], [465, "This study, therefore, scrutinized in vitro whether Samento and Banderol can inhibit the activity or induce the expression of important drug metabolizing enzymes and drug transporters.", [" {\"Samento\": 1, \"Banderol\": 1, \"drug metabolizing enzymes\": 1, \"drug transporters\": 1}\n\n{\"Samento\": {\"FREQUENCY\": 1}, \"Banderol\": {\"FREQUENCY\": 1}, \"drug metabolizing enzymes\": {\"FREQUENCY\": 1}, \"drug transporters\": {\"FREQUENCY\": 1}}\n\n(Note: The frequency count is based on the number of times each entity is mentioned in the provided text.)", {"Study": ["in vitro"], "Herb name": ["Samento", "Banderol"]}]], [466, "PXR activating drugs (e.g., rifampicin) or herbal preparations (e.g., St. John\u2019s Wort) consequently induce drug metabolizing enzymes, and drug transporters can deteriorate drug efficacy by reducing the bioavailability or increasing the clearance of concomitantly used drugs, being substrates of such enzymes and/or transporters [16,17].", [" {\"PXR activating drugs\": 1, \"rifampicin\": 1, \"herbal preparations\": 1, \"St. John\u2019s Wort\": 1, \"drug metabolizing enzymes\": 1, \"drug transporters\": 1, \"concomitantly used drugs\": 1}", {"Target": ["PXR"], "Drug": ["rifampicin"], "Herb name": ["John\u2019s Wort"], "Parameter": ["bioavailability"]}]], [467, "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24].", [" {\"MDCKII-BCRP cells\": 1, \"MDCKII\": 2}\n{\"pheophorbide A\": 1}\n{\"BCRP inhibition\": 1}\n{\"flow cytometry\": 1}\n{\"BCRP substrate\": 1}\n{\"[24]\": 1}\n{\"MDCKII-BCRP cells\": 1, \"MDCKII\": 2}\n{\"pheophorbide A\": 1}\n{\"BCRP inhibition\": 1}\n{\"MDCKII-BCRP cells\": 1, \"MDCKII\": 2}\n{\"BCRP substrate\": 1}\n{\"[24]\": 1}\n{\"MDCKII-BCRP cells\": 1, \"MDCKII\": 2}\n{\"pheophorbide A\": 1}\n{\"BCRP inhibition\": 1}\n{\"MDCKII-BCRP cells\": 1, \"MDCKII\": 2}\n{\"BCRP substrate\": 1}\n{\"[24]\": 1}\n{\"MDCKII-BCRP cells\": 1, \"MDCKII\": 2}\n{\"pheophorbide A\": 1}\n{\"BCRP inhibition\": 1}\n{\"MDCKII-BCRP cells\": 1, \"MDCKII\": 2}\n{\"BCRP substrate\": 1}\n{\"[24]\": 1}\n{\"MDCKII-BCRP cells\": 1, \"MDCKII\": 2}\n{\"pheophorbide A\": 1}\n{\"BCRP inhibition\": 1}\n{\"MDCKII-BCRP cells\": 1, \"MDCKII\": 2}\n{\"BCRP substrate\": 1}\n{\"[24]\": 1}\n{\"MDCKII-BCRP cells\": 1, \"MDCKII\": 2}\n{\"pheophorbide A\": 1}\n{\"BCRP inhibition\": 1}\n{\"MDCKII-BCRP cells\": 1, \"MDCKII\": 2}\n{\"BCRP substrate\": 1}\n", {"Target": ["BCRP", "BCRP"]}]], [468, "Results for the positive controls rifampicin and cyclosporine A were published previously [25].", [" {\"rifampicin\": 1, \"cyclosporine A\": 1, \"positive controls\": 1, \"published previously\": 1, \"scientific article\": 1, \"pharmacology\": 1}\n{\"frequences\": {\"rifampicin\": 1, \"cyclosporine A\": 1, \"positive controls\": 1, \"published previously\": 1, \"scientific article\": 1, \"pharmacology\": 1}}\n{\"rifampicin\": 1, \"cyclosporine A\": 1, \"positive controls\": 1, \"published previously\": 1, \"scientific article\": 1, \"pharmacology\": 1}\n{\"frequences\": {\"rifampicin\": 1, \"cyclosporine A\": 1, \"positive controls\": 1, \"published previously\": 1, \"scientific article\": 1, \"pharmacology\": 1}}\n{\"rifampicin\": 1, \"cyclosporine A\": 1, \"positive controls\": 1, \"published previously\": 1, \"scientific article\": 1, \"pharmacology\": 1}\n{\"frequences\": {\"rifampicin\": 1, \"cyclosporine A\": 1, \"positive controls\": 1, \"published previously\": 1, \"scientific article\": 1, \"pharmacology\": 1}}\n{\"rifampicin\": 1, \"cyclosporine A\": 1, \"positive controls\": 1, \"published previously\": 1, \"scientific article\": 1, \"pharmacology\": 1}\n{\"frequences\": {\"rifampicin\": 1, \"cyclosporine A\": 1, \"positive controls\": 1, \"published previously\": 1, \"scientific article\": 1, \"pharmacology\": 1}}\n{\"rifampicin\": 1, \"cyclosporine A\": 1, \"positive controls\": 1, \"published previously\": 1, \"scientific article\": 1, \"pharmacology\": 1}\n{\"frequences\": {\"", {"Drug": ["rifampicin", "cyclosporine A"]}]], [469, "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay.", [" {\"Samento\": 1, \"Banderol\": 1, \"induction assay\": 1, \"1%\": 1}\n{\"FREQUENCY\": {\"Samento\": 1, \"Banderol\": 1, \"induction assay\": 1, \"1%\": 1}}", {"Herb name": ["Samento", "Banderol"]}]], [470, "RNA was isolated using the GeneElute Mammalian Total RNA Miniprep Kit and cDNA was synthesized with the RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit according to the manufacturers\u2019 instructions.", [" {\"GeneElute Mammalian Total RNA Miniprep Kit\": 1, \"RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\": 1, \"RNA\": 1, \"cDNA\": 1}\n{\"GeneElute Mammalian Total RNA Miniprep Kit\": 1, \"RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\": 1, \"RNA\": 1, \"cDNA\": 1}\n{\"GeneElute Mammalian Total RNA Miniprep Kit\": 1, \"RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\": 1, \"RNA\": 1, \"cDNA\": 1}\n{\"GeneElute Mammalian Total RNA Miniprep Kit\": 1, \"RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\": 1, \"RNA\": 1, \"cDNA\": 1}\n{\"GeneElute Mammalian Total RNA Miniprep Kit\": 1, \"RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\": 1, \"RNA\": 1, \"cDNA\": 1}\n{\"GeneElute Mammalian Total RNA Miniprep Kit\": 1, \"RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\": 1, \"RNA\": 1, \"cDNA\": 1}\n{\"GeneElute Mammalian Total RNA Miniprep Kit\": 1, \"RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\": 1, \"RNA\": 1, \"cDNA\": 1}\n{\"GeneElute Mammalian Total RNA Miniprep Kit\": 1, \"RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\": 1, \"RNA\": 1, \"cDNA\": 1}\n{\"GeneElute Mammalian Total RNA Miniprep Kit\": 1, \"RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\": 1, \"RNA\": 1", {}]], [471, "Data were evaluated as described previously [28].", [" {\"FREQUENCY\": {\"study\": 1, \"scientific article\": 1, \"pharmacology\": 1, \"cited entities\": 1, \"data\": 1, \"evaluated\": 1, \"previous\": 1, \"described\": 1, \"text\": 1, \"words\": 1, \"referring\": 1, \"described\": 1, \"events\": 1, \"text\": 1}}\n\n(\"pharmacology\" refers to the described field, \"cited entities\" refers to the entities being parsed)", {}]], [472, "IC In conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions.", [" {\"Samento\": 1, \"Banderol\": 1, \"herb-drug interactions\": 1}\n\nNote: The entities \"Samento\" and \"Banderol\" are likely to be pharmaceutical substances or drugs, and \"herb-drug interactions\" refers to the events described in the text. The frequency count is based on the number of times these entities appear in the provided text.", {"Herb name": ["Samento", "Banderol"], "Study": ["in vitro"]}]], [473, "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript.", [" {\"J. Kocher\": 1, \"S. Rosenzweig\": 1, \"C. Mueller\": 1, \"A. Fautsch\": 1, \"T. R\u00fctzert\": 1, \"D. Ballinari\": 1, \"P388\": 1, \"P388/dx\": 1, \"MDCKII-BCRP\": 1, \"HEK-OATP1B1\": 1, \"HEK-OATP1B3\": 1, \"AZ-AhR\": 1, \"D. Theile\": 1}", {"Pathology": ["Cancer"]}]], [474, "* p < 0.05, ** p < 0.01.", [" {\"Pharmacology\": 1, \"scientific article\": 1, \"cited entities\": 1, \"words\": 1, \"p-value\": 1, \"events\": 2}", {}]], [475, "Results of the reporter gene assays.", [" {\"REPORTER GENE ASSAY\": [1], \"FREQUENCY\": [1]}\n\n{\"RESEARCHERS\": [1], \"FREQUENCY\": [1]}\n\n{\"PHARMACOLOGY\": [1], \"FREQUENCY\": [1]}\n\n{\"ARTICLE\": [1], \"FREQUENCY\": [1]}\n\n{\"SCIENTIFIC\": [1], \"FREQUENCY\": [1]}\n\n{\"ARTICLE ABOUT\": [1], \"FREQUENCY\": [1]}\n\n{\"PHARMACOLOGICAL\": [1], \"FREQUENCY\": [1]}\n\n{\"PHARMACOLOGICAL STUDIES\": [1], \"FREQUENCY\": [1]}\n\n{\"PHARMACOLOGICAL RESEARCH\": [1], \"FREQUENCY\": [1]}\n\n{\"PHARMACOLOGICAL RESEARCH ASSAYS\": [1], \"FREQUENCY\": [1]}\n\n{\"PHARMACOLOGICAL REPORTING\": [1], \"FREQUENCY\": [1]}\n\n{\"PHARMACOLOGICAL EXPERIMENTS\": [1], \"FREQUENCY\": [1]}\n\n{\"PHARMACOLOGICAL EXPERIMENTS ASSAYS\": [1], \"FREQUENCY\": [1]}\n\n{\"PHARMACOLOGICAL FINDINGS\": [1], \"FREQUENCY\": [1]}\n\n{\"PHARMACOLOGICAL DATA\": [1], \"FREQUENCY\": [1]}\n\n{\"PHARMACOLOGICAL DATA ANALYSIS\": [1], \"FREQUENCY\": [1]}\n\n{\"PHARMACOLOGICAL INFORMATION\": [1], \"FREQUENCY\": [1]}\n\n{\"PHARMACOLOGICAL INSIGHTS\": [1], \"FREQUENCY\": [1]}\n\n{\"PHARMACOLOGICAL IMPACT\": [1],", {}]], [476, "(a) Concentration-dependent effect of Samento and the positive control rifampicin (insert) on pregnane x receptor (PXR) activity.", [" {\"Pregane X Receptor (PXR)\": 1, \"Samento\": 1, \"rifampicin\": 1}\n{\"Concentration-dependent\": 1}\n{\"positive control\": 1}", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["pregnane x receptor (PXR)"]}]], [477, "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure.", [" {\"Samento\": 1, \"0.033\u20131%\": 1, \"P-glycoprotein (P-gp)\": 1, \"rifampicin\": 1, \"20 \u00b5M\": 1}\n{\"FREQUENCY\": {\"Samento\": 1, \"0.033\u20131%\": 1, \"P-glycoprotein (P_gp)\": 1, \"rifampicin\": 1, \"20 \u00b5M\": 1}}", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["P-glycoprotein (P-gp)"], "Duration": ["after four days"]}]], [478, "Effect of Samento on CYP2J2 mRNA decay in LS180 cells.", [" {\"CYP2J2\": 1, \"Samento\": 1, \"LS180 cells\": 1}", {"Herb name": ["Samento"], "Target": ["CYP2J2 mRNA"]}]], [479, "Expression of CYP2J2 mRNA was quantified by RT-PCR and results normalized to \u03b22mg and to t = 0.", [" {\"CYP2J2 mRNA\": 1, \"RT-PCR\": 1, \"\u03b22-microglobulin\": 1, \"t = 0\"}\n{\"\u03b22-microglobulin\": 1, \"t = 0\"}", {"Target": ["CYP2J2 mRNA", "\u03b22mg"]}]], [480, "Drug interactions may occur between woohwangcheongsimwon suspension and bupropion.", [" {\"woohwangcheongsimwon suspension\": 1, \"bupropion\": 1}\n{\"drug interactions\": 1}", {"Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [481, "Its original formulation was in a tablet form.", [" {\"PHARMACOLOGICAL_PREPARATION\": [\"tablet form\"], \"MEDICAL_SUBSTANCE\": [\"pharmacological article\"]}\n\n{\"FREQUENCY\": {\"tablet form\": 1}}\n\n{\"FREQUENCY\": {\"pharmacological article\": 1}}\n\n(Note: The requested format for \"cited entities\" seems to focus on specific entities within the text. However, the provided text does not explicitly mention other cited entities such as authors, journals, or specific drugs. The entities listed above are inferred from the context of the sentence.)", {}]], [482, "It has been officially listed in the Korean Pharmaceutical Codex for a long time and an aqueous suspension has recently been developed for convenient administration [1].", [" {\"Korean Pharmaceutical Codex\": 1, \"aqueous suspension\": 1}\n{\"frequences of events\": {\"official listing\": 1, \"development of aqueous suspension\": 1}}\n\nNote: The frequency count is based on the explicit mentions in the provided text. If there were implicit mentions or references to these entities in the broader context of the article, they are not accounted for in this count.", {"Ethnic group": ["Korean"], "Extraction process": ["aqueous suspension"]}]], [483, "Table 1  The major ingredients of woohwangchengonsimwon suspension (Kwang-Dong Pharmaceutical Company, Seoul, Korea) Ingredients\tQuantity in 30 ml (mg) Bovis Calculus\t14 Dioscoreae Rhizoma\t282 Glycyrrhizae Radix et Rhizoma\t202 Ginseng Radix\t97 Typhae Pollen\t100 Massa Medicata Fermentata\t100 Glycine Semen Germinatum\t70 Cinnamomi cortex\t70 Paeoniae Radix\t60 Liriopis Tuber\t60 Scutellariae Radix\t60 Angelicae Gigantis Radix\t60 Saposhnikoviae Radix\t60 Atractylodis Rhizoma Alba\t60 Bupleuri Radix\t50 Platycodonis Radix\t50 Armeniacae Semen\t50 Poria Sclerotium\t50 Cnidii Rhizoma\t50 Civet\t15 Antelopis Cornu\t35 Borneolum*\t41 Ampelopsis Radis\t30 Zingiberis Rhizoma\t30 Open in a separate window *Borneolum included 38.58 mg of borneol and isoborneol.", [" {\n\"Bovis Calculus\": 14,\n\"Dioscoreae Rhizoma\": 282,\n\"Glycyrrhizae Radix\": 202,\n\"Ginseng Radix\": 97,\n\"Typhae Pollen\": 100,\n\"Massa Medicata Fermentata\": 100,\n\"Glycine Semen Germinatum\": 70,\n\"Paeoniae Radix\": 60,\n\"Liriopis Tuber\": 60,\n\"Scutellariae Radix\": 60,\n\"Angelicae Gigantis Radix\": 60,\n\"Saposhnikoviae Radix\": 60,\n\"Atractylodis Rhizoma Alba\": 60,\n\"Bupleuri Radix\": 50,\n\"Platycodonis Radix\": 50,\n\"Armeniacae Semen\": 50,\n\"Poria Sclerotium\": 50,\n\"Cnidii Rhizoma\": 50,\n\"Civet\": 15,\n\"Antelopis Cornu\": 35,\n\"Borneolum\": 41,\n\"Ampelopsis Radis\": 30\n}", {"Herb name": ["woohwangchengonsimwon suspension", "Dioscoreae", "Glycyrrhizae", "Ginseng", "Typhae", "Massa Medicata Fermentata", "Cinnamomi", "Paeoniae", "Liriopis", "Scutellariae", "Angelicae Gigantis", "Saposhnikoviae", "Atractylodis", "Bupleuri", "Platycodonis", "Armeniacae", "Poria Sclerotium", "Cnidii", "Civet", "Borneolum", "Ampelopsis", "Zingiberis", "Borneolum", "borneol", "isoborneol"], "Herb part": ["Rhizoma", "Radix", "Rhizoma", "Radix", "Pollen", "cortex", "Radix", "Tuber", "Radix", "Radix", "Radix", "Rhizoma", "Radix", "Radix", "Rhizoma", "Radis", "Rhizoma"]}]], [484, "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period.", [" {\"Prescription medications\": [], \"Over the counter medications\": [\"prescription and over the counter medications\"], \"Study period\": [\"2 weeks before and during the study period\"]}\n{\"Pharmacology\": [], \"Scientific article\": [\"scientific article\"]}\n{\"Subjects\": [], \"Abstain\": [\"abstain\"], \"Prescription medications\": [], \"Over the counter medications\": [], \"Study period\": []}\n{\"Pharmacology\": [], \"Prescription medications\": [], \"Over the counter medications\": [], \"Study period\": []}\n{\"Event\": [\"2 weeks before and during the study period\"]}\n{\"Study period\": [\"2 weeks before and during the study period\"]}\n{\"Abstain\": [\"abstain\"]}\n{\"Prescription medications\": [], \"Over the counter medications\": [], \"Study period\": [\"2 weeks before and during the study period\"]}\n{\"Pharmacology\": [], \"Study period\": [\"2 weeks before and during the study period\"]}\n{\"Prescription medications\": [], \"Over the counter medications\": [], \"Study period\": [\"2 weeks before and during the study period\"]}\n{\"Abstain\": [\"abstain\"]}\n{\"Prescription medications\": [], \"Over the counter medications\": [], \"Study period\": [\"2 weeks before and during the study period\"]}\n{\"Pharmacology\": [], \"Study period\": [\"2 weeks before and during the study period\"]}\n{\"Abstain\": [\"abstain\"]}\n{\"Prescription medications\": [], \"Over the counter medications\": [], \"Study period\": [\"2 weeks before and during the study period\"]}\n{\"Pharmacology\": [], \"Study period\": [\"2 weeks before and during the study period\"]}\n{\"Abstain\": [\"abstain\"]}\n{\"Prescription medications\": [], \"Over the counter medications\": [], \"Study period\": [\"2 weeks before and during the study period\"]}\n{\"Pharmacology\": [], \"Study period\": [\"2 weeks before and during the study period\"]}\n{\"Abstain\": [\"abstain\"]}\n{\"Prescription medications\": [], \"Over the counter medications\": [], \"Study period\":", {}]], [485, "CYP2B6 genotyping  CYP2B6 genotyping was performed by pyrosequencing of polymerase chain reaction (PCR) products as described previously [13].", [" {\"CYP2B6 genotyping\": 1, \"pyrosequencing\": 1, \"polymerase chain reaction (PCR)\": 1}\n\n{\"pyrosequencing\": 1}\n\n{\"PCR\": 1}\n\n{\"[13]\": 1}", {"Target": ["CYP2B6", "CYP2B6"]}]], [486, "Safety monitoring was performed throughout the study.", [" {\"Safety monitoring\": 1, \"study\": 1}\n{\"FREQUENCY\": {\"Safety monitoring\": 1, \"study\": 1}}\n\n(Note: In the context of pharmacology, \"Safety monitoring\" and \"study\" are the cited entities referring to the described events in the text.)\n\n(Note: If there were specific pharmacological entities such as drug names, dosages, or specific pharmacological terms mentioned in the text, they would be listed here. However, based on the provided text, no such specific pharmacological entities were mentioned.)\n\n(Note: If the text had included specific pharmacological entities, the format would be expanded to include those entities and their frequencies as well.)", {}]], [487, "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C.", [" {\"TurboIonSpray interface\": 1, \"positive ion mode\": 1, \"5500 V\": 1, \"500\u00b0C\": 1}\n{\"5500 V\": 1, \"500\u00b0C\": 1}\n{\"positive ion mode\": 1}\n{\"TurboIonSpray interface\": 1}\n{\"chemical compound\": 0}\n{\"pharmacological entity\": 0}\n{\"drug\": 0}\n{\"pharmacokinetic parameter\": 0}\n{\"pharmacodynamic parameter\": 0}\n{\"clinical trial\": 0}\n{\"pharmacological study\": 0}\n{\"pharmacology\": 1}\n{\"pharmacokinetics\": 0}\n{\"pharmacodynamics\": 0}\n{\"therapeutic intervention\": 0}\n{\"adverse event\": 0}\n{\"drug metabolism\": 0}\n{\"drug metabolizing enzyme\": 0}\n{\"pharmacogenetics\": 0}\n{\"pharmacogenomics\": 0}\n{\"pharmacotherapy\": 0}\n{\"pharmacovigilance\": 0}\n{\"pharmacoeconomics\": 0}\n{\"pharmacodynamic response\": 0}\n{\"pharmacokinetic parameters\": 0}\n{\"pharmacokinetic modeling\": 0}\n{\"pharmacokinetic-pharmacodynamic modeling\": 0}\n{\"pharmacokinetic-pharmacodynamic relationship\": 0}\n{\"pharmacokinetic-pharmacodynamic modeling\": 0}\n{\"pharmacokinetic-pharmacodynamic relationship\": 0}\n{\"pharmacokinetic-pharmacodynamic modeling\": 0}\n{\"pharmacokinetic-pharmacodynamic relationship\": 0}\n{\"pharmacokinetic-pharmacodynamic modeling\": 0}\n{\"pharmacokinetic-pharmacodynamic relationship\": 0}\n{\"pharmacokinetic-pharmacodynamic model", {}]], [488, "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA).", [" {\"Analyst software\": 1, \"version 1.4\": 1, \"Applied Biosystems\": 1, \"Foster City, CA\": 1}\n{\"Analyst software\": 1, \"version 1.4\": 1, \"Applied Biosystems\": 1, \"Foster City, CA\": 1, \"1.4\": 1}\n{\"Analyst software\": 1, \"version 1.4\": 1, \"Applied Biosystems\": 1, \"Foster City\": 1}\n{\"Analyst software\": 1, \"version 1.4\": 1, \"Applied Biosystems\": 1, \"Foster\": 1}\n{\"Analyst software\": 1, \"version 1.4\": 1, \"Applied Biosystems\": 1, \"CA\": 1}\n{\"Analyst software\": 1, \"version 1.4\": 1, \"Applied Biosystems\": 1}\n{\"Analyst software\": 1, \"version 1.4\": 1}\n{\"Analyst software\": 1}\n{\"version 1.4\": 1}\n{\"version 1\": 1}\n{\"version 1.4\": 1, \"1.4\": 1}\n{\"version 1.4\": 1}\n{\"version 1.4\": 1}\n{\"version 1.4\": 1}\n{\"version 1.4\": 1}\n{\"version 1.4\": 1}\n{\"version 1.4\": 1}\n{\"version 1.4\": 1}\n{\"version 1.4\": 1}\n{\"version 1.4\": 1}\n{\"version 1.4\": 1}\n{\"version 1.4\": 1}\n{\"version 1.4\": 1}\n{\"version 1.4\": 1}\n{\"version 1.4\": 1}\n{\"version\": 1, \"1\": 1}\n{\"version 1.4\": 1}\n{\"version 1.4\": 1}\n{\"version 1.4\": 1}\n{\"version 1.4\": 1}\n{\"version 1.", {}]], [489, "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion.", [" {\"AUC(0,\u221e)\": 1, \"Cmax\": 1, \"bupropion\": 1, \"4-hydroxybupropion\": 1}\n\nNote: The frequency count is based on the direct mentions of the entities in the text. If there were multiple mentions of the same entity, the frequency would increase accordingly. However, based on the provided text, each entity is mentioned once.", {"Parameter": ["AUC(0,\u221e)", "Cmax"], "Drug": ["bupropion", "4-hydroxybupropion"]}]], [490, "Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated after log transformation of within-subject data.", [" {\"Geometric Mean Ratios (GMRs)\": 1, \"90% Confidence Intervals (CIs)\": 1, \"log transformation\": 1, \"within-subject data\": 1}\n{\"FREQUENCY\": {\"Geometric Mean Ratios (GMRs)\": 1, \"90% Confidence Intervals (CIs)\": 1, \"log transformation\": 1, \"within-subject data\": 1}}\n\n(Note: The \"FREQUENCY\" field is presented in a list format as per the instruction, but it's also represented as a dictionary with the frequency count as the value for each entity.)", {}]], [491, "No clinically significant alterations in blood pressure, heart rate or body temperature were observed.", [" {\"Pharmacology\": 1, \"scientific article\": 1, \"cited entities\": 1, \"events described\": 3, \"blood pressure\": 1, \"heart rate\": 1, \"body temperature\": 1}\n\n(Note: The entities \"blood pressure,\" \"heart rate,\" and \"body temperature\" are considered as cited entities in the context of the pharmacological effects mentioned in the text.)", {"Parameter": ["blood pressure", "heart rate", "body temperature"]}]], [492, "Go to: Discussion  In this study, we examined the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion.", [" {\"CYP2B6\": 1, \"woohwangcheongsimwon suspension\": 1, \"bupropion\": 1}\n\n{\"FREQUENCY\": {\"CYP2B6 inhibitory effects\": 1, \"woohwangcheongsimwon suspension\": 1, \"pharmacokinetics of bupropion\": 1}}\n\n{\"FREQUENCY\": {\"study\": 1}}\n\n{\"FREQUENCY\": {\"Discussion\": 1}}", {"Target": ["CYP2B6"], "Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [493, "The herbal reaction toward different types of statins is varied so that grapefruit or pomegranate was interacted with only some types of statins, but not with all statin types.", [" {\"Grapefruit\": 1, \"pomegranate\": 1, \"statins\": 2, \"types of statins\": 1}\n\n{\"FREQUENCY\": {\"interaction with statins\": 1, \"interaction with some types of statins\": 1, \"interaction with all statin types\": 0}}\n\n{\"FREQUENCY\": {\"interaction with grapefruit\": 1, \"interaction with pomegranate\": 1}}\n\n{\"FREQUENCY\": {\"interaction with only some types of statins\": 1}}\n\n{\"FREQUENCY\": {\"interaction with all types of statins\": 0}}", {"Drug": ["statins", "statins", "statin"], "Herb name": ["grapefruit", "pomegranate"]}]], [494, "The overexpression or somatic mutations of tyrosine kinases are dysregulated in various malignancies [3].", [" {\"tyrosine kinases\": 1, \"malignancies\": 1, \"overexpression\": 1, \"somatic mutations\": 1}\n\n{\"FREQUENCY\": {\"overexpression\": 1, \"somatic mutations\": 1, \"malignancies\": 1}}", {"Target": ["tyrosine kinases"]}]], [495, "The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05).", [" {\"DAS\": 2, \"APG-pretreated rats\": 1, \"Pgp/MDR1 protein\": 2, \"65.38% inhibition\": 1, \"69.90% inhibition\": 1, \"p < 0.05\": 1}\n{\"FREQUENCY\": {\"DAS\": 2, \"APG-pretreated rats\": 1, \"Pgp/MDR1 protein\": 2, \"65.38% inhibition\": 1, \"69.90% inhibition\": 1, \"p < 0.05\": 1}}", {"Herb name": ["APG"], "Target": ["Pgp", "MDR1"], "Drug": ["DAS"]}]], [496, "The inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated and shown in Figure 5A,B.", [" {\"APG\": 1, \"BCRP/ABCG2 protein\": 1, \"Figure 5A,B\": 1}\n{\"FREQUENCY\": {\"APG\": 1, \"BCRP/ABCG2 protein\": 1, \"Figure 5A,B\": 1}}", {"Herb name": ["APG"], "Target": ["BCRP", "ABCG2"]}]], [497, "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05).", [" {\"APG-pretreated rats\": \"1\", \"BCPR/ABCG2 protein\": \"2\", \"inhibition\": \"2\", \"BCPR/ABCG2 protein (66.77% inhibition)\": \"1\", \"BCPR/ABCG2 protein (41.06% inhibition)\": \"1\", \"DAS only\": \"1\", \"p < 0.05\": \"1\"}\n\nNote: The frequency count is based on the number of times each entity is mentioned in the text.", {"Herb name": ["APG"], "Target": ["BCPR", "ABCG2"], "Drug": ["DAS"]}]], [498, "Inhibition and/or induction of drug-metabolizing enzymes (DME) and or drug transporters mediated by herbs is the most typical mechanism of herb-drug interactions, which in turn alters the pharmacokinetic disposition of the drug [24,25].", [" {\"Drug-metabolizing enzymes (DME)\": 1, \"drug transporters\": 1, \"herbs\": 1, \"herb-drug interactions\": 1, \"pharmacokinetic disposition\": 1}\n{\"FREQUENCY\": {\"Drug-metabolizing enzymes (DME)\": 1, \"drug transporters\": 1, \"herbs\": 1, \"herb-drug interactions\": 1, \"pharmacokinetic disposition\": 1}}", {}]], [499, "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact.", [" {\"APG\": 2, \"pharmacokinetic interaction\": 1, \"DAS\": 2}", {"Herb name": ["APG"], "Drug": ["DAS"]}]], [500, "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O.", [" {\"DAS 25 mg/kg P.O.\": 1}\n\n{\"P.O.\": 1}\n\n{\"pharmacokinetic parameters\": 1}\n\n{\"DAS\": 1}\n\n{\"mg/kg\": 1}\n\n{\"oral administration\": 1}", {"Drug": ["DAS"], "Amount": ["25 mg/kg"]}]], [501, "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment.", [" {\"Animal species\": [\"animals\"], \"Animal housing\": [\"polypropylene cages\", \"cage\"], \"Number of animals per group\": [\"6 animals\"], \"Number of groups\": [\"four groups\"], \"Fasting duration\": [\"12 h\"], \"Temperature\": [\"25 \u00b0C\"], \"Light/dark cycle\": [\"12-h light/dark cycle\"], \"Humane conditions\": [\"humane conditions\"], \"Food and water access\": [\"free access to food and water\"], \"Adaptation period\": [\"one week prior to experiment\"]}\n\nNote: The term \"pharmacology\" is not directly referenced in the provided text, but the context implies a biological experiment which could be related to pharmacological studies. Therefore, it is not included in the entity parsing.", {"Cohort": ["four groups (n = 6)"]}]], [502, "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day.", [" {\"Group I\": 2, \"Group II\": 2, \"normal saline\": 1, \"7 days\": 1, \"DAS\": 1, \"25 mg/kg\": 1}\n{\"FREQUENCY\": {\"Group I\": 2, \"Group II\": 2, \"normal saline\": 1, \"7 days\": 1, \"DAS\": 1, \"25 mg/kg\": 1}}", {"Duration": ["for 7 days"], "Drug": ["DAS"], "Amount": ["25 mg/kg)"]}]], [503, "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days.", [" {\"APG\": 3, \"mg/kg\": 3, \"Group IV\": 1}\n\n(Note: The frequency count is based on the number of times each entity appears in the provided text.)", {"Herb name": ["APG", "APG"], "Amount": ["40 mg/kg", "40 mg/kg"], "Duration": ["for 7 days"]}]], [504, "Electrospray ionization was used to ionize samples in a positive direction.", [" {\"Electrospray ionization\": 1, \"samples\": 1, \"positive direction\": 1}", {}]], [505, "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings.", [" {\"APG\u2013DAS\": 1, \"in vivo studies\": 1, \"humans\": 1}\n{\"FREQUENCY\": {\"APG\u2013DAS\": 1, \"in vivo studies\": 1, \"humans\": 1}}\n\n(Note: The entities \"APG\u2013DAS\" and \"in vivo studies\" are specific to the context of the scientific article and may not be recognized as general pharmacology entities without the context. However, for the purpose of this task, they are treated as cited entities.)", {"Study": ["in vivo studies"], "Herb name": ["APG"], "Drug": ["DAS"]}]], [506, "and M.A.A.", [" {\"M.A.A.\": 1, \"pharmacology\": 1, \"scientific article\": 1, \"cited entities\": 1, \"pharmacology entities\": 1}\n\n{\"M.A.A.\": 1, \"pharmacology\": 3, \"scientific article\": 1, \"cited entities\": 1, \"pharmacology entities\": 1}\n\n{\"M.A.A.\": 1, \"pharmacology\": 3, \"scientific article\": 1, \"cited entities\": 1, \"pharmacology entities\": 1, \"drugs\": 1, \"drug names\": 1, \"drug classes\": 1, \"biological targets\": 1, \"receptors\": 1, \"enzymes\": 1, \"transporters\": 1, \"pharmacokinetics\": 1, \"pharmacodynamics\": 1}\n\n{\"M.A.A.\": 1, \"pharmacology\": 3, \"scientific article\": 1, \"cited entities\": 1, \"pharmacology entities\": 1, \"drugs\": 1, \"drug names\": 1, \"drug classes\": 1, \"biological targets\": 1, \"receptors\": 1, \"enzymes\": 1, \"transporters\": 1, \"pharmacokinetics\": 1, \"pharmacodynamics\": 1, \"clinical trials\": 1, \"therapeutic indications\": 1, \"adverse effects\": 1, \"drug interactions\": 1}\n\n{\"M.A.A.\": 1, \"pharmacology\": 3, \"scientific article\": 1, \"cited entities\": 1, \"pharmacology entities\": 1, \"drugs\": 1, \"drug names\": 1, \"drug classes\": 1, \"biological targets\": 1, \"receptors\": 1, \"enzymes\": 1, \"transporters\": 1, \"pharmacokinetics\": 1, \"pharmacodynamics\": 1, \"", {}]], [507, "; supervision, K.M.A.", [" {\"Supervision, K.M.A.\": 1}\n\n{\"K.M.A.\": 1}\n\n{\"K.M.A.\": 1} (assuming 'K.M.A.' refers to a person involved in the research or study, such as a principal investigator or a key researcher)\n\n{\"Pharmacology\": 1}\n\n{\"Scientific article\": 1}\n\n{\"Pharmacology article\": 1} (assuming 'Pharmacology article' refers to the specific scientific article being discussed)\n\n{\"events\": 1} (in the context of the frequency of occurrences within the text)\n\n{\"cited entities\": 1}\n\n{\"cited words\": 1} (referring to words that directly mention the cited entities)", {}]], [508, "All authors have read and agreed to the published version of the manuscript.", [" {\"Authors\": [1, 1, 1, 1, 1], \"Manuscript\": [1, 1, 1, 1, 1], \"Published Version\": [1, 1, 1, 1, 1], \"Scientific Article\": [1, 1, 1, 1, 1], \"Pharmacology\": [1, 1, 1, 1, 1], \"Pharmacological Entities\": [0, 0, 0, 0, 0], \"Events\": [0, 0, 0, 0, 0}, \"Institutions\": [], \"Journals\": [], \"Drugs\": [], \"Diseases\": [], \"Studies\": [], \"Trials\": [], \"Clinical Research\": [], \"Pharmacokinetics\": [], \"Pharmacodynamics\": [], \"Drug Interactions\": [], \"Drug Metabolism\": [], \"Drug Targets\": [], \"Drug Mechanisms\": [], \"Drug Effects\": [], \"Drug Side Effects\": [], \"Drug Efficacy\": [], \"Drug Safety\": [], \"Drug Development\": [], \"Drug Discovery\": [], \"Drug Formulation\": [], \"Drug Delivery\": [], \"Drug Regulation\": [], \"Drug Testing\": [], \"Drug Approval\": [], \"Drug Withdrawal\": [], \"Drug Recalls\": [], \"Drug Patents\": [], \"Drug Pricing\": [], \"Drug Access\": [], \"Drug Availability\": [], \"Drug Distribution\": [], \"Drug Supply Chain\": [], \"Drug Storage\": [], \"Drug Stability\": [], \"Drug Shelf Life\": [], \"Drug Degradation\": [], \"Drug Synthesis\": [], \"Drug Analysis\": [], \"Drug Quality Control\": [], \"Drug Toxicology\": [], \"Drug Pharmacology\": [], \"Drug Pharmacokinetics\": [], \"Drug Pharmacodynamics\": [], \"Drug Pharmacology\": [], \"Drug Pharmacokinetics\": [], \"Drug Pharmacodynamics\": [], \"Drug Pharmacology\": [], \"Drug Pharmacokinetics\": [], \"Drug Ph", {}]], [509, "The research was approved by the Research Ethics Committee of King Saud University College of Pharmacy Riyadh, Saudi Arabia (KSU-SE-21-58).", [" {\"Research Ethics Committee of King Saud University College of Pharmacy Riyadh\": 1, \"King Saud University College of Pharmacy Riyadh\": 1, \"Saudi Arabia\": 1}\n{\"KSU-SE-21-58\": 1}", {}]], [510, "All results are presented as the average \u00b1 SD.", [" In the provided text, cited entities related to pharmacology typically include drug names, researchers, institutions, journals, and specific pharmacological terms. However, without the actual text of the scientific article, I can't parse the entities directly. Instead, I'll illustrate how to identify and categorize these entities based on a hypothetical excerpt from such an article.\n\n### Hypothetical Article Excerpt:\n\n\"In a groundbreaking study published in the Journal of Pharmacology and Experimental Therapeutics, researchers from the University of Pharmacy discovered that Drug A significantly reduces the symptoms of Condition X. The study, led by Dr. Jane Smith and Dr. John Doe, involved a double-blind, placebo-controlled trial with 200 participants. The findings suggest that Drug A, when administered at a dose of 5mg, shows a 50% improvement in patient outcomes with a standard deviation of 5%.\"\n\n### Parsing Entities:\n\nBased on the hypothetical excerpt, the following entities can be identified:\n\n1. **Journal of Pharmacology and Experimental Therapeutics**: {\"FREQUENCY\": 1}\n2. **University of Pharmacy**: {\"FREQUENCY\": 1}\n3. **Drug A**: {\"FREQUENCY\": 2}\n4. **Condition X**: {\"FREQUENCY\": 1}\n5. **Dr. Jane Smith**: {\"FREQUENCY\": 1}\n6. **Dr. John Doe**: {\"FREQUENCY\": 1}\n7. **double-blind, placebo-controlled trial**: {\"FREQUENCY\": 1}\n8. **200 participants**: {\"FREQUENCY\": 1}\n9. **50% improvement**: {\"FREQUENCY\": 1}\n10. **5mg**: {\"FREQUENCY\": 1}\n11. **standard deviation of 5%**: {\"FREQUENCY\": 1}\n\nThis parsing", {}]], [511, "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment.", [" {\"BCRP/ABCG2 protein\": 2, \"DAS administration\": 1, \"APG pretreatment\": 1}\n\n(Note: The entities \"Hepatic\" and \"intestinal\" are not directly cited as entities but are related to the locations of BCRP/ABCG2 protein expression. However, they are not explicitly mentioned as cited entities in the provided text.)", {"Target": ["BCRP", "ABCG2"], "Drug": ["DAS"], "Herb name": ["APG"]}]], [512, "Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions.", [" {\"Cytochrome P-450 (CYP)\": 1, \"herb-drug interactions\": 1}\n{\"Phytochemicals\": 1}", {}]], [513, "If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population.", [" {\"CYP activity\": 1, \"herb-mediated changes\": 1, \"clinical relevance\": 1, \"population\": 1}\n{\"FREQUENCY\": {\"CYP activity\": 1, \"herb-mediated changes\": 1, \"clinical relevance\": 1, \"population\": 1}}\n\nNote: The entities \"herb\" and \"population\" are inferred from the context of the sentence, as they are likely to be the entities referred to in the scientific article about pharmacology. However, without the full text, this interpretation is based on the provided sentence.", {}]], [514, "Concomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly.", [" {\"Botanical supplements\": 1, \"prescription medications\": 1, \"elderly\": 1}\n{\"FREQUENCY\": {\"Botanical supplements\": 1, \"prescription medications\": 1, \"elderly\": 1}}", {}]], [515, "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women.", [" {\"SC extract\": 1, \"quadriceps muscle strength (QMS)\": 1, \"lactate\": 1, \"adult women\": 1}\n{\"SC extract\": {\"FREQUENCY\": 1}, \"quadriceps muscle strength (QMS)\": {\"FREQUENCY\": 1}, \"lactate\": {\"FREQUENCY\": 1}, \"adult women\": {\"FREQUENCY\": 1}}\n\nNote: The entities \"SC extract\" and \"quadriceps muscle strength (QMS)\" are considered as the main entities in the context of pharmacology, as they refer to a substance (SC extract) and a physiological parameter (QMS). \"Lactate\" is also relevant as it is a biological marker that can be affected by pharmacological interventions. \"Adult women\" is included as it specifies the demographic studied in the context of the pharmacological effect.", {"Herb name": ["SC extract"], "Parameter": ["quadriceps muscle strength (QMS)", "lactate"], "Sex": ["women"]}]], [516, "In ANOVA results, QMS (p = 0.001) and lactate level (p = 0.038) showed significant interactions.", [" {\"QMS\": 1, \"p-value\": 3, \"lactate level\": 1}\n\nNote: The frequency count is based on the number of times each entity is mentioned in the text. In this case, \"QMS\" and \"lactate level\" are mentioned once, while \"p-value\" is mentioned three times (twice as \"p\" and once as \"p-value\").", {"Parameter": ["lactate level"]}]], [517, "Our first hypothesis is that the supplementation of SC extract in humans can increase muscle strength.", [" {\"SC extract\": 1, \"supplementation\": 1, \"humans\": 1, \"muscle strength\": 1}\n{\"SC extract\": {\"FREQUENCY\": 1}, \"supplementation\": {\"FREQUENCY\": 1}, \"humans\": {\"FREQUENCY\": 1}, \"muscle strength\": {\"FREQUENCY\": 1}}", {"Herb name": ["SC extract"], "Parameter": ["muscle strength"]}]], [518, "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27].", [" {\"isokinetic knee extensions\": 1, \"leg\": 1, \"angular velocity\": 1, \"60 degrees/second\": 1, \"subjects\": 2, \"2 min\": 1, \"sets of measurements\": 1}\n{\"passive recovery\": 1}\n{\"main test session\": 1}\n{\"FREQUENCY\": {\"isokinetic knee extensions\": 1, \"leg\": 1, \"angular velocity\": 1, \"60 degrees/second\": 1, \"subjects\": 2, \"2 min\": 1, \"sets of measurements\": 1, \"passive recovery\": 1, \"main test session\": 1}}\n{\"Angular velocity\": 1}\n{\"FREQUENCY\": {\"isokinetic knee extensions\": 1, \"leg\": 1, \"angular velocity\": 1, \"60 degrees/second\": 1, \"subjects\": 2, \"2 min\": 1, \"sets of measurements\": 1, \"passive recovery\": 1, \"main test session\": 1, \"Angular velocity\": 1}}\n{\"60 degrees/second\": 1}\n{\"FREQUENCY\": {\"isokinetic knee extensions\": 1, \"leg\": 1, \"angular velocity\": 1, \"60 degrees/second\": 1, \"subjects\": 2, \"2 min\": 1, \"sets of measurements\": 1, \"passive recovery\": 1, \"main test session\": 1, \"Angular velocity\": 1, \"60 degrees/second\": 1}}\n{\"2 min\": 1}\n{\"FREQUENCY\": {\"isokinetic knee extensions\": 1, \"leg\": 1, \"angular velocity\": 1, \"60 degrees/second\": 1, \"subjects\": 2, \"2 min\": 1, \"sets of measurements\": 1, \"passive recovery\": 1, \"main test session\": 1, \"Angular velocity\": 1, \"60 degrees/second\": 1, \"2 min\": 1}}\n{\"sets of measurements\": 1}\n{\"FREQUENCY\": {\"isokinetic knee extensions\": 1,", {}]], [519, "The subject\u2019s knee joint center, measured using the femoral epicondyles as a joint center reference, was aligned with the axis of the isokinetic dynamometer.", [" {\"femoral epicondyles\": 1, \"knee joint center\": 1, \"isokinetic dynamometer\": 1}\n\nNote: The frequency count is based on the direct mention of the entities in the provided text. If the context implies the entity without directly naming it, it is not counted. In this case, the entities are directly named, hence the frequency count is as provided.", {}]], [520, "Plasma samples were obtained by centrifugation and stored at \u221280 \u00b0C.", [" {\"Plasma samples\": 1, \"centrifugation\": 1, \"\u221280 \u00b0C\": 1}\n{\"FREQUENCY\": {\"Plasma samples\": 1, \"centrifugation\": 1, \"\u221280 \u00b0C\": 1}}\n\n(Note: The term \"pharmacology\" itself was not directly cited in the provided text, but it is the scientific field to which the described entities belong. If the task was to identify entities directly related to pharmacology, then no specific pharmacology-related entities were mentioned in the text provided.)\n\n(Note: The text provided does not directly mention any pharmacological entities such as drugs, compounds, or specific pharmacological processes. However, the context implies a laboratory procedure that could be part of pharmacological research. If the task was to infer pharmacological entities from the context, it would be speculative and not based on direct mentions.)", {}]], [521, "The mean SC extract supplementation and placebo compliance were 97.3% (90.2\u2212100%) in the SC group and 95.8% (86.7\u2013100%) in the placebo group.", [" {\"SC Extract Supplementation\": 2, \"Placebo\": 1, \"SC group\": 1, \"placebo group\": 1}\n{\"SC Extract Supplementation frequency\": 2}\n{\"Placebo frequency\": 1}\n{\"SC group frequency\": 1}\n{\"placebo group frequency\": 1}", {"Herb name": ["SC extract", "SC"]}]], [522, "There were no significant differences between the groups for height, weight, or BMI at baseline (Table 1).", [" {\"Height\": [\"height\", \"baseline\", \"groups\", \"height, weight, or BMI at baseline\"], \"Weight\": [\"weight\", \"baseline\", \"groups\", \"height, weight, or BMI at baseline\"], \"BMI\": [\"BMI\", \"baseline\", \"groups\", \"height, weight, or BMI at baseline\"}", {"Parameter": ["BMI"]}]], [523, "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2.", [" {\"Resting lactate level\": 2, \"baseline\": 1, \"12 weeks\": 1, \"Figure 2\": 1}\n{\"FREQUENCY\": {\"Resting lactate level\": 2, \"baseline\": 1, \"12 weeks\": 1, \"Figure 2\": 1}}", {"Parameter": ["lactate level"], "Duration": ["12 weeks"]}]], [524, "have shown the association between high lactate production and reduced oxidative metabolism [47].", [" {\"Lactate production\": 1, \"Oxidative metabolism\": 1, \"Article\": 1, \"Scientific journal\": 1, \"Pharmacology\": 1, \"Scientific article\": 1, \"Study\": 1, \"Research\": 1, \"Association\": 1, \"Reduced\": 1, \"High\": 1, \"Event\": 1}\n\n{\"FREQUENCY\": {\"Lactate production\": 1, \"Oxidative metabolism\": 1, \"Article\": 1, \"Scientific journal\": 1, \"Pharmacology\": 1, \"Scientific article\": 1, \"Study\": 1, \"Research\": 1, \"Association\": 1, \"Reduced\": 1, \"High\": 1, \"Event\": 1}}", {"Parameter": ["lactate"]}]], [525, "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago.", [" {\"St. John's wort\": 1, \"herbal medicine\": 1, \"anti-depressant effects\": 1, \"drugs\": 1, \"bioavailability\": 1, \"efficacy\": 1}\n{\"St. John's wort\": {\"FREQUENCY\": 1}, \"herbal medicine\": {\"FREQUENCY\": 1}, \"anti-depressant effects\": {\"FREQUENCY\": 1}, \"drugs\": {\"FREQUENCY\": 1}, \"bioavailability\": {\"FREQUENCY\": 1}, \"efficacy\": {\"FREQUENCY\": 1}}", {"Study": ["reports"], "Herb name": ["St. John's wort (SJW)"], "Parameter": ["bioavailability"]}]], [526, "These interactions were caused by pregnane\u2010X\u2010receptor (PXR) activation.", [" {\"PREGNANE-X-RECEPTOR\": 1}", {"Target": ["pregnane\u2010X\u2010receptor (PXR)"]}]], [527, "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006).", [" {\"BORRELI&IZZO, 2009\": 1, \"CHRUBASIK-HAUSMANN, VLACHOJANNIS, & MCLACHLAN, 2019\": 1, \"GURLEY, FIFER, & GARDNER, 2012\": 1, \"IZZO, 2004\": 1, \"SOLEYMANI, BAHRASOLTANI, RAHIMI, & ABDOLLAHI, 2017\": 1, \"WHITTEN, MYERS, HAWRELAK, & WOHLMUTH, 2006\": 1}", {}]], [528, "SJW extracts as well as isolated constituents (hyperforin, hypericin, or flavonoids) have been investigated in vitro and in vivo for their interactions with a variety of potentially relevant targets for depression.", [" {\"SJW\": 1, \"isolated constituents\": 1, \"hyperforin\": 1, \"hypericin\": 1, \"flavonoids\": 1, \"interactions\": 1, \"relevant targets\": 1, \"depression\": 1}", {"Herb name": ["SJW extracts", "hyperforin", "hypericin", "flavonoids"], "Study": ["in vitro", "in vivo"], "Pathology": ["depression"]}]], [529, "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test.", [" {\"SJW extracts\": 1, \"tail suspension test\": 1, \"immobility\": 1, \"antidepressant treatment\": 1, \"Butterweck, Christoffel, et al., 2003\": 1, \"Machado et al., 2008\": 1, \"Tian et al., 2014\": 1}\n\n{\"SJW extracts\": \"1\", \"tail suspension test\": \"1\", \"immobility\": \"1\", \"antidepressant treatment\": \"1\", \"Butterweck, Christoffel, et al., 2003\": \"1\", \"Machado et al., 2008\": \"1\", \"Tian et al., 2014\": \"1\"}\n\nNote: The \"FREQUENCY\" field is represented as a count of occurrences, not a frequency in a time-based sense. If the task requires a time-based frequency, additional context would be needed. However, based on the given instruction, the count of occurrences is provided.", {"Drug": ["antidepressant treatment,"], "Herb name": ["SJW extracts"]}]], [530, "In the network of genes involved in drug metabolism, the PXR functions as a xenobiotic receptor or \u201cxenosensor,\u201d which, after ligand binding, translocates to the nucleus, where it binds to specific PXR response elements (PXRRE) in the promotor of various genes, modulating their transcription.", [" {\"PXR\": 2, \"xenobiotic receptor\": 1, \"xenosensor\": 1, \"ligand\": 1, \"nucleus\": 1, \"PXRRE\": 1, \"promotor\": 1, \"genes\": 1}", {"Target": ["PXR", "PXR response elements (PXRRE)"]}]], [531, "For OATP2B1, we have recently shown that this transporter is not only inhibited by hyperforin but also transports this constituent of SJW (Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018), thus influencing the intracellular transactivation of PXR by hyperforin (Sch\u00e4fer et al., 2019).", [" {\"OATP2B1\": 2, \"hyperforin\": 2, \"SJW\": 1, \"Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen\": 1, \"2018\": 1, \"Sch\u00e4fer et al., 2019\": 1}", {"Target": ["OATP2B1", "PXR"], "Herb name": ["hyperforin", "SJW", "hyperforin"]}]], [532, "This statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low\u2010hyperforin SJW extract (Zahner et al., 2019).", [" {\"Zahner et al., 2019\": 1}\n\n(Note: The frequency count here is based on the single occurrence of the cited entity within the provided text.)\n\n{\"low\u2010hyperforin SJW extract\": 1}\n\n(Note: The frequency count here is based on the single occurrence of the cited entity within the provided text.)", {"Herb name": ["low\u2010hyperforin SJW extract"]}]], [533, "Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies.", [" {\"Pharmacoepidemiology methods\": 1, \"bioinformatics\": 1, \"data mining\": 1, \"herb-drug interactions\": 1, \"clinical meaningful\": 1, \"cancer therapies\": 1}\n{\"Herb-drug interactions\": 1, \"cancer therapies\": 1}\n{\"Pharmacoepidemiology methods\": 1, \"bioinformatics\": 1, \"data mining\": 1}\n{\"Pharmacoepidemiology methods\": 1, \"bioinformatics\": 1, \"data mining\": 1, \"herb-drug interactions\": 1, \"clinical meaningful\": 1, \"cancer therapies\": 1}\n{\"Pharmacoepidemiology methods\": 1, \"bioinformatics\": 1, \"data mining\": 1}\n{\"Herb-drug interactions\": 1, \"cancer therapies\": 1}\n{\"Pharmacoepidemiology methods\": 1, \"bioinformatics\": 1, \"data mining\": 1}\n{\"Pharmacoepidemiology methods\": 1, \"bioinformatics\": 1, \"data mining\": 1}\n{\"Herb-drug interactions\": 1, \"cancer therapies\": 1}\n{\"Pharmacoepidemiology methods\": 1, \"bioinformatics\": 1, \"data mining\": 1}\n{\"Pharmacoepidemiology methods\": 1, \"bioinformatics\": 1, \"data mining\": 1}\n{\"Herb-drug interactions\": 1, \"cancer therapies\": 1}\n{\"Pharmacoepidemiology methods\": 1, \"bioinformatics\": 1, \"data mining\": 1}\n{\"Pharmacoepidemiology methods\": 1, \"bioinformatics\": 1, \"data mining\": 1}\n{\"Herb-drug interactions\": 1, \"cancer therapies\": 1}\n{\"Pharmacoepidemiology methods\": 1, \"bioinformatics\": 1, \"data mining\": 1}", {"Pathology": ["cancer"]}]], [534, "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions.", [" {\"Lingzhi\": 2, \"Yunzhi\": 2, \"systematic reviews\": 1, \"meta-analysis\": 1, \"adjunct for cancer treatment\": 1, \"clinical outcomes\": 1, \"mechanistic explanations\": 1}\n\nNote: The frequency count is based on the direct mentions of the entities in the text provided. If there were more instances where these entities were referred to indirectly or in different forms, those would not be captured in this count.", {"Herb name": ["Lingzhi", "Yunzhi"], "Pathology": ["cancer"]}]], [535, "If the control group also received medicinal mushrooms, there should be significant dosage differences of the mushrooms in the treatment group.", [" {\"Medicinal mushrooms\": 2, \"treatment group\": 1, \"control group\": 1}", {}]], [536, "Figure\u00a01 summarizes the process of database searching and literature selection.", [" {\"FREQUENCY\": {\"database searching\": 1, \"literature selection\": 1, \"Figure 1\": 1, \"pharmacology\": 1, \"scientific article\": 1}}\n\n{\"ENTITY\": [\"Figure 1\"]}\n\n{\"ENTITY\": [\"pharmacology\", \"scientific article\"]}", {}]], [537, "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100].", [" {\"Bax expression\": 1, \"CD4\": 2, \"CD4/CD8\": 1, \"CD3+\": 2, \"cytotoxic drugs\": 2, \"cytotoxicity\": 2, \"dose-related\": 1, \"dose-dependent\": 1, \"efficacy\": 2, \"eosinophils\": 1, \"epithelial cells\": 1, \"extracellular matrix\": 1, \"FUdR\": 1, \"gene expression\": 2, \"gene regulation\": 1, \"glutathione\": 1, \"granulocytes\": 1, \"hematopoietic cells\": 2, \"hematopoietic system\": 1, \"histone acetylation\": 1, \"histone deacetylation\": 1, \"histone methylation\": 1, \"histone methyltransferase\": 1, \"histone demethylase\": 1, \"histone deacetylase\": 1, \"histone deacetylase inhibitor\": 1, \"histone acetyltransferase\": 1, \"histone acetyltransferase inhibitor\": 1, \"histone methyltransferase inhibitor\": 1, \"histone methyltransferase inhibitor\": 1, \"histone demethylase\": 1, \"histone demethylase inhibitor\": 1, \"histone acetyltransferase inhibitor\": 1, \"histone deacetylase inhibitor\": 1, \"histone deacetylase inhibitor inhibitor\": 1, \"histone deacetylase inhibitor inhibitor\": 1, \"histone deacetylase inhibitor inhibitor\": 1, \"histone deacetylase inhibitor inhibitor\": 1, \"histone deacetylase inhibitor inhibitor\": 1, \"histone deacetylase inhibitor inhibitor\": 1, \"histone", {"Parameter": ["T cell apoptosis", "caspase 3 activity", "Bax expression", "cells count", "CD4", "CD4", "CD8", "WBC", "CD3+", "CD4+ T cells", "NK cells", "platelets", "WBC", "platelets", "bone marrow cells", "phagocytic activity", "antibody production", "caspase 3"], "Study": ["preclinical studies"], "Pathology": ["intestinal damage", "metastasis"], "Drug": ["5-FU", "5-FU"]}]], [538, "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49].", [" {\"Yunzhi-drug combinations\": 1, \"5-FU\": 1, \"carboplatin\": 1, \"cisplatin\": 1, \"cyclophosphamide\": 1, \"doxorubicin\": 1, \"etoposide\": 1, \"UFT\": 1, \"tumor recurrence\": 2, \"metastasis\": 1}", {"Herb name": ["Yunzhi"], "Drug": ["5-FU", "carboplatin", "cisplatin", "cyclophosphamide", "doxorubicin", "etoposide", "UFT"], "Pathology": ["tumor", "metastasis"]}]], [539, "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124].", [" {\"tumor cell angiogenesis\": 1, \"reactive oxygen species production\": 1, \"antitumor effect\": 1, \"inhibition\": 1, \"tumor cell angiogenesis [104]\": 1, \"reactive oxygen species production [124]\": 1}", {}]], [540, "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97].", [" {\"Paclitaxel\": 1, \"tumor metabolism\": 1, \"Warburg-related proteins\": 1, \"gut dysbiosis\": 1}\n\n{\"97\": 1}", {"Pathology": ["gut dysbiosis"], "Drug": ["paclitaxel"]}]], [541, "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131].", [" {\"Yunzhi\": 1, \"anticancer drugs\": 1, \"cytotoxicity\": 1, \"cytotoxic lymphocytes\": 1, \"tumor-infiltrating lymphocytes\": 1, \"suppressor T cells\": 1, \"superoxide dismutase (SOD)\": 1, \"lipid peroxide levels\": 1, \"cancer cells\": 1}", {"Herb name": ["Yunzhi"], "Drug": ["anticancer drugs"], "Parameter": ["suppressor T cells", "superoxide dismutase (SOD)", "lipid peroxide levels"], "Pathology": ["cancer"]}]], [542, "a.", [" {\"Pharmacology\": 1, \"scientific article\": 1, \"pharmacological entities\": 1, \"drugs\": 1, \"drug molecules\": 1, \"pharmacokinetics\": 1, \"pharmacodynamics\": 1, \"pharmaceutical compounds\": 1, \"pharmacologists\": 1, \"clinical trials\": 1, \"drug efficacy\": 1, \"drug safety\": 1, \"drug interactions\": 1, \"drug metabolism\": 1, \"drug absorption\": 1, \"drug excretion\": 1, \"pharmacology research\": 1, \"pharmacology studies\": 1, \"pharmacology journals\": 1, \"pharmacology conferences\": 1, \"pharmacology textbooks\": 1, \"pharmacology courses\": 1, \"pharmacology education\": 1, \"pharmacology curriculum\": 1, \"pharmacology departments\": 1, \"pharmacology labs\": 1, \"pharmacology researchers\": 1, \"pharmacology students\": 1, \"pharmacology professionals\": 1, \"pharmacology field\": 1, \"pharmacology discipline\": 1, \"pharmacology specialty\": 1, \"pharmacology subfield\": 1, \"pharmacology branch\": 1, \"pharmacology area\": 1, \"pharmacology topic\": 1, \"pharmacology subject\": 1, \"pharmacology topic\": 1, \"pharmacology subject\": 1, \"pharmacology subject\": 1, \"pharmacology subject\": 1, \"pharmacology subject\": 1, \"pharmacology subject\": 1, \"pharmacology subject\": 1, \"pharmacology subject\": 1, \"pharmacology subject\": 1, \"pharmacology subject\": 1, \"pharmacology subject\": 1, \"pharmacology subject\": 1, \"pharmacology subject\": 1, \"pharmacology subject\": 1", {}]], [543, "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171].", [" {\"T-box protein expressed in T cells (T-bet)\": 1, \"GATA-3\": 1, \"T helper cell balance\": 1, \"Bax expression\": 1, \"caspase 3 activity\": 1, \"Forkhead box protein 3 (Foxp3)\": 1, \"programmed death 1 (PD-1)\": 1}", {"Target": ["T-box protein expressed in T cells (T-bet)", "GATA-3", "caspase 3", "T cell", "Forkhead box protein 3 (Foxp3)", "programmed death 1 (PD-1)"]}]], [544, "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings.", [" {\"Medicinal mushrooms\": 1, \"chemotherapeutic drugs\": 1, \"adverse effects\": 1, \"clinical settings\": 1}\n\nNote: The frequency count is based on the direct mentions of the entities in the provided text. If there are synonyms or related terms used in the article that refer to these entities, they are not included in this count as per the instruction to only list words referring to the described entities.", {"Pathology": ["adverse effects"]}]], [545, "Table S4.", [" {\"FREQUENCY\": {\"Table S4\": 1}, \"ENTITIES\": [\"Table S4\"]}", {}]], [546, "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All.", [" In the provided text, the task is to identify and parse cited entities related to pharmacology. However, the text itself does not contain any specific cited entities or references to scientific articles. To fulfill the task as described, we would expect to find mentions of drugs, pharmacological terms, researchers, institutions, journals, or specific studies.\n\n\nSince no specific text with cited entities was provided, we cannot extract any frequencies of events or entities. If you have a specific text with pharmacological references, please provide it, and we can proceed with the task accordingly.\n\n\nFor the format requested, if we had a hypothetical text with cited entities, it might look something like this:\n\n\nHypothetical Text:\n\"In the study published in the Journal of Pharmacology, Smith et al. (2020) investigated the effects of Drug X on patients with condition Y. The researchers found that Drug X significantly improved patient outcomes.\"\n\n\nParsed Entities:\n\n- {\"Journal of Pharmacology\": 1}\n- {\"Smith et al. (2020)\": 1}\n- {\"Drug X\": 2}\n- {\"condition Y\": 1}\n\n\nFREQUENCY:\n\n- {\"Journal of Pharmacology\": 1}\n- {\"Smith et al. (2020)\": 1}\n- {\"Drug X\": 2}\n- {\"condition Y\": 1}", {}]], [547, "Not applicable.", [" {\"Pharmacology\": 1, \"scientific article\": 1, \"pharmacological entities\": 1, \"drugs\": 1, \"drug molecules\": 1, \"pharmacokinetics\": 1, \"pharmacodynamics\": 1, \"pharmaceutical compounds\": 1, \"pharmacologists\": 1, \"clinical trials\": 1, \"drug efficacy\": 1, \"drug safety\": 1, \"drug interactions\": 1, \"drug metabolism\": 1, \"drug absorption\": 1, \"drug excretion\": 1, \"pharmacology research\": 1, \"pharmacology studies\": 1, \"pharmacology journals\": 1, \"pharmacology conferences\": 1, \"pharmacology textbooks\": 1, \"pharmacology courses\": 1, \"pharmacology education\": 1, \"pharmacology curriculum\": 1, \"pharmacology departments\": 1, \"pharmacology labs\": 1, \"pharmacology researchers\": 1, \"pharmacology students\": 1, \"pharmacology professionals\": 1, \"pharmacology field\": 1, \"pharmacology discipline\": 1, \"pharmacology specialty\": 1, \"pharmacology subfield\": 1, \"pharmacology branch\": 1, \"pharmacology area\": 1, \"pharmacology topic\": 1, \"pharmacology subject\": 1, \"pharmacology topic\": 1, \"pharmacology subject\": 1, \"pharmacology subject\": 1, \"pharmacology subject\": 1, \"pharmacology subject\": 1, \"pharmacology subject\": 1, \"pharmacology subject\": 1, \"pharmacology subject\": 1, \"pharmacology subject\": 1, \"pharmacology subject\": 1, \"pharmacology subject\": 1, \"pharmacology subject\": 1, \"pharmacology subject\": 1, \"pharmacology subject\": 1", {}]], [548, "Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy.", [" {\"Breast cancer\": 1, \"complementary and alternative (CAM) treatment options\": 1, \"conventional cancer therapy\": 1}\n\n{\"FREQUENCY\": {\"Breast cancer\": 1, \"complementary and alternative (CAM) treatment options\": 1, \"conventional cancer therapy\": 1}}\n\n(Note: The frequency count is based on the number of times the entities appear in the text provided.)", {"Pathology": ["breast cancer", "side effects", "cancer"]}]], [549, "Approximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer.", [" {\"ER-positive breast cancer\": 1, \"hormonal therapy\": 1, \"early stage\": 1, \"metastatic\": 1}\n\n{\"ER\": 1, \"breast tumors\": 1}\n\n{\"FREQUENCY\": {\"ER-positive breast cancer\": 1, \"hormonal therapy\": 1, \"early stage\": 1, \"metastatic\": 1, \"ER\": 1, \"breast tumors\": 1}}", {"Pathology": ["breast tumors", "ER-positive breast cancer"], "Target": ["estrogen receptor (ER)"], "Drug": ["hormonal therapy"]}]], [550, "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313].", [" {\"Viscum album\": 2, \"Viscum album extracts (VAE)\": 1, \"breast cancer patients\": 1, \"cancer\": 2}\n{\"Clinical studies\": 1, \"benefits\": 1, \"patients\": 1, \"types of cancer\": 1}\n{\"[10\u201313]\": 2}\n{\"FREQUENCY\": {\"Viscum album\": 2, \"Viscum album extracts (VAE)\": 1, \"breast cancer patients\": 1, \"cancer\": 2, \"Clinical studies\": 1, \"benefits\": 1, \"patients\": 1, \"types of cancer\": 1, \"[10\u201313]\": 2}}\n\nNote: The frequency count is based on the direct mentions of the entities in the text provided. If there are implied references or synonyms that are not explicitly mentioned, they are not included in this count.", {"Study": ["Clinical studies"], "Herb name": ["Viscum album extracts (VAE)"], "Pathology": ["breast cancer", "cancer"]}]], [551, "5\u2009mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306\u2009ng/mL), and Iscador Qu spec.", [" {\"VAEM\": 1, \"Malus domestica\": 1, \"Lot 7054/0\": 1, \"total mistletoe lectin concentration\": 1, \"306 ng/mL\": 1, \"Iscador Qu spec.\": 1}\n{\"FREQUENCY\": {\"VAEM\": 1, \"Malus domestica\": 1, \"Lot 7054/0\": 1, \"total mistletoe lectin concentration\": 1, \"306 ng/mL\": 1, \"Iscador Qu spec.\": 1}}", {"Amount": ["5\u2009mg"], "Herb name": ["VAEM", "Malus domestica", "mistletoe lectin", "Iscador Qu"]}]], [552, "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA).", [" {\"(4-hydroxy-N-desmethyltamoxifen hydrochloride)\": 1, \"(E/Z)-endoxifen hydrochloride\": 1, \"(4-hydroxy)\": 1, \"(N-desmethyltamoxifen hydrochloride)\": 1, \"(4-hydroxy-N-desmethyltamoxifen hydrochloride)\": 1, \"(E2)\": 1, \"(dextrorphan-d)\": 1, \"Pooled human liver microsomes (HLMs)\": 1, \"50 donors\": 1, \"mixed gender\": 1}", {"Drug": ["(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride)", "dextrorphan-d"], "Target": ["\u03b2-estradiol (E2)"]}]], [553, "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig.", [" {\"Pharmacological agents\": [\"endoxifen\", \"VAEM\"], \"Statistical significance levels\": [\"*p\u00a0<\u20090.05\", \"**p\u00a0<\u20090.01\", \"***p\u00a0<\u20090.001\"], \"Biological process\": [\"concentration-dependent inhibition of proliferation\"}", {"Herb name": ["VAEM", "VAEM"], "Drug": ["endoxifen"]}]], [554, "Based on genotype combinations encoding for varying enzyme phenotypes, patients have been classified as poor, intermediate, extensive, or ultra-rapid metabolizers [32, 33].", [" {\"Genotype combinations\": 1, \"Enzyme phenotypes\": 1, \"Patients\": 1, \"Metabolizer classifications\": 1}", {}]], [555, "The metabolic activity of CYP2D6 was suggested to be associated with the long-term outcomes in breast cancer, although the studies are inconsistent [35].", [" {\"CYP2D6\": 1, \"breast cancer\": 1, \"studies\": 1}\n\nNote: The frequency count is based on the direct mentions of the entities in the provided text. If there were additional mentions of these entities in the broader context of the article, they would not be included in this count.", {"Target": ["CYP2D6"], "Pathology": ["breast cancer"]}]], [556, "The significant inter-individual variability of CYP2D6 activity due to genetic polymorphisms was mitigated by the use of pooled microsomes from 50 donors [41].", [" {\"CYP2D6\": 1, \"genetic polymorphisms\": 1, \"pooled microsomes\": 1, \"50 donors\": 1}\n{\"FREQUENCY\": {\"genetic polymorphisms\": 1}}\n\nNote: The frequency count is based on the number of times the entities appear in the provided text. The count is one for each entity mentioned.", {"Target": ["CYP2D6"]}]], [557, "(PDF 36 kb) Figure S2.", [" {\"FREQUENCY\": {\"scientific article\": 1, \"pharmacology\": 1, \"cited entities\": 2, \"words referring to cited entities\": [\"pharmacology\", \"scientific article\"]}}\n\n(Note: The provided text does not mention specific cited entities or their frequency. However, the task was to identify words referring to the described entities, which are \"scientific article\" and \"pharmacology\". The frequency count is based on the occurrence of these words in the given text.)", {}]], [558, "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM).", [" {\"CYP2D6\": 1, \"quinidine\": 1, \"Dextromethorphan\": 1, \"in vitro\": 1, \"inhibition profiles\": 1, \"\u03bcM\": 1}\n{\"FREQUENCY\": {\"CYP2D6\": 1, \"quinidine\": 1, \"Dextromethorphan\": 1, \"in vitro\": 1, \"inhibition profiles\": 1, \"\u03bcM\": 1}}", {"Drug": ["Dextromethorphan", "Quinidine"], "Study": ["in vitro"], "Target": ["CYP2D6"]}]], [559, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" {\"Springer Nature\": 1, \"neutral\": 1, \"jurisdictional claims\": 1, \"published maps\": 1, \"institutional affiliations\": 1}\n{\"Springer Nature\": 1, \"neutral\": 1, \"jurisdictional claims\": 1, \"published maps\": 1, \"institutional affiliations\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"ph", {}]], [560, "To our knowledge, there is no available information regarding pharmacokinetic interactions between captopril and H. sabdariffa.", [" {\"Captopril\": 1, \"H. sabdariffa\": 1}\n{\"Pharmacokinetic interactions\": 1}", {"Drug": ["captopril"], "Herb name": ["H. sabdariffa"]}]], [561, "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min.", [" {\"plasma\": 2, \"captopril\": 1, \"2-4-dibromoacetophenone\": 1, \"520 ppm\": 1, \"5% ammonia solution\": 1, \"sample\": 1, \"vortexed\": 1, \"incubated\": 1}\n{\"FREQUENCY\": {\"plasma\": 2, \"captopril\": 1, \"2-4-dibromoacetophenone\": 1, \"520 ppm\": 1, \"5% ammonia solution\": 1, \"sample\": 1, \"vortexed\": 1, \"incubated\": 1}}", {"Drug": ["captopril"]}]], [562, "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)", [" {\"Captopril\": 1, \"morning\": 1, \"two weeks\": 1, \"dosage\": 1, \"4.5 mg/kg body weight (BW)\": 1, \"p.o. (per os)\": 1}\n{\"Captopril\": {\"frequency\": 1}, \"morning\": {\"frequency\": 1}, \"two weeks\": {\"frequency\": 1}, \"dosage\": {\"frequency\": 1}, \"4.5 mg/kg body weight (BW)\": {\"frequency\": 1}, \"p.o. (per os)\": {\"frequency\": 1}}\n\n(Note: The \"daily\" frequency was not included as it was not directly tied to a specific entity in the provided text.)", {"Frequency": ["daily"], "Duration": ["for two weeks"], "Drug": ["captopril"], "Amount": ["4.5\u2009mg/200\u2009g BW"]}]], [563, "The animals were anaesthetized before blood collection process.", [" {\"ANIMALS\": [\"animals\"], \"PROCEDURES\": [\"anaesthetized\", \"blood collection process\"]}\n{\"FREQUENCY\": {\"anaesthetized\": 1, \"blood collection process\": 1}}\n\n(Note: The entities \"pharmacology\" and \"scientific article\" were not explicitly mentioned in the provided text, but they are related to the context of the document. However, based on the instruction to parse cited entities, we focused on the direct entities mentioned.)", {}]], [564, "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)", [" {\"Saline solution\": 1, \"p.o.\": 1}", {}]], [565, "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3).", [" {\"Captopril\": [\"captopril analysis\", \"captopril\"]}\n{\"Table 3\": [\"Table 3\"]}\n{\"within-run accuracy\": [\"within-run accuracy\"], \"within-run precision\": [\"within-run precision\"]}", {"Drug": ["captopril"]}]], [566, "In selectivity testing, six rats plasma was used.", [" {\"RATS\": 1, \"RATS PLAUSAGE\": 1, \"RATS PLASMA\": 1}\n{\"FREQUENCY\": {\"RATS\": 1, \"RATS PLAUSAGE\": 1, \"RATS PLASMA\": 1}}", {}]], [567, "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups.", [" {\"2-4-dibromoacetophenone\": 1, \"derivatization agent\": 1, \"sulfhydryl group\": 2, \"caproic acid\": 1, \"plasma sulfhydryl groups\": 1}\n{\"captopril\": 1}\n{\"plasma\": 1}\n{\"sulfhydryl\": 2}\n{\"2-4-dibromoacetophenone\": 1}\n{\"2-4-dibromoacetophenone-derivatized\": 1}\n{\"2-4-dibromoacetophenone-derivatized-caproate\": 1}\n{\"2-4-dibromoacetophenone-derivatized-caproate-sulfhydryl\": 1}\n{\"2-4-dibromoacetophenone-derivatized-caproate-sulfhydryl-plasma\": 1}\n{\"2-4-dibromoacetophenone-derivatized-caproate-sulfhydryl-plasma-binding\": 1}\n{\"2-4-dibromoacetophenone-derivatized-caproate-sulfhydryl-plasma-binding-prevent\": 1}\n{\"2-4-dibromoacetophenone-derivatized-caproate-sulfhydryl-plasma-binding-prevent-experiment\": 1}\n{\"2-4-dibromoacetophenone-derivatized-caproate-sulfhydryl-plasma-binding-prevent-experiment-used\": 1}\n{\"2-4-dibromoacetophenone-derivatized-caproate-sulfhydryl-plasma-binding-prevent-experiment-used-2-4-dibromoacetophenone\": 1}\n{\"2-4-dibromoacetophenone-derivatized-caproate-sulfhydryl-plasma-binding-prevent-experiment", {"Drug": ["captopril"]}]], [568, "Ammonia was used during derivatization since the reaction is optimal at basic pH.", [" {\"Ammonia\": 1, \"derivatization\": 1, \"reaction\": 1, \"basic pH\": 1}\n{\"FREQUENCY\": {\"Ammonia\": 1, \"derivatization\": 1, \"reaction\": 1, \"basic pH\": 1}}", {}]], [569, "The reaction was then stopped by adding formic acid [17].", [" {\"Formic Acid\": 1, \"reaction\": 1}", {}]], [570, "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter.", [" {\"H. sabdariffa extract\": 1, \"GSH level\": 1, \"PEPT1 transporter\": 1, \"coadministration\": 1}\n{\"FREQUENCY\": {\"coadministration\": 1}}\n\n(Note: The frequency count is based on the specific phrases mentioned in the text. If the task requires counting individual words, the frequency would be different. However, since the task is to find cited entities, the phrases are considered as the entities in this context.)", {"Duration": ["Two weeks"], "Herb name": ["H. sabdariffa"], "Target": ["GSH", "PEPT1 transporter"]}]], [571, "2016; Eng et\u00a0al.", [" {\"FREQUENCY\": {\"2016\": 1, \"Eng et al.\": 1}}\n\n- \"2016\" refers to the year when the study or publication by Eng et al. was released.\n\n- \"Eng et al.\" refers to the authors of the study or publication, with \"et al.\" being an abbreviation for \"et alia,\" which means \"and others\" in Latin, used when citing a work with multiple authors.", {}]], [572, "2016).", [" {\"2016\": 1, \"pharmacology\": 2, \"scientific article\": 1, \"pharmacology-related entities\": 1, \"cited entities\": 1}\n\n(Note: The term \"pharmacology-related entities\" refers to the entities mentioned in the context of pharmacology, such as drugs, biological systems, and pharmacological concepts. \"Cited entities\" refers to the specific entities that are cited within the scientific article.)", {}]], [573, "Water and food (laboratory rodent chow, Shanghai, China) were allowed ad libitum.", [" {\"Laboratory rodent chow\": 1, \"Shanghai, China\": 1}\n{\"Ad libitum\": 1}\n{\"Water\": 1}\n{\"Food\": 1}\n{\"Laboratory rodent\": 1}\n{\"Chow\": 1}\n{\"China\": 1}", {}]], [574, "The analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA).", [" {\"Agilent 1290 series liquid chromatography system\": 1, \"Agilent Technologies\": 1, \"Palo Alto, CA, USA\": 1}\n{\"Agilent\": 1, \"1290 series\": 1, \"liquid chromatography system\": 1, \"Palo Alto\": 1, \"CA\": 1, \"USA\": 1}\n{\"liquid chromatography system\": 1}\n{\"Agilent Technologies\": 1}\n{\"Palo Alto, CA, USA\": 1}\n{\"Agilent 129 columns\": 0}\n{\"Agilent 1290 series\": 0}\n{\"Agilent 1290\": 0}\n{\"Agilent 1290 series liquid chromatography\": 0}\n{\"Agilent 1290 series liquid chromatography system\": 0}\n{\"Agilent liquid chromatography system\": 0}\n{\"Agilent liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA)\": 0}\n{\"Agilent liquid chromatography system (Agilent Technologies)\": 0}\n{\"Agilent liquid chromatography system (Palo Alto, CA, USA)\": 0}\n{\"Agilent liquid chromatography system (Palo Alto):\": 0}\n{\"Agilent liquid chromatography system (CA, USA)\": 0}\n{\"Agilent liquid chromatography system (USA)\": 0}\n{\"Agilent liquid chromatography system (Agilent):\": 0}\n{\"Agilent liquid chromatography system (Agilent Technologies):\": 0}\n{\"Agilent liquid chromatography system (Palo Alto, CA, USA):\": 0}\n{\"Agilent liquid chromatography system (Palo Alto):\": 0}\n{\"Agilent liquid chromatography system (CA, USA):\": 0}\n{\"Agilent liquid chromatography system (USA):\": 0}\n{\"Agilent liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA)\": 0}\n{\"Agilent", {}]], [575, "Statistical analysis of results obtained from clinical study was performed using Student\u2019s paired t-test.", [" {\"Student\u2019s paired t-test\": 1}\n\n{\"clinical study\": 1}\n\n{\"Statistical analysis\": 1}", {"Study": ["clinical study"]}]], [576, "The results suggest that the herb-drug interaction between GLT and AC might occur when they were co-administered.", [" {\"GLT\": 1, \"AC\": 1, \"herb-drug interaction\": 1}\n{\"co-administered\": 1}\n\n{\"FREQUENCY\": {\"herb-drug interaction\": 1, \"co-administered\": 1}}\n\n(Note: The entities \"GLT\" and \"AC\" are assumed to refer to specific drugs or herbal compounds mentioned in the broader context of the scientific article, even though they are not explicitly defined in the provided text.)", {"Herb name": ["GLT"], "Drug": ["AC"]}]], [577, "HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?", [" {\"FREQUENCY\": [\"pharmacology\", \"clinical pharmacology\", \"translational science\", \"drug\", \"medication\", \"therapeutic intervention\", \"drug development\", \"drug action\", \"drug metabolism\", \"drug-receptor interaction\", \"pharmacokinetics\", \"pharmacodynamics\", \"pharmacogenomics\", \"pharmacotherapy\", \"pharmacology research\", \"clinical trials\", \"drug efficacy\", \"drug safety\", \"drug resistance\", \"pharmacological target\", \"pharmacological effect\", \"pharmacological intervention\", \"pharmacological outcome\", \"pharmacological model\", \"pharmacological mechanism\", \"pharmacological endpoint\", \"pharmacological endpoint measurement\", \"pharmacological endpoint analysis\", \"pharmacological endpoint interpretation\", \"pharmacological endpoint optimization\", \"pharmacological endpoint optimization strategy\", \"pharmacological endpoint optimization method\", \"pharmacological endpoint optimization result\", \"pharmacological endpoint optimization outcome\", \"pharmacological endpoint optimization impact\", \"pharmacological endpoint optimization potential\", \"pharmacological endpoint optimization challenge\", \"pharmacological endpoint optimization opportunity\", \"pharmacological endpoint optimization solution\", \"pharmacological endpoint optimization implementation\", \"pharmacological endpoint optimization evaluation\", \"pharmacological endpoint optimization assessment\", \"pharmacological endpoint optimization improvement\", \"pharmacological endpoint optimization enhancement\", \"pharmacological endpoint optimization advancement\", \"pharmacological endpoint optimization innovation\", \"pharmacological endpoint optimization development\", \"pharmacological endpoint optimization discovery\", \"pharmacological endpoint optimization identification\", \"pharmacological endpoint optimization recognition\", \"pharmacological endpoint optimization acknowledgment\", \"pharmacological endpoint optimization appreciation\", \"pharmacological endpoint optimization gratitude\", \"pharmacological endpoint optimization thankfulness\", \"pharmacological endpoint optimization reciprocity\", \"pharmacological endpoint optimization mutuality\", \"pharmacological endpoint optimization interdependence\", \"pharmacological endpoint optimization interconnectedness\", \"pharmacological endpoint optimization interrelation\", \"pharmacological endpoint optimization interplay\", \"pharmacological endpoint optimization interaction", {}]], [578, "(n\u00a0=\u00a06).", [" {\"PHARMACOLOGICAL_DRUG_NAMES\": [\"drug_name_1\", \"drug_name_2\", \"drug_name_3\", \"drug_name_4\", \"drug_name_5\", \"\"], \"DRUG_BRANCHES\": [\"branch_name_1\", \"branch_name_2\", \"branch_name_3\", \"branch_name_4\", \"branch_name_5\", \"\"], \"DRUG_CLASSES\": [\"drug_class_1\", \"drug_class_2\", \"drug_class_3\", \"drug_class_4\", \"drug_class_5\", \"\"], \"DRUG_ACTIONS\": [\"action_1\", \"action_2\", \"action_3\", \"action_4\", \"action_5\", \"\"], \"DRUG_MECHANISMS\": [\"mechanism_1\", \"mechanism_2\", \"mechanism_3\", \"mechanism_4\", \"mechanism_5\", \"\"], \"DRUG_REACTIONS\": [\"reaction_1\", \"reaction_2\", \"reaction_3\", \"reaction_4\", \"reaction_5\", \"\"], \"DRUG_INTERACTIONS\": [\"interaction_1\", \"interaction_2\", \"interaction_3\", \"interaction_4\", \"interaction_5\", \"\"], \"DRUG_SIDE_EFFECTS\": [\"side_effect_1\", \"side_effect_2\", \"side_effect_3\", \"side_effect_4\", \"side_effect_5\", \"\"], \"DRUG_CLINICAL_TRIALS\": [\"trial_name_1\", \"trial_name_2\", \"trial_name_3\", \"trial_name_4\", \"trial_name_5\", \"\"], \"DRUG_CLINICAL_STAGES\": [\"stage_1\", \"stage_2\", \"stage_3\", \"stage_4\", \"stage_5\", \"\"}, \"DRUG_COMPANIES\": [\"company_name_1\", \"company_name_2\", \"company_name_3\", \"company_name_4\", \"company_name_5\", \"\"], \"DRUG_BRANCH", {"Amount": ["6"]}]], [579, "wrote the manuscript.", [" {\"FREQUENCY\": {\"manuscript\": 1}}\n\n{\"FREQUENCY\": {\"authors\": 1}}\n\n{\"FREQUENCY\": {\"pharmacology\": 1}}\n\n{\"FREQUENCY\": {\"scientific article\": 1}}\n\n{\"FREQUENCY\": {\"cited entities\": 1}}\n\n{\"FREQUENCY\": {\"events\": 1}} (Note: 'events' here refers to the act of citing, which is a less common usage but fits the context of the task.)", {}]], [580, "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S.", [" {\"S.M.\": 1, \"Y.O.\": 1, \"R.T.\": 1, \"E.H.\": 1, \"T.O.\": 1, \"H.O.\": 1, \"K.S.\": 1}", {}]], [581, "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.", [" {\"S.M.\": 1, \"Y.O.\": 1, \"R.T.\": 1, \"J.K.\": 1, \"H.W.\": 1, \"M.F.\": 1, \"K.S.\": 1}", {}]], [582, "Eugenia jambolana (EJ) is an Indian traditional herb widely used for the treatment of diabetes mellitus.", [" {\"Eugenia jambolana (EJ)\": 1, \"Indian traditional herb\": 1, \"diabetes mellitus\": 1}\n{\"Eugenia jambolana\": 1, \"EJ\": 1}\n{\"diabetes mellitus\": 1}", {"Herb name": ["Eugenia jambolana (EJ)"], "Ethnic group": ["Indian"], "Pathology": ["diabetes mellitus"]}]], [583, "Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study.", [" {\"SITA\": 1, \"combination\": 1, \"blood glucose level\": 1, \"pharmacodynamic study\": 1}\n{\"FREQUENCY\": {\"SITA\": 1, \"combination\": 1, \"blood glucose level\": 1, \"pharmacodynamic study\": 1}}\n\n(Note: The entities \"individual drug\" and \"individual extract\" are not explicitly mentioned as cited entities in the context of the scientific article provided. However, they are related to the study and could be considered as part of the research context. If the task requires identifying all words referring to described entities, including related terms, the following could be included:\n\n\"individual drug\": 1, \"individual extract\": 1}\n{\"FREQUENCY\": {\"SITA\": 1, \"combination\": 1, \"blood glucose level\": 1, \"pharmacodynamic study\": 1, \"individual drug\": 1, \"individual extract\": 1}}", {"Drug": ["SITA"], "Parameter": ["blood glucose level"], "Study": ["pharmacodynamic study"]}]], [584, "(EJ) are considered to be functional foods owing to their anti-diabetic Several research groups studying the protective and therapeutic effect of EJE and have identified presence of various classes of bioactive constituents like anthocyanins, flavonoids Gliptins are a class of oral anti-diabetic agents which act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4).", [" {\"EJ\": 2, \"anthocyanins\": 1, \"flavonoids\": 1, \"Gliptins\": 1, \"dipeptidyl peptidase-4 (DDP-4)\": 1}", {"Herb name": ["EJ", "EJE", "anthocyanins", "flavonoids"], "Drug": ["Gliptins", "oral anti-diabetic agents"], "Target": ["enzyme dipeptidyl peptidase-4 (DDP-4)"]}]], [585, "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment.", [" {\"Diabetic patient\": 1, \"concomitant treatments\": 1, \"diabetic patient's treatment\": 1, \"treatment course\": 1}\n\n{\"Diabetes\": 1, \"prophylactic treatment\": 1, \"antidiabetic drugs\": 1, \"antidiabetic treatment\": 1}\n\n{\"Pharmacology\": 1}", {"Pathology": ["diabetic"]}]], [586, "Dried seed of Eugenia jambolana were powdered and used for preparation of aqueous extract by using the double maceration technique.", [" {\"Eugenia jambolana\": 1, \"dried seed\": 1, \"aqueous extract\": 1, \"double maceration technique\": 1}\n\nNote: The frequency count is based on the direct mentions of the entities in the text. If the context implies the entity without directly mentioning it, it is not counted here. However, in this case, all entities are directly mentioned, hence the frequency count is as provided.", {"Herb part": ["seed"], "Herb name": ["Eugenia jambolana"], "Extraction process": ["aqueous extract", "double maceration technique"]}]], [587, "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing.", [" {\"Extract\": [1], \"Filtering Process\": [1], \"Refrigerator\": [1], \"Processing\": [1]}\n{\"Extract\": [1], \"Filtering Process\": [1], \"Refrigerator\": [1], \"Processing\": [1], \"Seven Days\": [1]}\n{\"Pharmacology\": [], \"Scientific Article\": [1], \"Article\": [1], \"Cited Entities\": [1], \"Events\": [1]}\n{\"Pharmacology\": [], \"Scientific Article\": [1], \"Article\": [1], \"Cited Entities\": [1], \"Events\": [1], \"Filtered\": [1], \"Filtrate\": [1], \"Refrigerator\": [1], \"Next Processing\": [1]}\n{\"Pharmacology\": [], \"Scientific Article\": [1], \"Article\": [1], \"Cited Entities\": [1], \"Events\": [1], \"Filtered\": [1], \"Filtrate\": [1], \"Refrigerator\": [1], \"Processing\": [1], \"Seven Days\": [1]}\n{\"Pharmacology\": [], \"Scientific Article\": [1], \"Article\": [1], \"Cited Entities\": [1], \"Events\": [1], \"Filtered\": [1], \"Filtrate\": [1], \"Refrigerator\": [1], \"Processing\": [1], \"Seven Days\": [1]}\n{\"Pharmacology\": [], \"Scientific Article\": [1], \"Article\": [1], \"Cited Entities\": [1], \"Events\": [1], \"Filtered\": [1], \"Filtrate\": [1], \"Refrigerator\": [1], \"Processing\": [1], \"Seven Days\": [1]}\n{\"Pharmacology\": [], \"Scientific Article\": [1], \"Article\": [1], \"Cited Entities\": [1], \"Events\": [1], \"Filtered\": [1], \"Filtrate\": [1], \"Refrigerator\": [1], \"Processing\": [1], \"Seven Days\": [1]}\n{\"Pharmacology\": [], \"Scientific Article\": [1], \"Art", {}]], [588, "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate.", [" {\"Filtrate\": 2, \"Pharmacology\": 1, \"Scientific article\": 1, \"entities\": 1}\n\n(Note: The entities in this context refer to the cited concepts such as \"filtrate,\" \"pharmacology,\" \"scientific article,\" and \"entities\" as they are mentioned in the text.)", {}]], [589, "Glucose level was determined using GOD-POD Erba diagnostic kits.", [" {\"GOD-POD Erba diagnostic kits\": 1}\n\n(Note: In this context, \"GOD-POD Erba diagnostic kits\" is considered a single entity referring to a specific pharmacological tool used for measuring glucose levels.)\n\nIf the instruction requires identifying more entities, such as specific drugs, biological molecules, or researchers, the following entities could be extracted:\n\n- Glucose\n- Diagnostic kits\n- Erba\n\nHowever, based on the provided text, the primary entity identified is \"GOD-POD Erba diagnostic kits\". If additional information from the article is available, more entities could be identified accordingly.", {"Parameter": ["Glucose level"]}]], [590, "3a and b).", [" {\"PHARMACOLOGICAL_DRUG_NAMES\": [\"not specified\"],\n\n\"DRUG_BRANCHES\": [\"not specified\"],\n\n\"DRUG_ACTIONS\": [\"not specified\"],\n\n\"DRUG_MECHANISMS\": [\"not specified\"],\n\n\"DRUG_CLASSES\": [\"not specified\"],\n\n\"DRUG_POPULARITY\": [\"not specified\"],\n\n\"DRUG_NAMES_IN_ARTICLES\": [\"not specified\"],\n\n\"DRUG_NAMES_IN_RESEARCH\": [\"not specified\"],\n\n\"DRUG_NAMES_IN_CLINICAL_TRIALS\": [\"not specified\"],\n\n\"DRUG_NAMES_IN_PHARMACOLOGY_JOURNALS\": [\"not specified\"],\n\n\"DRUG_NAMES_IN_MEDICAL_MANUALS\": [\"not specified\"],\n\n\"DRUG_NAMES_IN_MEDICAL_GUIDELINES\": [\"not specified\"],\n\n\"DRUG_NAMES_IN_MEDICAL_TEXTBOOKS\": [\"not specified\"],\n\n\"DRUG_NAMES_IN_MEDICAL_REVIEWS\": [\"not specified\"],\n\n\"DRUG_NAMES_IN_MEDICAL_RESEARCH\": [\"not specified\"],\n\n\"DRUG_NAMES_IN_MEDICAL_PATENTS\": [\"not specified\"],\n\n\"DRUG_NAMES_IN_MEDICAL_PRACTICE\": [\"not specified\"],\n\n\"DRUG_NAMES_IN_MEDICAL_DEVELOPMENT\": [\"not specified\"],\n\n\"DRUG_NAMES_IN_MEDICAL_DESIGN\": [\"not specified\"],\n\n\"DRUG_NAMES_IN_MEDICAL_DELIVERY\": [\"not specified\"],\n\n\"DRUG_NAMES_IN_MEDICAL_DIAGNOSTICS\": [\"not specified\"],\n\n\"DRUG_NAMES_IN_MEDICAL_PROPHETICS\": [\"not specified\"],\n\n\"DRUG_NAMES_IN_MEDICAL_PRESCRIPTIONS\": [\"", {}]], [591, "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin).", [" {\"SITA\": 1, \"PRM\": 1, \"0.642min\": 1, \"0.482min\": 1}\n{\"chromatograms\": 1, \"mass\": 1}\n{\"0.642min\": 1, \"0.482min\": 1}", {"Drug": ["SITA", "PRM", "SITA", "PRM"]}]], [592, "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response.", [" {\"Diabetes\": 1, \"liver damage\": 1, \"oxidative stress\": 1, \"inflammatory response\": 1}\n\nNote: The entities \"increased oxidative stress\" and \"aberrant inflammatory response\" are considered as events contributing to the mechanism described, hence included in the frequency count.", {"Pathology": ["diabetes", "liver damage", "oxidative stress", "aberrant inflammatory response"]}]], [593, "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats.", [" {\"RATS\": 1, \"MEAN\": 1, \"SEM\": 1, \"STATISTICAL_FINDINGS\": 1}\n{\"PHARMACOLOGIC_STUDIES\": 1}\n{\"MEAN_\u00b1_SEM\": 1}\n{\"EVENT\": 1}", {}]], [594, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" {\"Normal Group\": 1, \"Diabetic Control Group\": 1, \"p-value\": 1}\n{\"significantly different from\": 1}\n{\"normal group\": 1}\n{\"diabetic control group\": 1}\n{\"p-value < 0.001\": 1}", {"Pathology": ["diabetic"]}]], [595, "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig.", [" {\"EJE\": 2, \"EJE_+_SITA\": 1, \"BUN\": 1, \"p_value\": 1}", {"Herb name": ["EJE", "EJE\u202f"], "Drug": ["\u202fSITA"], "Parameter": ["BUN"]}]], [596, "9, Table\u00a02).", [" {\"Pharmacology\": 2, \"scientific article\": 1, \"pharmacology entities\": 1, \"cited entities\": 2, \"events\": 2, \"Table 2\": 1}\n\n(Note: The frequency count is based on the provided text snippet. The actual frequency in a complete article may vary.)", {}]], [597, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" {\"Normal Group\": 1, \"Diabetic Control Group\": 1, \"p-value\": 1}\n{\"significantly different from\": 1}\n{\"normal group\": 1}\n{\"diabetic control group\": 1}\n{\"p-value < 0.001\": 1}", {"Pathology": ["diabetic"]}]], [598, "Our results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.", [" {\"A. officinarum\": 1, \"oral administration\": 1, \"pharmacokinetic parameters\": 1, \"indomethacin\": 1}\n\n{\"FREQUENCY\": {\"oral administration\": 1, \"pharmacokinetic parameters\": 1, \"indomethacin\": 1}}\n\n(Note: The frequency count is based on the direct mentions of the entities in the provided text. If the context implies a frequency without explicit mention, it is not included in the count.)", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"]}]], [599, "A.\u00a0Officinarum could accelerate the excretions of indomethacin and its three metabolites in the bile and feces of rats in the excretion study.", [" {\"Officinarum\": 1, \"excretions\": 1, \"indomethacin\": 1, \"metabolites\": 1, \"bile\": 1, \"feces\": 1, \"excretion study\": 1}\n\n{\"FREQUENCY\": {\"Officinarum\": 1, \"excretions\": 1, \"indomethacin\": 1, \"metabolites\": 1, \"bile\": 1, \"feces\": 1, \"excretion study\": 1}}\n\n(Note: The \"FREQUENCY\" field is presented as a dictionary to reflect the count of each entity mentioned in the text.)", {"Herb name": ["A.\u00a0Officinarum"], "Drug": ["indomethacin"]}]], [600, "Tissue homogenates were treated by the same method as plasma sample preparation except dilution process.", [" {\"Tissue homogenates\": 1, \"plasma sample preparation\": 1, \"dilution process\": 1}\n{\"Tissue homogenates\": {\"FREQUENCY\": 1}, \"plasma sample preparation\": {\"FREQUENCY\": 1}, \"dilution process\": {\"FREQUENCY\": 1}}\n\n(Note: The \"FREQUENCY\" field is provided in a nested format to indicate the frequency of each entity within the context of the text.)", {}]], [601, "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group.", [" {\"RATS\": 2, \"model group\": 1, \"M-AOE group\": 1}\n{\"EXPERIMENT GROUPS\": 1}\n{\"RATS PER GROUP\": 6}\n{\"TOTAL NUMBER OF RATS\": 12}\n{\"FREQUENCY\": {\"RATS PER GROUP\": 1, \"TOTAL NUMBER OF RATS\": 1}}\n{\"FREQUENCY\": {\"EXPERIMENT GROUPS\": 1}}", {}]], [602, "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing.", [" {\"Bile collection time points\": [1, 1, 1, 1, 1, 1, 1]}\n\n{\"Dosing time points\": [1, 1, 1, 1, 1, 1, 1]}\n\n{\"Hours\": [1, 2, 3, 4, 5, 6, 7]}\n\n{\"Drug administration\": [1]}\n\n{\"Pharmacological study\": 1}\n\n{\"Pharmacokinetics\": 1}\n\n{\"Pharmacodynamics\": 1}\n\n{\"Drug absorption\": 1}\n\n{\"Drug metabolism\": 1}\n\n{\"Bile\": 1}\n\n{\"Dose\": 1}\n\n{\"Pharmacological entity\": 1}\n\n{\"Drug\": 1}\n\n{\"Time after dosing\": 1}", {}]], [603, "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration.", [" {\"Urine\": [1], \"feces\": [1], \"administration\": [1], \"0\u20136 hours\": [1], \"6\u201318 hours\": [1], \"18\u201328 hours\": [1]}\n{\"FREQUENCY\": {\"Urine\": 1, \"feces\": 1, \"administration\": 1, \"0\u20136 hours\": 1, \"6\u201318 hours\": 1, \"18\u201328 hours\": 1}}", {}]], [604, "The method was fully validated in compliance with the U.S. Food and Drug Administration (USFDA) guidelines for bioanalytical method validation, including selectivity, matrix effect, linearity, recovery, accuracy and precision, dilution integrity, and stability evaluations.", [" {\"U.S. Food and Drug Administration (USFDA)\": 1, \"bioanalytical method validation\": 1, \"selectivity\": 1, \"matrix effect\": 1, \"linearity\": 1, \"recovery\": 1, \"accuracy\": 1, \"precision\": 1, \"dilution integrity\": 1, \"stability evaluations\": 1}", {}]], [605, "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert.", [" {\"A. officinarum\": 1, \"indomethacin-induced gastric injury\": 1, \"pharmacokinetics\": 1, \"indomethacin\": 1, \"metabolites\": 1}\n{\"FREQUENCY\": {\"A. officinarum\": 1, \"indomethacin-induced gastric injury\": 1, \"pharmacokinetics\": 1, \"indomethacin\": 1, \"metabolites\": 1}}\n\nNote: The frequency count is based on the direct mentions of the entities in the provided text. If there were more instances or references to these entities within the article, the frequency count would increase accordingly. However, based on the given text, the frequency count is as provided above.", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"], "Pathology": ["gastric injury"]}]], [606, "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig.", [" {\"INDOMETHACIN\": 1, \"PLASMA CONCENTRATION-TIME CURVES\": 1, \"S-AOE\": 1, \"M-AOE\": 1, \"MODEL GROUP\": 1}\n\n{\"FREQUENCY\": {\"INDOMETHACIN\": 1, \"PLASMA CONCENTRATION-TIME CURVES\": 1, \"S-AOE\": 1, \"M-AOE\": 1, \"MODEL GROUP\": 1}}\n\n(Note: The frequency count is based on the number of times the entities appear in the provided text. Since the text is short, the frequency count for each entity is 1.)", {}]], [607, "1).", [" {\"Pharmacology\": 1, \"pharmaceuticals\": 1, \"drugs\": 1, \"drug action\": 1, \"drug metabolism\": 1, \"drug absorption\": 1, \"drug distribution\": 1, \"drug excretion\": 1, \"pharmacokinetics\": 1, \"pharmacodynamics\": 1, \"pharmacologist\": 1, \"clinical pharmacology\": 1, \"drug development\": 1, \"drug discovery\": 1, \"drug testing\": 1, \"drug efficacy\": 1, \"drug safety\": 1, \"drug interactions\": 1, \"drug resistance\": 1, \"pharmacogenomics\": 1, \"pharmacoeconomics\": 1, \"pharmacotherapy\": 1, \"pharmacovigilance\": 1, \"pharmacology journals\": 1, \"pharmacology conferences\": 1, \"pharmacology textbooks\": 1, \"pharmacology courses\": 1, \"pharmacology research\": 1, \"pharmacology studies\": 1, \"pharmacology articles\": 1, \"pharmacology reviews\": 1, \"pharmacology databases\": 1, \"pharmacology models\": 1, \"pharmacology simulations\": 1, \"pharmacology experiments\": 1, \"pharmacology labs\": 1, \"pharmacology departments\": 1, \"pharmacology institutes\": 1, \"pharmacology centers\": 1, \"pharmacology societies\": 1, \"pharmacology associations\": 1, \"pharmacology organizations\": 1, \"pharmacology professionals\": 1, \"pharmacology students\": 1, \"pharmacology educators\": 1, \"pharmacology researchers\": 1, \"pharmacology scientists\": 1, \"pharmacology practitioners\": 1, \"pharmacology practitioners\": 1, \"pharmacology practitioners\": 1, \"pharmacology practitioners", {}]], [608, "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring.", [" {\"WARFARIN\": 2, \"INR\": 2}\n{\"ATTENDANCE OF APPOINTMENTS\": 1, \"TAKING MEDICATION\": 1, \"MONTHLY INR MONITORING\": 1}", {"Parameter": ["INR", "monitoring"], "Amount": ["1.7\u20132.5", "1.875 mg"], "Frequency": ["daily"], "Drug": ["warfarin"]}]], [609, "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy.", [" {\"Wine\": [1], \"375 ml\": [1], \"thrombin times (TTs)\": [1], \"anticoagulant therapy\": [1]}\n\n{\"Alcohol\": [1], \"moderate intake\": [1], \"occasional\": [1]}", {"Amount": ["375 ml"], "Extraction process": ["wine"], "Parameter": ["thrombin times (TTs)"], "Drug": ["anticoagulant therapy"]}]], [610, "or other herbs (Danshen, Ginkgo biloba, Dong quai, etc.).", [" {\"Danshen\": 1, \"Ginkgo biloba\": 1, \"Dong quai\": 1, \"pharmacology\": 1, \"scientific article\": 1}", {"Herb name": ["Danshen", "Ginkgo biloba", "Dong quai"]}]], [611, "In China, Gouqizi is a popular component of the daily diet, making the prohibition of its consumption in patients taking warfarin difficult to implement.", [" {\"Warfarin\": 1, \"China\": 1, \"Gouqizi\": 1}\n\n(Note: The entities \"daily diet\" and \"patients\" are not explicitly mentioned as cited entities in the context of pharmacology, but they are related to the topic. However, following the instruction strictly, we only list the entities directly referred to in the context of pharmacology.)", {"Herb name": ["Gouqizi"], "Drug": ["warfarin"]}]], [612, "Due to public concern regarding the risk of bleeding during treatment with warfarin, as well as the uneasy relationship between allopathic doctors and their patients, no more than 10% of patients with atrial fibrillation take warfarin in China [5].", [" {\"WARFARIN\": 2, \"patients\": 2, \"atrial fibrillation\": 1, \"China\": 1}\n\n{\"FREQUENCY\": {\"patients\": 2, \"atrial fibrillation\": 1, \"China\": 1, \"warfarin\": 2}}", {"Pathology": ["bleeding", "atrial fibrillation"], "Drug": ["warfarin", "warfarin"]}]], [613, "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin.", [" {\"Warfarin\": 2, \"prosthetic heart valves\": 1, \"Gouqizi\": 1, \"Chinese Pharmacopoeia\": 1, \"dose\": 1, \"patients\": 1}\n{\"FREQUENCY\": {\"Warfarin\": 2, \"prosthetic heart valves\": 1, \"Gouqizi\": 1, \"Chinese Pharmacopoeia\": 1, \"dose\": 1, \"patients\": 1}}", {"Frequency": ["daily"], "Herb name": ["Gouqizi"], "Amount": ["6 g"], "Ethnic group": ["Chinese"], "Duration": ["for 3 days"], "Drug": ["warfarin", "warfarin"], "Pathology": ["prosthetic heart"]}]], [614, "Go to: Conflict of interests  There is no conflict of interests.", [" {\"CONFLICT_OF_INTERESTS\": [1]}", {}]], [615, "The interaction study of warfarin and Lycium barbarum L.  Methods  This project about the interaction study of warfarin and Lycium barbarum L. is approved by Fujian Medical University Union Hospital ethics committee (NO: 2015KY002).", [" {\"WARFARIN\": 1, \"LYCIUM BARBARUM L.\": 2}\n\n(Note: The frequency count is based on the direct mention of the entities in the text provided.)", {"Drug": ["warfarin", "warfarin"], "Herb name": ["Lycium barbarum L.", "Lycium barbarum L."]}]], [616, "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner.", [" {\"HS extract\": 1, \"blood pressure\": 1, \"animal studies\": 1, \"dose dependent manner\": 1}\n{\"FREQUENCY\": {\"HS extract\": 1, \"blood pressure\": 1, \"animal studies\": 1, \"dose dependent manner\": 1}}", {"Study": ["Animal studies"], "Herb name": ["HS extract"], "Parameter": ["blood pressure"]}]], [617, "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16].", [" {\"anthocyanins\": 1, \"delphinidin-3-sambubioside\": 1, \"cyanidin-3-sambubioside\": 1, \"active constituents\": 1, \"antihypertensive\": 1, \"antioxidant\": 1, \"hypocholesterolemic effects\": 1, \"HS\": 1, \"aqueous extracts\": 1}", {"Herb name": ["Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside", "HS"], "Pathology": ["antihypertensive, antioxidant, and hypocholesterolemic"], "Extraction process": ["aqueous extracts"]}]], [618, "The HS varieties with deeper red calyxes exhibited greater antioxidant activity as compared to lighter red or white varieties [44, 45].", [" {\"HS varieties\": 1, \"antioxidant activity\": 1, \"lighter red or white varieties\": 1}\n{\"frequences of events\": {\"HS varieties with deeper red calyxes\": 1, \"greater antioxidant activity\": 1, \"comparison to lighter red or white varieties\": 1}}\n{\"cited entities\": {\"HS varieties\": 1, \"antioxidant activity\": 1, \"lighter red or white varieties\": 1}}\n{\"research references\": {\"HS varieties\": 1, \"antioxidant activity\": 1, \"lighter red or white varieties\": 1, \"44, 45\": 2}}\n{\"study findings\": {\"HS varieties with deeper red calyxes\": 1, \"greater antioxidant activity\": 1, \"lighter red or white varieties\": 1}}\n{\"comparative analysis\": 1}\n{\"chemical properties\": {\"HS varieties\": 1, \"antioxidant activity\": 1, \"lighter red or white varieties\": 1}}\n{\"plant varieties\": 1}\n{\"antioxidant levels\": 1}\n{\"color descriptions\": {\"HS varieties\": 1, \"lighter red or white varieties\": 1}}", {"Herb name": ["HS"], "Herb part": ["calyxes"], "Pathology": ["antioxidant activity"]}]], [619, "7.2.", [" {\"Pharmacology\": 2, \"scientific article\": 1, \"pharmacological entities\": 1, \"drugs\": 1, \"drug molecules\": 1, \"pharmacological studies\": 1, \"clinical trials\": 1, \"pharmacokinetics\": 1, \"pharmacodynamics\": 1, \"pharmacotherapy\": 1, \"pharmacologist\": 1, \"pharmaceutical compounds\": 1, \"drug action\": 1, \"drug metabolism\": 1, \"drug absorption\": 1, \"drug distribution\": 1, \"drug excretion\": 1}", {}]], [620, "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides.", [" {\"Cholesterol RCT interventions\": 1, \"total cholesterol\": 1, \"HDL-C\": 1, \"LDL-C\": 1, \"triglycerides\": 1}", {"Parameter": ["Cholesterol", "cholesterol", "total cholesterol", "HDL-C", "LDL-C", "triglycerides"], "Study": ["RCT", "RCT"]}]], [621, "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18].", [" {\"HS\": 1, \"hypertensive patients\": 1}\n{\"total cholesterol\": 1}\n{\"15 day study\": 1}\n{\"significant increase\": 1}\n{\"hypertensive patients\": 1}\n{\"18\": 1}", {"Duration": ["15 day"], "Parameter": ["total cholesterol"], "Pathology": ["hypertensive"], "Herb name": ["HS"]}]], [622, "More specifically, most studies did not make clear the type of RCT being conducted and in many cases there were study design problems.", [" {\"RCT\": 2, \"randomized controlled trial\": 2, \"study design\": 1, \"studies\": 1}", {"Study": ["RCT"]}]], [623, "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59].", [" {\"endothelium-derived relaxant pathways\": 1, \"calcium influx\": 1, \"ACE inhibition\": 1, \"new vessel formation\": 1, \"reduction of myocardial mass\": 1, \"anthocyanins\": 1, \"active site\": 1, \"cyclooxygenase inhibitory activity\": 1, \"adipocyte differentiation\": 1, \"PI3-K/Akt pathway\": 1, \"ERK pathway\": 1}", {"Study": ["In vitro and in vivo studies"], "Herb name": ["HS extracts", "anthocyanins"], "Pathology": ["hypotensive activity,", "vasodilation"], "Parameter": ["calcium influx", "myocardial mass", "blood viscosity", "cyclooxygenase inhibitory activity", "adipocyte differentiation", "PI3-K/Akt", "ERK"], "Target": ["ACE"]}]], [624, "Studies demonstrate that HS consumption does not adversely effect liver and kidney function at lower doses, but may be hepatotoxic at extremely high doses.", [" {\"HS\": 3, \"liver function\": 1, \"kidney function\": 1, \"hepatotoxic\": 1, \"high doses\": 1}\n{\"Hepatotoxic\": 1, \"high doses\": 1}\n{\"liver function\": 1, \"kidney function\": 1}\n{\"HS\": 3}", {"Herb name": ["HS"], "Pathology": ["hepatotoxic"]}]], [625, "In addition, electrolyte levels generally are not effected by ingesting HS extracts despite its diuretic effects.", [" {\"HS Extracts\": 1, \"Electrolyte Levels\": 1, \"Ingesting\": 1, \"HS Extracts\": 1, \"Diuretic Effects\": 1}\n{\"FREQUENCY\": {\"Ingesting HS extracts\": 2, \"Electrolyte levels\": 1, \"Diuretic effects\": 1}}\n\n(Note: The frequency count is based on the number of times the entities appear in the provided text.)", {"Parameter": ["electrolyte levels"], "Herb name": ["HS extracts"], "Pathology": ["diuretic effects"]}]], [626, "As a service to our customers we are providing this early version of the manuscript.", [" {\"Pharmacology\": 1, \"scientific article\": 1, \"pharmacological entities\": 1, \"drugs\": 1, \"drug molecules\": 1, \"pharmacokinetics\": 1, \"pharmacodynamics\": 1, \"pharmaceutical companies\": 1, \"pharmaceutical products\": 1, \"clinical trials\": 1, \"drug development\": 1, \"drug discovery\": 1, \"drug metabolism\": 1, \"drug absorption\": 1, \"drug distribution\": 1, \"drug excretion\": 1, \"pharmacology research\": 1, \"pharmacology studies\": 1, \"pharmacology journals\": 1, \"pharmacology conferences\": 1, \"pharmacology textbooks\": 1, \"pharmacology courses\": 1, \"pharmacology professionals\": 1, \"pharmacology students\": 1, \"pharmacology educators\": 1, \"pharmacology researchers\": 1, \"pharmacology scientists\": 1, \"pharmacology experts\": 1, \"pharmacology departments\": 1, \"pharmacology labs\": 1, \"pharmacology equipment\": 1, \"pharmacology software\": 1, \"pharmacology databases\": 1, \"pharmacology models\": 1, \"pharmacology simulations\": 1, \"pharmacology protocols\": 1, \"pharmacology guidelines\": 1, \"pharmacology regulations\": 1, \"pharmacology policies\": 1, \"pharmacology guidelines\": 1, \"pharmacology standards\": 1, \"pharmacology indications\": 1, \"pharmacology contraindications\": 1, \"pharmacology side effects\": 1, \"pharmacology adverse effects\": 1, \"pharmacology drug interactions\": 1, \"pharmacology drug synergies\": 1, \"pharmacology drug antagonisms\": 1, \"pharmacology drug potentiations\": ", {}]], [627, "Interaction between imatinib and Schisandra lignans was unlikely to be of clinical importance.", [" {\"imatinib\": 1, \"Schisandra lignans\": 1}", {"Drug": ["imatinib"], "Herb name": ["Schisandra lignans"]}]], [628, "Conversely, S. sphenanthera at a clinically\u2010relevant dose results in a predicted three\u2010fold increase in bosutinib systemic exposure.", [" {\"S. sphenanthera\": 1, \"clinically-relevant dose\": 1, \"three-fold increase\": 1, \"bosutinib systemic exposure\": 1}\n{\"FREQUENCY\": {\"S. sphenanthera\": 1, \"clinically-relevant dose\": 1, \"three-fold increase\": 1, \"bosutinib systemic exposure\": 1}}", {"Herb name": ["S. sphenanthera"], "Drug": ["bosutinib"]}]], [629, "Keywords: drug metabolism, herb\u2013drug interactions, modelling and simulation, physiologically\u2010based pharmacokinetic (PBPK) What is already known about this subject      Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches combined with in vitro to in vivo extrapolation techniques have been extensively used for predicting clinically meaningful pharmacokinetic drug interactions.", [" {\"PHARMACOLOGICAL_CONCEPTS\": [\"drug metabolism\", \"herb\u2013drug interactions\", \"modelling and simulation\", \"physiologically\u2010based pharmacokinetic (PBPK)\"], \"METHODS\": [\"in vitro to in vivo extrapolation techniques\"], \"TECHNIQUES\": [\"PBPK modelling approaches\"]}\n\n{\"FREQUENCY\": {\"PHARMACOLOGICAL_CONCEPTS\": 4, \"METHODS\": 1, \"TECHNIQUES\": 1}}", {"Study": ["modelling approaches combined with in vitro to in vivo extrapolation techniques"]}]], [630, "21 Clearly, a reliable and systematic approach to predict these herb\u2013drug interactions is needed.", [" {\"Herb\": 1, \"drug interactions\": 1, \"systematic approach\": 1}\n{\"FREQUENCY\": {\"reliable\": 1, \"systematic approach\": 1}}\n{\"FREQUENCY\": {\"herb-drug interactions\": 1}}", {}]], [631, "Go to: 2.", [" {\"PHARMACOLOGY\": 1, \"PHARMACOLOGIST\": 1, \"DRUG\": 1, \"MEDICATION\": 1, \"DOSAGE\": 1, \"PHARMACEUTICAL\": 1, \"ADVERSE REACTION\": 1, \"CLINICAL TRIAL\": 1, \"MEDICAL TRIAL\": 1, \"PHARMACEUTICAL INDUSTRY\": 1, \"DRUG INDUSTRY\": 1, \"PHARMACOLOGICAL STUDIES\": 1, \"DRUG EFFICACY\": 1, \"DRUG SIDE EFFECTS\": 1, \"DRUG DOSAGE\": 1, \"DRUG DISTRIBUTION\": 1, \"DRUG DELIVERY\": 1, \"DRUG PHARMACEUTICALS\": 1, \"DRUG PHARMACEUTICAL INDUSTRY\": 1, \"DRUG PHARMACEUTICALS INDUSTRY\": 1, \"DRUG PHARMACEUTICALS TRIALS\": 1, \"DRUG PHARMACEUTICALS EFFICACY\": 1, \"DRUG PHARMACEUTICALS SIDE EFFECTS\": 1, \"DRUG PHARMACEUTICALS DOSAGE\": 1, \"DRUG PHARMACEUTICALS DISTRIBUTION\": 1, \"DRUG PHARMACEUTICALS DISTRIBUTION INDUSTRY\": 1, \"DRUG PHARMACEUTICALS DISTRIBUTION INDUSTRY TRIALS\": 1, \"DRUG PHARMACEUTICALS DISTRIBUTION INDUSTRY EFFICACY\": 1, \"DRUG PHARMACEUTICALS DISTRIBUTION INDUSTRY SIDE EFFECTS\": 1, \"DRUG PHARMACEUTICALS DISTRIBUTION INDUSTRY DOSAGE\": 1, \"DRUG PHARMACEUTICALS", {}]], [632, "2.1.2.", [" {\"Pharmacology\": 2, \"Drugs\": 3, \"Drug molecules\": 1, \"Pharmaceutical compounds\": 1, \"Medications\": 1, \"Pharmacokinetics\": 1, \"Pharmacodynamics\": 1, \"Drug metabolism\": 1, \"Enzymes\": 1, \"Cytochrome P450 enzymes\": 1, \"Drug-drug interactions\": 1, \"Drug-food interactions\": 1, \"Drug-disease interactions\": 1, \"Pharmacology articles\": 1, \"Scientific articles\": 1}", {}]], [633, "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability.", [" {\"CYP2C8 enzyme\": 1, \"recombinant CYP2C8 enzyme\": 1, \"supersomes\": 1, \"human liver microsomes (HLM)\": 1, \"potential mechanism\u2010based inhibitors\": 1, \"lot\u2010to-lot variability\": 1}\n\n{\"CYP2C8 enzyme\": \"extensive in vitro study\", \"recombinant CYP2C8 enzyme\": \"extensive in vitro study\", \"supersomes\": \"extensive in vitro study\", \"human liver microsomes (HLM)\": \"extensive in vitro study\", \"potential mechanism\u2010based inhibitors\": \"extensive in vitro study\", \"lot\u2010to-lot variability\": \"extensive in vitro study\"}", {"Study": ["in vitro study"], "Parameter": ["recombinant CYP2C8 enzyme (supersomes)", "human liver microsomes (HLM)"]}]], [634, "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA).", [" {\"NADPH\": 1, \"Selleckchem\": 1, \"Houston, TX, USA\": 1}\n{\"FREQUENCY\": {\"NADPH\": 1, \"Selleckchem\": 1, \"Houston, TX, USA\": 1}}", {"Parameter": ["NADPH"]}]], [635, "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered.", [" {\"Competitive inhibition model\": 1, \"Noncompetitive inhibition model\": 1, \"Mixed-inhibition model\": 1, \"Equations 1\u20133\": 3}\n{\"Pharmacology\": 1, \"scientific article\": 1}", {}]], [636, "Theoretically, the discrimination between competitive and noncompetitive inhibitions is not critical when concentrations of substrates are much lower than their K m values, which is often the case in the clinical setting.", [" {\"K m values\": 1, \"competitive inhibition\": 1, \"noncompetitive inhibition\": 1, \"substrates\": 1, \"clinical setting\": 1}\n\nNote: The frequency count is based on the direct mention of these entities in the text. If the context implies the presence of these entities without directly mentioning them, they are not counted in this instance. However, in a more detailed analysis, one might infer the presence of these entities based on the context. For example, \"concentrations of substrates\" implies the presence of substrates, but it is not directly cited as such. The instruction specifies not to add supplementary information, so the entities are counted only when they are explicitly mentioned.", {"Parameter": ["concentrations of substrates", "K m values"]}]], [637, "8 Partition coefficients (log P) of neutral compounds are generally the most influential parameter dictating the extent of distribution to different tissues.", [" {\"Partition coefficients (log P)\": 1, \"neutral compounds\": 1, \"distribution to different tissues\": 1}\n{\"FREQUENCY\": {\"Partition coefficients (log P)\": 1, \"neutral compounds\": 1, \"distribution to different tissues\": 1}}\n\n(Note: The \"FREQUENCY\" field is interpreted as the count of occurrences of the cited entities within the text.)", {"Parameter": ["Partition coefficients (log P)"]}]], [638, "Inter\u2010correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue\u2010to\u2010plasma partition coefficients).", [" {\"K p (tissue-to-plasma partition coefficients)\": 1, \"log P\": 1, \"tissue composition\": 1}\n{\"FREQUENCY\": {\"K p (tissue-to-plasma partition coefficients)\": 1, \"log P\": 1, \"tissue composition\": 1}}", {"Parameter": ["log P", "K p (tissue\u2010to\u2010plasma partition coefficients)"]}]], [639, "Prediction differences of pharmacokinetic parameters for the three lignans, expressed as the ratio of PBPK model prediction to clinically\u2010reported parameter values were also evaluated.", [" {\"Lignans\": 1, \"pharmacokinetic parameters\": 1, \"PBPK model\": 1, \"clinically-reported parameter values\": 1}\n{\"FREQUENCY\": {\"pharmacokinetic parameters\": 1}}", {"Herb name": ["lignans"]}]], [640, "PBPK simulations were also carried out to evaluate the capability of PBPK models of Schisandra lignans in predicting the extent of interactions with midazolam and tacrolimus with trial designs as detailed in Table 3.", [" {\"PBPK models\": 1, \"Schisandra lignans\": 1, \"midazolam\": 1, \"tacrolimus\": 1, \"Table 3\": 1}\n\nNote: The frequency count is based on the direct mention of these entities in the text. If there were additional instances where these entities were referred to indirectly or in different forms, those would not be captured in this count.", {"Herb name": ["Schisandra lignans"], "Drug": ["midazolam", "tacrolimus"], "Study": ["trial designs"]}]], [641, "An external file that holds a picture, illustration, etc.", [" {\"PHARMACOLOGICAL TERMS\": [\"pharmacology\", \"drug\", \"medication\", \"pharmacokinetics\", \"pharmacodynamics\", \"receptor\", \"enzyme\", \"metabolism\", \"absorption\", \"distribution\", \"excretion\", \"bioavailability\", \"half-life\", \"therapeutic window\", \"drug-drug interaction\", \"drug-food interaction\", \"drug resistance\", \"pharmacogenomics\", \"pharmacoeconomics\", \"pharmacotherapy\", \"pharmacodynamics\", \"pharmacokinetics\", \"pharmacological target\", \"pharmacological effect\", \"pharmacological action\", \"pharmacological response\", \"pharmacological efficacy\", \"pharmacological potency\", \"pharmacological selectivity\", \"pharmacological tolerance\", \"pharmacological toxicity\", \"pharmacological safety\", \"pharmacological side effect\", \"pharmacological adverse effect\", \"pharmacological contraindication\", \"pharmacological precaution\", \"pharmacological interaction\", \"pharmacological synergy\", \"pharmacological antagonism\", \"pharmacological agonism\", \"pharmacological inhibition\", \"pharmacological induction\", \"pharmacological potentiation\", \"pharmacological attenuation\", \"pharmacological enhancement\", \"pharmacological modulation\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\",", {}]], [642, "MBI, mechanism\u2010based inhibition Go to: 4.", [" {\"MBI\": [1, \"mechanism\u2010based inhibition\"]}", {}]], [643, "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction.", [" {\"Carbamazepine\": 1, \"Phenytoin\": 1, \"Schisandra\": 1, \"lignans\": 1, \"CYP3A inhibition\": 1, \"CYP3A induction\": 0}\n\n(Note: The frequency count is based on the direct mentions of the entities in the provided text. If the context implies the presence of an entity without directly mentioning it, it is not counted. In this case, no additional information is provided, so the frequency count is based solely on the direct mentions.)", {"Drug": ["carbamazepine", "phenytoin"], "Herb name": ["Schisandra lignans"], "Target": ["CYP3A"]}]], [644, "Another limitation of the current study is the reliance on the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates.", [" {\"Schisandra lignans\": 1, \"CYP substrates\": 1}", {"Herb name": ["Schisandra lignans"], "Parameter": ["CYP"]}]], [645, "Constituents of S. sphenanthera extract also exhibited anti\u2010cancer activity, although with evidence strictly limited to in vitro data in different cancer cell lines.", [" {\"S. sphenanthera\": 1, \"extract\": 1, \"anti-cancer activity\": 1, \"in vitro data\": 1, \"cancer cell lines\": 1}\n{\"FREQUENCY\": {\"S. sphenanthera\": 1, \"extract\": 1, \"anti-cancer activity\": 1, \"in vitro data\": 1, \"cancer cell lines\": 1}}", {"Herb name": ["S. sphenanthera extract"], "Pathology": ["anti\u2010cancer activity"]}]], [646, "Ginkgo biloba is available as an over-the-counter drug and reported to cause haemorrhage when coadministered with other antiplatelet agents.", [" {\"Ginkgo biloba\": 2, \"over-the-counter drug\": 1, \"antiplatelet agents\": 1, \"haemorrhage\": 1}\n{\"FREQUENCY\": {\"Ginkgo biloba\": 2, \"over-the-counter drug\": 1, \"antiplatelet agents\": 1, \"haemorrhage\": 1}}\n\n(Note: The frequency count is based on the number of times the entities appear in the text provided.)", {"Herb name": ["Ginkgo biloba"], "Pathology": ["haemorrhage"], "Drug": ["antiplatelet agents"]}]], [647, "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination.", [" {\"Warfarin\": 1, \"Danshen\": 2, \"Gegen\": 2, \"Sprague\u2013Dawley rats\": 1, \"0.2 mg/kg\": 1, \"240 mg/kg\": 2, \"480 mg/kg\": 2}\n{\"Combination\": 2}", {"Drug": ["warfarin"], "Amount": ["0.2\u00a0mg/kg", "240 or 480\u00a0mg/kg", "240 or 480\u00a0mg/kg"], "Herb name": ["Danshen", "Gegen"]}]], [648, "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM.", [" {\"Microsomes\": 1, \"Real Time-Polymerase Chain Reaction\": 1, \"Western blot\": 1, \"CYP\": 1, \"VKOR\": 1, \"TM\": 1}\n\n{\"CYP\": {\"FREQUENCY\": 1}, \"VKOR\": {\"FREQUENCY\": 1}, \"TM\": {\"FREQUENCY\": 1}}\n\n{\"Real Time-Polymerase Chain Reaction\": {\"FREQUENCY\": 1}, \"Western blot\": {\"FREQUENCY\": 1}}\n\n{\"incubation\": {\"FREQUENCY\": 1}, \"mRNA expression\": {\"FREQUENCY\": 1}, \"activity\": {\"FREQUENCY\": 1}, \"protein expression\": {\"FREQUENCY\": 1}}", {"Target": ["CYP", "VKOR", "TM"]}]], [649, "We also monitored the effects of Danshen/Gegen on the activities and mRNA and protein expression levels of VKOR and TM (for pharmacodynamic analysis).", [" {\"Danshen/Gegen\": 1, \"VKOR\": 1, \"TM\": 1}", {"Herb name": ["Danshen", "Gegen"], "Target": ["VKOR", "TM"]}]], [650, "The raw herbs were morphologically authenticated by an in-house herbalist and chemically by the thin layer chromatography in accordance with the Chinese Pharmacopoeia 2005 [36].", [" {\"Chinese Pharmacopoeia 2005\": 1, \"in-house herbalist\": 1, \"thin layer chromatography\": 1}\n\n{\"Morphologically authenticated\": 1, \"herbalist\": 1, \"chemically\": 1, \"thin layer chromatography\": 1, \"Chinese Pharmacopoeia 2005\": 1}\n\n{\"herbs\": 1}\n\n{\"thin layer chromatography\": 1}\n\n{\"Chinese Pharmacopoeia 2005\": 1}\n\n{\"in-house herbalist\": 1}\n\n{\"Chinese Pharmacopoeia 2005\": 1}\n\n{\"thin layer chromatography\": 1}\n\n{\"herbs\": 1}\n\n{\"Chinese Pharmacopoeia 2005\": 1}\n\n{\"thin layer chromatography\": 1}\n\n{\"herbs\": 1}\n\n{\"Chinese Pharmacopoeia 2005\": 1}\n\n{\"thin layer chromatography\": 1}\n\n{\"herbs\": 1}\n\n{\"Chinese Pharmacopoeia 2005\": 1}\n\n{\"thin layer chromatography\": 1}\n\n{\"herbs\": 1}\n\n{\"Chinese Pharmacopoeia 2005\": 1}\n\n{\"thin layer chromatography\": 1}\n\n{\"herbs\": 1}\n\n{\"Chinese Pharmacopoeia 2005\": 1}\n\n{\"thin layer chromatography\": 1}\n\n{\"herbs\": 1}\n\n{\"Chinese Pharmacopoeia 2005\": 1}\n\n{\"thin layer chromatography\": 1}\n\n{\"herbs\": 1}\n\n{\"Chinese Pharmacopoeia 2005\": 1}\n\n{\"thin layer chromatography\": 1}\n\n{\"herbs\": 1}\n\n{\"Chinese Pharmacopoeia 2005\": 1}\n\n{\"th", {"Ethnic group": ["Chinese"]}]], [651, "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA).", [" {\"The Plant List\": 1, \"Sigma-Aldrich\": 1, \"Racemic warfarin\": 1, \"diclofenac sodium\": 1, \"naringin\": 1}\n{\"The Plant List\": \"FREQUENCY\": 1, \"Sigma-Aldrich\": \"FREQUENCY\": 1, \"Racemic warfarin\": \"FREQUENCY\": 1, \"diclofenac sodium\": \"FREQUENCY\": 1, \"naringin\": \"FREQUENCY\": 1}\n{\"internal standards\": \"FREQUENCY\": 1}\n{\"St. Louis, MO, USA\": 1}", {"Drug": ["warfarin", "diclofenac sodium"], "Herb name": ["naringin"]}]], [652, "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection.", [" {\"Linear Gradient Elution\": 2, \"solvent A\": 2, \"5%\": 3, \"10%\": 2, \"17%\": 1, \"35%\": 1, \"90%\": 2, \"5 min\": 3, \"13 min\": 1, \"12 min\": 1, \"10 min\": 2, \"30 min\": 1, \"90\u00a0min\": 1, \"total running time\": 1, \"injection\": 1}\n{\"Pharmacology\": 1, \"scientific article\": 1}", {}]], [653, "Compared with the vehicle control group, there was a significant increase of 420\u00a0% (P\u00a0<\u00a00.001) in the mRNA expression ratio of CYP2C6 in the positive control group.", [" {\"CYP2C6\": 1, \"positive control group\": 1, \"vehicle control group\": 1, \"mRNA expression ratio\": 1}\n{\"FREQUENCY\": {\"mRNA expression ratio\": 1}}\n\n(Note: The frequency count is based on the provided text. If the text were longer or contained more instances of these entities, the frequency count would be higher accordingly.)", {"Target": ["CYP2C6"]}]], [654, "Furthermore, no inductive effects were observed in the mRNA expression level of CYP2C6 for both doses of Danshen compared with the vehicle control group.", [" {\"CYP2C6\": 1, \"Danshen\": 2, \"vehicle control group\": 1}\n\n(Note: The frequency count is based on the number of times each entity appears in the provided text.)", {"Target": ["CYP2C6"], "Herb name": ["Danshen"]}]], [655, "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.", [" {\"P-values\": [\"P\u00a0<\u00a00.05\", \"**P\u00a0<\u00a00.01\", \"***P\u00a0<\u00a00.001\"]}\n\n{\"Vehicle control group\": [\"compared with the vehicle control group\"]}", {}]], [656, "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM.", [" {\"Danshen\": 1, \"Gegen\": 1, \"microcirculation\": 1, \"platelet aggregation\": 1, \"warfarin\": 1, \"VKOR\": 1, \"TM\": 1}\n\n{\"FREQUENCY\": {\"Danshen\": 1, \"Gegen\": 1, \"microcirculation\": 1, \"platelet aggregation\": 1, \"warfarin\": 1, \"VKOR\": 1, \"TM\": 1}}", {"Herb name": ["Danshen", "Gegen"], "Drug": ["warfarin"], "Target": ["VKOR", "TM"]}]], [657, "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32].", [" {\"WARFARIN\": 2, \"DFG-warfarin combination\": 1, \"plasma concentration\": 1, \"PT time\": 1, \"rats\": 1}\n\n{\"FREQUENCY\": {\"WARFARIN\": 2, \"DFG-warfarin combination\": 1, \"plasma concentration\": 1, \"PT time\": 1, \"rats\": 1}}", {"Herb name": ["DFG"], "Drug": ["warfarin", "warfarin"], "Parameter": ["PT time"]}]], [658, "Taken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG.", [" {\"Gegen\": 1, \"DFG\": 1, \"effects\": 1, \"study\": 1}\n\nNote: \"Gegen\" and \"DFG\" are assumed to be entities related to pharmacology in this context, possibly referring to a specific compound or drug. \"Effects\" and \"study\" are also considered entities as they are part of the scientific discourse. If \"Gegen\" and \"DFG\" are not pharmacological entities, they would not be included in the list. However, based on the given information, this interpretation is made.", {"Herb name": ["Gegen", "DFG"]}]], [659, "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322].", [" {\"Gegen\": 1, \"warfarin\": 2, \"Danshen\": 1}", {"Study": ["clinical reports", "case reports"], "Herb name": ["Gegen", "Danshen"], "Drug": ["warfarin", "warfarin"]}]], [660, "CYP enzymes represent some of the most highly conserved entities among different species, with relatively small differences in the primary amino acid sequences of the CYP enzymes across different species [50, 51].", [" {\"CYP enzymes\": 1, \"entities\": 2, \"species\": 2, \"primary amino acid sequences\": 1}\n\n{\"frequences\": {\"CYP enzymes\": 1, \"species\": 2}}", {"Target": ["CYP enzymes", "CYP enzymes"]}]], [661, "Although these isoforms are expressed in several different species, a high degree of similarity in their gene sequences between rats and human may not automatically result in similar levels of catalytic specificity and activity.", [" {\"isoforms\": 1, \"species\": 2, \"gene sequences\": 1, \"rats\": 1, \"human\": 1}\n{\"similarity\": 1, \"degree\": 1, \"catalytic specificity\": 1, \"activity\": 1}", {}]], [662, "Algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose [54].", [" {\"Warfarin\": 1, \"genetic factors\": 1, \"physical factors\": 1, \"predictive models\": 1, \"individualized predictive models\": 1}\n{\"events\": 1}\n{\"FREQUENCY\": {\"predictive models\": 1}}\n{\"research\": 1}\n{\"studies\": 1}\n{\"scientific article\": 1}\n{\"pharmacology\": 1}\n{\"cited entities\": 5} (including Warfarin, genetic factors, physical factors, predictive models, and individualized predictive models)", {"Drug": ["warfarin"]}]], [663, "Furthermore, CYP1A-, CYP2C- and CYP3A-inducing agents were found in the ethyl acetate extract, but not in the aqueous extract of Danshen [57].", [" {\"CYP1A-inducing agents\": 1, \"CYP2C-inducing agents\": 1, \"CYP3A-inducing agents\": 1, \"ethyl acetate extract\": 1, \"aqueous extract\": 1, \"Danshen\": 1}", {"Target": ["CYP1A-", "CYP2C-", "CYP3A-"], "Extraction process": ["ethyl acetate extract", "aqueous extract"], "Herb name": ["Danshen"]}]], [664, "This finding is also supported by Yueng\u2019s study, where the major tanshinone components rather than the aqueous extract of Danshen showed effects on warfarin hydroxylation in vitro and in vivo [58].", [" {\"Yueng's study\": 1, \"major tanshinone components\": 1, \"aqueous extract of Danshen\": 1, \"warfarin hydroxylation\": 1, \"in vitro\": 1, \"in vivo\": 1}", {"Herb name": ["tanshinone", "Danshen"], "Extraction process": ["aqueous extract"], "Drug": ["warfarin"], "Study": ["in vitro and in vivo"]}]], [665, "In our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells because of the poor absorption and bioavailability of SAB.", [" {\"SAB\": 3}\n\n{\"Danshen granules\": 1}\n\n{\"in vivo effects\": 1}\n\n{\"cells\": 1}\n\n{\"poor absorption\": 1}\n\n{\"bioavailability\": 1}", {"Herb name": ["SAB", "Danshen", "SAB"], "Study": ["in vivo effects"], "Parameter": ["bioavailability"]}]], [666, "All of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results.", [" {\"Pharmacology\": 1, \"scientific article\": 1, \"pharmacology\": 1, \"in vitro\": 1, \"in vivo\": 1, \"discrepancies\": 1, \"results\": 1}\n\n{\"FREQUENCY\": {\"in vitro\": 1, \"in vivo\": 1}}", {"Study": ["in vitro", "in vivo"]}]], [667, "liver cytochrome P450 vitamin K epoxide reductase vitamin K vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay Beikang Ge and Zhen Zhang contributed equally to this work BKG, ZZh and ZZu conceived and designed the study.", [" {\"liver cytochrome P450\": 1, \"vitamin K epoxide reductase\": 1, \"vitamin K\": 2, \"thrombomodulin\": 1, \"Danshen\u2013Gegen Formula\": 1, \"salvianolic acid B\": 1, \"phenobarbital\": 1, \"beta-naphthoflavone\": 1, \"cyclophosphamide\": 1, \"enzyme-linked immunosorbent assay\": 1, \"Beikang Ge\": 1, \"Zhen Zhang\": 1}", {"Target": ["liver cytochrome P450", "vitamin K epoxide reductase", "vitamin K", "vitamin K", "thrombomodulin"], "Herb name": ["Danshen", "Gegen", "salvianolic acid B"], "Drug": ["phenobarbital", "cyclophosphamide"]}]], [668, "There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer.", [" {\"Ginkgo biloba\": 1, \"hormone therapy\": 1, \"early stage breast cancer\": 1}\n{\"FREQUENCY\": {\"Ginkgo biloba\": 1, \"hormone therapy\": 1, \"early stage breast cancer\": 1}}\n\n(Note: The provided text does not explicitly mention other entities such as authors, journals, or specific pharmacological terms. Therefore, no additional entities were identified in this particular text.)", {"Drug": ["hormone therapy"], "Herb name": ["ginkgo biloba"], "Sex": ["women"], "Pathology": ["early stage breast cancer"]}]], [669, "Sample preparation was based on the publication by (Beer et al.", [" {\"BEER ALANS\": [1]}\n{\"PUBLICATION\": [1]}\n{\"PUBLISHER\": [1]}\n{\"PUBLICATION ALANS\": [1]}\n{\"PUBLISHER ALANS\": [1]}\n{\"PUBLISHER AND ALANS\": [1]}\n{\"PUBLISHER AND ALANS\": [1]}\n{\"PUBLISHER AND ALTERNATE OF\": [1]}\n{\"PUBLISHER AND ALTERNATE OF ALANS\": [1]}\n{\"PUBLISHER AND ALTERNATE OF ALTERNATE OF\": [1]}\n{\"PUBLISHER AND ALTERNATE OF ALTERNATE OF ALANS\": [1]}\n{\"PUBLISHER AND ALTERNATE OF ALTERNATE OF ALTERNATE OF\": [1]}\n{\"PUBLISHER AND ALTERNATE OF ALTERNATE OF ALTERNATE OF ALANS\": [1]}\n{\"PUBLISHER AND ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF\": [1]}\n{\"PUBLISHER AND ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF\": [1]}\n{\"PUBLISHER AND ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF\": [1]}\n{\"PUBLISHER AND ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF\": [1]}\n{\"PUBLISHER AND ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF\": [1]}\n{\"PUBLISHER AND ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERNATE OF ALTERN", {}]], [670, "The extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each analyte.", [" {\"Human plasma\": 1, \"mean recovery\": 1, \"88%\": 1, \"each analyte\": 1}\n{\"FREQUENCY\": {\"mean recovery\": 1, \"88%\": 1, \"each analyte\": 1}}", {}]], [671, "No endogenous peaks were identified in the extracted ion chromatograms that would cause interference with drug quantitation.", [" {\"Ion Chromatograms\": 1, \"Extracted Ion Chromatograms\": 1, \"Endogenous Peaks\": 1, \"Drug Quantitation\": 1}\n{\"FREQUENCY\": {\"Extracted Ion Chromatograms\": 1, \"Endogenous Peaks\": 1, \"Drug Quantitation\": 1}}\n\n(Note: The frequency count is based on the single occurrence of each entity within the provided text.)", {}]], [672, "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy.", [" {\"Adjuvant Chemotherapy\": 1, \"women\": 1, \"37 months\": 1, \"113 months\": 1}\n\nNote: The frequency count is based on the direct mentions of the entities in the text. The range \"4\u2013113 months\" is also considered as an entity referring to the time since completion of chemotherapy.", {"Drug": ["adjuvant chemotherapy"]}]], [673, "Competing interests          The authors have declared no conflicts of interests.", [" {\"FREQUENCY\": {\"authors\": 1, \"conflicts of interests\": 1, \"competing interests\": 1}}\n\n(Note: The entities \"authors\" and \"conflicts of interests\" are inferred from the text provided, as they are directly mentioned in the instruction. \"Competing interests\" is also mentioned as a specific entity related to the topic of competing interests.)", {}]], [674, "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008).", [" {\"Mangifera indica\": 1, \"in vitro inhibition\": 1, \"Potential for clinically important\": 1, \"chronic diseases\": 1, \"patients\": 3, \"alternative remedies\": 1, \"conventional medications\": 1, \"self-medication\": 1, \"dietary supplements\": 1, \"herbal medicines\": 1, \"dietary supplements\": 1, \"herbal medicines\": 1}", {"Pathology": ["diabetes", "hypertension", "hyperlipidemia", "malaria fever"], "Study": ["In vitro"], "Herb name": ["Mangifera indica"]}]], [675, "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014).", [" {\"Alstonia boonei\": 1, \"Bauhinia monandra\": 1, \"Picralima nitida\": 1, \"sub-Saharan Africa\": 1, \"India\": 1, \"hypertension\": 1, \"diabetes\": 1, \"asthma\": 1, \"peptic ulcer\": 1, \"cancer\": 1, \"antimalarials\": 1, \"antimicrobials\": 1, \"minor ailments\": 1}", {"Herb name": ["Alstonia boonei", "Bauhinia monandra", "Picralima nitida"], "Pathology": ["hypertension", "diabetes", "asthma", "peptic ulcer", "cancer"]}]], [676, "These isoenzymes are responsible for the metabolism of over 70% of prescription and over\u2010the\u2010counter medications (Rendic & Guengerich, 2014).", [" {\"CITED_PERSONS\": [\"Rendic\", \"Guengerich\"], \"FREQUENCY\": {\"CITED_PERSONS\": 2}, \"CITED_WORKS\": [\"2014\"], \"FREQUENCY\": {\"CITED_WORKS\": 1}, \"PHARMACOLOGY_TERMS\": [\"isoenzymes\", \"metabolism\", \"prescription medications\", \"over-the-counter medications\"]}\n\n{\"CITED_PERIODS\": [], \"FREQUENCY\": {\"CITED_PERIODS\": 0}}\n\n{\"MEDICATIONS\": [], \"FREQUENCY\": {\"MEDICATIONS\": 0}}\n\n{\"MEDICATION_CLASSES\": [], \"FREQUENCY\": {\"MEDICATION_CLASSES\": 0}}\n\n{\"MEDICATION_ACTIONS\": [], \"FREQUENCY\": {\"MEDICATION_ACTIONS\": 0}}\n\n{\"MEDICATION_REACTIONS\": [], \"FREQUENCY\": {\"MEDICATION_REACTIONS\": 0}}\n\n{\"MEDICATION_ADVERSE_EFFECTS\": [], \"FREQUENCY\": {\"MEDICATION_ADVERSE_EFFECTS\": 0}}\n\n{\"MEDICATION_DOSAGE\": [], \"FREQUENCY\": {\"MEDICATION_DOSAGE\": 0}}\n\n{\"MEDICATION_DURATION\": [], \"FREQUENCY\": {\"MEDICATION_DURATION\": 0}}\n\n{\"MEDICATION_CLINICAL_STAGES\": [], \"FREQUENCY\": {\"MEDICATION_CLINICAL_STAGES\": 0}}\n\n{\"MEDICATION_PHARMACOLOGICAL_PROCESSES\": [\"metabolism\"], \"FREQUENCY\": {\"MEDICATION_PHARMACOLOGICAL_PROCESSES\": 1}}\n\n{\"MEDICATION_PHARMACOLOGICAL_PROCESSES_TYPES\": [\"isoenzymes\"], \"FREQUENCY\": {\"MEDICATION_PHAR", {}]], [677, "Little is known of the effect of most tropical medicinal herbs on the metabolic capacity of CYP isoenzymes.", [" {\"Tropical medicinal herbs\": 1, \"CYP isoenzymes\": 1}\n{\"FREQUENCY\": {\"effect on CYP isoenzymes\": 1}}\n{\"FREQUENCY\": {\"metabolic capacity\": 1}}\n{\"FREQUENCY\": {\"studies\": 0}}\n{\"FREQUENCY\": {\"pharmacological effects\": 0}}\n{\"FREQUENCY\": {\"therapeutic uses\": 0}}\n{\"FREQUENCY\": {\"research\": 0}}\n{\"FREQUENCY\": {\"clinical trials\": 0}}\n{\"FREQUENCY\": {\"drug interactions\": 0}}\n{\"FREQUENCY\": {\"toxicological effects\": 0}}\n{\"FREQUENCY\": {\"pharmacokinetics\": 0}}\n{\"FREQUENCY\": {\"pharmacodynamics\": 0}}\n{\"FREQUENCY\": {\"drug metabolism\": 1}}\n{\"FREQUENCY\": {\"enzyme inhibition\": 0}}\n{\"FREQUENCY\": {\"enzyme induction\": 0}}\n{\"FREQUENCY\": {\"cytochrome P450\": 1}}\n{\"FREQUENCY\": {\"metabolic pathways\": 0}}\n{\"FREQUENCY\": {\"enzyme isoforms\": 0}}\n{\"FREQUENCY\": {\"substrate specificity\": 0}}\n{\"FREQUENCY\": {\"substrate affinity\": 0}}\n{\"FREQUENCY\": {\"substrate turnover\": 0}}\n{\"FREQUENCY\": {\"substrate concentration\": 0}}\n{\"FREQUENCY\": {\"enzyme kinetics\": 0}}\n{\"FREQUENCY\": {\"enzyme regulation\": 0}}\n{\"FREQUENCY\": {\"enzyme localization\": 0}}\n{\"FREQUENCY\": {\"enzyme structure\": 0}}\n{\"FREQUENCY\": {\"enzyme nomenclature\": 0}}\n{\"FRE", {"Target": ["CYP isoenzymes"]}]], [678, "Each mixture was filtered, concentrated, and freeze\u2010dried.", [" {\"mixture\": 1, \"filtered\": 1, \"concentrated\": 1, \"freeze-dried\": 1}\n{\"FREQUENCY\": {\"filtered\": 1, \"concentrated\": 1, \"freeze-dried\": 1}}\n\n(Note: The term \"this\" at the beginning of the instruction is not considered an entity related to pharmacology, as it does not refer to a specific cited entity within the context of the provided text. However, if \"this\" were part of a citation or a specific term within the article, it would be included in the analysis accordingly.)", {}]], [679, "Acetic acid and HPLC\u2010grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany).", [" {\"Acetic acid\": 1, \"HPLC-grade acetonitrile\": 1, \"Merck\": 1, \"LiChrosolv GG\": 1, \"Darmstadt\": 1, \"Germany\": 1}\n{\"Acetic acid\": [\"acetic acid\"], \"HPLC-grade acetonitrile\": [\"HPLC-grade acetonitrile\"], \"Merck\": [\"Merck\"], \"LiChrosolv GG\": [\"LiChrosolv GG\"], \"Darmstadt\": [\"Darmstadt\"], \"Germany\": [\"Germany\"]}\n{\"FREQUENCY\": {\"Acetic acid\": 1, \"HPLC-grade acetonitrile\": 1, \"Merck\": 1, \"LiChrosolv GG\": 1, \"Darmstadt\": 1, \"Germany\": 1}}", {}]], [680, "Positive controls (see Supporting Information data, Table S1), CYP isoenzymes inhibited, and concentration used in the N\u2010in\u2010one assay are as reported in the validated methods (Turpeinen et\u00a0al., 2005; Tolonen et\u00a0al., 2007; Showande et\u00a0al., 2013).", [" {\"CYP isoenzymes\": 1, \"N\u2010in\u2010one assay\": 1, \"Turpeinen et\u00a0al., 2005\": 1, \"Tolonen et\u00a0al., 2007\": 1, \"Showande et\u00a0al., 2013\": 1}", {"Target": ["CYP isoenzymes"]}]], [681, "Multiple reaction monitoring (MRM) mode using positive ion mode.", [" {\"MRM\": 1, \"positive ion mode\": 1}\n{\"pharmacology\": 1}\n{\"positive ion\": 1}\n{\"ion mode\": 1}\n{\"scientific article\": 1}\n{\"pharmacology\": 1}\n{\"positive ion mode\": 1}\n{\"MRM\": 1}", {}]], [682, "Fifty percent inhibitory concentration (IC   where A\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations.", [" {\"Fifty percent inhibitory concentration (IC50)\": 1, \"aqueous extract of herb\": 1, \"incubations\": 1}\n{\"log of concentration\": 1}\n{\"concentration\": 1}\n{\"herb\": 1}", {"Parameter": ["Fifty percent inhibitory concentration"], "Extraction process": ["aqueous extract"]}]], [683, "In vitro herb\u2013drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb\u2013drug interactions and to help design appropriate in vivo herb\u2013drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013).", [" {\"FREQUENCY\": {\"in vitro herb-drug interactions studies\": 1, \"commonly used herbs\": 1, \"potentially significant in vivo herb-drug interactions\": 1, \"in vivo herb-drug interaction studies\": 1, \"Fasinu, Bouic, & Rosenkranz, 2012\": 1, \"Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013\": 1}", {"Study": ["In vitro herb\u2013drug interactions studies", "in vivo herb\u2013drug interaction studies"]}]], [684, "Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs.", [" {\"Musa sapientum\": 1, \"Tetracarpidium conophorum\": 1, \"Allium sativum\": 1, \"human CYP isoenzymes\": 1, \"aqueous extracts\": 1}\n\n{\"FREQUENCY\": {\"Musa sapientum\": 1, \"Tetracarpidium conophorum\": 1, \"Allium sativum\": 1, \"human CYP isoenzymes\": 1, \"aqueous extracts\": 1}}", {"Target": ["CYP isoenzymes"], "Extraction process": ["aqueous extracts"], "Herb name": ["Musa sapientum", "Tetracarpidium conophorum", "Allium sativum"], "Herb part": ["unripe fruits", "seeds", "bulbs"]}]], [685, "Though we did not report any inhibition of CYP isoenzymes by Allium sativum, the discrepancies in these reports and ours may be due to the extraction procedure, assay method, concentration and type of the extract used and enzyme sources.", [" {\"Allium sativum\": 1, \"CYP isoenzymes\": 1, \"enzyme sources\": 1, \"assay method\": 1, \"concentration\": 1, \"extraction procedure\": 1}\n{\"FREQUENCY\": {\"Allium sativum\": 1, \"CYP isoenzymes\": 1, \"enzyme sources\": 1, \"assay method\": 1, \"concentration\": 1, \"extraction procedure\": 1}}", {"Target": ["CYP isoenzymes"], "Herb name": ["Allium sativum"]}]], [686, "In this study, aqueous extract of oven\u2010dried Allium sativum bulbs was used.", [" {\"ALLIUM_SATIVUM\": 1}\n\n(Note: The frequency count is based on the number of times the entity \"Allium sativum\" is mentioned in the text. In this case, it is mentioned once.)\n\n{\"EXTRACT\": 1}\n\n(Note: The frequency count is based on the number of times the entity \"aqueous extract\" is mentioned in the text. In this case, it is mentioned once.)\n\n{\"BULBS\": 1}\n\n(Note: The frequency count is based on the number of times the entity \"bulbs\" is mentioned in the text. In this case, it is mentioned once.)\n\n{\"OVEN_DRYING\": 1}\n\n(Note: The frequency count is based on the number of times the entity \"oven drying\" is mentioned in the text. In this case, it is mentioned once.)\n\n{\"PHARMACOLOGY\": 0}\n\n(Note: The frequency count is based on the number of times the entity \"pharmacology\" is mentioned in the text. In this case, it is not mentioned.)\n\n{\"SATIVUM_BULBS\": 0}\n\n(Note: The frequency count is based on the number of times the entity \"Sativum bulbs\" is mentioned in the text. In this case, it is not mentioned as a separate entity but rather as part of \"Allium sativum bulbs\".)\n\n{\"EXTRACT_OF\": 1}\n\n(Note: The frequency count is based on the number of times the entity \"extract of\" is mentioned in the text. In this case, it is mentioned once.)\n\n{\"OVEN_DRIED\": 0}\n\n(Note: The frequency count is based on the number of times the entity \"oven dried\" is mentioned in the text. In this case, it is not mentioned as a separate entity but rather as part of \"oven drying\".)\n\n{\"ALLIUM_SATIVUM_BULBS\": 0}\n\n(Note: The frequency count is based on the number of times the entity \"Allium sativum bulbs\" is mentioned in the text. In this case, it is not mentioned as a separate entity but rather as part of \"Allium sativum bulbs", {"Extraction process": ["aqueous extract of oven\u2010dried"], "Herb name": ["Allium sativum"], "Herb part": ["bulbs"]}]], [687, "Aqueous extract of Moringa oleifera leaves showed weak inhibition of CYP1A2 and CYP2C9.", [" {\"Moringa oleifera\": 1, \"Moringa oleifera leaves\": 1, \"CYP1A2\": 1, \"CYP2C9\": 1}\n\n{\"FREQUENCY\": {\"Moringa oleifera\": 1, \"Moringa oleifera leaves\": 1, \"CYP1A2\": 1, \"CYP2C9\": 1}}", {"Extraction process": ["Aqueous extract"], "Herb name": ["Moringa oleifera"], "Herb part": ["leaves"], "Target": ["CYP1A2", "CYP2C9"]}]], [688, "Strandell et\u00a0al.", [" {\"STRANDIELL_AL\": 1}\n\n{\"PHARMACOLOGICAL_SUBJECT\": 1}\n\n{\"ARTICLE_TYPE\": 1}\n\n{\"JOURNAL_NAME\": 1}\n\n{\"PUBLICATION_DATE\": \"\"}\n\n{\"ARTICLE_NUMBER\": \"\"}\n\n{\"AUTHORS\": \"Strandell et al.\"}\n\n{\"ARTICLE_SOURCE\": \"\"}\n\n{\"ARTICLE_JOURNAL\": \"\"}\n\n{\"ARTICLE_YEAR\": \"\"}\n\n{\"ARTICLE_DOI\": \"\"}\n\n{\"ARTICLE_PAGES\": \"\"}\n\n{\"ARTICLE_ABSTRACT\": \"\"}\n\n{\"ARTICLE_BODY\": \"\"}\n\n{\"ARTICLE_CONCLUSION\": \"\"}\n\n{\"ARTICLE_FUTURE_WORK\": \"\"}\n\n{\"ARTICLE_METHODOLOGY\": \"\"}\n\n{\"ARTICLE_PHARMACOLOGICAL_SUBJECT\": \"pharmacology\"}\n\n{\"ARTICLE_FREQUENCY\": {\"STRANDIELL_AL\": 1}}", {}]], [689, "(2000).", [" {\"Pharmacology\": 1, \"scientific article\": 1, \"pharmacological entities\": 1, \"drugs\": 1, \"drug molecules\": 1, \"pharmacokinetics\": 1, \"pharmacodynamics\": 1, \"pharmaceutical compounds\": 1, \"pharmacology-related terms\": 1, \"pharmacological studies\": 1, \"pharmacology research\": 1, \"pharmacology articles\": 1, \"pharmacology literature\": 1, \"pharmacology publications\": 1, \"pharmacology journals\": 1, \"pharmacology journals articles\": 1, \"pharmacology research articles\": 1, \"pharmacology research publications\": 1, \"pharmacology research literature\": 1, \"pharmacology research articles in journals\": 1, \"pharmacology research articles in scientific journals\": 1, \"pharmacology research articles in pharmacology journals\": 1, \"pharmacology research articles in pharmacology journals\": 1, \"pharmacology research articles in pharmacology literature\": 1, \"pharmacology research articles in pharmacology literature\": 1, \"pharmacology research articles in pharmacology literature\": 1, \"pharmacology research articles in pharmacology literature\": 1, \"pharmacology research articles in pharmacology literature\": 1, \"pharmacology research articles in pharmacology literature\": 1, \"pharmacology research articles in pharmacology literature\": 1, \"pharmacology research articles in pharmacology literature\": 1, \"pharmacology research articles in pharmacology literature\": 1, \"pharmacology research articles in pharmacology literature\": 1, \"pharmacology research articles in pharmacology literature\": 1, \"pharmacology research articles in pharmacology literature\": 1, \"pharmacology research articles in pharmacology literature\": 1, \"pharmacology research articles in pharmacology literature\": 1, \"pharmacology research articles in pharmacology literature", {}]], [690, "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb.", [" {\"Gongronema latifolium\": 1, \"Alstonia boonei\": 1, \"in vivo inhibitory activity\": 1, \"CYP1A2\": 1, \"CYP2C19\": 1, \"CYP3A4\": 1, \"in vitro\": 1, \"phytochemicals\": 1, \"herb\": 1}", {"Herb name": ["Gongronema latifolium", "Alstonia boonei"], "Target": ["CYP1A2", "CYP2C19", "CYP3A4"], "Study": ["in vitro"], "Parameter": ["IC"]}]], [691, "Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines.", [" {\"Limited Liability Company (Ltd.)\": 1, \"Varanasi, India\": 1, \"polyherbal formulation\": 1, \"menopause symptoms\": 1, \"allopathic medicines\": 1}\n{\"Limited Liability Company (Ltd.)\": 1, \"Varanasi, India\": 1, \"polyherbal formulation\": 1, \"menopause symptoms\": 1, \"allopathic medicines\": 1}\n{\"patented\": 1, \"polyherbal formulation\": 1, \"menopause symptoms\": 1, \"allopathic medicines\": 1}\n{\"menopause symptoms\": 1, \"allopathic medicines\": 1}\n{\"patented\": 1, \"polyherbal formulation\": 1, \"menopause symptoms\": 1}\n{\"allopathic medicines\": 1}\n{\"patented\": 1, \"polyherbal formulation\": 1}\n{\"menopause symptoms\": 1}\n{\"allopathic medicines\": 1}\n{\"patented\": 1, \"polyherbal formulation\": 1}\n{\"menopause symptoms\": 1}\n{\"allopathic medicines\": 1}\n{\"patented\": 1, \"polyherbal formulation\": 1}\n{\"menopause symptoms\": 1}\n{\"allopathic medicines\": 1}\n{\"patented\": 1, \"polyherbal formulation\": 1}\n{\"menopause symptoms\": 1}\n{\"allopathic medicines\": 1}\n{\"patented\": 1, \"polyherbal formulation\": 1}\n{\"menopause symptoms\": 1}\n{\"allopathic medicines\": 1}\n{\"patented\": 1, \"polyherbal formulation\": 1}\n{\"menopause symptoms\": 1}\n{\"allopathic medicines\": 1}\n{\"patented\": 1, \"polyherbal formulation\": 1}\n{\"menopause symptoms\": 1}\n{\"allopathic medicines\": 1}\n{\"patented\": 1, \"polyherbal formulation\": 1}\n{\"menopause", {"Pathology": ["menopause symptoms"]}]], [692, "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines.", [" {\"Transition to menopause\": 1, \"problematic symptoms\": 1, \"hot flashes\": 1, \"night sweats\": 1, \"sleep disturbances\": 1, \"sexual dysfunction\": 1, \"mood disorders\": 1, \"weight gain\": 1, \"cognitive declines\": 1}\n\n{\"2020\": 1}\n\n{\"81\": 1}", {"Pathology": ["menopause", "hot flashes", "night sweats", "sleep disturbances", "sexual dysfunction", "mood disorders", "weight gain", "cognitive declines"]}]], [693, "34860-2.5L-R) and ammonium acetate (catalog No.", [" {\"Pharmacological Entities\": [\"pharmacology\", \"ammonium acetate\", \"catalog No.\"}\n\n{\"Cited Publications\": [\"34860-2.5L-R\"]}\n\n{\"Catalog Numbers\": [\"catalog No. 34860-2.5L-R\"]}\n\n{\"Chemical Compounds\": [\"ammonium acetate\"]}", {}]], [694, "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No.", [" {\"IC50\": [frequencies of half-maximal inhibitory concentration events], \"pharmacology\": [frequencies of pharmacology events], \"medical college hospital\": [frequencies of medical college hospital events], \"SRM Medical College Hospital\": [frequencies of SRM Medical College Hospital events], \"SRM Institute of Science and Technology\": [frequencies of SRM Institute of Science and Technology events], \"ethics committees\": [frequencies of ethics committees events], \"approval No.\": [frequencies of approval No. events]}\n\n{\"IC50\": 1, \"pharmacology\": 1, \"medical college hospital\": 1, \"SRM Medical College Hospital\": 1, \"SRM Institute of Science and Technology\": 1, \"ethics committees\": 1, \"approval No.\": 1}", {}]], [695, "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder.", [" {\"Cardiovascular disease\": [],\n \"Pulmonary disease\": [],\n \"Hepatic disease\": [],\n \"Renal disease\": [],\n \"Hematologic disease/disorder\": [],\n \"Gastrointestinal disease/disorder\": [],\n \"Endocrine disease/disorder\": [],\n \"Immunologic disease/disorder\": [],\n \"Dermatologic disease/disorder\": [],\n \"Neurologic disease/disorder\": [],\n \"Volunteers\": [],\n \"Clinically significant history\": [],\n \"Cardiovascular\": [],\n \"Pulmonary\": [],\n \"Hepatic\": [],\n \"Renal\": [],\n \"Hematologic\": [],\n \"Gastrointestinal\": [],\n \"Endocrine\": [],\n \"Immunologic\": [],\n \"Dermatologic\": [],\n \"Neurologic\": [],\n \"Pharmacology\": [],\n \"Scientific article\": []}", {"Pathology": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"]}]], [696, "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation.", [" {\"Female volunteers\": 1, \"pregnant\": 1, \"serum human chorionic gonadotropin\": 1, \"breastfeeding\": 1, \"treatment cessation\": 1, \"child\": 1}\n{\"Pregnancy\": 1, \"Breastfeeding\": 1, \"Planning to conceive\": 1}\n{\"Screening\": 1, \"Check-in\": 1}\n{\"Treatment cessation\": 1}\n{\"30 days\": 1}\n{\"Volunteers\": 1}\n{\"Pharmacology\": (not mentioned in the text, hence not included)\n{\"Serum human chorionic gonadotropin\": 1}\n{\"Human chorionic gonadotropin\": 1}\n{\"Volunteers\": 1}\n{\"Female\": 1}\n{\"Female volunteers\": 1}\n{\"Pregnant\": 1}\n{\"Breastfeeding\": 1}\n{\"Planning to conceive\": 1}\n{\"Treatment cessation\": 1}\n{\"Child\": 1}\n{\"30 days\": 1}\n{\"Female\": 1}\n{\"Female volunteers\": 1}\n{\"Pregnant\": 1}\n{\"Breastfeeding\": 1}\n{\"Planning to conceive\": 1}\n{\"Treatment cessation\": 1}\n{\"30 days\": 1}\n{\"Volunteers\": 1}\n{\"Pharmacology\": (not mentioned in the text, hence not included)\n{\"Serum human chorionic gonadotropin\": 1}\n{\"Human chorionic gonadotropin\": 1}\n{\"Volunteers\": 1}\n{\"Female\": 1}\n{\"Female volunteers\": 1}\n{\"Pregnant\": 1}\n{\"Breastfeeding\": 1}\n{\"Planning to conceive\": 1}\n{\"Treatment cessation\": 1}\n{\"30 days\": 1}\n{\"Volunteers\": 1}\n{\"Pharmacology\": (not mentioned in the text, hence", {"Sex": ["Female"], "Parameter": ["serum human chorionic gonadotropin"], "Duration": ["30 days"]}]], [697, "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups.", [" {\"PLACEBO\": 1, \"MenocueAct formulation\": 1, \"500 mg\": 1, \"BID\": 1, \"double-blind\": 1}\n{\"FREQUENCY\": {\"PLACEBO\": 1, \"MenocueAct formulation\": 1, \"500 mg\": 1, \"BID\": 1, \"double-blind\": 1}}", {"Drug": ["placebo"], "Herb name": ["MenoAct851"], "Amount": ["500 mg"], "Duration": ["14 days"]}]], [698, "Double-blinded treatments were allocated using sequentially numbered drug containers.", [" {\"Drug Containers\": 1, \"Double-blinded treatments\": 1}\n{\"Sequentially Numbered\": 1}\n{\"Allocation Method\": 1}\n{\"Treatments\": 1}\n{\"Scientific Article\": 1}\n{\"Pharmacology\": 1}\n{\"Article\": 1}\n{\"Word Referring to Described Entities\": \"drug containers, double-blinded treatments, sequentially numbered, allocation method, treatments, scientific article, pharmacology, article\"}\n{\"FREQUENCY\": {\"Drug Containers\": 1, \"Double-blinded treatments\": 1, \"Sequentially Numbered\": 1, \"Allocation Method\": 1, \"Treatments\": 1, \"Scientific Article\": 1, \"Pharmacology\": 1, \"Article\": 1}}\n{\"Double-blinded treatments\": 1, \"sequentially numbered\": 1, \"drug containers\": 1}\n{\"Allocation Method\": 1, \"Treatments\": 1}\n{\"Scientific Article\": 1, \"Pharmacology\": 1}\n{\"Article\": 1}\n{\"Double-blinded treatments\": 1, \"sequentially numbered\": 1, \"drug containers\": 1}\n{\"Allocation Method\": 1, \"Treatments\": 1}\n{\"Scientific Article\": 1, \"Pharmacology\": 1}\n{\"Article\": 1}\n{\"Double-blinded treatments\": 1, \"sequentially numbered\": 1, \"drug containers\": 1}\n{\"Allocation Method\": 1, \"Treatments\": 1}\n{\"Scientific Article\": 1, \"Pharmacology\": 1}\n{\"Article\": 1}\n{\"Double-blinded treatments\": 1, \"sequentially numbered\": 1, \"drug containers\": 1}\n{\"Allocation Method\": 1, \"Treatments\": 1}\n{\"Scientific Article\": 1, \"Pharmacology\": 1}\n{\"Article\": 1}\n{\"Double-blind", {}]], [699, "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04.", [" {\"Simvastatin\": 1, \"Simvastatin hydroxy acid\": 1, \"Lovastatin\": 1, \"internal standard\": 1, \"plasma concentrations\": 1, \"Figure 4\": 1}", {"Drug": ["simvastatin", "simvastatin hydroxy acid", "lovastatin"]}]], [700, "Values are expressed as mean (SD).", [" In the provided text, cited entities related to pharmacology would typically include drug names, researchers, institutions, journals, and specific pharmacological terms. However, since the text of the scientific article is not provided, I can only guide you on how to identify and parse these entities based on a hypothetical example.\n\nFor instance, if the article mentioned the following:\n\n\"In a study published in the Journal of Pharmacology, researchers from Harvard University investigated the effects of Drug A and Drug B on patients with condition X. The study, led by Dr. Jane Doe, found that Drug A had a mean efficacy of 75% (SD: 10) with a standard deviation of 5, while Drug B had a mean efficacy of 70% (SD: 12) with a standard deviation of 6.\"\n\nThe parsed entities would be:\n\n- Journal of Pharmacology: 1\n- Harvard University: 1\n- Dr. Jane Doe: 1\n- Drug A: 2\n- Drug B: 2\n- condition X: 1\n- mean efficacy: 2\n- standard deviation (SD): 2\n\nThe format for the parsed entities would be:\n\n{\n  \"Journal of Pharmacology\": 1,\n  \"Harvard University\": 1,\n  \"Dr. Jane Doe\": 1,\n  \"Drug A\": 2,\n  \"Drug B\": 2,\n  \"condition X\": 1,\n  \"mean efficacy\": 2,\n  \"standard deviation (SD)\": 2\n}\n\nPlease provide the actual text of the scientific article for a precise extraction of entities.", {}]], [701, "A difference was considered significant at P < 0.05.", [" {\"P\": 1, \"significant\": 1, \"0.05\": 1}", {}]], [702, "(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin.", [" {\"Simvastatin\": 1, \"volunteer\": 1, \"40 mg\": 1, \"oral dose\": 1}\n{\"Plasma\": 1}\n{\"Volunteer\": 1}", {"Frequency": ["single oral dose"], "Amount": ["40 mg"], "Drug": ["simvastatin"]}]], [703, "Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability.", [" {\"Herb-drug interactions\": 1, \"herbal medicines\": 1, \"herbal formulations\": 1, \"bioavailability\": 1}\n{\"Herb-drug interactions\": 1, \"herbal medicines\": 1, \"herbal formulations\": 1, \"bioavailability\": 1}\n{\"popularity\": 1}\n{\"development\": 1}\n{\"worldwide\": 1}\n{\"improved\": 1}\n{\"incidence\": 1}\n{\"predicted\": 1}\n{\"increase\": 1}", {"Parameter": ["bioavailability"]}]], [704, "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.", [" {\"g-Nomic\u00ae Software\": 1, \"Abel Saldarreaga Marin\": 1, \"Marc Cendros\": 1, \"Carlos J Ciudad\": 1, \"Ana Sabater\": 1, \"65-year-old man\": 1, \"ischemic heart disease\": 1, \"stent\": 1, \"hypertension\": 1, \"diabetes\": 1, \"severe fatigue\": 1, \"bleeding\": 1, \"herbal supplementations\": 1}\n{\"FREQUENCY\": {\"g-Nomic\u00ae Software\": 1, \"Abel Saldarreaga Marin\": 1, \"Marc Cendros\": 1, \"Carlos J Ciudad\": 1, \"Ana Sabater\": 1, \"65-year-old man\": 1, \"ischemic heart disease\": 1, \"stent\": 1, \"hypertension\": 1, \"diabetes\": 1, \"severe fatigue\": 1, \"bleeding\": 1, \"herbal supplementations\": 1}}", {"Study": ["Case Report", "case report"], "Pathology": ["Fatigue", "Bleeding", "severe fatigue", "bleeding", "ischemic heart disease", "hypertension", "diabetes"], "Herb name": ["Herbal Supplementations"], "Age": ["65-year-old"], "Sex": ["man"]}]], [705, "Drug interactions can be considered illnesses by themselves.", [" {\"Drug Interactions\": 1, \"Pharmacology\": 1, \"Illnesses\": 1}\n{\"Drug Interactions\": 2, \"Pharmacology\": 1}\n{\"Drug Interactions\": 1, \"Illnesses\": 1}\n{\"Pharmacology\": 1}\n{\"Illnesses\": 1}\n{\"Drug Interactions\": 1, \"Pharmacology\": 1}\n{\"Drug Interactions\": 1, \"Illnesses\": 1}\n{\"Pharmacology\": 1}\n{\"Illnesses\": 1}\n{\"Drug Interactions\": 1, \"Pharmacology\": 1}\n{\"Drug Interactions\": 1, \"Illnesses\": 1}\n{\"Pharmacology\": 1}\n{\"Illnesses\": 1}\n{\"Drug Interactions\": 1, \"Pharmacology\": 1}\n{\"Drug Interactions\": 1, \"Illnesses\": 1}\n{\"Pharmacology\": 1}\n{\"Illnesses\": 1}\n{\"Drug Interactions\": 1, \"Pharmacology\": 1}\n{\"Drug Interactions\": 1, \"Illnesses\": 1}\n{\"Pharmacology\": 1}\n{\"Illnesses\": 1}\n{\"Drug Interactions\": 1, \"Pharmacology\": 1}\n{\"Drug Interactions\": 1, \"Illnesses\": 1}\n{\"Pharmacology\": 1}\n{\"Illnesses\": 1}\n{\"Drug Interactions\": 1, \"Pharmacology\": 1}\n{\"Drug Interactions\": 1, \"Illnesses\": 1}\n{\"Pharmacology\": 1}\n{\"Illnesses\": 1}\n{\"Drug Interactions\": 1, \"Pharmacology\": 1}\n{\"Drug Interactions\": 1, \"Illnesses\": 1}\n{\"Pharmacology\": 1}\n{\"Illnesses\": 1}\n{\"Drug Interactions\": 1, \"Pharmacology\": 1}\n{\"Drug Interactions\": 1, \"Illnesses\": 1}\n", {"Pathology": ["illnesses"]}]], [706, "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions.", [" {\"Medication\": [\"interactions\", \"medication\"], \"Lifestyle\": [\"lifestyle\", \"measures\", \"interactions\", \"lifestyle interactions\"]}\n\n{\"Researchers\": [\"evaluating\"], \"Outcome\": [\"measures\"]}\n\n{\"Pharmacology\": [\"scientific article\"]}", {}]], [707, "Object name is PGPM-14-963-g0003.jpg Figure 3  Drug interactions and drug \u2013 lifestyle reported by the personalized prescription software.", [" {\"FREQUENCY\": {\"PGPM-14-963-g0003\": 1, \"figure\": 1, \"drug interactions\": 1, \"personalized prescription software\": 1}}\n\n\nNote: The entities \"drug interactions\" and \"personalized prescription software\" are conceptual entities referring to the described entities in the context of the scientific article. The specific image filename \"PGPM-14-963-g0003.jpg\" is also considered an entity as it refers to a visual representation within the article.", {}]], [708, "Therefore, two commonly used herbal medicines, echinacea and policosanol were investigated for their potential to interact with warfarin.", [" {\"Echinacea\": 1, \"policosanol\": 1, \"warfarin\": 1}", {"Herb name": ["echinacea", "policosanol"], "Drug": ["warfarin"]}]], [709, "CYP2C9 and VKORC1 genotyping  The CYP2C9*1,*2 and *3 polymorphisms of CYP2C9 were detected by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis.", [" {\"CYP2C9\": 3, \"CYP2C9*1\": 1, \"CYP2C9*2\": 1, \"CYP2C9*3\": 1, \"VKORC1\": 1, \"genotyping\": 1, \"polymorphism\": 1, \"polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis\": 1}\n{\"FREQUENCY\": {\"CYP2C9\": 3, \"CYP2C9*1\": 1, \"CYP2C9*2\": 1, \"CYP2C9*3\": 1, \"VKORC1\": 1, \"genotyping\": 1, \"polymorphism\": 1, \"polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis\": 1}}", {"Target": ["CYP2C9", "VKORC1", "CYP2C9*1,*2 and *3 polymorphisms of CYP2C9"]}]], [710, "All subjects completed the study and no adverse events related to either of the herbal medicines or warfarin were reported.", [" {\"Herbal medicines\": 2, \"Warfarin\": 1}\n{\"Study participants\": 1}\n{\"Adverse events\": 1}\n{\"Warfarin\": 1}", {"Pathology": ["adverse events"], "Drug": ["warfarin"]}]], [711, "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate.", [" {\"AGONIST\": [\"ADP*\"]}\n{\"CONTROL_GROUP\": [\"Control\"]}\n{\"DRUG_TREATMENT\": [\"Policosanol treatment\", \"Echinacea treatment\"]}\n{\"AGONIST_MEAN\": [\"Mean (95% CI)\"]}\n{\"DRUG_TREATMENT_AGONIST_MEAN\": [\"Mean (95% CI)\"]}\n{\"AGONIST_GEOMETRIC_MEAN_RATIO\": [\"Geometric mean ratio to control (90% CI)\"]}\n{\"DRUG_TREATMENT_AGONIST_GEOMETRIC_MEAN_RATIO\": [\"Geometric mean ratio to control (90% CI)\"]}\n{\"DRUG_TREATMENT_MEAN\": [\"Mean (95% CI)\"]}\n{\"DRUG_TREATMENT_GEOMETRIC_MEAN_RATIO\": [\"Geometric mean ratio to control (90% CI)\"]}\n{\"DRUG_TREATMENT_AGONIST_MEAN\": [\"Mean (95% CI)\"]}\n{\"DRUG_TREATMENT_AGONIST_GEOMETRIC_MEAN_RATIO\": [\"Geometric mean ratio to control (90% CI)\"]}\n{\"DRUG_TREATMENT_AGONIST_MEAN\": [\"Mean (95% CI)\"]}\n{\"DRUG_TREATMENT_AGONIST_GEOMETRIC_MEAN_RATIO\": [\"Geometric mean ratio to control (90% CI)\"]}\n{\"DRUG_TREATMENT_AGONIST_MEAN\": [\"Mean (95% CI)\"]}\n{\"DRUG_TREATMENT_AGONIST_GEOMETRIC_MEAN_RATIO\": [\"Geometric mean ratio to control (90% CI)\"]}\n{\"DRUG_TREATMENT_AGONIST_MEAN\": [\"Mean (95% CI)\"]}\n{\"DRUG_TREATMENT_AGONIST_GEOMETRIC_MEAN_RATIO\": [\"Geometric mean ratio to control (90% CI)", {"Parameter": ["Platelet aggregation"], "Herb name": ["echinacea", "policosanol", "Policosanol", "Echinacea"]}]], [712, "Trough plasma concentrations of the major echinacea alkamide tetraene ranged from 1 to 23 ng ml\u22121, and the Cmax was found to range from 13 to 65 ng ml\u22121.", [" {\"Echinacea alkamide tetraene r\": 2, \"ng ml\u22121\": 2, \"Cmax\": 1}\n\n(\"plasma concentrations\", \"echinacea alkamide tetraene r\", \"ng ml\u22121\", \"Cmax\")", {"Herb name": ["echinacea alkamide tetraene"], "Parameter": ["Cmax"]}]], [713, "Interestingly, this effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics.", [" {\"S-warfarin\": 2}\n\n(Note: The frequency count is based on the single occurrence of the entity \"S-warfarin\" in the provided text.)", {"Drug": ["(S)-warfarin", "warfarin"]}]], [714, "Gorski et al.", [" {\"GORSKI\": 1, \"et al.\": 1}\n\n(Note: The frequency count is based on the occurrence of the entities within the context provided. If the context were longer, the frequency count might be higher.)", {}]], [715, "The reason for the discrepancy with previous studies remains unclear.", [" {\"PHARMACOLOGICAL TITLES\": [\"pharmacology\"], \"DRUG NAMES\": [], \"PHARMACOLOGISTS\": [], \"PHARMACOLOGICAL STUDIES\": [\"previous studies\"], \"PHARMACOLOGICAL PHASES\": [], \"PHARMACOLOGICAL EVENTS\": [\"discrepancy\"], \"PHARMACOLOGICAL EVENT TIMES\": [], \"PHARMACOLOGICAL LOCATIONS\": []}\n\n{\"FREQUENCY\": {\"PHARMACOLOGICAL STUDIES\": 1}}\n{\"FREQUENCY\": {\"PHARMACOLOGICAL EVENTS\": 1}}\n{\"FREQUENCY\": {\"PHARMACOLOGICAL TITLES\": 1}}\n{\"FREQUENCY\": {\"PHARMACOLOGICAL EVENT TIMES\": 1}}\n{\"FREQUENCY\": {\"PHARMACOLOGICAL LOCATIONS\": 0}}\n{\"FREQUENCY\": {\"DRUG NAMES\": 0}}\n{\"FREQUENCY\": {\"PHARMACOLOGISTS\": 0}}\n{\"FREQUENCY\": {\"PHARMACOLOGICAL PHASES\": 0}}\n{\"FREQUENCY\": {\"PHARMACOLOGICAL LOCATIONS\": 0}}\n{\"FREQUENCY\": {\"PHARMACOLOGICAL PHASES\": 0}}\n{\"FREQUENCY\": {\"PHARMACOLOGICAL EVENTS\": 0}}\n{\"FREQUENCY\": {\"PHARMACOLOGICAL LOCATIONS\": 0}}\n{\"FREQUENCY\": {\"PHARMACOLOGISTS\": 0}}\n{\"FREQUENCY\": {\"PHARMACOLOGICAL PHASES\": 0}}\n{\"FREQUENCY\": {\"PHARMACOLOGICAL LOCATIONS\": 0}}\n{\"FREQUENCY\": {\"PHARMACOLOGISTS\": 0}}\n{\"FREQUENCY\": {\"PHARMACOLOGICAL", {}]], [716, "A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively).", [" {\"Herb-drug use\": 3, \"cancer patients\": 1, \"oncology and urology clinics\": 1, \"University Hospital of the West Indies\": 1, \"Kingston\": 1, \"Jamaican prescription drug users\": 1, \"health care professionals\": 1, \"awareness\": 1}\n\n{\"Survey frequency\": 4}", {"Pathology": ["cancer"], "Ethnic group": ["Jamaican"]}]], [717, "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9].", [" {\"Allium sativum\": 1, \"Hypericum perforatum\": 1, \"Panax ginseng\": 1, \"Ginkgo biloba\": 1}\n\n{\"clinical studies\": 1, \"researched plants\": 1, \"commonly researched\": 1}", {"Study": ["Clinical studies"], "Herb name": ["garlic (Allium sativum)", "St. John\u2019s wort (Hypericum perforatum)", "Panax ginseng", "Ginkgo biloba"]}]], [718, "Key phytochemicals were individually assessed for their impact on CYP1A2 activity.", [" {\"CYP1A2\": 1, \"phytochemicals\": 1, \"impact\": 1}\n{\"FREQUENCY\": {\"CYP1A2 activity\": 1, \"phytochemicals\": 1, \"impact\": 1}}", {"Target": ["CYP1A2"]}]], [719, "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions.", [" {\"IC\": 2, \"in vitro\": 1, \"CYP assays\": 1, \"herb-drug interactions\": 1}\n{\"FREQUENCY\": {\"IC\": 2, \"in vitro\": 1, \"CYP assays\": 1, \"herb-drug interactions\": 1}}", {"Study": ["In vitro CYP assays"]}]], [720, "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica.", [" {\"beta-Sitosterol\": 1, \"cadina-4,10(15)-dien-3-one\": 1, \"lignans\": 1, \"dehydropodophyllotoxin\": 1, \"deoxydehydropodophyllotoxin\": 1, \"4\u2032-demethyldesoxypodophyllotoxin\": 1, \"5\u2032-methoxydehydropodophyllotoxin\": 1, \"dehydro-b-peltatin methyl ether\": 1, \"Department of Chemistry, University of the West Indies, Mona Campus, Jamaica\": 1}", {"Herb name": ["\u03b2-Sitosterol", "cadina-4,10(15)-dien-3-one", "lignans", "dehydropodophyllotoxin", "deoxydehydropodophyllotoxin", "4\u2032-demethyldesoxypodophyllotoxin", "5\u2032-methoxydehydropodophyllotoxin", "dehydro-b-peltatin methyl ether"]}]], [721, "The resulting liquor was suction-filtered through type 1 Whatman filter paper and stored in a sealed darkened glass container.", [" {\"Type 1 Whatman filter paper\": 1, \"sealed darkened glass container\": 1}\n\nNote: The entities mentioned in the text are specific items related to the pharmacological process described. However, the text does not explicitly mention any pharmacological entities such as drugs, compounds, or biological molecules. The entities listed are related to the equipment and storage used in the process. If the focus is strictly on pharmacological entities, the text provided does not contain any. However, I've included them as per the task's requirement to identify all words referring to described entities, even if they are not directly related to pharmacology.", {"Extraction process": ["liquor"]}]], [722, "The following chromatographic methods were employed.", [" {\"CHROMATOGRAPHIC_METHODS\": 1}\n\n{\"CHROMATOGRAPHIC_DEVICES\": 0}\n\n{\"CHROMATOGRAPHIC_COMPONENTS\": 0}\n\n{\"CHEMICAL_SUBSTANCES\": 0}\n\n{\"PHARMACOLOGIC_STUDIES\": 0}\n\n{\"PHARMACOLOGIC_TREATMENTS\": 0}\n\n{\"PHARMACOLOGIC_DRUGS\": 0}\n\n{\"PHARMACOLOGIC_EXPERIMENTS\": 0}\n\n{\"PHARMACOLOGIC_RESEARCHERS\": 0}\n\n{\"PHARMACOLOGIC_ARTICLES\": 0}\n\n{\"PHARMACOLOGIC_PUBLICATIONS\": 0}\n\n{\"PHARMACOLOGIC_JOURNALS\": 0}\n\n{\"PHARMACOLOGIC_PAPERS\": 0}\n\n{\"PHARMACOLOGIC_PRACTICES\": 0}\n\n{\"PHARMACOLOGIC_PATIENTS\": 0}\n\n{\"PHARMACOLOGIC_CLINICAL_TRIALS\": 0}\n\n{\"PHARMACOLOGIC_STUDIES_FREQUENCY\": \"\"}\n\n{\"PHARMACOLOGIC_TREATMENTS_FREQUENCY\": \"\"}\n\n{\"PHARMACOLOGIC_DRUGS_FREQUENCY\": \"\"}\n\n{\"PHARMACOLOGIC_EXPERIMENTS_FREQUENCY\": \"\"}\n\n{\"PHARMACOLOGIC_RESEARCHERS_FREQUENCY\": \"\"}\n\n{\"PHARMACOLOGIC_ARTICLES_FREQUENCY\": \"\"}\n\n{\"PHARMACOLOGIC_PUBLICATIONS_FREQUENCY\": \"\"}\n\n{\"PHARMACOLOGIC_JOURNALS_FREQUENCY\": \"\"}\n\n{\"PHARMACOLOGIC_PAPERS_FREQUENCY", {}]], [723, "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above.", [" {\"LC-MS\": 1, \"Waters LCT Time of Flight Mass Spectrometer\": 1, \"Waters Micromass Ltd.\": 1, \"Waters Alliance 2690 HPLC\": 1, \"Mass Lynx V4.1 software\": 1, \"HPLC conditions\": 1}", {}]], [724, "[15] to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6.", [" {\"cytochrome P450\": 1, \"natural products\": 1, \"inhibition potential\": 1, \"P450 enzymes\": 1, \"CYPs 1A1\": 1, \"CYPs 1A2\": 1, \"CYPs 1B1\": 1, \"CYPs 3A4\": 1, \"CYPs 2D6\": 1}", {"Target": ["cytochrome P450", "P450 enzymes", "CYPs 1A1, 1A2, 1B1, 3A4 and 2D6"]}]], [725, "[35].", [" {\"Pharmacology\": 1, \"scientific article\": 1, \"pharmacological entities\": 1, \"drugs\": 1, \"drug molecules\": 1, \"pharmacokinetics\": 1, \"pharmacodynamics\": 1, \"pharmaceutical compounds\": 1, \"pharmacology-related terms\": 1, \"pharmacological studies\": 1, \"pharmacological research\": 1, \"pharmacological agents\": 1, \"pharmacological effects\": 1, \"pharmacological interventions\": 1, \"pharmacological entities\": 1, \"pharmacological concepts\": 1, \"pharmacological terminology\": 1, \"pharmacological literature\": 1, \"pharmacological references\": 1, \"pharmacological sources\": 1, \"pharmacological journals\": 1, \"pharmacological publications\": 1, \"pharmacological studies\": 1, \"pharmacological experiments\": 1, \"pharmacological trials\": 1, \"pharmacological data\": 1, \"pharmacological findings\": 1, \"pharmacological outcomes\": 1, \"pharmacological effects\": 1, \"pharmacological mechanisms\": 1, \"pharmacological pathways\": 1, \"pharmacological processes\": 1, \"pharmacological reactions\": 1, \"pharmacological responses\": 1, \"pharmacological interactions\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"pharmacological effects\": 1, \"ph", {}]], [726, "100 \u00b5L of various concentrations of the extracts, and the ascorbic acid control, in methanol, were added to 100 \u00b5L of a 0.02% (w/v) stock solution of the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) in methanol.", [" {\"Extracts\": 1, \"concentrations\": 1, \"methanol\": 2, \"ascorbic acid\": 1, \"control\": 1, \"2,2-diphenyl-1-picrylhydrazyl (DPPH)\": 1}\n{\"FREQUENCY\": {\"Extracts\": 1, \"concentrations\": 1, \"methanol\": 2, \"ascorbic acid\": 1, \"control\": 1, \"2,2-diphenyl-1-picrylhydrazyl (DPPH)\": 1}}\n\nNote: The frequency count is based on the number of times each entity is mentioned in the text.", {}]], [727, "Structures of phytochemicals identified in the aqueous extract of H. verticillata (aerial, dried).", [" {\"H. verticillata\": 1, \"aqueous extract\": 1, \"phytochemicals\": 1, \"structures\": 1}\n\nNote: The frequency count is based on the direct mentions of the entities in the provided text. If there are synonyms or related terms used in the article that refer to these entities, they are not included in this count as per the instruction to only parse cited entities.", {"Extraction process": ["the aqueous extract"], "Herb name": ["H. verticillata"], "Herb part": ["aerial"]}]], [728, "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve.", [" {\"Curcumin\": 1, \"plasma concentration-time curve\": 1, \"area under the plasma concentration-time curve\": 1, \"area under the first moment of plasma drug concentration-time curve\": 1}\n\n{\"p\": 1}\n\n(Note: The frequency count is based on the direct mention of the entities in the provided text. If the context implies a frequency without explicit mention, it is not included.)", {"Herb name": ["curcumin"], "Parameter": ["area under the plasma concentration-time curve", "area under the first moment of plasma drug concentration-time curve"]}]], [729, "Worse than the Disease?", [" {\"Disease\": [\"worse than the Disease\"], \"Pharmacology\": [\"pharmacology\"], \"Scientific Article\": [\"scientific article\"], \"Pharmacologist\": [\"pharmacologist\"], \"Drug\": [\"drug\"], \"Treatment\": [\"treatment\"], \"Research\": [\"research\"]}\n{\"Frequency\": {\"Disease\": 1, \"Pharmacology\": 1, \"Scientific Article\": 1, \"Pharmacologist\": 1, \"Drug\": 1, \"Treatment\": 1, \"Research\": 1}}\n\n(Note: The phrase \"worse than the Disease\" is not a cited entity but a comparative statement. However, it was included in the frequency count as it is part of the text.)", {"Pathology": ["the Disease"]}]], [730, "An external file that holds a picture, illustration, etc.", [" {\"PHARMACOLOGICAL TERMS\": [\"pharmacology\", \"drug\", \"medication\", \"pharmacokinetics\", \"pharmacodynamics\", \"receptor\", \"enzyme\", \"metabolism\", \"absorption\", \"distribution\", \"excretion\", \"bioavailability\", \"half-life\", \"therapeutic window\", \"drug-drug interaction\", \"drug-food interaction\", \"drug resistance\", \"pharmacogenomics\", \"pharmacoeconomics\", \"pharmacotherapy\", \"pharmacodynamics\", \"pharmacokinetics\", \"pharmacological target\", \"pharmacological effect\", \"pharmacological action\", \"pharmacological response\", \"pharmacological efficacy\", \"pharmacological potency\", \"pharmacological selectivity\", \"pharmacological tolerance\", \"pharmacological toxicity\", \"pharmacological safety\", \"pharmacological side effect\", \"pharmacological adverse effect\", \"pharmacological contraindication\", \"pharmacological precaution\", \"pharmacological interaction\", \"pharmacological synergy\", \"pharmacological antagonism\", \"pharmacological agonism\", \"pharmacological inhibition\", \"pharmacological induction\", \"pharmacological potentiation\", \"pharmacological attenuation\", \"pharmacological enhancement\", \"pharmacological modulation\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\", \"pharmacological optimization\",", {}]], [731, "Five days after presentation, her symptoms had completely resolved.", [" {\"Symptoms\": 1, \"Patient\": 1}\n{\"Presentation\": 1, \"Days\": 5}\n{\"Resolution\": 1}\n{\"Pharmacology\": \"\", \"Drug\": \"\", \"Dosage\": \"\", \"Side Effects\": \"\", \"Therapeutic Effect\": \"\", \"Disease\": \"\", \"Condition\": \"\", \"Treatment\": \"\", \"Pharmacokinetics\": \"\", \"Pharmacodynamics\": \"\", \"Drug Interaction\": \"\", \"Drug Metabolism\": \"\", \"Drug Excretion\": \"\"}", {}]], [732, "The naturopathic literature from which most information about rashes caused by Lomatium is drawn do not indicate a well-studied treatment of the rash aside from supportive care and cessation of Lomatium ingestion.", [" {\"Lomatium\": 2, \"rashes\": 1, \"naturopathic literature\": 1, \"supportive care\": 1, \"cessation\": 1, \"Lomatium ingestion\": 1}\n{\"FREQUENCY\": {\"Lomatium\": 2, \"rashes\": 1, \"naturopathic literature\": 1, \"supportive care\": 1, \"cessation\": 1, \"Lomatium ingestion\": 1}}", {"Pathology": ["rashes", "the rash"], "Herb name": ["Lomatium", "Lomatium"]}]], [733, "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis.", [" {\"glucocorticoids\": 1, \"extract\": 1, \"antihistamines\": 1}\n{\"FREQUENCY\": {\"glucocorticoids\": 1, \"extract\": 1, \"antihistamines\": 1}}\n\n(Note: The term \"pharmacology\" itself is not an entity cited in the provided text, but it is the field of study related to the entities mentioned.)", {"Pathology": ["the rash", "pruritis"], "Drug": ["glucocorticoids", "antihistamines"]}]], [734, "To explore more, we would like to investigate the interactions between OS and selected single herbs from these Wen Bing formulas.", [" {\"OS\": 1, \"Wen Bing formulas\": 1, \"single herbs\": 1}\n{\"FREQUENCY\": {\"OS\": 1, \"Wen Bing formulas\": 1, \"single herbs\": 1}}", {"Drug": ["OS"], "Herb name": ["Wen Bing formulas"]}]], [735, "A commercially available, standardized and purified Radix Scutellariae extract (RS) was obtained from Shanghai U-sea Biotech Co., Ltd. (Shanghai, China) with a batch number of 110208 and a quality of control standard number of WS-10001-(HD-0989)-2002.", [" {\"Radix Scutellariae\": 1, \"Radix Scutellariae extract\": 1, \"Shanghai U-sea Biotech Co., Ltd.\": 1, \"batch number\": 1, \"WS-10001-(HD-0989)-2002\": 1}\n{\"Frequency\": {\"Radix Scutellariae\": 1, \"Radix Scutellariae extract\": 1, \"Shanghai U-sea Biotech Co., Ltd.\": 1, \"batch number\": 1, \"WS-10001-(HD-0989)-2002\": 1}}", {"Herb name": ["Radix Scutellariae extract (RS)"]}]], [736, "Albuterol (as internal standard) was purchased from Sigma-Aldrich Chem.", [" {\"Albuterol\": 1, \"internal standard\": 1, \"Sigma-Aldrich Chemical Company\": 1}\n\nNote: The frequency count is based on the number of times each entity is mentioned in the provided text. If the text had more instances of these entities, the frequency count would increase accordingly. However, based on the given text, the frequency count is as provided above.", {}]], [737, "Hygromycin B, glycyl-sarcosine (Gly-Sar) and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich Chem.", [" {\"Hygromycin B\": 1, \"glycyl-sarcosine (Gly-Sar)\": 1, \"thiazolyl blue tetrazolium bromide (MTT)\": 1, \"Sigma-Aldrich Chemicals\": 1}\n{\"Hygromycin B\": 1, \"glycyl-sarcosine (Gly-Sar)\": 1, \"thiazolyl blue tetrazolium bromide (MTT)\": 1, \"Sigma-Aldrich Chemicals\": 1}\n{\"Hygromycin B\": 1, \"glycyl-sarcosine (Gly-Sar)\": 1, \"thiazolyl blue tetrazolium bromide (MTT)\": 1, \"Sigma-Aldrich Chemicals\": 1}", {}]], [738, "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS.", [" {\"dichlorvos\": 1, \"8mg/mL\": 1, \"PBS\": 1}\n{\"dichlorvos_concentration\": 1, \"PBS_volume\": 1}\n\n(Note: The FREQUENCY values are given as the number of occurrences of the entities in the text. The entities are directly related to the pharmacological context of the text.)", {}]], [739, "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity.", [" {\"Day 5\": 1, \"30 minutes\": 1, \"8 PM\": 1, \"rats\": 2, \"antiviral activity\": 1, \"inferior vena\": 1, \"blood\": 1}\n{\"Dose\": 1, \"10 mL\": 1}\n{\"anesthetized\": 1}\n{\"determination\": 1}\n{\"collected\": 1}\n{\"rats\u2019\": 1}\n{\"rats\u2019 inferior vena\": 1}", {}]], [740, "The incubation system for rat plasma contains 1\u202f\u03bcg/mL of OS and 10% rat plasma since the super-fast reaction rate of 100% rat plasma resulted in no discrimination for nearly all the studied herb/herbal components.", [" {\"OS\": 1, \"rat plasma\": 2}", {}]], [741, "The formation rate of OSA could be significantly suppressed by all the herb/herbal components.", [" {\"OSA\": 1, \"herb/herbal components\": 1}\n{\"FREQUENCY\": {\"OSA suppression\": 1}}\n{\"FREQUENCY\": {\"herb/herbal components\": 1}}", {"Drug": ["OSA"]}]], [742, "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs.", [" {\"RLM\": 1, \"hCE1\": 1, \"ten marker components\": 1, \"Figs\": 1}\n\nNote: In this context, \"RLM\" and \"hCE1\" are considered as cited entities referring to specific methods or assays, and \"ten marker components\" refers to the biological entities being measured. \"Figs\" refers to the figures in the scientific article where the trends are displayed.", {}]], [743, "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism.", [" {\"HDI\": 1, \"anti-influenza herbs/herbal components\": 1, \"in-vitro experiments\": 1, \"absorption and metabolism\": 1}\n\n(Note: The term \"P\" in \"S4, the P\" is not clearly an entity related to the described entities in the context of pharmacology, so it is not included in the output.)", {"Study": ["in-vitro experiments"], "Drug": ["OS"]}]], [744, "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig.", [" {\"RS\": 2, \"OS\": 2, \"OSA\": 1, \"co-administration\": 1, \"systemic exposure\": 1, \"Figure\": 1}", {"Herb name": ["RS"], "Drug": ["OS", "OSA"]}]], [745, "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig.", [" {\"RS\": [1], \"OSA\": [1], \"OS\": [1], \"rat urine samples\": [1], \"co-administration\": [1]}", {"Drug": ["OSA", "OS"], "Herb name": ["RS"]}]], [746, "S8).", [" In the provided text, it's not possible to extract specific entities or their frequencies without the actual content of the scientific article. However, I can guide you on how to identify and parse cited entities in a scientific article about pharmacology once you have the text.\n\nTo identify and parse cited entities in a scientific article, you should look for the following types of entities:\n\n1. Drug names: These are usually capitalized and may include chemical names or brand names.\n2. Diseases or medical conditions: These are often capitalized and may include specific names or classifications.\n3. Organizations: Names of pharmaceutical companies, research institutions, or professional organizations.\n4. Researchers: Names of authors, researchers, or scientists.\n5. Publications: Titles of journals, conferences, or specific articles.\n\nOnce you have the text, you can use the following format to record the frequency of each entity:\n\n{\n  \"Drug names\": {\"Frequency\": [frequency of drug names], \"Entities\": [\"Drug1\", \"Drug2\",...]},\n  \"Diseases/Medical conditions\": {\"Frequency\": [frequency of diseases/medical conditions], \"Entities\": [\"Condition1\", \"Condition2\",...]},\n  \"Organizations\": {\"Frequency\": [frequency of organizations], \"Entities\": [\"Org1\", \"Org2\",...]},\n  \"Researchers\": {\"Frequency\": [frequency of researchers], \"Entities\": [\"Researcher1\", \"Researcher2\",...]},\n  \"Publications\": {\"Frequency\": [frequency of publications], \"Entities\": [\"Publication1\", \"Publication2\",...]},\n}\n\nIf no information is found for a specific entity, leave the corresponding fields empty. For example:\n\n{\n  \"Drug names\": {\"Frequency\": 0, \"Entities\": []},\n  \"Diseases/Medical conditions\": {\"Frequency\": 0, \"Entities\": []},\n  \"Organizations\": {\"Frequency\": 0, \"Entities\": []},\n  \"Researchers\": {\"Frequency\": 0, \"Entities\": []},\n  \"Publications\": {\"Frequency\": 0, \"Entities", {}]], [747, "In our current study, a screening platform based on microsomes, enzymes, cells and influenza viruses have for the first time been developed and utilized to screen potential interaction between OS and anti-influenza herb/herbal components.", [" {\"Microsomes\": 1, \"enzymes\": 1, \"cells\": 1, \"influenza viruses\": 1, \"OS\": 1, \"anti-influenza herb/herbal components\": 1}\n{\"FREQUENCY\": {\"microsomes\": 1, \"enzymes\": 1, \"cells\": 1, \"influenza viruses\": 1, \"OS\": 1, \"anti-influenza herb/herbal components\": 1}}\n\n(Note: The frequency count is based on the direct mentions of the entities in the provided text.)", {"Drug": ["OS"]}]], [748, "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components.", [" {\"HERBAL EXTRACTS\": 1, \"HERBAL COMPONENTS\": 1, \"RAT PLASTRA\": 1, \"OS\": 1, \"HYDROLYSIS\": 1, \"%INHIBITION RATE\": 1}", {"Amount": ["500\u202f\u03bcg/mL", "100\u202f\u03bcg/mL"], "Drug": ["OS"]}]], [749, "The hydrolase activities in rat plasma may be originated from more than one kind of enzymes (not only hCE1) and the inhibition activities of these herbal components to each kind of hydrolysis enzymes are different.", [" {\"hydrolase\": 1, \"rat plasma\": 1, \"enzymes\": 1, \"hCE1\": 1, \"herbal components\": 1, \"inhibition activities\": 1, \"hydrolysis enzymes\": 1}", {"Target": ["hCE1"]}]], [750, "After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS.", [" {\"Hierbal components (herbs/herbal components)\": [1], \"Oxidative stress (OS)\": [1], \"Human Development Index (HDI)\": [1], \"Absolute z-score\": [1], \"level of HDI relevancy\": [1]}\n\n{\"Pharmacology\": [1], \"scientific article\": [1], \"pharmacology\": [1], \"pharmacological effects\": [1], \"pharmacodynamics\": [1], \"pharmacokinetics\": [1], \"pharmacotherapy\": [1], \"pharmacology-related entities\": [1]}\n\n{\"events\": [1]}\n\n{\"frequences\": [1]}\n\n{\"FREQUENCY\": [1]}", {"Drug": ["OS", "OS"]}]], [751, "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats.", [" {\"RS\": 3, \"BIO\": 2, \"OS\": 3, \"Table 1\": 1, \"pop-PK model\": 2, \"metabolic clearance (CL)\": 1, \"platform\": 1, \"six-dimension in-vitro screening\": 1, \"in-vivo pharmacokinetics\": 1, \"rats\": 1, \"ex-vivo pharmacodynamic evaluation\": 1}", {"Herb name": ["RS", "RS", "RS"], "Parameter": ["BIO", "AUC"], "Drug": ["OS", "OS"], "Study": ["in-vitro screening", "in-vivo", "ex-vivo"]}]], [752, "Radix Isatidis (Root of Isatis indigotica Fort., Banlangen).", [" {\"Radix Isatidis\": 1, \"Root of Isatis indigotica Fort.\": 1, \"Banlangen\": 1}", {"Herb name": ["Radix Isatidis", "Isatis indigotica Fort"], "Herb part": ["Root"]}]], [753, "Fructus Arctii (Fruit of Arctium lappa L., Niubangzi).", [" {\"Fructus Arctii\": 1, \"Arctium lappa L.\": 1, \"Niubangzi\": 1}", {"Herb name": ["Fructus Arctii", "Arctium lappa L."], "Herb part": ["Fruit"]}]], [754, "30%\u201370% of clinical breast cancer patients use natural products, which may increase the likelihood of drug interactions.", [" {\"Clinical Breast Cancer Patients\": 1, \"Natural Products\": 1, \"Drug Interactions\": 1}\n{\"FREQUENCY\": {\"Clinical Breast Cancer Patients\": 1, \"Natural Products\": 1, \"Drug Interactions\": 1}}\n\n(Note: The percentages mentioned in the instruction are not entities but rather descriptive statistics. Therefore, they are not included in the parsed entities list.)", {"Pathology": ["breast cancer"]}]], [755, "Conclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking.", [" {\"TAM\": 1, \"natural products\": 1, \"pre-clinical studies\": 1, \"clinical evidence\": 1}\n\n(Note: The entities \"TAM\" and \"natural products\" are inferred from the context of the conclusion, as they are the primary subjects of the potential interactions being discussed.)", {"Herb name": ["natural products"], "Drug": ["TAM"], "Study": ["pre-clinical studies"]}]], [756, "Of all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010).", [" {\"CAM treatment\": 1, \"breast cancer patients\": 1, \"complementary and alternative medicine\": 1, \"Wanchai et al., 2010\": 1}\n{\"FREQUENCY\": {\"CAM treatment\": 1, \"breast cancer patients\": 1, \"complementary and alternative medicine\": 1, \"Wanchai et al., 2010\": 1}}\n\nNote: The frequency count is based on the specific phrases and entities mentioned in the provided text. If there were no specific mentions of these entities, the frequency count would be zero for those entities. However, in this case, all the specified entities are mentioned once, hence the frequency count is 1 for each.", {"Pathology": ["cancer", "breast cancer"]}]], [757, "), dried orange peel (Citrus aurantium L.), Anemarrhena (Anemarrhena asphodeloides Bunge), Phellodendron bark (Phellodendron amurense Rupr.", [" {\"CITED_PHARMACOLOGICAL_ENTITIES\": {\"Citrus aurantium L.\": 1, \"Anemarrhena asphodeloides Bunge\": 1, \"Phellodendron amurense Rupr.\": 1, \"dried orange peel\": 1, \"Anemarrhena\": 1, \"Phellodendron bark\": 1}", {"Herb name": ["dried orange peel (Citrus aurantium L.)", "Anemarrhena (Anemarrhena asphodeloides Bunge)", "Phellodendron bark (Phellodendron amurense Rupr."]}]], [758, "), Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)", [" {\"Licorice (Glycyrrhiza glabra L.)\": 1, \"Ginger (Zingiber officinale Roscoe)\": 1, \"Lilyturf (Ophiopogon japonicus (Thunb.)\": 1}", {"Herb name": ["Licorice (Glycyrrhiza glabra L.)", "Ginger (Zingiber officinale Roscoe)", "Lilyturf (Ophiopogon japonicus (Thunb.)"]}]], [759, "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013).", [" {\"APOPOPTOSIS\": 1, \"autophagy\": 1, \"cell cycle arrest\": 1, \"anti-cancer drugs\": 1, \"Chen and Karantza-Wadsworth, 2009\": 1, \"Wang et al., 2011\": 1, \"Kon et al., 2013\": 1}\n\n{\"FREQUENCY\": {\"APOPOPTOSIS\": 1, \"autophagy\": 1, \"cell cycle arrest\": 1, \"anti-cancer drugs\": 1, \"Chen and Karantza-Wadsworth, 2009\": 1, \"Wang et al., 2011\": 1, \"Kon et al., 2013\": 1}}", {"Pathology": ["anti-cancer", "apoptosis, autophagy, and cell cycle arrest"]}]], [760, "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018).", [" {\"HES\": 1, \"PIP\": 1, \"BV\": 1, \"TAM\": 1, \"MCF7\": 1, \"T47D\": 1, \"Khamis et al., 2018\": 1}\n{\"FREQUENCY\": {\"HES\": 1, \"PIP\": 1, \"BV\": 1, \"TAM\": 1, \"MCF7\": 1, \"T47D\": 1, \"Khamis et al., 2018\": 1}}\n\nNote: The frequency count is based on the direct mentions of the entities in the provided text. If there were multiple instances of the same entity, the frequency would increase accordingly. However, in this specific text, each entity is mentioned only once.", {"Herb name": ["HES", "PIP", "BV"], "Drug": ["TAM"], "Pathology": ["anti-proliferative effect", "apoptosis"]}]], [761, "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010).", [" {\"MCF-7\": 1, \"T-47D\": 1, \"Cho et al., 2010\": 1}\n{\"TAM\": 1}\n{\"synergistic inhibitory effect\": 1}\n{\"MCF-7 cell growth\": 1}\n{\"T-47D cell growth\": 1}", {"Drug": ["TAM"], "Parameter": ["MCF-7 and T-47D cell growth"]}]], [762, "Mistletoe (Viscum album L.) derived medicinal preparations are widely used and registered as medicines in many European countries.", [" {\"Mistletoe (Viscum album L.)\": 1, \"medicinal preparations\": 1, \"medicines\": 1, \"European countries\": 1}\n{\"Viscum album\": 1}\n{\"L.\": 1}\n{\"Medicinal preparations\": 1}\n{\"Medicines\": 1}\n{\"European countries\": 1}", {"Herb name": ["Mistletoe (Viscum album L.)"], "Ethnic group": ["European"]}]], [763, "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012).", [" {\"MCF-7\": 2, \"TAM-resistant\": 2, \"Evn-50\": 1, \"Vitex negundo L.\": 1, \"TAM\": 2, \"cell viability\": 1, \"cell growth\": 1, \"apoptosis\": 1, \"TAM resistance\": 1}", {"Drug": ["TAM", "TAM", "TAM", "TAM"], "Herb name": ["10 Evn-50", "Vitex negundo L."], "Extraction process": ["ethyl acetate extract"], "Parameter": ["cell viability", "cell growth"]}]], [764, "Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010).", [" {\"Jaeumkanghwa soup (JEKHT)\": 1, \"traditional herbs\": 1, \"Jung et al., 2010\": 1}\n{\"Jaeumkanghwa soup (JEKHT)\": 1, \"traditional herbs\": 1, \"Jung et al., 2010\": 1}\n{\"Jaeumkanghwa soup (JEKHT)\": 1, \"traditional herbs\": 1, \"2010\": 1}\n{\"Jaeumkanghwa soup (JEKHT)\": 1, \"herbs\": 1, \"2010\": 1}\n{\"Jaeumkanghwa soup (JEKHT)\": 1, \"herbs\": 1}\n{\"traditional herbs\": 1}\n{\"Jung et al., 2010\": 1}\n{\"2010\": 1}\n{\"traditional herbs\": 1}\n{\"Jung et al.\": 1}\n{\"2010\": 1}\n{\"traditional herbs\": 1}\n{\"Jung\": 1}\n{\"et al.\": 1}\n{\"2010\": 1}\n{\"traditional\": 1}\n{\"herbs\": 1}\n{\"Jung\": 1}\n{\"et\": 1}\n{\"al\": 1}\n{\"2010\": 1}\n{\"traditional\": 1}\n{\"herbs\": 1}\n{\"Jung\": 1}\n{\"et\": 1}\n{\"al\": 1}\n{\"2010\": 1}\n{\"traditional\": 1}\n{\"herbs\": 1}\n{\"Jung\": 1}\n{\"et\": 1}\n{\"al\": 1}\n{\"2010\": 1}\n{\"traditional\": 1}\n{\"herbs\": 1}\n{\"Jung\": 1}\n{\"et\": 1}\n{\"al\": 1}\n{\"2010\": 1}\n{\"traditional\": 1}\n{\"herbs\": 1}\n{\"Jung\": 1}\n{\"et\":", {"Herb name": ["Jaeumkanghwa soup (JEKHT)"]}]], [765, "Jiawei Xiaoyao San (JWXYS) is a very common Chinese herbal formula used by the Chinese for thousands of years (Chen et al., 2014).", [" {\"JWXYS\": 1, \"Chinese herbal formula\": 1, \"Chinese\": 1, \"Chen et al., 2014\": 1}\n\nNote: The frequency count is based on the number of times the entities appear in the provided text. If the context suggests that the entities are mentioned more than once but the exact count cannot be determined from the text, the frequency is represented as at least 1.", {"Herb name": ["Jiawei Xiaoyao San (JWXYS)"], "Ethnic group": ["Chinese", "Chinese"], "Duration": ["for thousands of years"]}]], [766, "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015).", [" {\"Rahate, A. and Rajasekaran, S. (2015): Protective effect\": 1, \"protective effect\": 1, \"dose-dependent\": 1}\n{\"Rahate, A.\": 1, \"Rajasekaran, S.\": 1}\n{\"2015\": 1}\n{\"Protective effect\": 1}\n{\"dose-dependent\": 1}", {"Pathology": ["protective effect"]}]], [767, "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b).", [" {\"DDB\": 1, \"oxidative stress\": 1, \"TAM-intoxicated liver injury\": 1, \"rats\": 1, \"antioxidant enzymes\": 1, \"sGPT\": 1, \"sGOT\": 1, \"glutathione\": 1, \"TBARS\": 1, \"liver transaminases\": 1, \"El-Beshbishy, 2005b\": 1}\n\n{\"TDB\": \"\", \"oxidative stress status\": \"\", \"TAM\": \"\", \"liver injury\": \"\", \"rats\": \"\", \"antioxidant enzymes\": \"\", \"sGPT\": \"\", \"sGOT\": \"\", \"glutathione\": \"\", \"TBARS\": \"\", \"liver transaminases\": \"\", \"El-Beshbishy, 2005b\": \"\"}", {"Herb name": ["DDB"], "Pathology": ["the oxidative stress", "liver injury"], "Drug": ["TAM"], "Parameter": ["antioxidant enzymes", "the activity of sGPT and sGOT", "glutathione concomitant", "TBARS", "liver transaminases"]}]], [768, "Studies have shown that just the monitoring of protein expression levels is insufficient in understanding transcription activity in vitro (Gord\u00e2n et al., 2009).", [" {\"Gord\u00e2n et al., 2009\": 1}\n{\"protein expression levels\": 1}\n{\"transcription activity\": 1}\n{\"in vitro\": 1}", {"Parameter": ["protein expression levels"]}]], [769, "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP.", [" {\"OAT1/3\": 1, \"MDR1\": 1, \"BCRP\": 1, \"GA\": 1, \"PCA\": 1}\n\n- \"OAT1/3\" appears once as an entity affected by GA and PCA.\n\n- \"MDR1\" appears once as an entity induced by GA and PCA.\n\n- \"BCRP\" appears once as an entity induced by GA and PCA.\n\n- \"GA\" appears once as a substance with inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP.\n\n- \"PCA\" appears once as a substance with inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP.", {"Herb name": ["GA", "PCA"], "Target": ["OAT1/3", "MDR1", "BCRP"]}]], [770, "Communicable diseases are still leading causes of death and disability globally, according to WHO\u2019s Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020).", [" {\"WHO\": 2, \"Global Health Estimates\": 1, \"GBD Diseases and Injuries\": 1, \"2000-2019\": 1, \"communicable diseases\": 1, \"death\": 1, \"disability\": 1}\n{\"FREQUENCY\": {\"WHO\": 2, \"Global Health Estimates\": 1, \"GBD Diseases and Injuries\": 1, \"2000-2019\": 1, \"communicable diseases\": 1, \"death\": 1, \"disability\": 1}}", {"Pathology": ["Communicable diseases"]}]], [771, "ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011).", [" {\"DON (P. capitatum)\": 1, \"Chinese herbal plant\": 1, \"urinary tract infections\": 1, \"pyelonephritis\": 1, \"prostatitis\": 1, \"Chinese Pharmacopoeia Commission\": 1, \"2010\": 1, \"Liao et al., 2011\": 1}\n\n{\"urinary tract infections\": 1, \"pyelonephritis\": 1, \"prostatitis\": 1}\n\n{\"Chinese Pharmacopoeia Commission\": 1, \"2010\": 1, \"Liao et al., 2011\": 1}", {"Herb name": ["ex D. Don (P. capitatum)"], "Ethnic group": ["Chinese", "Chinese"], "Drug": ["antibacterial agents"], "Pathology": ["urinary tract infections", "pyelonephritis", "prostatitis"]}]], [772, "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies.", [" {\"GA\": 1, \"PCA\": 2, \"PCE tracer components\": 1, \"HDIs studies\": 1}\n{\"GA\": 1, \"PCA\": 2, \"PCE tracer components\": 1, \"HDIs studies\": 1}\n{\"GA\": 1, \"PCA\": 2, \"PCE tracer components\": 1, \"HDIs studies\": 1}\n{\"PCE tracer components\": 1, \"HDIs studies\": 1}\n{\"GA\": 1, \"PCA\": 2, \"PCE tracer components\": 1, \"HDIs studies\": 1}\n{\"GA\": 1, \"PCA\": 2, \"PCE tracer components\": 1, \"HDIs studies\": 1}\n{\"PCE tracer components\": 1, \"HDIs studies\": 1}\n{\"PCE tracer components\": 1, \"HDIs studies\": 1}\n{\"PCE tracer components\": 1, \"HDIs studies\": 1}\n{\"PCE tracer components\": 1, \"HDIs studies\": 1}\n{\"PCE tracer components\": 1, \"HDIs studies\": 1}\n{\"PCE tracer components\": 1, \"HDIs studies\": 1}\n{\"PCE tracer components\": 1, \"HDIs studies\": 1}\n{\"PCE tracer components\": 1, \"HDIs studies\": 1}\n{\"PCE tracer components\": 1, \"HDIs studies\": 1}\n{\"PCE tracer components\": 1, \"HDIs studies\": 1}\n{\"PCE tracer components\": 1, \"HDIs studies\": 1}\n{\"PCE tracer components\": 1, \"HDIs studies\": 1}\n{\"PCE tracer components\": 1, \"HDIs studies\": 1}\n{\"PCE tracer components\": 1, \"HDIs studies\": 1}\n{\"PCE tracer components\": 1, \"HDIs studies\": 1}\n{\"PCE tracer components\": 1, \"HDIs studies\": 1}\n{\"PCE tracer components\": 1, \"HDIs studies\": 1}\n{\"PCE tracer components\": 1,", {"Herb name": ["GA", "PCA", "PCE"]}]], [773, "Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990).", [" {\"CIP\": 2, \"Vance-Bryan et al., 1990\": 1}\n{\"FREQUENCY\": {\"CIP\": 2, \"Vance-Bryan et al., 1990\": 1}}\n{\"CIP\": \"2\", \"Vance-Bryan et al., 1990\": \"1\"}\n{\"CIP\": \"2\", \"Vance-Bryan et al.\": \"1\", \"1990\": \"1\"}\n{\"CIP\": \"2\", \"Vance-Bryan\": \"1\", \"et\": \"1\", \"al\": \"1\", \"1990\": \"1\"}\n{\"CIP\": \"2\", \"Vance\": \"1\", \"Bryan\": \"1\", \"et\": \"1\", \"al\": \"1\", \"1990\": \"1\"}\n{\"CIP\": \"2\", \"Vance-Bryan\": \"1\", \"et\": \"1\", \"al\": \"1\", \"1990\": \"1\"}\n{\"CIP\": \"2\", \"Vance-Bryan et al.\": \"1\", \"1990\": \"1\"}\n{\"CIP\": \"2\", \"Vance-Bryan et al.\": \"1\"}\n{\"CIP\": \"2\", \"Vance-Bryan et al.\": \"1\", \"1990\": \"1\"}\n{\"CIP\": \"2\", \"Vance-Bryan et al.\": \"1\", \"1990\": \"1\"}\n{\"CIP\": \"2\", \"Vance-Bryan et al.\": \"1\", \"1990\": \"1\"}\n{\"CIP\": \"2\", \"Vance-Bryan et al.\": \"1\", \"1990\": \"1\"}\n{\"CIP\": \"2\", \"Vance-Bryan et al.\": \"1\", \"1990\": \"1\"}\n{\"CIP\": \"2\", \"Vance-Bryan et al.\": \"1\", \"1990\": \"1\"}\n{\"CIP\": \"2\", \"Vance-Bryan et al.\": \"1\", \"1990\": \"1", {"Drug": ["CIP"]}]], [774, "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012).", [" {\"CIP\": 4, \"ATP-binding cassette transporters\": 2, \"intestinal secretion\": 1, \"biliary excretion\": 1, \"secretion into breast milk\": 1, \"Vance-Bryan et al., 1990\": 1, \"Merino et al., 2006\": 1, \"Ando et al., 2007\": 1, \"Mulgaonkar et al., 2012\": 1}", {"Drug": ["CIP"]}]], [775, "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A.", [" {\"Gradient Elution Program\": [1, 1, 1, 1, 1]}\n{\"0\u20138.5 min\": [1]}\n{\"97% A\": [2, 2]}\n{\"8.7\u201311 min\": [1]}\n{\"60% A\": [1]}\n{\"11.5\u201313.5 min\": [1]}\n{\"10% A\": [1]}\n{\"14\u201315 min\": [1]}\n{\"97% A\": [1]}", {}]], [776, "The supernate was utilized for the quantification of GA, PCA, and CIP.", [" {\"Supernate\": 1, \"Quantification\": 1, \"GA\": 1, \"PCA\": 1, \"CIP\": 1}\n{\"FREQUENCY\": {\"Supernate\": 1, \"Quantification\": 1, \"GA\": 1, \"PCA\": 1, \"CIP\": 1}}\n\n(Note: The term \"utilized\" is not explicitly listed as an entity but is part of the context in which \"Supernate\" is used. However, it is not a standalone entity in the context of pharmacology citation.)", {"Herb name": ["GA", "PCA"], "Drug": ["CIP"]}]], [777, "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively.", [" {\"CIP\": 2, \"ofloxacin\": 2, \"332.1\u2192288.1\": 1, \"362.2\u2192318.1\": 1, \"internal standard\": 1}\n{\"FREQUENCY\": {\"CIP\": 2, \"ofloxacin\": 2, \"332.1\u2192288.1\": 1, \"362.2\u2192318.1\": 1, \"internal standard\": 1}}", {"Drug": ["CIP", "ofloxacin"]}]], [778, "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively.", [" {\"CIP\": 1, \"PCE\": 1, \"GA\": 1, \"PCA\": 1, \"Figures\": 2}\n\n(Note: The frequency count for \"Figures\" is based on the mention of two figures, so it's counted as 2.)", {"Drug": ["CIP"], "Herb name": ["PCE", "GA", "PCA"]}]], [779, "PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively.", [" {\"PCE\": 3, \"ciprofloxacin\": 2, \"K Tissue distribution coefficients\": 1, \"tissue distribution profiles\": 1, \"intravenous administration\": 1, \"intragastric administration\": 1, \"rats\": 2, \"Figures 7A,B\": 1}", {"Herb name": ["PCE", "PCE", "GA", "PCE"], "Drug": ["ciprofloxacin (CIP)", "CIP", "CIP"]}]], [780, "CIP significantly increased the K  Tissue distribution profiles of gallic acid (GA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of PCA in the absence and| presence of CIP are shown in Figures 8A,B, respectively.", [" {\"CIP\": 3, \"ciprofloxacin\": 2, \"PCE\": 1, \"PCA\": 1, \"gallic acid (GA)\": 1, \"tissue distribution\": 2, \"plasma distribution coefficients\": 1, \"Figures 8A,B\": 2}", {"Drug": ["CIP", "ciprofloxacin", "CIP"], "Herb name": ["gallic acid (GA)", "PCE", "PCA"]}]], [781, "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia.", [" {\"liver metabolism\": 1, \"biliary excretion\": 1, \"renal epithelia\": 1, \"intestinal epithelia\": 1, \"CIP\": 2}\n\nNote: The frequency count is based on the direct mentions of the entities in the provided text. If the context implies an entity without a direct mention, it is not included in the count.", {"Drug": ["CIP", "CIP"]}]], [782, "The study was funded by the Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030), and the National Science and Technology Major Project of China under Grant number (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine.", [" {\"Scientific Research Project of Tianjin Municipal Education Commission\": 2, \"2021ZD017\": 1, \"2021ZD030\": 1, \"National Science and Technology Major Project of China\": 1, \"Grant number\": 1, \"2018ZX09734-002\": 1, \"Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine\": 1}", {"Ethnic group": ["Chinese"]}]], [783, "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [" {\"Authors\": [1], \"conflict of interest\": [1], \"commercial relationships\": [1], \"financial relationships\": [1]}\n{\"Research\": [1]}\n{\"Pharmacology\": [1]}\n{\"Scientific article\": [1]}\n{\"events\": [1]}\n{\"described\": [1]}\n{\"cited entities\": [1]}\n{\"words\": [1]}\n{\"described in text\": [1]}", {}]], [784, "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.", [" {\"Pharmacology Articles\": 1, \"Scientific Articles\": 1, \"Pharmacology\": 1, \"Scientific Article\": 1, \"Publisher\": 1, \"Manufacturer\": 1, \"Product\": 1, \"Evaluation\": 1, \"Claim\": 1}", {}]], [785, "Click here for additional data file.", [" {\"PHARMACOLOGICAL AGENTS\": [\"drug\", \"medication\", \"pharmacological agent\", \"compound\", \"substance\"],\n\n\"PHARMACOLOGY\": [\"pharmacology\", \"pharmacological\", \"pharmacological action\", \"drug action\", \"drug metabolism\", \"drug absorption\", \"drug distribution\", \"drug elimination\"],\n\n\"DRUG NAMES\": [\"aspirin\", \"ibuprofen\", \"acetaminophen\", \"paracetamol\", \"amoxicillin\", \"cephalexin\", \"metformin\", \"lisinopril\", \"atorvastatin\", \"citalopram\", \"sertraline\", \"fluoxetine\", \"levothyroxine\", \"methotrexate\", \"prednisone\", \"hydrochlorothiazide\", \"furosemide\", \"losartan\", \"amlodipine\", \"warfarin\", \"insulin\", \"glimepiride\", \"metformin\", \"glipizide\", \"repaglinide\", \"pioglitazone\", \"rosiglitazone\", \"sitagliptin\", \"vildagliptin\", \"canagliflozin\", \"empagliflozin\", \"dapagliflozin\", \"linagliptin\", \"aliskiren\", \"losartan\", \"valsartan\", \"amlodipine\", \"atenolol\", \"metoprolol\", \"propranolol\", \"carvedilol\", \"acebutolone\", \"nadolol\", \"pindolol\", \"metoprolol tartrate\", \"metoprolol succinate\", \"atenolol tartrate\", \"atenolol succinate\", \"propranolol tartrate\", \"propranolol succinate\", \"carvedilol tartrate\", \"carvedilol succinate\", \"lisinopril\", \"enalapril\", \"benazepril\", \"losartan\", \"valsartan\", \"amlodipine\", \"hydrochlorothiazide\", \"furosemide\", \"levothyroxine\", \"methotrexate\", \"prednisone", {}]], [786, "All tests were performed at similar laboratory environmental conditions controlling for air temperature, barometric pressure, and relative humidity.", [" {\"Air temperature\": 1, \"barometric pressure\": 1, \"relative humidity\": 1, \"laboratory\": 1, \"environmental conditions\": 1, \"tests\": 1, \"pharmacology\": 1}\n{\"FREQUENCY\": {\"Air temperature\": 1, \"barometric pressure\": 1, \"relative humidity\": 1, \"laboratory\": 1, \"environmental conditions\": 1, \"tests\": 1, \"pharmacology\": 1}}\n{\"Air temperature\": \"air temperature\", \"barometric pressure\": \"barometric pressure\", \"relative humidity\": \"relative humidity\", \"laboratory\": \"laboratory\", \"environmental conditions\": \"environmental conditions\", \"tests\": \"tests\", \"pharmacology\": \"pharmacology\"}\n{\"Air temperature\": 1, \"barometric pressure\": 1, \"relative humidity\": 1, \"laboratory\": 1, \"environmental conditions\": 1, \"tests\": 1, \"pharmacology\": 1}\n{\"FREQUENCY\": {\"Air temperature\": 1, \"barometric pressure\": 1, \"relative humidity\": 1, \"laboratory\": 1, \"environmental conditions\": 1, \"tests\": 1, \"pharmacology\": 1}}\n{\"Air temperature\": \"air temperature\", \"barometric pressure\": \"barometric pressure\", \"relative humidity\": \"relative humidity\", \"laboratory\": \"laboratory\", \"environmental conditions\": \"environmental conditions\", \"tests\": \"tests\", \"pharmacology\": \"pharmacology\"}\n{\"Air temperature\": 1, \"barometric pressure\": 1, \"relative humidity\": 1, \"laboratory\": 1, \"environmental conditions\": 1, \"tests\": 1, \"pharmacology\": 1}\n{\"FREQUENCY\": {\"Air temperature\": 1, \"barometric pressure\": 1, \"relative humidity\": 1, \"laboratory\": 1, \"environmental conditions\": 1, \"tests\": 1, \"pharmacology\": 1}}\n{\"Air temperature\": \"", {}]], [787, "The scale was anchored at each end with the labels \u201cnot at all\u201d (0 mm) and \u201cextremely\u201d (100 mm).", [" {\"Anchors\": [1], \"Extremes\": [1], \"Scale\": [1], \"Not at all\": [1], \"Extremely\": [1], \"mm\": [1], \"Pharmacology\": [], \"Scientific article\": [], \"Cited entities\": [1]}\n\nNote: \"Pharmacology\" and \"Scientific article\" are not directly cited entities in the text but are mentioned as the context of the article. However, \"Cited entities\" is identified as the entities referred to in the text, which in this case are the descriptors of the scale.", {}]], [788, "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001).", [" {\"CHO\": 1, \"YM\": 1, \"PLC\": 1, \"AUC\": 1, \"13.3\": 1, \"15.00\": 1, \"p < 0.001\": 1}\n{\"FREQUENCY\": {\"CHO\": 1, \"YM\": 1, \"PLC\": 1, \"AUC\": 1, \"13.3\": 1, \"15.00\": 1, \"p < 0.001\": 1}}\n\nNote: The entities \"CHO\", \"YM\", \"PLC\", \"AUC\", \"13.3\", \"15.00\", and \"p < 0.001\" refer to the described entities in the context of the scientific article about pharmacology.", {"Parameter": ["AUC", "CHO"], "Herb name": ["YM"]}]], [789, "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3).", [" {\"TEALLOCATION\": [\"Total Energy Expenditure (TEE)\"], \"TREATMENT_GROUPS\": [\"YM\", \"PLC\"], \"EXERCISE_TIME\": [\"exercise time\", \"Figure 3\"]}\n\n{\"FREQUENCY\": {\"Total Energy Expenditure (TEE)\": 1, \"YM vs. PLC\": 1, \"exercise time\": 1, \"Figure 3\": 1}}", {"Parameter": ["Total Energy Expenditure (TEE)"], "Herb name": ["YM"], "Drug": ["PLC"]}]], [790, "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22].", [" {\"low to moderate exercise intensities\": 1, \"incremental protocol\": 1, \"previous study\": 1, \"24% increase\": 1}\n\nNote: The entities \"low to moderate exercise intensities\" and \"incremental protocol\" are conceptual entities referring to methods of exercise intensity and testing protocols, respectively. \"Previous study\" refers to the source of the information. \"24% increase\" refers to the specific finding mentioned in the text.", {}]], [791, "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21].", [" {\"YM\": 2, \"studies\": 2, \"human participants\": 2, \"metabolic rate\": 1, \"RER\": 1, \"acutely\": 1, \"12 weeks\": 1, \"blood lipid metabolites\": 1, \"healthy obese participants\": 1}\n{\"previous studies\": 1, \"promising effects\": 1, \"ingestion\": 2, \"obese participants\": 1}", {"Herb name": ["YM"], "Duration": ["12 weeks"], "Pathology": ["healthy"]}]], [792, "The metabolic effects include adrengenic effects and stimulated central nervous system associated with caffeine, anti-lipolytic, and hypocholesterolemic properties in chlorogenic acids (mono- and di-caffeolquinic acids) hydroxycinnamic acids (caffeic acid, quinic acid) and triterpenic saponins, and other minerals and vitamins [5].", [" {\"caffeine\": 2, \"chlorogenic acids\": 1, \"mono-caffeolquinic acid\": 1, \"di-caffeolquinic acid\": 1, \"mono-caffeic acid\": 1, \"quinic acid\": 1, \"triterpenic saponins\": 1, \"minerals\": 1, \"vitamins\": 1}", {"Herb name": ["caffeine"]}]], [793, "However, further research is required to assess active ingredients of YM capsules and analyze their bioavailability following ingestion.", [" {\"YM capsules\": 1, \"active ingredients\": 1, \"bioavailability\": 1, \"ingestion\": 1}\n{\"FREQUENCY\": {\"YM capsules\": 1, \"active ingredients\": 1, \"bioavailability\": 1, \"ingestion\": 1}}", {"Herb name": ["YM"], "Parameter": ["bioavailability"]}]], [794, "Favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols.", [" {\"Fat and weight-loss supplementation protocols\": 1, \"psychomotor effects\": 1, \"mood state\": 1, \"satiety\": 1}\n{\"Fat and weight-loss supplementation protocols\": 1, \"favorable psychomotor effects\": 1, \"mood state\": 1, \"satiety\": 1}\n{\"psychomotor effects\": 1, \"mood state\": 1, \"satiety\": 1}\n{\"fat and weight-loss supplementation protocols\": 1, \"favorable psychomotor effects\": 1, \"mood state\": 1}\n{\"fat and weight-loss supplementation protocols\": 1, \"favorable psychomotor effects\": 1, \"satiety\": 1}\n{\"psychomotor effects\": 1, \"mood state\": 1, \"satiety\": 1}\n{\"fat and weight-loss supplementation protocols\": 1, \"favorable psychomotor effects\": 1, \"mood state\": 1}\n{\"fat and weight-loss supplementation protocols\": 1, \"favorable psychomotor effects\": 1, \"satiety\": 1}\n{\"psychomotor effects\": 1, \"mood state\": 1, \"satiety\": 1}\n{\"fat and weight-loss supplementation protocols\": 1, \"favorable psychomotor effects\": 1, \"mood state\": 1}\n{\"fat and weight-loss supplementation protocols\": 1, \"favorable psychomotor effects\": 1, \"satiety\": 1}\n{\"psychomotor effects\": 1, \"mood state\": 1, \"satiety\": 1}\n{\"fat and weight-loss supplementation protocols\": 1, \"favorable psychomotor effects\": 1, \"mood state\": 1}\n{\"fat and weight-loss supplementation protocols\": 1, \"favorable psychomotor effects\": 1, \"satiety\": 1}\n{\"psychomotor", {}]], [795, "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment.", [" {\"BF%\": [1], \"females\": [1], \"physically active\": [1], \"fat-loss outcomes\": [1], \"exercise training\": [1], \"YM\": [2]}\n\nNote: The frequency count is based on the number of times the entities appear in the text. The word \"YM\" is mentioned twice, which might refer to the same entity, but without further context, it's counted as two separate mentions.", {"Sex": ["females"], "Herb name": ["YM", "YM", "YM"]}]], [796, "R.A. collected the data and contributed to data analysis and manuscript writing.", [" {\"R.A.\": 3, \"data collection\": 1, \"data analysis\": 1, \"manuscript writing\": 1}\n{\"R.A.\": 3, \"data collection\": 1, \"data analysis\": 1, \"manuscript writing\": 1}\n{\"R.A.\": 3, \"data collection\": \"\", \"data analysis\": 1, \"manuscript writing\": 1}\n{\"R.A.\": 3, \"data collection\": \"\", \"data analysis\": 1, \"manuscript writing\": 1}\n{\"R.A.\": 3, \"data collection\": \"\", \"data analysis\": \"\", \"manuscript writing\": 1}\n{\"R.A.\": 3, \"data collection\": \"\", \"data analysis\": \"\", \"manuscript writing\": 1}\n{\"R.A.\": 3, \"data collection\": \"\", \"data analysis\": \"\", \"manuscript writing\": \"\"}\n{\"R.A.\": 3, \"data collection\": \"\", \"data analysis\": \"\", \"manuscript writing\": \"\"}\n{\"R.A.\": 3, \"data collection\": \"\", \"data analysis\": \"\", \"manuscript writing\": \"\"}\n{\"R.A.\": 3, \"data collection\": \"\", \"data analysis\": \"\", \"manuscript writing\": \"\"}\n{\"R.A.\": 3, \"data collection\": \"\", \"data analysis\": \"\", \"manuscript writing\": \"\"}\n{\"R.A.\": 3, \"data collection\": \"\", \"data analysis\": \"\", \"manuscript writing\": \"\"}\n{\"R.A.\": 3, \"data collection\": \"\", \"data analysis\": \"\", \"manuscript writing\": \"\"}\n{\"R.A.\": 3, \"data collection\": \"\", \"data analysis\": \"\", \"manuscript writing\": \"\"}\n{\"R.A.\": 3, \"data collection\": \"\", \"data analysis\": \"\", \"manuscript writing\": \"\"}\n{\"R.A.\": 3, \"data collection\": \"\", \"data analysis\": \"\", \"manuscript writing\": \"\"}\n{\"R.A.\": 3, \"data collection\": \"\", \"data analysis\": \"\", \"manuscript writing\": \"\"}\n{\"R.A.\": 3, \"data collection\": \"\", \"data analysis\":", {}]], [797, "Co., Seoul, Korea) and their identity was kindly confirmed by Prof. Yeong Bae Seo (a specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea).", [" {\"Prof. Yeong Bae Seo\": 1, \"Natural Products Research Institute\": 1, \"Seoul National University\": 1, \"Seoul, Korea\": 2}\n\n{\"Celosia crista\": 1, \"Celosia plumosa\": 1, \"Celosia parviflora\": 1, \"Celosia scabra\": 1, \"Celosia sp.\", \"Celosia\": 1}\n\n{\"Co., Seoul, Korea\": 1}\n\n{\"Natural Products Research Institute, Seoul National University, Seoul, Korea\": 1}", {}]], [798, "[ HEK293 cells transiently overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters were purchased from Corning-Gentest (Tewksbury, MA, USA).", [" {\"OAT1\": 1, \"OAT3\": 1, \"OCT1\": 1, \"OCT2\": 1, \"OATP1B1\": 1, \"OATP1B3\": 1, \"Corning-Gentest\": 1, \"Tewksbury, MA, USA\": 1}\n\n{\"FREQUENCY\": {\"purchased\": 1, \"HEK293 cells\": 1, \"transiently overexpressing\": 1, \"transporters\": 1, \"were\": 1, \"acquired\": 1}}\n\n{\"OAT1\": 1, \"OAT3\": 1, \"OCT1\": 1, \"OCT2\": 1, \"OATP1B1\": 1, \"OATP1B3\": 1}\n\n{\"FREQUENCY\": {\"purchased\": 1, \"HEK293 cells\": 1, \"transiently overexpressing\": 1, \"transporters\": 1}}\n\n{\"OAT1\": 1, \"OAT3\": 1, \"OCT1\": 1, \"OCT2\": 1, \"OATP1B1\": 1, \"OATP1B3\": 1, \"Corning-Gentest\": 1, \"Tewksbury\": 1, \"MA\": 1, \"USA\": 1}\n\n{\"FREQUENCY\": {\"purchased\": 1, \"HEK293 cells\": 1, \"transiently overexpressing\": 1, \"transporters\": 1, \"were\": 1, \"acquired\": 1}}", {"Parameter": ["OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters"]}]], [799, "Food and water were supplied ad libitum.", [" {\"Food\": 1, \"water\": 1, \"ad libitum\": 1}\n{\"Pharmacology\": 0}\n{\"Pharmacologist\": 0}\n{\"Pharmacological agent\": 0}\n{\"Pharmacokinetics\": 0}\n{\"Pharmacodynamics\": 0}\n{\"Pharmacotherapy\": 0}\n{\"Pharmacology article\": 1}\n{\"Scientific article\": 1}", {}]], [800, "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane.", [" {\"Rats\": 1, \"polyethylene tubing\": 1, \"PE-50\": 1, \"Natsume Co\": 1, \"Tokyo, Japan\": 1, \"jugular vein\": 1, \"sampling\": 1, \"isoflurane\": 1}\n\nNote: The frequency count is based on the direct mentions of the entities in the text. If a word refers to an entity but is not explicitly named, it may not be captured in this method. For example, \"cannulated\" refers to the rats but is not named directly. However, the instruction was to find words referring to described entities, and in this context, it's assumed that the reader understands \"cannulated\" refers to the rats. If a more nuanced understanding is required, additional context would be needed.", {"Parameter": ["anesthesia"], "Drug": ["isoflurane"]}]], [801, "Mass Hunter software (Agilent Technologies) was used for LC-MS/MS system control and data processing.", [" {\"Mass Hunter software\": 1, \"Agilent Technologies\": 1, \"LC-MS/MS system\": 1}\n{\"Agilent Technologies\": {\"FREQUENCY\": 1}}\n{\"LC-MS/MS system\": {\"FREQUENCY\": 1}}", {}]], [802, "showed that the practice of herbal co-medication with prescription drugs cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6].", [" {\"Herbal co-medication\": 1, \"prescription drugs\": 1, \"patient demographics\": 1, \"respondents\": 1, \"38%\": 1}\n\n{\"Prescription drugs\": 1, \"concomitant herbal use\": 1, \"38%\": 1}", {}]], [803, "Since the accidental discovery of the ability of grapefruit juice to alter the pharmacokinetic profiles of felodipine through the inhibition of cytochrome P450 (CYP) and P-glycoprotein (P-gp), more studies have elucidated various mechanisms of HDI [11].", [" {\"grapefruit juice\": 1, \"pharmacokinetic profiles\": 1, \"felodipine\": 1, \"cytochrome P450 (CYP)\": 1, \"P-glycoprotein (P-gp)\": 1, \"HDI\": 1}", {"Herb name": ["grapefruit juice"], "Drug": ["felodipine"], "Target": ["cytochrome P450 (CYP)", "P-glycoprotein (P-gp)"]}]], [804, "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian.", [" {\"TERMINALIA/COMIPHORA AYURVEDIC MIXTURE\": [1], \"ECHINACEA\": [1], \"GINKGO\": [1], \"GINSENG\": [1], \"HYDROXYCUT\": [1], \"KAVA\": [1], \"KRATOM\": [1], \"MORINGA\": [1], \"PIPERINE\": [1], \"RHODIALE\": [1], \"ST. JOHN\u2019S WORT\": [1], \"TERMINALIA/COMIPHORA\": [1], \"TERMINALIA/COMIPHORA AYURVEDIC\": [1], \"TERMINALIA/COMIPHORA AYURVEDIC MIXTURE\": [1]}", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "hydroxycut", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic", "valerian"]}]], [805, "Phytoestrogens and other bioactive components of celery can interact with the DMEs, including those in the CYP450 family.", [" {\"Celery\": 1, \"phytoestrogens\": 1, \"bioactive components\": 1, \"DMEs\": 1, \"CYP450 family\": 1}\n{\"Celery\": {\"FREQUENCY\": 1}, \"phytoestrogens\": {\"FREQUENCY\": 1}, \"bioactive components\": {\"FREQUENCY\": 1}, \"DMEs\": {\"FREQUENCY\": 1}, \"CYP450 family\": {\"FREQUENCY\": 1}}", {"Herb name": ["celery"], "Target": ["DMEs", "CYP450 family"]}]], [806, "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions.", [" {\"HDIs\": 2, \"scientific article\": 1, \"pharmacology\": 1, \"clinical decisions\": 1}\n\nNote: The entities \"HDIs\" and \"clinical decisions\" are inferred from the context of the provided text. \"scientific article\" and \"pharmacology\" are directly mentioned in the text. \"anecdotal pieces of evidence\" is not an entity but a phrase describing the nature of the evidence.", {}]], [807, "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61].", [" {\"Ginkgo biloba\": 1, \"cognition decline\": 1, \"memory loss\": 1, \"anxiety and mood disorders\": 1, \"fatigue\": 1, \"cardiovascular disorders\": 1}\n\n{\"Review and meta-analysis\": 1, \"published data\": 1}", {"Study": ["Several controlled clinical studies"], "Herb name": ["ginkgo"], "Pathology": ["cognition decline", "memory loss", "anxiety", "mood disorders", "fatigue", "cardiovascular disorders"]}]], [808, "He was reported to have experienced a seizure before his death, and the toxicological autopsy results revealed subtherapeutic serum levels for both drugs.", [" {\"seizure\": 1, \"toxicological autopsy\": 1, \"subtherapeutic serum levels\": 1, \"drugs\": 1}\n{\"FREQUENCY\": {\"seizure\": 1, \"toxicological autopsy\": 1, \"subtherapeutic serum levels\": 1, \"drugs\": 1}}\n\n(Note: The frequency count is based on the number of times the entities appear in the provided text.)", {"Pathology": ["seizure"]}]], [809, "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88].", [" {\"Ginseng\": 1, \"phytochemicals\": 1, \"CYP3A4\": 1, \"midazolam\": 1, \"human studies\": 1}\n\n{\"CYP3A4\": {\"FREQUENCY\": 1}}\n{\"phytochemicals\": {\"FREQUENCY\": 1}}\n{\"midazolam\": {\"FREQUENCY\": 1}}\n{\"human studies\": {\"FREQUENCY\": 1}}\n{\"Ginseng\": {\"FREQUENCY\": 1}}", {"Herb name": ["ginseng"], "Target": ["CYP3A4"], "Parameter": ["AUC"], "Drug": ["midazolam"], "Study": ["human studies"]}]], [810, "Chronic use of ginseng on its own has been associated with manic psychosis [90].", [" {\"Ginseng\": 1, \"chronic use\": 1, \"manic psychosis\": 1, \"90\": 1}\n{\"FREQUENCY\": {\"chronic use\": 1, \"manic psychosis\": 1, \"90\": 1}}\n\nNote: The number \"1\" indicates the frequency of each entity mentioned in the text.", {"Herb name": ["ginseng"], "Pathology": ["manic psychosis"]}]], [811, "The pharmacological activities of kava have been attributed to kavalactones, which are concentrated in the rhizomes [96].", [" {\"Kavalactones\": 1, \"rhizomes\": 1}", {"Herb name": ["kava", "kavalactones"], "Herb part": ["rhizomes"]}]], [812, "Despite the general concern about its safety, kava is still popularly consumed for CNS benefits.", [" {\"Kava\": 1, \"CNS benefits\": 1}\n{\"Safety concerns\": 1, \"popularity\": 1}", {"Herb name": ["kava"]}]], [813, "A study in 18 health volunteers did not show any clinically relevant interaction between kava and bromazepam [104].", [" {\"Kava\": 1, \"Bromazepam\": 1, \"Health volunteers\": 1, \"Clinically relevant interaction\": 1}\n{\"FREQUENCY\": {\"Kava\": 1, \"Bromazepam\": 1, \"Health volunteers\": 1, \"Clinically relevant interaction\": 1}}\n\n(Note: The frequency count is based on the direct mentions of the entities in the provided text. If the context implies a broader category or related concept, it is not counted here as per the instruction to only parse cited entities.)", {"Cohort": ["18 health volunteers"], "Herb name": ["kava"], "Drug": ["bromazepam"]}]], [814, "Kratom is also used as complementary medicine to manage diabetes, diarrhea, improve circulation, enhance alertness and concentration, and increase libido [111-114].", [" {\"Kratom\": 1, \"complementary medicine\": 1, \"diabetes\": 1, \"diarrhea\": 1, \"circulation\": 1, \"alertness\": 1, \"concentration\": 1, \"libido\": 1}", {"Herb name": ["Kratom"], "Pathology": ["diabetes", "diarrhea"]}]], [815, "Apart from CYP/P-gp induction, SJW mediates interactions through its serotonergic effects.", [" {\"CYP/P-gp induction\": 1, \"SJW\": 1, \"serotonergic effects\": 1}\n{\"FREQUENCY\": {\"CYP/P-gp induction\": 1, \"SJW\": 1, \"serotonergic effects\": 1}}\n\nNote: The entities \"CYP/P-gp induction\" and \"SJW\" refer to pharmacological entities, while \"serotonergic effects\" refers to a pharmacological action or effect. The frequency count is based on the number of times these entities are mentioned in the provided text.", {"Herb name": ["SJW"]}]], [816, "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate.", [" {\"SJW\": 1, \"CYP3A4\": 1, \"2-way, open-label crossover study\": 1, \"21 healthy subjects\": 1, \"midazolam\": 1}\n{\"FREQUENCY\": {\"SJW\": 1, \"CYP3A4\": 1, \"2-way, open-label crossover study\": 1, \"21 healthy subjects\": 1, \"midazolam\": 1}}\n\n(Note: \"SJW\" might not be a recognized entity in pharmacology. If it's a typo or a specific term within the context of the article, please provide additional context. Otherwise, it's treated as a non-pharmacological entity for the purpose of this exercise.)", {"Herb name": ["SJW"], "Target": ["CYP3A4"], "Study": ["open-label crossover study"], "Cohort": ["21 healthy subjects"], "Drug": ["midazolam"]}]], [817, "This is important because the vast majority of herbal products are orally administered.", [" {\"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1, \"Herbal Products\": 1", {}]], [818, "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood.", [" {\"Herbal products\": 2, \"mixtures\": 1, \"herbal species\": 1, \"dietary supplements\": 1, \"biological disposition\": 1}\n{\"FREQUENCY\": {\"Herbal products\": 2, \"mixtures\": 1, \"herbal species\": 1, \"dietary supplements\": 1, \"biological disposition\": 1}}", {}]], [819, "CYP3A4 and P-gp are richly expressed in the human small intestinal enterocytes.", [" {\"CYP3A4\": 1, \"P-gp\": 1, \"human small intestinal enterocytes\": 1}\n\n(Note: The frequency count is based on the number of times the entities appear in the provided text.)", {}]], [820, "This review identified 13 herbal products - celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian \u2013 all of which have shown interactions with specific neuropsychiatric drugs.", [" {\"HERBAL_PRODUCTS\": [13]}\n{\"NEUROPSYCHIATRIC_DRUGS\": []}\n{\"NEUROPSYCHIATRIC_INTERACTIONS\": []}\n{\"NEUROPSYCHIATRIC_TREATMENTS\": []}\n{\"NEUROPSYCHIATRIC_SYMPTOMS\": []}\n{\"NEUROPSYCHIATRIC_DISORDERS\": []}\n{\"NEUROPSYCHIATRIC_RESEARCH\": [\"review\"]}\n{\"NEUROPSYCHIATRIC_REVIEW\": [1]}\n{\"NEUROPSYCHIATRIC_ARTICLES\": []}\n{\"NEUROPSYCHIATRIC_STUDIES\": []}\n{\"NEUROPSYCHIATRIC_CLINICAL_TRIALS\": []}\n{\"NEUROPSYCHIATRIC_MEDICINES\": []}\n{\"NEUROPSYCHIATRIC_PHARMACOLOGY\": []}\n{\"NEUROPSYCHIATRIC_PHARMACOLOGY_ARTICLES\": []}\n{\"NEUROPSYCHIATRIC_PHARMACOLOGY_RESEARCH\": []}\n{\"NEUROPSYCHIATRIC_PHARMACOLOGY_REVIEW\": []}\n{\"NEUROPSYCHIATRIC_PHARMACOLOGY_PRODUCTS\": []}\n{\"NEUROPSYCHIATRIC_PHARMACOLOGY_DRUGS\": []}\n{\"NEUROPSYCHIATRIC_PHARMACOLOGY_INTERACTIONS\": []}\n{\"NEUROPSYCHIATRIC_PHARMACOLOGY_TREATMENTS\": []}\n{\"NEUROPSYCHIATRIC_PHARMACOLOGY_SYMPTOMS\": []}\n{\"NEUROPSYCHIATRIC_PHARMACOLOGY_DISORDERS\": []}\n{\"NEUROPSYCHIAT", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic mixture", "valerian"], "Herb part": ["hydroxycut"], "Drug": ["neuropsychiatric drugs"]}]], [821, "Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs.", [" {\"Medicinal herbs\": 1, \"natural bioactive compounds\": 1, \"drugs\": 1}", {}]], [822, "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation.", [" {\"Sirolimus\": 1, \"calcineurin inhibitors\": 2, \"kidney transplantation\": 1}\n{\"FREQUENCY\": {\"Sirolimus\": 1, \"calcineurin inhibitors\": 2, \"kidney transplantation\": 1}}\n\n(Note: The frequency count is based on the number of times the entities appear in the text provided.)", {"Drug": ["Sirolimus", "calcineurin inhibitors", "calcineurin inhibitors"]}]], [823, "This is especially important for drugs with a narrow therapeutic window.", [" {\"Drugs\": [\"pharmacology\", \"drugs\", \"narrow therapeutic window\"]}\n\n{\"Researchers\": [\"scientific article\"]}\n\n{\"Therapeutic Window\": [\"narrow therapeutic window\"]}\n\n{\"Pharmacology\": [\"pharmacology\"]}\n\n{\"Scientific Article\": [\"scientific article\"]}", {}]], [824, "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors.", [" {\"tacrolimus\": 2, \"tacrolimus-based immunosuppression\": 1, \"sirolimus\": 1, \"treatment\": 2}\n{\"tremors\": 1}", {"Drug": ["tacrolimus", "tacrolimus", "sirolimus"], "Pathology": ["tremors"]}]], [825, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" {\"Serum Creatinine Level\": 1}\n\n{\"\u00b5mol/L\": 1}\n\n{\"Stability\": 1}", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [826, "Contrary to this safety perception, herb\u2013drug interactions could lead to serious adverse effects.", [" {\"Herb\": 1, \"drug\": 1, \"adverse effects\": 1}", {"Pathology": ["adverse effects"]}]], [827, "Author contributions: MK drafted the initial and final versions of the manuscript.", [" {\"Author Contributions\": [\"MK drafted the initial and final versions of the manuscript.\"],\n\n\"Pharmacology\": [\"pharmacology\"],\n\n\"Scientific Article\": [\"scientific article\"],\n\n\"Cited Entities\": [\"pharmacology\", \"scientific article\"]}", {}]], [828, "Sirolimus is an immunosuppressive drug used to prevent graft rejection.", [" {\"SIRLIMUS\": 1, \"immunosuppressive drug\": 1, \"prevent graft rejection\": 1}", {"Drug": ["Sirolimus"], "Pathology": ["graft rejection"]}]], [829, "Therapeutic drug monitoring is required as with other immunosuppressive drugs.", [" {\"Therapeutic drug monitoring\": 1, \"immunosuppressive drugs\": 1}\n{\"Pharmacology\": 1}\n{\"scientific article\": 1}\n{\"pharmacology\": 1}\n{\"immunosuppressive drugs\": 1}\n{\"drug monitoring\": 1}", {}]], [830, "Parsley, Petroselinum crispum, is a food, spice, and also a medicinal herb.", [" {\"Petroselinum crispum\": 1, \"pharmacology\": 0, \"scientific article\": 0, \"cited entities\": 0, \"events\": 0}\n\n{\"Petroselinum crispum\": 1, \"pharmacology\": 0, \"scientific article\": 0, \"cited entities\": 0, \"events\": 0}\n\n{\"Petroselinum crispum\": 1, \"pharmacology\": 0, \"scientific article\": 0, \"cited entities\": 0, \"events\": 0}\n\n{\"Petroselinum crispum\": 1, \"pharmacology\": 0, \"scientific article\": 0, \"cited entities\": 0, \"events\": 0}\n\n{\"Petroselinum crispum\": 1, \"pharmacology\": 0, \"scientific article\": 0, \"cited entities\": 0, \"events\": 0}\n\n{\"Petroselinum crispum\": 1, \"pharmacology\": 0, \"scientific article\": 0, \"cited entities\": 0, \"events\": 0}\n\n{\"Petroselinum crispum\": 1, \"pharmacology\": 0, \"scientific article\": 0, \"cited entities\": 0, \"events\": 0}\n\n{\"Petroselinum crispum\": 1, \"pharmacology\": 0, \"scientific article\": 0, \"cited entities\": 0, \"events\": 0}\n\n{\"Petroselinum crispum\": 1, \"pharmacology\": 0, \"scientific article\": 0, \"cited entities\": 0, \"events\": 0}\n\n{\"Petroselinum crispum\": 1, \"pharmacology\": 0, \"scientific article\": 0, \"cited entities\": 0, \"events\": 0}\n\n{\"Petroselinum crispum\": 1, \"pharmacology\": 0, \"scientific article\": 0, \"cited entities\": 0, \"events\":", {"Herb name": ["Parsley", "Petroselinum crispum"]}]], [831, "Previous studies have shown the interactions between sirolimus and drugs that affect the activities of metabolizing enzymes and transporter proteins.", [" {\"sirolimus\": 1, \"drugs\": 1, \"metabolizing enzymes\": 1, \"transporter proteins\": 1}", {"Drug": ["sirolimus"]}]], [832, "Parsley is a food, spice, and also a medicinal herb.", [" {\"Parsley\": 3, \"food\": 1, \"spice\": 1, \"medicinal herb\": 1}\n\nNote: The frequency count is based on the number of times each entity is mentioned in the provided text.", {"Herb name": ["Parsley"]}]], [833, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" {\"Serum Creatinine Level\": 1}\n\n{\"\u00b5mol/L\": 1}\n\n{\"Stability\": 1}", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [834, "In this patient, we reported the possible effect of parsley juice on the level of sirolimus.", [" {\"Parsley Juice\": 1, \"sirolimus\": 1}\n{\"FREQUENCY\": {\"parsley juice\": 1, \"sirolimus\": 1}}\n\n(Note: In the context of entity parsing for scientific articles, it's important to clarify that \"parsley juice\" and \"sirolimus\" are the entities referred to in the text. Parsley juice is not a pharmacological entity but is mentioned in the context of a study, while sirolimus is a pharmacological entity, a drug. However, based on the task's instructions, both are treated as entities for the purpose of this exercise.)", {"Drug": ["sirolimus"]}]], [835, "Funding: The authors received no financial support for the research, authorship, and/or publication of this article.", [" {\"FREQUENCY\": {\"financial support\": 1, \"research\": 1, \"authorship\": 1, \"publication\": 1}}\n{\"FREQUENCY\": {\"authors\": 1}}\n{\"FREQUENCY\": {\"article\": 1}}\n{\"FREQUENCY\": {\"pharmacology\": 1}}\n{\"FREQUENCY\": {\"scientific article\": 1}}\n{\"FREQUENCY\": {\"funding\": 1}}\n{\"FREQUENCY\": {\"no financial support\": 1}}\n{\"FREQUENCY\": {\"research\": 1}}\n{\"FREQUENCY\": {\"authorship\": 1}}\n{\"FREQUENCY\": {\"publication\": 1}}", {}]], [836, "Data are expressed as mean \u00b1 S. D. (n = 6).", [" {\"Pharmacology Articles\": [1], \"Scientific Journals\": [1], \"Research Studies\": [1], \"Mean\": [1], \"Standard Deviation (S.D.)\": [1], \"Sample Size (n)\": [1]}", {}]], [837, "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil.", [" {\"Epimedium sagittatum extract\": 1, \"sildenafil\": 1}\n{\"group 1\": 1, \"group 2\": 2, \"group 3\": 1}\n{\"statistically significant differences\": 1}\n{\"herb-drug interaction\": 1}", {"Parameter": ["AUC"], "Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"], "Drug": ["sildenafil"]}]], [838, "et Zucc.)", [" {\"ZINC\": 1, \"pharmacology\": 1, \"ZINC-221375\": 1, \"ZINC-330743\": 1, \"ZINC-357474\": 1, \"ZINC-369542\": 1, \"ZINC-375687\": 1, \"ZINC-375688\": 1, \"ZINC-375689\": 1, \"ZINC-375690\": 1, \"ZINC-375691\": 1, \"ZINC-375692\": 1, \"ZINC-375693\": 1, \"ZINC-375694\": 1, \"ZINC-375695\": 1, \"ZINC-375696\": 1, \"ZINC-375697\": 1, \"ZINC-375698\": 1, \"ZINC-375699\": 1, \"ZINC-375700\": 1, \"ZINC-375701\": 1, \"ZINC-375702\": 1, \"ZINC-375703\": 1, \"ZINC-375704\": 1, \"ZINC-375705\": 1, \"ZINC-375706\": 1, \"ZINC-375707\": 1, \"ZINC-375708\": 1, \"ZINC-375709\": 1, \"ZINC-375710\": 1, \"ZINC-375711\": 1, \"ZINC-375712\": 1, \"ZINC-375713\": 1, \"ZINC-375714\": 1, \"ZINC-375715\": 1,", {}]], [839, "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect.", [" {\"Epimedium sagittatum\": 1, \"herbal drug effect\": 1, \"pretreatment period\": 1}\n{\"frequences\": {\"Epimedium sagittatum\": 1, \"herbal drug effect\": 1, \"pretreatment period\": 1}}\n\n(Note: The frequency count is based on the specific words referring to the entities in the provided text. If there were no specific mentions of these entities, the frequency count for each would be 0.)", {"Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"]}]], [840, "The combined extraction solution was then evaporated to dryness.", [" {\"EVAPORATOR\": [1], \"EVAPORATOR_COMPOUND\": [1], \"EVAPORATOR_SOLUTION\": [1], \"EVAPORATOR_DRYING\": [1]}\n{\"EVAPORATOR_COMPOUND\": [1], \"EVAPORATOR_SOLUTION\": [1]}\n{\"EVAPORATOR_DRYING\": [1]}\n{\"EVAPORATOR\": [1]}\n{\"EVAPORATOR_COMPOUND\": [1], \"EVAPORATOR_SOLUTION\": [1]}\n{\"EVAPORATOR_DRYING\": [1]}\n{\"EVAPORATOR\": [1]}\n{\"EVAPORATOR_COMPOUND\": [1]}\n{\"EVAPORATOR_SOLUTION\": [1]}\n{\"EVAPORATOR_DRYING\": [1]}\n{\"EVAPORATOR\": [1]}\n{\"EVAPORATOR_COMPOUND\": [1]}\n{\"EVAPORATOR_SOLUTION\": [1]}\n{\"EVAPORATOR_DRYING\": [1]}\n{\"EVAPORATOR\": [1]}\n{\"EVAPORATOR_COMPOUND\": [1]}\n{\"EVAPORATOR_SOLUTION\": [1]}\n{\"EVAPORATOR_DRYING\": [1]}\n{\"EVAPORATOR\": [1]}\n{\"EVAPORATOR_COMPOUND\": [1]}\n{\"EVAPORATOR_SOLUTION\": [1]}\n{\"EVAPORATOR_DRYING\": [1]}\n{\"EVAPORATOR\": [1]}\n{\"EVAPORATOR_COMPOUND\": [1]}\n{\"EVAPORATOR_SOLUTION\": [1]}\n{\"EVAPORATOR_DRYING\": [1]}\n{\"EVAPORATOR\": [1]}\n{\"EVAPORATOR_COMPOUND\": [1]}\n{\"EVAPORATOR_SOLUTION\": [1]}\n{\"EVAPORATOR_DRYING\": [1]}\n{\"EVAPORATOR\": [1]}\n{\"EVAPOR", {}]], [841, "Maxim extract are available from the authors.", [" {\"Pharmacology\": 1, \"scientific article\": 1, \"pharmacological entities\": 1, \"drugs\": 1, \"drug molecules\": 1, \"pharmacokinetics\": 1, \"pharmacodynamics\": 1, \"pharmaceutical compounds\": 1, \"pharmacologists\": 1, \"clinical trials\": 1, \"drug development\": 1, \"drug discovery\": 1, \"drug metabolism\": 1, \"drug absorption\": 1, \"drug distribution\": 1, \"drug excretion\": 1, \"pharmacology research\": 1, \"pharmacology studies\": 1, \"pharmacology literature\": 1, \"pharmacology journals\": 1, \"pharmacology publications\": 1, \"pharmacology databases\": 1, \"pharmacology textbooks\": 1, \"pharmacology courses\": 1, \"pharmacology education\": 1, \"pharmacology curriculum\": 1, \"pharmacology programs\": 1, \"pharmacology departments\": 1, \"pharmacology institutes\": 1, \"pharmacology centers\": 1, \"pharmacology researchers\": 1, \"pharmacology students\": 1, \"pharmacology professionals\": 1, \"pharmacology experts\": 1, \"pharmacology scientists\": 1, \"pharmacology practitioners\": 1, \"pharmacology practitioners\": 1, \"pharmacology practitioners\": 1, \"pharmacology practitioners\": 1, \"pharmacology practitioners\": 1, \"pharmacology practitioners\": 1, \"pharmacology practitioners\": 1, \"pharmacology practitioners\": 1, \"pharmacology practitioners\": 1, \"pharmacology practitioners\": 1, \"pharmacology practitioners\": 1, \"pharmacology practitioners\": 1, \"pharmacology practitioners\": 1, \"pharmac", {"Herb name": ["Maxim"], "Extraction process": ["extract"]}]], [842, "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13].", [" {\"Bilia and C\u00e9u Costas review\": 1, \"Europe\": 1, \"regulatory environment\": 1, \"practical effects\": 1}\n\nNote: The word \"Europe\" is considered an entity referring to the geographical region in this context. If the focus is strictly on pharmacology and regulatory entities, \"Europe\" might not be included unless it's directly related to pharmacological regulations. However, based on the given text, it's included as it's part of the regulatory environment discussion.", {}]], [843, "It most often means that we have less knowledge of benefits, as well as risks.", [" {\"Pharmacology\": 1, \"scientific article\": 1, \"pharmacological entities\": 1, \"drugs\": 1, \"benefits\": 1, \"risks\": 1}", {}]], [844, "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years.", [" {\"Analgesic Drugs\": 1, \"Non-pharmacological Treatments\": 1, \"Patients\": 1}\n{\"FREQUENCY\": {\"Analgesic Drugs\": 1, \"Non-pharmacological Treatments\": 1, \"Patients\": 1}}", {"Drug": ["analgetic drugs"]}]], [845, "From the combined literature, a list of the most frequently occurring species was established.", [" {\"Species\": 1, \"List\": 1, \"Literature\": 1, \"Scientific Article\": 1}", {}]], [846, "They found a prevalence of 56.6%.", [" {\"PREVALENCE\": [\"56.6%\"]}", {}]], [847, "Most surveys on complementary and alternative therapy or supplement use by those patients did not ask for the species used [4,19,29] or were conducted outside of the geographical area of this review [30,31,32], or both [33,34].", [" {\"Species used\": [4, 19, 29, 30, 31, 32, 33, 34]}\n\n{\"Geographical area of the review\": [30, 31, 32, 33, 34]}", {}]], [848, "Thus, two studies from Canada and the USA were screened to find plants that patients might use.", [" {\"Canada\": 1, \"USA\": 1, \"plants\": 1, \"patients\": 1}", {}]], [849, "A Spanish study reports Aloe vera [37].", [" {\"ALOEVERA\": 1, \"SPANISH STUDY\": 1, \"REPORT\": 1, \"37\": 1}\n\nNote: The frequency count is based on the assumption that the specific words or phrases are directly referring to the entities mentioned in the instruction. The context of the entire article would provide a more accurate frequency count.", {"Ethnic group": ["Spanish"], "Herb name": ["Aloe vera"]}]], [850, "Many potentially hepatotoxic herbs are not studied extensively enough to determine a safe daily dose.", [" {\"Potentially Hepatotoxic Herbs\": 1, \"safe daily dose\": 1}\n{\"Extensive Studies\": 1}\n{\"Safe Daily Dose\": 1}", {"Pathology": ["hepatotoxic"], "Frequency": ["daily"]}]], [851, "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention.", [" {\"Opioids\": 2, \"pain relief\": 2, \"patients\": 1, \"surgical intervention\": 1}\n\nNote: In this context, \"short-term use\" and \"to bridge the time\" are not explicitly cited as entities but can be inferred as related to the pharmacological context. However, they are not included in the entity list as per the instruction.", {"Drug": ["opioids"], "Pathology": ["pain"]}]], [852, "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117].", [" {\"Patient\": [\"another patient\", \"this patient\"], \"Liver Injury\": [\"liver injury\"], \"500 mg leaf powder\": [\"500 mg leaf powder\"], \"laxative\": [\"laxative\"]}\n{\"FREQUENCY\": {\"Patient\": 2, \"Liver Injury\": 1, \"500 mg leaf powder\": 1, \"laxative\": 1}}", {"Pathology": ["liver injury"], "Amount": ["500 mg"], "Herb part": ["leaf"], "Extraction process": ["powder"], "Frequency": ["every 2\u20133 days"]}]], [853, "There are only food supplements available, with insufficiently defined product quality.", [" {\"Food Supplements\": 1, \"Product Quality\": 1}", {}]], [854, "Cannabis preparations are emerging as a promising option for co-treatment of inflammatory diseases.", [" {\"Cannabis preparations\": 1, \"inflammatory diseases\": 1}\n\nNote: The frequency count is based on the single occurrence of each entity in the provided text. If the text were longer and contained multiple mentions of these entities, the frequency would increase accordingly.", {"Herb name": ["Cannabis"], "Pathology": ["inflammatory diseases"]}]], [855, "This is debated, and there are hints to possible beneficial effects [135].", [" {\"Pharmacology\": 1, \"scientific article\": 1, \"pharmacology\": 1, \"cited entities\": 1, \"events\": 1, \"described in text\": 1, \"hints\": 1, \"possible beneficial effects\": 1}\n\n{\"FREQUENCY\": {\"cited entities\": 1}}\n\n(\"pharmacology\" and \"pharmacology\" are considered the same entity, hence the frequency is 2)", {}]], [856, "The European pharmacopoeia monographs pulverized dried bulbs of Allium sativum containing at least 0.45% allicin [154].", [" {\"Allium sativum\": 1, \"pulverized dried bulbs\": 1, \"0.45% allicin\": 1}\n{\"European pharmacopoeia\": 1, \"monographs\": 1}\n{\"154\": 1}", {"Cohort": ["European"], "Herb part": ["bulbs"], "Herb name": ["Allium sativum", "allicin"], "Amount": ["0.45%"]}]], [857, "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154].", [" {\"Ginkgolic acid\": 1, \"5 ppm\": 1}", {"Extraction process": ["refined quantified dry extract"], "Herb name": ["ginkgolic acid"], "Amount": ["5 ppm"]}]], [858, "Based on cases of severe bleeding events associated with ginkgo [169,170], the plant has been suspected to increase bleeding risk of patients with anticoagulant or platelet inhibiting co-medication.", [" {\"Ginkgo\": 2, \"bleeding events\": 1, \"severe bleeding\": 1, \"risk\": 1, \"anticoagulant\": 1, \"platelet inhibiting co-medication\": 1}\n{\"FREQUENCY\": {\"Ginkgo\": 2, \"bleeding events\": 1, \"severe bleeding\": 1, \"risk\": 1, \"anticoagulant\": 1, \"platelet inhibiting co-medication\": 1}}", {"Pathology": ["severe bleeding events", "bleeding risk"], "Herb name": ["ginkgo"], "Drug": ["anticoagulant or platelet inhibiting co-medication"]}]], [859, "There are in vitro experiments confirming thrombin inhibition [172].", [" {\"Thrombin inhibition\": 1, \"in vitro experiments\": 1, \"scientific article\": 1, \"pharmacology\": 1}\n{\"FREQUENCY\": {\"in vitro experiments\": 1, \"thrombin inhibition\": 1, \"scientific article\": 1, \"pharmacology\": 1}}\n{\"Thrombin inhibition\": \"172\"}\n{\"in vitro experiments\": \"1\"}\n{\"scientific article\": \"1\"}\n{\"pharmacology\": \"1\"}", {"Study": ["in vitro experiments"], "Target": ["thrombin"]}]], [860, "The term \u201cginseng\u201d can be used for several drugs.", [" {\"GINSENG\": 1}", {"Herb name": ["ginseng"]}]], [861, "Seong et al.", [" {\"SEONG_LABEL\": 1, \"LABEL\": 2, \"LABEL_GROUP\": 1, \"LABEL_SET\": 1, \"LABEL_TYPE\": 1, \"LABEL_CLASS\": 1, \"LABEL_CATEGORY\": 1, \"LABEL_SUBCATEGORY\": 1, \"LABEL_SUBCATEGORY_SUBSUBCATEGORY\": 1, \"LABEL_SUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY\": 1, \"LABEL_SUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY\": 1, \"LABEL_SUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY\": 1, \"LABEL_SUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY\": 1, \"LABEL_SUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY\": 1, \"LABEL_SUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY\": 1, \"LABEL_SUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY\": 1, \"LABEL_SUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY_SUBSUBCATEGORY\": 1, \"", {}]], [862, "A scientific opinion of EFSA [196] from 2018 states that the common food consumption is safe, as there are only few cases of HILI associated with tea consumption despite the widespread use.", [" {\"EFSA\": 1, \"scientific opinion\": 1, \"EFSA [196]\": 1, \"2018\": 1, \"common food consumption\": 1, \"HILI\": 1, \"tea consumption\": 1}\n{\"FREQUENCY\": {\"scientific opinion\": 1, \"EFSA [196]\": 1, \"2018\": 1, \"common food consumption\": 1, \"HILI\": 1, \"tea consumption\": 1}}\n\nNote: The numbers in the \"FREQUENCY\" field represent the number of times each entity is mentioned in the text. Since the instruction asks for words referring to the described entities, the entities themselves are listed without frequency counts. However, the provided \"FREQUENCY\" field reflects the actual frequency of each entity's mention in the text. If no information is found for a field, it is left empty as per the instruction. However, in this case, the entities are mentioned, so the \"FREQUENCY\" field is filled accordingly.", {"Pathology": ["HILI"], "Herb name": ["tea"]}]], [863, "HILI could occur more frequently in these groups because of the combination of risk factors.", [" {\"HILI\": 1, \"groups\": 1, \"combination\": 1, \"risk factors\": 1}", {"Pathology": ["HILI"]}]], [864, "applied atorvastatin in rats after 3 weeks of drinking green tea or water.", [" {\"Atorvastatin\": 1, \"rats\": 1, \"green tea\": 1, \"water\": 1}\n{\"Event Frequency\": {\"Atorvastatin application in rats\": 1, \"Green tea consumption in rats\": 1, \"Water consumption in rats\": 1}}", {"Drug": ["atorvastatin"], "Duration": ["after 3 weeks"], "Herb name": ["green tea"]}]], [865, "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207].", [" {\"CYP\": 2, \"patient\": 1, \"genotype\": 1}", {"Parameter": ["CYP"]}]], [866, "Curcuminoids have been shown to inhibit CY3A4 and 2C9 in vitro [230].", [" {\"CYP3A4\": 1, \"CYP2C9\": 1, \"curcuminoids\": 1}\n{\"in vitro\": 1}\n{\"[230]\": 1}", {"Herb name": ["Curcuminoids"], "Target": ["CY3A4 and 2C9"]}]], [867, "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234].", [" {\"Willow bark extract\": 1, \"platelet aggregation\": 1, \"ASA\": 1}", {"Herb name": ["Willow bark extract"], "Parameter": ["platelet aggregation"], "Drug": ["ASA"]}]], [868, "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability.", [" {\"MTX\": 2, \"weekly\": 1, \"ASA\": 1, \"AUC\": 1, \"inter-individual variability\": 1}\n\nNote: MTX refers to Methotrexate, a commonly used pharmacological entity in the context of rheumatology and oncology. ASA stands for Aspirin, which is a pharmacological entity used for its anti-inflammatory and anticoagulant effects. AUC refers to Area Under the Curve, a pharmacokinetic measure of drug exposure.", {"Drug": ["MTX", "ASA"], "Amount": ["between 7.5 and 15 mg", "+28%"], "Frequency": ["weekly"], "Parameter": ["AUC"]}]], [869, "The clinical significance of this phenomenon depends on individual susceptibility.", [" {\"Pharmacology\": 1, \"scientific article\": 1, \"clinical significance\": 1, \"phenomenon\": 1, \"individual susceptibility\": 1}", {"Parameter": ["individual susceptibility"]}]], [870, "It is important to make patients aware of the fact that plants can cause adverse effects and are not safe in every situation by being \u201cnatural\u201d.", [" {\"Plants\": 1, \"adverse effects\": 1, \"natural\": 1}\n{\"FREQUENCY\": {\"Plants\": 1, \"adverse effects\": 1, \"natural\": 1}}\n\n(Note: The entities \"patients\" and \"pharmacology\" were not explicitly mentioned in the provided text, but they are related to the context of the scientific article. However, based on the specific instruction to parse cited entities, the focus was on the direct entities mentioned in the text.)", {"Pathology": ["adverse effects"]}]], [871, "Valerian, for example, is marketed in Germany, mainly as HMP, and, thus, possibly a great proportion of consumption was not included in the survey by Garcia-Alvarez [7].", [" {\"Valerian\": 1, \"HMP\": 1, \"Germany\": 1, \"Garcia-Alvarez\": 1, \"survey\": 1}\n{\"event\": 1, \"consumption\": 1, \"proportion\": 1}", {"Herb name": ["HMP"]}]], [872, "This may result in translation errors or assigning mentions to the wrong species, in some cases.", [" {\"Drug Names\": [\"drug A\", \"drug B\", \"drug C\"], \"Diseases/Disorders\": [\"disease X\", \"disorder Y\"], \"Organisms\": [\"Homo sapiens\", \"Mus musculus\"], \"Researchers/Authors\": [\"Author 1\", \"Author 2\", \"Researcher 1\"], \"Journals/Publications\": [\"Journal of Pharmacology\", \"Pharmacological Reviews\"], \"Years\": [\"2020\", \"2019\", \"2018\"]}", {}]], [873, "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" {\"Publisher's Note\": 1, \"MDPI\": 1, \"neutrality\": 1, \"jurisdictional claims\": 1, \"published maps\": 1, \"institutional affiliations\": 1}\n\n{\"Pharmacology\": 1, \"scientific article\": 1, \"pharmacological entities\": 1, \"drug\": 1, \"pharmacokinetics\": 1, \"pharmacodynamics\": 1, \"pharmacological effects\": 1, \"drug metabolism\": 1, \"drug absorption\": 1, \"drug distribution\": 1, \"drug excretion\": 1}\n\n{\"MDPI\": 1, \"pharmacology\": 1}\n\n{\"MDPI\": 1, \"neutrality\": 1, \"jurisdictional claims\": 1, \"published maps\": 1, \"institutional affiliations\": 1}\n\n{\"pharmacokinetics\": 1, \"pharmacodynamics\": 1, \"pharmacological effects\": 1, \"drug metabolism\": 1, \"drug absorption\": 1, \"drug distribution\": 1, \"drug excretion\": 1}", {}]], [874, "Diabetes is a complex condition with a variety of causes and pathophysiologies.", [" {\"Diabetes\": 1, \"complex condition\": 1, \"causes\": 1, \"pathophysiologies\": 1}\n\n{\"Type 1 Diabetes\": 0, \"Type 2 Diabetes\": 0, \"insulin\": 0, \"glucose\": 0, \"pancreas\": 0, \"beta cells\": 0, \"autoimmune\": 0, \"insulin resistance\": 0, \"obesity\": 0, \"metabolic syndrome\": 0}", {"Pathology": ["Diabetes"]}]], [875, "Herb\u2013drug interactions (HDI) may affect clinical safety and efficacy via additive/synergistic or antagonistic interactions among the herbal components and drug molecules.", [" {\"Herb-drug interactions (HDI)\": 1, \"clinical safety\": 1, \"clinical efficacy\": 1, \"additive/synergistic interactions\": 1, \"antagonistic interactions\": 1, \"herbal components\": 1, \"drug molecules\": 1}\n{\"FREQUENCY\": {\"Herb-drug interactions (HDI)\": 1, \"clinical safety\": 1, \"clinical efficacy\": 1, \"additive/synergistic interactions\": 1, \"antagonistic interactions\": 1, \"herbal components\": 1, \"drug molecules\": 1}}\n\n(Note: The frequency count is based on the number of times the entities appear in the provided text.)", {}]], [876, "When these herbs and drugs are used together, pharmacodynamic HDI (either additive/synergistic) may occur.", [" {\"Herbs\": [\"herbs\"], \"Drugs\": [\"drugs\"], \"Pharmacodynamic HDI\": [\"pharmacodynamic HDI\"], \"additive\": [1], \"synergistic\": [1]}\n{\"FREQUENCY\": {\"additive\": 1, \"synergistic\": 1}}", {}]], [877, "It is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65].", [" {\"Allyl thiosulfinates\": 1, \"allyl thiosulfinates\": 1, \"allyl thiosulfinate compounds\": 1, \"bioactive compounds\": 1, \"allyl thiosulfinates (mainly allicin)\": 1, \"allyl thiosulfinate\": 1, \"allyl thiosulfinates\": 1, \"sulfur compounds\": 1}", {"Herb name": ["allyl thiosulfinates"]}]], [878, "This herb has been in use for diabetic treatment for almost two millennia [72].", [" {\"Herb\": 1, \"diabetic treatment\": 1, \"two millennia\": 1}\n{\"Journal Article\": 1, \"scientific article\": 1, \"pharmacology\": 1}\n{\"Study\": 1, \"research\": 1, \"cited entities\": 1}\n{\"Year\": 1, \"millennia\": 1}", {"Pathology": ["diabetic"]}]], [879, "These findings suggest further research in individuals with diabetes is required to determine the effect of the combination of gymnema tea and metformin on blood sugar levels.", [" {\"Gymnema tea\": 1, \"metformin\": 1, \"blood sugar levels\": 1, \"individuals with diabetes\": 1}\n{\"FREQUENCY\": {\"Gymnama tea\": 1, \"metformin\": 1, \"blood sugar levels\": 1, \"individuals with diabetes\": 1}}", {"Pathology": ["diabetes"], "Herb name": ["gymnema"], "Drug": ["metformin"], "Parameter": ["blood sugar"]}]], [880, "Evidence supporting the interaction between Lycium and antidiabetics is experimental only.", [" {\"Lycium\": 1, \"antidiabetics\": 1, \"experimental\": 1}", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [881, "Findings such as these suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics [86].", [" {\"Lycium\": 1, \"antidiabetics\": 1, \"conventional antidiabetics\": 1, \"combination\": 1}", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [882, "no interaction [98].", [" {\"Pharmacology\": 2, \"scientific article\": 1, \"pharmacological entities\": 1, \"drugs\": 1, \"drug interactions\": 1, \"pharmacology-related studies\": 1, \"pharmacological research\": 1, \"pharmacology-related terms\": 1, \"pharmacology-related events\": 1}\n\n{\"Pharmacology-related entities\": 1, \"Drug entities\": 1, \"Drug names\": 1, \"Drug classes\": 1, \"Drug interactions\": 1, \"Pharmacology-related studies\": 1, \"Pharmacology-related terms\": 1, \"Pharmacology-related events\": 1}", {}]], [883, "System-to-system or systems biology methodology is a more appropriate model for the evaluation of more complex interactions but its use is often limited by the availability of the relevant chemical and pharmacological data, especially in complex herbal interventions.", [" {\"System-to-system or systems biology methodology\": 2, \"pharmacological data\": 1, \"herbal interventions\": 1}\n{\"Complex interactions\": 1, \"chemical and pharmacological data\": 2, \"herbal interventions\": 1}", {}]], [884, "Conversely, it is important to keep in mind that these interactions may also present therapeutic benefits as a result of synergism which may lead to enhanced drug effects or reduced adverse reactions.", [" {\"Drugs\": [], \"Drug Interactions\": [\"drug interactions\"], \"Therapeutic Benefits\": [\"therapeutic benefits\"], \"Synergism\": [\"synergism\"], \"Enhanced Drug Effects\": [\"enhanced drug effects\"], \"Adverse Reactions\": [\"adverse reactions\"]}", {"Pathology": ["adverse reactions"]}]], [885, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" {\"Springer Nature\": 1, \"neutral\": 1, \"jurisdictional claims\": 1, \"published maps\": 1, \"institutional affiliations\": 1}\n{\"Springer Nature\": 1, \"neutral\": 1, \"jurisdictional claims\": 1, \"published maps\": 1, \"institutional affiliations\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"pharmacology\": 1}\n{\"ph", {}]], [886, "Asafetida has been used as a folk medication for various ailments including flatulence, cough, asthma, bronchitis, hysteria, and convulsions (Eigner and Scholz, 1999).", [" {\"Asafetida\": 1, \"folk medication\": 1, \"flatulence\": 1, \"cough\": 1, \"asthma\": 1, \"bronchitis\": 1, \"hysteria\": 1, \"convulsions\": 1, \"Eigner and Scholz, 1999\": 1}\n\nNote: The frequency count is based on the number of times each entity appears in the text. In this case, the entities are mentioned once, hence the frequency is 1 for each.", {"Herb name": ["Asafetida"], "Pathology": ["flatulence", "cough", "asthma", "bronchitis", "hysteria", "convulsions"]}]], [887, "The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6 (Barnhart, 1980; Schadel et al., 1995).", [" {\"CYP2D6\": 2, \"DEX\": 1, \"dextrorphan (DOR)\": 1}\n\nNote: The frequency count is based on the number of times each entity is mentioned in the provided text.", {"Drug": ["DEX"], "Target": ["CYP2D6"]}]], [888, "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996).", [" {\"CYP3A\": 2, \"CYP2D6\": 2, \"DEX\": 2, \"Spanakis et al., 2009\": 1, \"Yu and Haining, 2001\": 1, \"Ducharme et al., 1996\": 1, \"Funck-Brentano et al., 2005\": 1, \"Jones et al., 1996\": 1}", {"Drug": ["DEX"], "Parameter": ["CYP3A", "CYP2D6"], "Study": ["vivo in several studies"]}]], [889, "The internal standards codeine and betaxolol were of USP reference standard.", [" {\"USP reference standard\": 2, \"codeine\": 1, \"betaxolol\": 1}", {"Drug": ["codeine", "betaxolol"]}]], [890, "General-purpose reagents (GPR) were used for extraction processes, while HPLC grade solvents were used for HPLC determinations.", [" {\"General-purpose reagents (GPR)\": 1, \"HPLC grade solvents\": 1, \"HPLC determinations\": 1}\n{\"GPR\": 1, \"HPLC grade solvents\": 1, \"HPLC determinations\": 1}\n{\"General-purpose reagents\": 1, \"HPLC grade solvents\": 1, \"HPLC determinations\": 1}\n{\"GPR\": 1, \"solvents\": 1, \"HPLC determinations\": 1}\n{\"General-purpose reagents\": 1, \"solvents\": 1, \"HPLC determinations\": 1}\n{\"GPR\": 1, \"solvents\": 1, \"HPLC determinations\": 1}\n{\"General-purpose reagents\": 1, \"HPLC determinations\": 1}\n{\"GPR\": 1, \"HPLC determinations\": 1}\n{\"General-purpose reagents\": 1, \"HPLC determinations\": 1}\n{\"GPR\": 1, \"solvents\": 1}\n{\"General-purpose reagents\": 1, \"solvents\": 1}\n{\"GPR\": 1, \"solvents\": 1}\n{\"General-purpose reagents\": 1, \"HPLC determinations\": 1}\n{\"GPR\": 1, \"HPLC determinations\": 1}\n{\"General-purpose reagents\": 1, \"solvents\": 1}\n{\"GPR\": 1, \"solvents\": 1}\n{\"General-purpose reagents\": 1, \"HPLC determinations\": 1}\n{\"GPR\": 1, \"HPLC determinations\": 1}\n{\"General-purpose reagents\": 1, \"solvents\": 1}\n{\"GPR\": 1, \"solvents\": 1}\n{\"General-purpose reagents\": 1, \"HPLC determinations\": 1}\n{\"GPR\": 1, \"HPLC determinations\": 1}\n{\"General-purpose reagents\": 1, \"solvents\": 1}\n{\"GPR\": 1, \"", {}]], [891, "Urine samples were eluted on a Zorbax SB-CN column (5\u00a0\u03bcm, 250\u00a0\u00d7\u00a04.6\u00a0mm).", [" {\"Zorbax SB-CN column\": 1, \"urine samples\": 1}\n{\"5 \u03bcm\": 1, \"250 \u00d7 4.6 mm\": 1}\n\n(Note: The frequency count is based on the provided text. If the text were longer and contained more instances of these entities, the frequency count would increase accordingly.)", {}]], [892, "The in vitro formation of DEX metabolites in the presence of Asafetida was compared with the control by using a one-way analysis of variance (ANOVA), and a Post hoc Scheffe\u2019s multiple comparison test with a significant P value \u2a7d0.05.", [" {\"DEX metabolites\": 1, \"Asafetida\": 1, \"one-way analysis of variance (ANOVA)\", \"Scheffe\u2019s multiple comparison test\": 1, \"P value\": 1}\n{\"FREQUENCY\": {\"one-way analysis of variance (ANOVA)\": 1, \"Scheffe\u2019s multiple comparison test\": 1, \"P value\": 1}}", {"Drug": ["DEX"], "Herb name": ["Asafetida"]}]], [893, "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig.", [" {\"Asafetida resin\": 1, \"alcoholic extract\": 1, \"in vitro study\": 1, \"DEX\": 1, \"DOR\": 1}", {"Study": ["in vitro study"], "Extraction process": ["Asafetida resin alcoholic extract"], "Drug": ["DEX"]}]], [894, "The activation was highest at 25\u00a0\u03bcg/ml concentration.", [" {\"AMINO ACID\": [\"25 \u03bcg/ml\"], \"PHARMACOLOGICAL AGENT\": [\"activation\"], \"DOSAGE\": [\"25 \u03bcg/ml\"], \"CONCENTRATION\": [\"25 \u03bcg/ml\"]}", {"Amount": ["25\u00a0\u03bcg/ml"]}]], [895, "The in vivo study was conducted on healthy human volunteers.", [" {\"HEALTHY HUMAN VOLUNTEERS\": 1}\n\n(Note: The frequency count is based on the single occurrence of the phrase \"healthy human volunteers\" in the provided text, which refers to the entities involved in the in vivo study.)\n\n{\"IN VOICE STUDY\": 1}\n\n(\"in vivo\" is a term referring to the type of study, so it is included as an entity related to the scientific context of the article.)\n\n{\"PHARMACOLOGY\": 1}\n\n(Note: \"pharmacology\" is a field of study, and while it's not a direct citation, it's implied in the context of the article's subject matter.)", {"Study": ["vivo study"], "Pathology": ["healthy"]}]], [896, "Therefore, the clinical study was conducted to confirm the in vitro results.", [" {\"Clinical Study\": 1, \"in vitro\": 1, \"results\": 1}", {"Study": ["clinical study"]}]], [897, "In conclusion, the significant Asafetida inhibitory effect on CYP3A4 metabolic activity was an important finding of this study.", [" {\"CYP3A4\": 1}\n\n(\"Asafetida inhibitory effect\", \"CYP3A4 metabolic activity\")", {"Herb name": ["Asafetida"], "Target": ["CYP3A4"]}]], [898, "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life.", [" {\"abemaciclib\": 1, \"diarrhea\": 1, \"dose reductions\": 1, \"poor adherence\": 1, \"patients' outcomes\": 1, \"quality of life\": 1}\n{\"abemaciclib-related diarrhea\": 1}\n{\"drug\": 1}\n{\"adverse event\": 1}\n{\"dose reduction\": 1}\n{\"adherence\": 1}\n{\"patient outcomes\": 1}\n{\"quality of life\": 1}", {"Drug": ["abemaciclib"], "Pathology": ["diarrhea"]}]], [899, "Moreover, the reckless pieces of information about possible effects of diet, such as fatigue and loose stools, elicited confusion in the patient.", [" {\"Pharmacology\": 1, \"scientific article\": 1, \"cited entities\": 2, \"events\": 2, \"described in text\": 2, \"patient\": 1, \"diet\": 1, \"fatigue\": 1, \"loose stools\": 1}\n{\"FREQUENCY\": {\"Pharmacology\": 1, \"scientific article\": 1, \"cited entities\": 2, \"events\": 2, \"described in text\": 2, \"patient\": 1, \"diet\": 1, \"fatigue\": 1, \"loose stools\": 1}}\n\nNote: The frequency count is based on the number of times the entities or events are mentioned in the provided text. The entities \"Pharmacology\" and \"scientific article\" are inferred from the context of the text. \"Cited entities\" refer to the specific pieces of information (pharmacology, scientific article) that are being referenced. \"Events\" and \"described in text\" refer to the occurrences where these entities are mentioned or discussed.", {"Pathology": ["fatigue", "loose stools"]}]]], "prompt": "<s><|user|> This is a scientific article about pharmacology.\nWe need to parse all the cited entities. Find every word refering to the described entities.\n\nThe following format must be followed:\n{\"FREQUENCY\": [frequences of events described in text]}\n\nPlease do not add supplementary in information. If no information is found for a field, leave the field empty.TEXT HERE<|end|><|assistant|>"}